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Abstract 
 
 
Background and Objectives: When the benefits and risks of mammography are considered, 
the risk of radiation-induced cancer is calculated only for the breast using the mean glandular 
dose (MGD). Whilst MGD is a useful concept, it has many limitations. This thesis aims to 
establish a novel method to determine and convey radiation risk from full field digital 
mammography (FFDM) screening using lifetime effective risk. 
Method: For effective risk calculations, organ doses as well as examined breast MGD are 
required. Screening mammography was simulated by exposing a breast phantom for cranio-
caudal and medio-lateral oblique for each breast using 16 FFDM machines. An 
anthropomorphic dosimetry phantom loaded with thermo-luminescent detectors (TLDs) was 
positioned in contact with the breast phantom to simulate the client‘s body. Once the risk per 
individual was calculated, total effective lifetime risk across 48 worldwide screening 
programmes was calculated. The total effective risk data sets were analysed to establish a 
regression model to predict the effective risk of any screening programme. Graphs were 
generated to extrapolate the total effective risk of any screening programme of specific 
screening commencement age and frequency considering the MGD differences of different 
FFDM machines. Since the highest radiation dose after examined breast was received by 
contralateral breast, the effect of a contralateral breast lead shield on effective risk was also 
investigated. 
Results: Large differences in the effective lifetime risk exist between worldwide screening 
programmes. The effective lifetime risk varied from approximately 50 cases/10
6
 to more than 
1000 cases/10
6
. These differences were mainly attributed to the commencement age and 
frequency of screening. Since tissue radio-sensitivity reduces with age, the cessation age of 
screening mammography does not result in a noteworthy effect on the total effective risk. 
The use of contralateral breast shield reduces the total effective risk by about 1.5% for most 
worldwide screening programmes. 
 XIX 
 
Conclusion:  A novel method has been proposed to assess radiation-induced cancer risk from 
FFDM screening which considers the radiation dose received by all body tissues in addition 
to the examined breast. Using effective risk, the data is more likely to be understandable by 
screening clients and referring clinicians, unlike MGD which is not readily available or 
understandable by the general populace. This novel method and the data are compatible with 
the incoming European Commission legislation about giving the patient information on 
radiation risk. 
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Chapter One 
Introduction and Thesis Outline 
 
1.1 Introduction 
Diagnostic procedures that use X-radiation are one of the most common and useful tools in 
medicine. It is used in hospitals and clinics to non-invasively diagnose, stage and monitor 
progression of disease within the body (Brady, 2012). However, medical X-rays are the 
largest source of man-made ionising radiation to which humans are exposed in many 
developed countries (European Commission, 2008). The link between patient radiation dose 
in X-ray examinations and cancer incidence, makes dosimetry an area of great importance in 
diagnostic radiology (Meghzifene, Dance, McLean, & Kramer, 2010). This is particularly 
true for screening practices because healthy individuals are exposed to potentially harmful 
ionising radiation (Sechopoulos, Bliznakova, Qin, Fei, & Feng, 2012).  
Mammography is the most important screening test for the investigation of breast cancer in 
asymptomatic women; it is used to detect breast cancer in its early stages (Aznar et al., 
2005). Mean glandular dose (MGD) is the recommended dosimetric quantity used to express 
the radiation risk in screening mammography (European Commission, 2013; IAEA, 2011). 
However, some limitations have been identified with the use of this measurement. First, 
MGD only includes the radiation dose of the examined breast, ignoring the radiation dose 
received by body tissues due to scattered radiation. Second, the individual‘s age, which 
affects tissue‘s radio-sensitivity, is not considered in MGD calculations. Third, MGD 
generated data (mGy), is highly technical, and cannot be easily understood by the general 
public (screening clients). Therefore in this thesis a new dosimetric method for radiation risk 
assessment from screening mammography has been established - effective risk. Effective risk 
is a measure of radiation-induced cancer from screening mammography.  
1.2 Rationale, Aim and Objectives 
New European Commission legislation outlines the patient's right to have information about 
the risk of X-radiation associated with radiological examinations. This is particularly 
important for screening practices in which healthy individuals are examined. Mammography 
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is one of the most common screening procedures using X-ray. Many countries have a 
national organised screening mammography programme with different recommendations. 
The radiation risk from screening mammography is an essential point to screening 
justification. Presently no method exists to give risk estimates from screening 
mammography; equally no data which could be easily understood by patients exist. 
Therefore, this thesis aims to propose a novel method to assess and convey the risk of 
radiation-induced cancer from screening mammography. 
The Objectives: 
 Determine a novel method to assess radiation risk from screening mammography. 
 Use the method to estimate the radiation risk (cancers induced per million people 
screened) for different screening scenarios. 
 Use the method to compare radiation risk for different countries‘ screening programmes. 
 Use the method to determine whether a contralateral breast secondary radiation shield has 
value in reducing the radiation risk. 
1.3 Thesis Structure 
This thesis comprises of eight chapters, which are summarised in Figure (1-1), as follows: 
Chapter 1: “Introduction and Thesis Outline” - Includes a brief introduction, thesis 
rationale, aim and objectives and a description of the thesis layout.  
Chpater 2: “Breast Anatomy, Cancer and Imaging Modalities” - In this chapter 
background information about the female breast is addressed. This information helps to 
understand the effect of normal breast anatomy variations, particularly the breast density and 
size, on breast radiation dosimetry. Within this chapter the information will be presented in 
five main sections: Firstly, a breast anatomy section, comprising of the macroscopic and 
microscopic anatomical characteristics of the female breast. Secondly, the breast density 
definition, importance, and different scales used for breast density classifications will be 
explained. Thirdly, breast cancer and breast cancer risk factors will be presented. Fourthly, 
different breast imaging modalities used to investigate and diagnose breast cancer will be 
examined. Fifthly, the breast cancer screening modalities will be displayed.   
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Chapter 3: “Mammography: Development, Physics and Clinical Aspects” - This chapter 
commences with information about the origin and most prominent historical development 
points in mammography. The mammography dosimetric aspects during those periods are also 
explained. Next the physical aspects of digital mammography are explained. The physics and 
instrumentation of FFDM and DBT will then be reported. Following this, the anatomical 
characteristics of breast tissue in standard mammograms (CC and MLO projections images) 
and in supplementary projections will be presented. Finally, the last section of this chapter 
will be focused on screening mammography justification with regard to its advantages (breast 
cancer mortality reduction) and disadvantages (radiation risk, over diagnosis, false negative 
and false positive).  
Chapter 4: “Mammography Dosimetry” - This chapter commences with an explanation of 
the risk of low radiation doses likely to be received from screening mammography. 
Following this, a comprehensive literature review of mammography dosimetry will be 
included. In this context the studies investigating the radiation dose to breast tissue and other 
body tissue from mammography will be considered. The mammography dosimetric methods 
including dose modelling by Monte Carlo and dose measurement instruments will be 
considered. In the last section of this chapter, breast tissue equivalent materials will be 
reviewed as mammographic dosimetry tools.  
Chapter 5: “Materials and Methods” - This chapter commences with the methodology 
used for organ dose measurement, this includes a detailed explanation of the organ dose 
measurement process using the TLDs and the examined breast MGD calculation. Next, the 
method of how the generated organ dose data can be used for the calculation of effective risk 
and total effective risk of 48 worldwide screening programmes will be described. However 
some of the programmes have same recommendations resulting in 22 different programmes. 
Following this, the three methods of total effective risk modelling will be considered. Finally 
the design and use of a contralateral breast lead shield will be explained comprehensively in 
the last section of the chapter. 
Chapter 6: “Results” - This chapter commences with an outline of the data amassed using 
the method.  The data is organised into four sections: The first contains data of the measured 
organ radiation dose from complete screening exposures for 16 FFDM machines. The second 
shows the total effective risk of the 48 worldwide screening programmes. The third shows 
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the total effective risk modelling data and graphs. The fourth shows the organ radiation dose 
data and total effective risk of the 48 worldwide screening programmes for four FFDM 
machines with the use of the contralateral breast shield. 
Chapter 7: “Discussion” - The data presented in the sixth chapter (results chapter) is 
discussed and links between the existing body of evidence are made. This chapter is set out 
in the same manner as the results chapter, where the data from each section is discussed 
separately. The final component of this chapter considers the limitations of the work 
presented in this thesis and what might be undertaken to address these limitations in future 
work. 
Chapter 8: “Conclusions” - This chapter summarises the findings of the thesis in a concise 
manner.  
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Figure (1-1) A flowchart illustrating the outline of this PhD thesis. 
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Chapter Two 
Breast Anatomy, Cancer and Imaging Modalities 
 
2.1 Chapter Overview 
This chapter comprises of background information about normal breast anatomy and breast 
cancer. Since the breast density is the second most important breast cancer risk factor, breast 
density and breast classification methods have been considered along with the other risk 
factors. The physical principle of breast imaging modalities, including mammography, breast 
computed tomography (CT), breast ultrasound and magnetic resonance imaging (MRI), have 
been reviewed in later sections. The last section of this chapter focuses on the breast cancer 
screening techniques and the feasibility of each one in reference to breast cancer mortality 
reduction and their cost-effectiveness. These techniques are breast self-examination and why 
it is recommended to be replaced by breast self-awareness, clinical breast examination, 
mammography, breast ultrasound and breast MRI.  
2.2 Breast Anatomy 
The mature female breast is ‗tear drop‘ shaped and is located on the anterior chest wall 
(Darlington, 2015). The base of the breast extends from the level of the second to the sixth 
ribs longitudinally, and between the boundary of the sternum and the mid-axillary line 
transversely, Figure (2-1). The majority of breast tissue is usually located in its upper lateral 
quadrant (Ellis, 2004; Pandya & Moore, 2011). The internal structure of the breast is similar 
for all females. However, its size and shape differs in relation to many factors: race, diet, age, 
status of female parity and menopausal status (Standring & Gray, 2008). 
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Figure (2-1) Shows the breast relations (Drake, Vogl, & Mitchell, 2015). 
The female breast is fundamentally composed of fat, connective tissue and glandular tissue; 
the latter being the functional part of the breast tissue. Glandular tissue is a type of highly 
modified and specialised sweat gland (Brandt, Karemore, Karssemeijer, & Nielsen, 2011; 
Pandya & Moore, 2011). It changes with age as a response to body hormones (Allen, 2012). 
Early in childhood, the adipose tissue constitutes the majority of breast tissue. However, the 
glandular tissue begins to develop at puberty and continues until maturity when it 
progressively changes to adipose tissue (Dance, Skinner, & Carlsson, 1999). The glandular 
tissue in each breast is divided into 15-20 lobes, each with tree shape tubular structures 
branching out from the nipple. Each lobe includes 10-100 lobules which have a number of 
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acini, where the milk and hormones are produced (Darlington, 2015; Diffey, 2012). The 
functional unit of the breast is known as the terminal ductal lobular unit (TDLU) which is 
made up an acini, an intralobular terminal duct and an extralobular duct, Figure (2-2). Both 
the acini and the ducts are formed of a one cell thick epithelial layer surrounded by 
myoepithelial layer and basement membrane (Darlington, 2015). The fraction of glandular 
tissue in the breast is known as breast density (Vachon et al., 2007).  
 
Figure (2-2) Illustrates the Terminal Ductal Lobular Unit (TDLU) (Darlington, 2015). 
Connective and fat tissues can be considered as supportive tissues in the breast. Two 
different types of connective tissues can be identified within the breast: Interlobular 
connective tissue holds the breast tissue together and is spread between the lobules; 
Intralobular connective tissue is a specialised type of connective tissue found around the 
terminal ductal lobular unit. Breast fat tissue is present between the mammary glands 
(Kopans 2007). Externally the whole breast is covered by 0.5–2.0 mm of skin except the area 
directly surrounding the nipple where the skin becomes thicker, as it contains sweat glands, 
sebaceous glands and hair follicles, to form the areola. Just beneath the skin there is a 2–2.5 
cm thick layer of subcutaneous fat covering the breast. At the breast level, the superficial 
layer of fascia divides into two layers. The superficial layer surrounds the breast under the 
subcutaneous fat and the deep layer surrounds the posterior aspect of the breast lying on the 
fascia of the pectoralis major muscle. Between these two layers of fascia a retro-mammary 
space is formed which is filled by fat tissue (Darlington, 2015). 
The determination of breast size or volume can be achieved by physical procedures, either by 
molding the breast in plastic or by submerging the breast in water and determining its volume 
by measuring the volume of displaced water according to Archimedes‘ principle. Accurate 
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determination of breast volume is not easy and can be carried out by digital methods (Veitch, 
Burford, Dench, Dean, & Griffin, 2012). Alonzo-Proulx, Jong, and Yaffe (2012) used digital 
mammography to study some breast characteristics, such as the breast volume, for 55087 
digital mammograms from 15351 Canadian women. They found that the mean breast volume 
for all studied women was 687cm
3
 with slight differences in different age groups. For 
example, it was 703cm
3
 and 736cm
3
 for 50-55 year and 55-65 year age groups. These 
variations are due to the change of female breast volume with age. A greater mean breast 
volume around 820cm
3
 has been found for British women by Diffey (2012). Wang et al. 
(2013) utilised ultrasound system to measure female breast volume and stated that the breast 
volume for around 57% of 306 adult Chinese females was between 400-800 cm
3
.   
2.3 Breast Density 
Breast density is a measure of breast composition.  It reflects the percentage of glandular 
tissue in the breast. Since it is basically assessed by mammography, it is expressed as 
mammographic density (Boyd, Martin, Yaffe, & Minkin, 2011). Mammographic density was 
first described in 1976 by Wolf as an independent risk factor for breast cancer (Ding & 
Molloi, 2012). Generally, younger women have denser breast than older women, and after 
the age of 40 the mammographic density progressively reduces with age due to hormonal 
changes (ACS, 2015b). However, Chelliah, Voon, and Ahamad (2013) reported that this 
process is slower in Chinese women compared to Malay and Indian women. They also 
reported that there is an inverse relationship between the mammographic density and body 
mass index (BMI) for the studied population (Chelliah et al., 2013). Breast density is either 
estimated qualitatively by a clinician or quantitatively by computer-assisted methods 
(Tagliafico et al., 2013). The film-screen mammographic images were formally digitised for 
computer-assisted breast density measurements. Presently, two dimensional or three 
dimensional breast images from different imaging modalities (FFDM, DBT, CT, MRI and 
US) are utilised (Alonzo-Proulx et al., 2012; Ekpo & McEntee, 2014; Salvatore et al., 2014; 
Tagliafico et al., 2013). 
 Sometimes the mammographic density is measured by two-dimensional means and 
expressed as the ratio of the area of dense glandular tissue to that of the whole breast (Stone, 
Ding, Warren, Duffy, & Hopper, 2010). In the general population, 26% - 32% of women 
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have high breast density which is 50% or greater (Vachon et al., 2007). A more logical 
method for breast density estimation can be utilised and is based on volume, here the breast 
density is expressed as volumetric breast density (VBD) (Alonzo-Proulx et al., 2010). 
According to Alonzo-Proulx et al. (2012), the mean value of VBD for 15351 women was 
30.5%. Alonzo-Proulx et al. also demonstrated that VBD reduces by 2% per year on average 
as the age increases from 35 to 75 years. On average, the breasts of Asian women are thinner 
and denser than those of European and North American women, and in European women 
they are thinner and less dense than in North American women (Geeraert, Klausz, Muller, 
Bloch, & Bosmans, 2012).  
Different methods have been used to classified female breasts according to their densities:  
2.3.1 Wolf Classification 
Wolf semi-quantitatively classified the female breast density into four categories: N1, mostly 
fatty breast; P1, less than one-third of the ductal structures are prominent; P2, more than one-
third of the ductal structures are prominent; DY, extensively dense breast (dysplasia) (Boyd 
et al., 2010).  
2.3.2 Tabar Classification  
A semi-quantitative five level classification system developed by Gram, Funkhouser, and 
Tabar (1997), who classified the breast density depending on a parenchymal pattern as 
follows: 
Category I: the mammogram has scalloped contours with fatty lucent areas and 1-2 mm 
evenly distributed nodular densities. 
Category II: the mammogram has entirely lucent fatty areas and 1-2 mm evenly distributed 
nodular densities.  
Category III: the mammogram‘s retroareolar area ductal structures are prominent. 
Category IV: the mammogram has large nodular and linear densities. 
Category V:  the mammogram is homogeneous with the ground glass shape pattern. 
2.3.3 BI-RADS Classification 
The American College of Radiology developed the Breast Imaging Reporting and Data 
System (BI-RADS) which places breasts into four density categories: fatty breast with less 
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than 25% density, scattered fibroglandular with 25%-50% density, heterogeneous with 51%-
75% density, and dense breast with more than 75% density (D‘Orsi et al., 2013). BI-RADS‘ 
classification is the most accepted breast density classification and is the most commonly 
used (Ekpo, Hogg, Highnam, & McEntee, 2015).  
2.3.4 Boyd Classification  
Boyd used six categories to express breast density depending on the clinician‘s assessment 
and computer assessed measurements. These categories are 0, < 10%, 10% to < 25%, 25% to 
< 50%, 50% to < 75% and 75-100% (Boyd, Jensen, Cooke, & Han, 1992).  
2.3.5 Summary  
The importance of breast density appears in three areas: first, it affects the sensitivity of 
mammography - the denser the breast the lower the sensitivity for cancer detection because 
small lesions can be obscured by dense glandular tissue (Ford, Marcus, & Lum, 1999; Helvie 
& Rosen, 2011); second, breast cancer risk assessment - many researchers studied the 
relationship between breast density and breast cancer incidence, and they indicated 
mammographic breast density as the second substantial risk factor for breast cancer after age 
(Kontos et al., 2011); third, estimation of breast radiation dose - the validity of breast dose 
estimation could be improved by accurate measurement of breast density because the breast 
composition is an essential factor in breast dosimetry (Alonzo-Proulx et al., 2010). Overall, 
dense breasts indubitably absorb more radiation dose than fatty breasts; dense breasts are also 
associated with a reduction in mammography cancer detection accuracy (ACOG, 2015). 
2.4 Breast Cancer 
2.4.1 Breast Cancer Types 
Breast cancer is an uncontrolled change in growth of breast tissue which mostly results in 
lump formation. This lump is known as a breast tumor (NHSBSP, 2013a). Depending on the 
place where the cancer develops, breast cancers are classified into ductal carcinoma, 
constituting about 90% of breast cancers, and lobular carcinoma, constituting up to 10% of 
breast cancers (Peart, 2005). The majority of breast cancers are invasive or infiltrating 
cancers which are formed in breast lobules or ducts and invade the surrounding breast tissues 
(ACS, 2011a).  Another type of breast cancer, known as in situ carcinoma, proliferates in 
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epithelial cells of the duct wall but does not invade the basement membrane (Wentz & 
Parsons, 1997).  
2.4.2 Breast Cancer Risk Factors 
An individual‘s probability of developing breast cancer is called the breast cancer risk, 
sometimes referred to as the breast cancer lifetime risk. It is controlled by a large number of 
factors, but unfortunately a full explanation for the mechanism of how these factors affect 
cells cannot be given as it is not known (Hackney, 2015). The importance of breast cancer 
risk factor assessment has increased progressively over time in screening recommendations 
and preventive strategies (Kontos et al., 2011).  
2.4.2.1 Unchangeable Risk Factors (Gender and Age) 
The main two unchangeable risk factors are gender and age. More than 99% of breast cancer 
cases are in females (Anderson, Jatoi, Tse, & Rosenberg, 2010; Kopans 2007). Under the age 
of twenty years, breast cancer is very rare and only about 0.3% of breast cancer cases occur 
in females within their third decade (Finkel, 2005). However, about half of the breast cancer 
cases occur between 50-69 years (Hackney, 2015).  
2.4.2.2 Relationship of Cancer with Breast Density 
Since the identification of mammographic density as a breast cancer risk factor by Dr. Wolf, 
who found a 22-fold increase in breast cancer risk for women with DY category breast 
compared to those with N1 category breast, it has become an area of great interest for many 
researchers (Shepherd et al., 2011). Studies have revealed that for women with high breast 
density, the cancer risk may be between 4-6 times more than for women with lower breast 
density (Brandt et al., 2011).  In 2007, Boyd et al. (2007) introduced a breast cancer risk 
model based on data from 1112 women. This model quantified the relative breast cancer risk 
for each breast density category as in Table (2-1) (Kontos et al., 2011). 
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Table (2-1) Breast cancer relative risk of different 
breast densities according to Boyd‘s model. 
Breast density (%) Breast cancer relative risk 
Less than 10 1.2 
10 to < 25 2.2 
25 to < 50 2.4 
50 to < 75 3.4 
75-100 5.3 
More recently, in 2015, ACOG (2015) published their report number 625 in which they 
tabulated the relative risk of breast cancer for BI-RADS categories 3 and 4 as 1.2 and 2.1, 
respectively. Overall, they concluded that a dense breast is more liable to develop breast 
cancer than a fatty breast. 
2.4.2.3 Genetic Factors 
About 10-15% of the women with breast cancer have a breast cancer family history (Vetto, 
Luoh, & Naik, 2009). Women with one first degree relative (sister, mother, daughter) 
diagnosed with breast cancer have a 1.8 times more risk of developing breast cancer risk than 
those with no family history of it. This breast cancer risk is increased to 3 and 4 times as the 
number of first degree relatives, diagnosed with breast cancer, increases to 2 and 3 women 
(ACS, 2013a). 
Moreover, it has been found that between 5-10% of breast cancer cases are due to mutations, 
which occur in less than 1% of general population, in the inherited breast cancer 
susceptibility genes BRCA1 and BRCA2. These inherited genes increase breast cancer risk 
10 fold. Other rare inherited genes, such as Tumour Protein 53 (TP53), also contribute to 
increased breast cancer risk (ACS, 2013a; Hackney, 2015). 
2.4.2.4 Other Factors 
Other factors include personal history of breast cancer. Women with previous history of 
breast cancer are at 3-5 times more risk of developing an additional breast cancer than others. 
Socio-economic status is also an important factor; recent studies have reported that about 
53% of breast cancer cases occur in developed countries. The use of hormonal therapy leads 
to an increased breast cancer incidence. Finally lifestyle factors, including a lack of physical 
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activity, smoking, incorrect diet, and alcohol consumption also raise the risk of developing 
breast cancer (ACS, 2015c; Kopans, 2007).    
2.4.3 Breast Cancer Statistics  
Breast cancer is a major public health problem and is the fifth most common cause of cancer 
deaths worldwide (Ferlay et al., 2013). It is reported to be the most frequently detected 
cancer among women in many countries. In 2012, breast cancer constituted 25% of new 
cancer cases in women when about 1.7 million new breast cancer cases were recorded 
worldwide (ACS, 2015c). Breast cancer morbidity differs significantly between regions: it is 
at least two to three times more common in America and Western Europe than in East Asian 
nations, where the latter show lower rates than African nations (UNSCEAR, 2008).  The 
figures of breast cancer incidence range from 270 per million in Middle Africa and Eastern 
Asia to 920 per million in Northern America (Ferlay et al., 2013). In the US, breast cancer 
incidence showed a noticeable reduction (~7%) between 2002 and 2003. This reduction may 
be due to a reduction of menopausal hormone therapies (ACS, 2011b).  In the UK, however, 
the smaller number of pregnancies, utilisation of hormones as contraceptives and obesity 
have attributed to an increase in breast cancer incidence between 1975 and 2003 (HPA, 
2011).  
With regard to breast cancer mortality, its rates have steadily decreased in developed 
countries. For instance, in England it has reduced by 37% between 1971 and 2011 (ONS, 
2012). In the same way, a 5.2% per year reduction can be seen in the US between 1990 and 
2011 (ACS, 2011b). These reductions in mortality rates are primarily due to prevention of 
breast cancer (cancer incidence reduction), early detection of breast cancer by screening, and 
the improvement of cancer treatment methods (ACS, 2011b; Säbel & Aichinger, 1996). In 
spite of this decline in breast cancer mortality in developed countries, breast cancer still has 
the second highest cancer mortality rate, after lung cancer (ACS, 2015c; Dellie, Rao, 
Admassie, & Meshesha, 2013; ONS, 2012). However, in developing countries the leading 
cause of cancer death was the breast cancer - about 44% of breast cancer deaths in the world 
occurred in Asian countries and 12%, 8% in African and Latin American countries (ACS, 
2015c). 
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2.5 Breast Imaging Modalities 
2.5.1 Mammography 
The production of low contrast, fine detail, two-dimensional breast images using X-ray is 
known as mammography (Law, 2006). Unlike screening mammograms, which are 
undertaken on healthy asymptomatic women, diagnostic mammograms are utilised to 
investigate breast tissue abnormalities in women with either breast symptoms or abnormal 
findings resulting from a screening mammogram (ACS, 2015a). To date, there are two 
technologies for mammography - conventional film-screen mammography or digital 
mammography, which has progressively replaced film-screen techniques (Schueller et al., 
2008). The main advantages of digital mammography over film-screen are that it is more 
sensitive in cancer detection within dense breasts and has a lower associated radiation dose 
(Pagliari et al., 2012). However, some film-screen systems can produce images with spatial 
resolution three times better than those of digital detectors (Obenauer, Hermann, & Grabbe, 
2003). Overall, studies such as the Digital Mammographic Imaging Screening Trial (DMIST) 
have illustrated that for a screening population (50-69 years old) both film-screen and digital 
mammography are equal in diagnostic accuracy. Nevertheless, the use of digital 
mammography improves diagnostic accuracy for younger population with dense 
heterogeneous breast (Pagliari et al., 2012; Pisano  et al., 2005; Thierens et al., 2009).  
Despite the reported superiority of digital mammography in breast cancer detection, it has 
been found that 20% - 30% of breast cancers cannot be detected by two-dimensional 
mammograms due to the superimposition of dense breast tissue with cancers (Rafferty et al., 
2013). To overcome the mammographic ‗anatomical noise‘, Digital Breast Tomosynthesis 
(DBT) is used to produce three-dimensional images by reconstructing low dose, two-
dimensional, thin slice images of breast volume (Svahn et al., 2012). This is achieved, as in 
conventional tomography, by the movement of the X-ray tube across an arc or linearly above 
the breast in order to expose the breast at different small angles (Williams, Judy, Gunn, & 
Majewski, 2010). Consequently, each plane of the breast can be clearly seen with less tissue 
overlap, thereby improving the lesion detectability (Young, 2006).   
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2.5.2 Breast Computed Tomography (BCT)   
Compared to DBT, dedicated BCT allows the acquisition of high resolution volumetric 
breast image data (Sechopoulos, Bliznakova, Qin, Fei, & Feng, 2012). Accordingly, BCT can 
overcome the problem of tissue overlap resulting in accurate detection of breast cancers 
whilst at the same time obtaining more detailed information about the shape, location, and 
size of any lesion (Shen et al., 2014). Dedicated BCT consists of a gantry, which encloses the 
X-ray tube and detector assembly, that rotates around the breast during imaging. To avoid 
unnecessary radiation to the woman‘s chest, the breast is protruded downward through an 
opening in the patients‘ table while the woman is lying in prone position; see Figure (2-3) 
(Shaw & Whitman, 2013). Breast compression is not required during BCT making the 
technique more comfortable than the conventional mammographic procedure (Shen et al., 
2014). The potential cost of BCT comes from the complex processes associated with data 
acquisition, analysis, visualisation, and interpretation (Russo, Coppola, Mettivier, Montesi, & 
Lauria, 2009). Although the reduced dose in dedicated BCT when compared to conventional 
chest CT, dedicated BCT exposes breast tissue to a higher radiation dose than mammography 
(Sechopoulos et al., 2012).  
 
                                                               
(a)                                                                                 (b) 
Figure (2-3) Shows a diagram for dedicated breast CT (a) Woman positioning and (b) 
Gantry design with examined breast (Shaw & Whitman, 2013). 
 2.5.3 Breast Ultrasound 
Breast ultrasound is one of the most common tools used for breast cancer detection. Since 
ultrasonography has lower specificity for breast cancer detection than mammography, it is 
primarily used as a diagnostic tool within a triple assessment process (Jan, Mattoo, Salroo, & 
Ahangar, 2010; Silverstein et al., 2009). The lower cost of ultrasound compared to 
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mammography is the main advantage of breast ultrasonography over mammography. Also, 
more detailed information about lesion size, boundary and blood circulation can be obtained 
by ultrasound (Wang et al., 2013). However, the high false-positive rate and the time 
required for ultrasonic examinations make breast ultrasonography unlikely to be a cost-
effective screening technique. Therefore, it is used as a supplementary screening tool for 
intermediate cancer risk women and for those with dense breasts (Kopans, 2007).  
Breast ultrasound depends on the production of longitudinal mechanical waves with 
frequencies higher than the audible range (20 - 20000 Hz). For medical imaging 1 - 15 MHz 
frequencies are used. In general, higher frequencies result in better resolution within the 
ultrasonic image so that more than 10 MHz frequency is often required for mammography. 
The scan head of an ultrasound system contains a number of piezoelectric crystals 
(transducers) which emit the ultrasound wave; they then receive the reflected back waves 
from the tissue. The reflected portion is used to determine the [acoustic] properties of the 
tissue. Then, the reflected ultrasonic waves are recorded over time to produce a two-
dimensional image called a B-mode image. Colour and power Doppler techniques are 
additional tools of diagnostic ultrasound. Both of them are of great importance in breast 
cancer detection because they give information about a lesion‘s vascularity. The principle of 
work for both is similar and depends on ultrasound frequency shift due to blood motion.  
Colour Doppler ultrasound gives information about the speed and direction of motion. Power 
Doppler ultrasound is more flow sensitive than colour Doppler but it does not give 
information about flow direction (Kopans, 2007; Whitman, Khisty, & Stafford, 2013).  
2.5.4 Breast Magnetic Resonance Imaging (MRI) 
Clinical MRI utilises a strong magnetic field to polarize the magnetic moment of water 
molecule protons in the body. Next, an oscillating magnetic field, within the radiofrequency 
range, is applied to rotate the magnetisation vector into a transverse plane to the magnetic 
field. This oscillating magnetisation is measured by a radiofrequency coil which gives the 
primary MRI signal (Lane, Stafford, & Whitman, 2013). The MRI signal produces high 
contrast cross-sectional images of breast tissue (Saslow et al., 2007). Similar to breast CT, in 
MRI procedures women should lie prone with their breast protruding in a specially designed 
platform. No breast compression is required. However, the MRI scan time is long, often up to 
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an hour, as in most cases contrast enhancement is required (ACS, 2015a). Breast MRI is 
widely used for screening high risk women and for pre/post-operative evaluation of breast 
cancers (Lane et al., 2013).  
2.6 Breast Cancer Screening 
Screening is an examination or test used to investigate the presence of a certain disease, such 
as cancer, in a group of healthy asymptomatic people (ACS, 2014). It may also be used to 
determine the people at high risk of a disease before they have it (Gøtzsche, Hartling, 
Nielsen, & Brodersen, 2012). The performance of any screening test is assessed by a study 
known as a screening trial which investigates whether the screening practice achieves its 
aims or not. The main purpose of screening is to reduce disease mortality in a screened 
population compared to that in an unscreened population (control group). This can be 
achieved by the early detection of the disease when recovery is still possible (Boyle, 2003). 
The biological onset of some diseases may precede its symptoms by months or even years. 
Breast cancer is considered one of these progressively developed diseases. It is believed that 
breast cancer starts with one malignant cell which proliferates to form the tumour (Finkel, 
2005). Symptomatic breast cancer is usually large and already metastatic. However, breast 
cancers detected by screening are mostly small and restricted within the breast (ACS, 2014). 
Accordingly, the early detection of breast cancer is undoubtedly useful (Baines, 2011; Gilbert 
et al., 2015). For the early detection of breast cancer many screening tests are used such as 
breast self-examination (BSE), clinical breast examination (CBE), mammography, MRI and 
breast ultrasound. 
2.6.1 Breast Self-Examination (BSE)   
Breast self-examination was first recommended in the 1930s as a breast cancer screening 
method (Ford et al., 1999). The Finnish study, based on Mama programme data, was the only 
study that reported breast cancer mortality reduction due to breast self-examination (Ford et 
al., 1999; Gastrin et al., 1994). However, all other randomised trials which have investigated 
breast cancer mortality reduction by breast self-examination concluded that there was no 
noteworthy reduction in breast cancer mortality. It may even increase the false-positive rate 
(Tirona, 2013). Therefore, most health organisations recommend against BSE, except the 
American Cancer Society (ACS) which recommended it optionally for women older than 20 
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years (Nelson et al., 2016). Some organisations recommend breast self-awareness (BSA) 
instead of BSE (Tirona, 2013). The aim of BSA is to teach the women, older than 20 years, 
about the normal look of their breast and encourage them to report any suspicious changes in 
their breast to health professionals as quickly as possible (ACS, 2014). 
2.6.2 Clinical Breast Examination (CBE) 
Clinical breast examination is usually done by experienced health professionals (ACS, 2014). 
In screening trials it has been found that CBE helps to reduce breast cancer mortality (Smith  
et al., 2003). The sensitivity of CBE for cancer detection is 54%, while its specificity is 94% 
(Tirona, 2013). CBE is recommended once every three years for women ages 20-40 who 
have an average risk of developing breast cancer, and annually for women older than 40 
years (ACS, 2013a). The clinical performance of CBE can also be evidenced by screening 
trial which took place in rural area of Sudan wherein 10309 women were screened by trained 
volunteers. This study reported that 12 women became disease-free after treatment. 
Accordingly, they concluded that CBE is a useful screening tool in low-income communities 
where other screening modalities are unavailable (Abuidris et al., 2013).  
2.6.3 Mammography Screening 
Mammography is the most important breast cancer screening modality. It is recommended by 
organisations in more than 35 countries worldwide. The recommendations of screening 
mammography are different in various countries. These differences are attributed to the age 
of breast cancer incidence in each population and to the results of screening trials upon which 
the programme‘s recommendations are designed (ICSN, 2015; Nelson et al., 2016; TOP, 
2013).  
The effect of adding three-dimensional DBT imaging to the screening process and its 
efficacy is the focus of many researchers (Ciatto et al., 2013). In some instances researchers 
have assessed DBT as a screening modality with a view to replacing the two-dimensional 
mammogram (Lang et al., 2016). More details about screening mammography including the 
screening starting age, frequency, justification and controversies will be discussed in section 
3.7 (page 53).   
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2.6.4 Magnetic Resonance Imaging (MRI) Screening  
In some countries MRI screening is recommended annually along with mammography for 
high breast cancer risk women because it has higher sensitivity for cancer detection than 
mammography (ACS, 2014). Nevertheless, it cannot replace mammography screening 
because of the lack of standards for MRI screening imaging procedures, interpretation and 
performance (whether it is cost-effective or not). Also, it is a very high cost procedure and 
requires a long examination time (Tirona, 2013).  
2.6.5 Ultrasound Screening  
Despite the high sensitivity of ultrasound for breast cancer detection, it is not recommended 
as a screening tool. This is because of the long examination time, its high false-positive rate 
and its image quality, which is variable depending on the examiner‘s skill (ACS, 2014; 
Nelson et al., 2016). The feasibility of using ultrasound for breast cancer screenings was 
investigated by Wang et al. (2013) in a rural area of China. They concluded that ultrasound is 
more sensitive than mammography for breast cancer detection in Chinese women younger 
than 55 years old, with lower cost and more convenience for breast screening in such areas 
(Wang et al., 2013).  
2.7 Chapter Summary  
In addition to mammography, there are many breast imaging modalities including CT, 
ultrasound and MRI. In regard to cost-effectiveness, none of these techniques can replace 
mammography as a screening tool but can be supplementary to it. Breast self-examination is 
no longer being recommended by many breast cancer care organisations, with self-breast 
awareness being recommended instead. Clinical breast examination is a useful method for 
the early detection of breast cancer but its feasibility is still limited when compared to 
mammography. Overall, until now mammography has been considered the gold standard in 
breast cancer screening.  
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Chapter Three 
Mammography: Development, Physics and Clinical Aspects 
 
3.1 Chapter Overview 
Mammographic technique is the main focus of this chapter. To begin with, the historic 
development of mammography, ranging from the production of early mammographic images 
to the development of the first dedicated mammographic machine will be reviewed. The 
radiation dose reduction achieved through the introduction of the mammography machine 
will also be highlighted. In general the radiation dose associated with mammography has 
reduced from approximately 150 mGy for early industrial non-screen film systems to less 
than 2 mGy for present day full field digital mammography (FFDM). In dedicated 
mammography machines, the use of a molybdenum anode X-ray tube has helped to improve 
image quality and reduce the radiation dose. Anti-scatter grids have also allowed an 
improvement in mammographic image quality but at the cost of an increased radiation dose. 
Beam collimators and breast compression further reduce the radiation dose and increase 
image quality.  
This chapter will also discuss the physical principles of the different digital image receptor 
types (e.g. direct and indirect conversion detectors), along with that of the FFDM machine. 
Improved breast cancer detectability at a lower radiation dose has been reported in the 
majority of screening performance trials for FFDM, when compared to film-screen 
mammography. The physical principle, instrumentation and clinical performance of digital 
breast tomosynthesis (DBT), which is the new generation of digital mammography, will also 
be considered. The addition of 3D tomographic images to 2D FFDM imaging has resulted in 
improved breast cancer detectability but with an increase in radiation dose.  
The last two sections of this chapter comprise of a comprehensive review of breast tissue 
appearances in mammographic standard images and screening mammography performance. 
Screening mammography trials used breast cancer mortality reduction as a measure of 
performance. A 20-30% reduction in breast cancer mortality has been reported by most 
screening trials. However, other researchers documented that the results of such screening 
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trials have been exaggerated. These results, alongside reports of over-diagnosis, have limited 
the net benefit from screening mammography. Despite the screening mammography 
controversy, many countries worldwide have organised screening programme since there is 
no strong evidence against screening mammography. The overall risk of radiation-induced 
cancer from screening mammography is reported to be small and as a result is not considered 
in the evaluation of breast cancer screening programmes.   
3.2 The Origins of Mammography Imaging – Equipment and Rudiments of 
Technique 
Concerns about breast disease were reported long before the discovery of X-rays (Wentz & 
Parsons, 1997). The first reported attempt to use X-rays for breast tissue imaging was by 
Salamon, a German surgeon, in 1913. He imaged 3000 mastectomy specimens observing the 
close correlation between the radiographic and pathologic abnormalities of breast tissue 
under investigation. He also described the radiographic appearance of malignant breast 
lesions. However, mammography only began being performed on patients from the mid to 
late 1920s in Europe, the United States, and South America where it helped to explain many 
breast abnormalities (Vyborny & Schmidt, 1989). The radiographic appearance of benign 
breast lesions and their distinctive features over breast carcinomas were reported by Walter 
Vogel (1931, as cited in Gold, Bassett, & Widoff, 1990). In the same year, Seabold (1931) 
documented his findings about breast disease detected by radiography. Work by Gershon-
Cohen  and Strickler (1938) described the normal radiographic appearances of breast tissue at 
different ages and across a range of menstrual conditions. The diagnostic information 
available from early mammograms was restricted due to technical limitations of the 
mammography equipment available in this period. This compelled many researchers to use 
different contrast agents such as gases for pneumocystography or iodinated compounds for 
ductography.  Many studies reported the adverse effects of such contrast agents (Romano & 
McFetridge, 1938). Therefore, to address these mammographic limitations, developments in 
mammography technologies were required (Vyborny & Schmidt, 1989). 
Early mammograms were performed using conventional radiography machines with tungsten 
anode tubes. Most of these tubes had a minimum energy level of 50 kVp, with some of them 
going down to 40 kVp (Law, 2006). Warren (1930) developed a stereoscopic system for in 
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vivo breast tumour identification. He utilised double sided emulsion film and dual high speed 
intensifying screens. Exposure factors of 60 kVp, 70 mA, and a 2.5s exposure time were 
used. Using his system, Warren (1930) investigated breast cancer in 119 preoperative 
patients and found that the mammographic false positives and false negatives were evident in 
6.7% of the examined patients. Following on from this work, many investigators started to 
develop mammographic techniques to improve the quality of the images. 
The correlation between radiographic calcification and breast cancer was first documented in 
a Spanish article by Leborgne in 1949 (as cited in Gold, Bassett, & Widoff, 1990).  The same 
report also highlighted the importance of breast compression for calcification visibility in 
mammograms. Another study published by Leborgne (1951) investigated the radiographic 
appearance of palpable breast cancers. He confirmed that the use of slight compression by a 
cotton pad placed between the breast and the cone, a conical tool made of copper and 
extended from the X-ray tube window down to the breast to collimate the X-ray bream, 
improved mammographic image quality. The different radiographic appearances of benign 
and malignant breast calcifications were also described by Leborgne (1951). In this study, 
Leborgne (1951) utilised 30 kV X-rays, non-screen films, a 60 cm focal-film distance, and 5 
mAs for each 1 cm of breast thickness. Breast compression, together with good collimation 
and the use of non-screen films, were further advocated by Ingleby and Gershon-Cohen 
(1960) as means by which to generate high contrast images. Gershon-Cohen also suggested 
the simultaneous exposure of two non-screens films with 0.5mm aluminium layer between 
them to overcome breast thickness non-uniformity. The aluminium attenuates the X-ray 
photons reaching the lower film and consequently the upper film which receives higher 
exposure will demonstrate the thicker juxtathoracic portion of the breast, and the thinner 
peripheral portion will be demonstrated by the lower (less) exposed film (Gold, Bassett, & 
Widoff, 1990).  
3.2.1 Early Developments of Image Receptor  
High quality breast images were produced by Egan (1960) who used high resolution 
industrial films (without an intensifying screen) with high current (300 mA), 6 seconds time 
and 26-28 kV X-ray. Egan (1960) also placed a lead shield under the film holder to protect 
the gonads from possible radiation. The industrial films were supplied in envelopes rather 
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than cassettes. The main advantage of these industrial non-screen films were that they 
produce fine detail with relatively lower patient exposure at the breast surface compared to 
conventional film-screen. The processing of industrial films was achieved by conventional 
wet (manual) techniques. In order to obtain more detailed mammograms, some centres used 
two films of different speeds in the same envelope. The low speed film was to demonstrate 
information within radiolucent areas, while the high speed film was to demonstrate 
information within denser areas (Law, 2006).  
Higher quality breast images, achieved due to edge enhancement, were produced in the 
1960s by using xeromammography. Gould, Ruzicka, Sanchez-Ubeda, and Perez (1960) 
reported the superiority of xeromammography over industrial non-screen film with regard to 
mammographic image quality (Gold et al., 1990; Odle, 2004). In xeromammography a thin 
sheet of photoconducting amorphous selenium contained within a lightproof cassette was 
used for image recording. After exposure, the breast image information was recorded on a 
charged selenium plate forming the latent image which becomes visible after it is dusted with 
thermoplastic powder. Next, plastic coated papers were used for the permanent recording of 
the image (Assiamah, 2004). The main advantage of xeromammography over direct film 
mammography was the possibility of obtaining more acceptable images using conventional 
radiography tubes with tungsten/aluminium targets/filters and at conventional kilo-voltages 
(~50 kVp)  (Huda, Nickoloff, & Boone, 2008; Vyborny & Schmidt, 1989). In addition to its 
use with conventional radiography machines, xeromammography can also be used with 
dedicated mammographic machines that use molybdenum/aluminium target/filter 
combinations.  However, xeromammography was replaced by the more efficient film-screen 
mammography in 1990 (Odle, 2004).  
Double-sided emulsion films with dual intensifying screens have been used in conventional 
radiography to record the image. In such systems the X-ray photons are more efficiently 
absorbed by the intensifying screen than by film, and are then converted into light photons 
which produce the image on the film (Vyborny & Schmidt, 1989). This process has the 
advantage of reducing patient dose by about 8 times, but it has the disadvantage of increasing 
image unsharpness (Huda et al., 2008). In order to reduce image unsharpness in 
mammography, single-sided emulsion film with a single thin intensifying screen is used, 
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because a thinner intensifying phosphor layer screen produces less image unsharpness. In the 
mammographic energy range the photoelectric cross-sections of intensifying screen phosphor 
are very high and result in efficient X-ray photon recording, even with the thin phosphor 
layer (Vyborny & Schmidt, 1989). Since each screen emits a narrow wavelength of light, the 
film had to be sensitive to that wavelength. Both the screen and wavelength-specific film 
were manually placed inside black plastic bags or envelopes in a darkroom. To achieve firm 
contact between them, the bag or envelope must be a sealed vacuum. This evacuation process 
was performed either manually or automatically. Manual evacuation was achieved through 
an opening supplied with a nozzle in one corner of the bag and a special hand pump - in this 
case the bags were reusable. Automatic evacuation was performed via a box which heat 
sealed the envelope after the evacuation of the air. For the latter, the bags could be reused 3-5 
times. This process was used until the late 1980s wherein the mammography cassettes were 
introduced (Law, 2006). 
3.2.2 Dedicated Mammography Machine Development 
Throughout the development of mammography, the key to producing the required high 
quality mammograms with an acceptable radiation dose was through the introduction of 
dedicated mammography machines (Odle, 2004). The earliest dedicated mammography 
machine was the Senograph. It was developed and tested in 1965 by Charles Gros in 
collaboration with Compagnie Generale de Radiographie (CGR) (Steen & Tiggelen, 2007). 
Senograph was subsequently marketed by CGR from 1967 (Nass, Henderson, & Lashof, 
2001). It was the first commercial mammography system with molybdenum/molybdenum 
target/filter combinations (Vyborny & Schmidt, 1989). For mammographic imaging, the 
useful part of the molybdenum X-ray beam is the characteristic radiation of molybdenum, 
because the energy of its K-edge characteristic radiation is approximately 20 keV, where the 
majority of its other characteristic radiations have energies around 19 keV. For a tungsten 
anode, the continuous X-ray beam with 10-20 keV is the useful portion for breast imaging 
because the characteristic radiations of tungsten have energies 69 keV and around 9 keV for 
the K and L edges (Law, 2006). The use of molybdenum target tubes resulted in the 
production of lower energy radiation with a more limited energy range than that produced by 
conventional radiography tubes. This resulted in optimum image contrast (Vyborny & 
Schmidt, 1989).  
 26 
 
The nominal focal spot size of the Senograph tube was 0.7 mm. This focal spot size reduced 
geometric unsharpness, which in turn improved the mammographic image quality by 
increasing the contrast between the glandular tissue, fat tissue, and calcification (Gold et al., 
1990). The X-ray tube stand and film holder of the Senograph were designed to facilitate 
optimum patient positioning during the examination (Vyborny & Schmidt, 1989). Moreover, 
a copper cone extending from the X-ray tube down to the breast was provided with 
Senograph. This cone offered advantages in scatter radiation reduction; it also helped in 
breast localisation. Cones of different shapes and sizes, semicircular and elliptical, were 
available to accommodate different breast sizes and shapes. In later generations of dedicated 
mammography machines both the collimation and compression devices were built in. In 
early dedicated mammography machines the compression device was an inflatable balloon 
within the cone and was pumped up after patient positioning (Law, 2006). 
3.2.3 Mammography Developments during the 1980s and 1990s 
During the 1980s and 1990s mammographic equipment improved greatly. For instance, the 
nominal focal spot size decreased to 0.2 mm and 0.5 mm for small and large foci (Law, 
2006). This reduction in focal spot size increased breast image sharpness by minimising 
geometrical unsharpness (Säbel & Aichinger, 1996). However, the use of such a focal spot 
size increases the tube thermal loading, resulting in potential for damage to the anode.  
Prolonged exposure times may reduce thermal loading but this brings with it an added risk of 
patient movement. In order to reduce this risk, rotating anode tubes were developed 
(Bushong, 2013). For additional image quality enhancement, mammography machines 
employed grids in order to reduce the scattered radiation which reached the film. However, 
these grids increased the patient radiation dose by 3 times or more. For mammographic 
purposes, the grids had 32 lines per inch with 5:1 grid ratios (Law, 2006). The air gap 
technique was developed as an alternative to the  grid but had the same disadvantage with 
regards to patient dose,  again increasing it by 25-30% (Jacobson, 2001). The later 
development of the magnification technique helped to clarify suspicious areas and 
microcalcifications without the need for the air gap technique (Säbel & Aichinger, 1996).  
Since the molybdenum/molybdenum target/filter combination was suitable for average 
breasts only, other target/filter combinations were introduced such as molybdenum/rhodium 
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(Mo/Rh), (rhodium/rhodium (Rh/Rh), and tungsten/rhodium (W/Rh). The target/filter 
combination is determined by compressed breast thickness and breast composition (density) 
(Law, 2006). Also, tubes with dual track anodes have been produced. One of these tracks was 
molybdenum and the other was either rhodium or tungsten. Filters are automatically selected 
depending on the track material. Automatic exposure control (AEC) was introduced to obtain 
a constant mean optical density regardless of breast thickness, breast composition and 
exposure factors. However, this was changed with the introduction of film-screen because 
mammographic image quality depends on the X-ray beam (Säbel & Aichinger, 1996). 
Ionisation chambers or other electronic X-ray detectors were connected within the exposure 
time control circuit; these were placed beneath the film cassette. When the required amount 
of radiation is reached the exposure is terminated automatically. Later, post exposure mAs 
meters were also added to the AEC (Law, 2006).  
Different film screen assemblies were then introduced with different film speeds (Law, 
2006). The sensitivity of the film-screen combination system is defined by a quantity called 
system dose. This represents the required air kerma to produce the receptor-specific exposure 
(Säbel & Aichinger, 1996). Since the required tube kVp for mammography is low (25-35 
kVp) when compared to general radiographic procedures, dedicated X-ray generators for 
mammography were introduced with tube voltages down to around 25 kVp in steps of 1 kV. 
Finally, in order to achieve more patient comfort and better image quality with less radiation 
dose, collimation and compression devices were developed. Motorised compression devices 
were introduced, and diaphragms, which are two pairs of adjustable lead hemistiches 
mounted within the X-ray tube behind the tube window with a light source to illuminate the 
X-ray field, were utilised instead of copper cones (Law, 2006; Statkiewicz-Sherer, Visconti, 
& Ritenour, 2010).  
3.3 Digital Mammography 
Currently there are two different types of digital mammography technologies (computed 
radiography and digital radiography) as well as conventional film-screen (Pagliari et al., 
2012). In regards to digital technologies, the image receptor replaces film-screen with the 
introduction of digital detectors (Ongeval, 2007). The digital detectors were initially used for 
general radiography but rapidly became integrated into mammography machine design 
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(Schueller et al., 2008). The changeover to digital radiography was not an easy process, as 
many issues had first to be considered; these included technical factors, patient management 
and image quality. Patient radiation dose was a concern during the changeover period 
because the dynamic range of digital detectors, which was wider than that of film-screen, 
result in an increase in patient radiation dose by as much as 40-103% (Lança & Silva, 
2009a). However, this wide dynamic range helped to improve the radiographic image quality 
(Uffmann & Schaefer-Prokop, 2009). 
The term full field digital mammography (FFDM) is used in literature with reference to both 
digital mammographic technologies. However, the term small field digital mammography 
(SFDM) is utilised to indicate breast imaging with stereoscopic biopsy (Pagliari et al., 2012). 
The first FFDM machine was approved for clinical use in 2000 by the Food and Drug 
Administration (FDA) in the USA (Mekasut, 2011).  
3.3.1 Types of Digital Mammography Detectors  
With regard to digital detector types, digital mammography systems are classified into two 
subsections: computed radiography (CR) systems; and digital radiography (DR) systems. The 
latter is subdivided into indirect and direct digital radiography (Lança & Silva, 2009a). 
However, other researchers who classified digital systems into direct digital radiography 
(DR) and indirect digital radiography systems which also include computed radiography 
(CR) (Mothiram, Brennan, Lewis, Moran, & Robinson, 2014).  
3.3.1.1 Computed Radiography (CR) 
CR was first introduced in the early 1980s (Lança & Silva, 2009a). This was the earliest 
digital technology employed for mammography (James, 2004). Here the photostimulable 
phosphor detectors, known as storage phosphor screens (SPS), were used instead of 
traditional films inside special cassettes. They were still standard size of film-screen cassettes 
(Lança & Silva, 2009a). These image detectors could be thus used with conventional X-ray 
systems (Testagrossa et al., 2012). Exposing SPS to X-rays resulted in an excitation process 
through the movement of valence band electrons to the conduction band, thereby forming the 
latent image as an electronic signal. The SPS was then scanned with a laser in the reader; this 
converted the latent image to blue light which was proportional to the amount of incident X-
ray on the SPS. Finally, a photomultiplier system in the reader converted the blue light to an 
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electronic signal which was then available as a digital dataset. To ensure that the SPS was 
free from any residual charge, it was then scanned with high intensity white light. Typically 
25% of the latent image was lost from the SPS within 10 minutes to 8 hours (James, 2004; 
Lança & Silva, 2009a). The main disadvantage of this type of digital detector is the lack of 
spatial resolution due to light scattering. Thicker phosphor layer detectors are more sensitive 
to radiation but more light scattering is produced (Testagrossa et al., 2012).  
3.3.1.2 Indirect Digital Mammography 
The initial digital mammography (DM) systems utilised indirect conversion detectors. In this 
type of detector the image capturing process was achieved in two steps, using charge couple 
devices (CCD). The first step includes the X-ray energy to light photon conversion, which is 
then converted to an electronic signal in the second step (Smith, 2005). The CCD technology 
involves the use of phosphor, and millions of optic fibers on coupling plates. The main 
function of the optic fibers is to transfer light from the phosphor to the CCD. This is then 
digitised (Pisano & Yaffe, 2005). The early CCD was limited to a small field size of 5 cm X 
5 cm. The success of these limited field size systems in digital spot mammography, for 
stereoscopic needle biopsy, led to the development of this technology in larger field sizes of 
1cm X 22 cm, using an array of four phosphor-CCD assemblies. These detectors were 
synchronised with a slit collimated X-ray beam to scan the breast perpendicularly to a 
patient‘s body producing 22 cm X 30 cm images (James, 2004). The required image 
acquisition time was about 6 seconds longer than that required by large area detectors. Due to 
slit collimation, the scattered radiation was reduced significantly thereby eliminating the need 
for a grid (Pisano & Yaffe, 2005).   
Amorphous silicon flat-panel detectors, commonly known as large area detectors, are another 
form of indirect digital radiography detectors. They were introduced to clinical use in the late 
1990s (Lança & Silva, 2009a). They were made of a thallium activated caesium iodide 
(CsI:Tl) phosphor layer acting as an X-ray absorber, and a light sensitive two-dimensional 
(rectangular) array of  photo-diodes. The incident X-ray beam on the detector is absorbed by 
the CsI:Tl layer releasing light photons. This light is then converted into an electronic signal 
by the photo-diodes. The electronic signal is then finally captured by thin film transistors 
(TFTs). Since the CsI:Tl crystals are designed in needle like channels and both the Cs and I 
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have high atomic numbers (for Cs Z=55 and for I Z=53), this technique exhibits high 
efficiency for X-ray absorption (80-90%). CsI:Tl light is in the green area of the light 
spectrum where the photo-diodes have relatively  high absorption efficiency (approximately 
80%) (Cowen, Kengyelics, & Davies, 2008). The principle advantage of this detector type is 
that it can be used for radiographic procedures which require rapid sequence imaging. 
However, its main limitations are the high cost, that format changing is difficult, and that the 
detector‘s element size cannot be easily reduced (Pisano & Yaffe, 2005). 
3.3.1.3 Direct Digital Mammography 
Amorphous selenium-based detectors avoid multiple conversions of X-ray photon energy, 
from light photons to an electronic signal, via direct X-ray conversion (James, 2004). This 
conversion process eliminates the light scattering problem associated with indirect 
conversion detectors. Direct conversion digital detectors are made from a layer of amorphous 
selenium (a-Se) mounted on the top of the image plate which consists of a regular matrix of 
storage capacitors and thin film transistors (Cowen et al., 2008). Before exposing the a-Se to 
X-ray, its surface is charged with a uniform positive charge. The uniform surface charge 
pattern is partially discharged when the X-rays are absorbed by the a-Se. The amount of 
discharge is proportional to the energy of the absorbed X-ray photons. This charge 
distribution forms the latent image as an electronic signal (James, 2004). This electronic 
signal is read by the thin film transistor array (NHSBSP, 2009). This type of detector is 
exemplary for use in digital mammography because its absorption efficiency is high, it 
produces high resolution images, and its dose efficiency is good (Qian, 2013).    
3.3.2 FFDM Performance  
Important features of digital mammography are the wide dynamic range, which is about 400 
fold compared to that of a film-screen system, and the linear relationship between the 
radiation dose reaching the detector and the signal intensity produced. Also, the inverse 
relationship between the radiation dose at the detector and the image contrast is eliminated 
because both image contrast and brightness can be separately optimised after image 
acquisition (Obenauer, Hermann, & Grabbe, 2003; Uffmann & Schaefer-Prokop, 2009). Also 
there are additional benefits of FFDM including easier archiving and easy-to-share image 
data (Silverstein et al., 2009). 
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In FFDM, the overall image quality is determined by spatial resolution, image contrast, 
signal-to-noise ratio, and dose efficiency (Smith, 2005). Since the image acquisition, display 
and storage are achieved separately in FFDM, the image optimisation process is different 
from that in film-screen (Park, Kim, Choi, Oh, & Kim, 2011). Accordingly, the FFDM 
allows the optimisation of image acquisition, display, and storage processes separately 
(Pisano & Yaffe, 2005). The optimisation of image acquisition is dependent on digital 
detector optimisation, selected X-ray spectrum (target/filter combination) and exposure 
factors (Park et al., 2011).  Digital detector characteristics that control the image acquisition 
process are field and pixel sizes, dynamic range, sensitivity, internal noise and readout 
(Lança & Silva, 2009b). National and European standards determine the required contrast 
resolution and the accepted radiation dose (European Commission, 2006; IAEA, 2011). They 
also proposed 100 µm as the maximum accepted pixel size and 18 ± 1cm X 24 ± 1cm as the 
minimum detector size to accommodate large breasts (Schulz-Wendtland, Fuchsjager, 
Wacker, & Hermann, 2009). For soft copy image display, two high resolution monitors (5 
megapixels) should be used (IAEA, 2011). This ‗reporting-grade‘ workstation should include 
software with a wide range of processing tools which enable image manipulation, such as 
image gray scale invert, window level and width change, zooming, edge enhancement, and 
measuring tools. Finally, the use of a picture archiving and communication systems (PACS) 
facilitates better digital archiving and sharing with others (teleradiology) (James, 2004; 
NHSBSP, 2009).  
It has been reported that digital mammography provides better contrast resolution with lower 
patient dose than film-screen systems (NHSBSP, 2009; Smith, 2005). The superiority of 
digital mammography has been investigated by many researchers. Work by Gennaro and di 
Maggio (2006) compared the mean glandular dose (MGD) of 300 film-screen cranio-caudal 
mammograms with 296 FFDM cranio-caudal mammograms. They found that the use of 
FFDM reduces MGD by about 15% for thin breast and 30-40% for thick breast. The main 
limitation of Gennaro and di Maggio‘s (2006) work was that they compared the MGD of 
images taken by one film-screen system with that of images taken by one FFDM machine; 
MGD variations of different systems were not considered. More recently, Hendrick et al. 
(2010) evaluated the technical performance of both film-screen and FFDM systems for 4366 
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women who underwent screening mammography by both techniques. They reported a 22% 
reduction in breast MGD with the use of FFDM.  
With regard to FFDM image quality evaluation, most researchers used breast cancer 
detectability as a means to investigate the performance of FFDM compared to film-screen, 
see Table (3-1). All of the studies in Table (3-1) concluded that the cancer detectability of 
FFDM was equal or better than that of film-screen. The mammographic image quality of 
FFDM was compared with that of film-screen for 200 women wherein one of their breasts 
was examined by FFDM and the other one by film-screen. The results of this work indicate 
equal accuracy for both FFDM and film-screen in some studied criteria, while the FFDM was 
more accurate in other criteria (Fischmann, Siegmann, Wersebe, Claussen, & Muller-
Schimpfle, 2005).    
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Table (3-1) A summary of the main screening trials which investigated the superiority of 
FFDM over FSM in breast cancer detection. 
Study Author Participants number Study results 
Chiarelli et al. (2013) 220520 women by DR, 64210 
by CR and 403688 women by 
FSM 
DR and FSM are equivalent, 
CR showed lower cancer 
detectability. 
Hambly et al. (2009) 
(INBSP
*
 Study) 
35204 women by FFDM and 
153619 women by FSM 
FFDM has significantly higher 
cancer detectability and recall 
rate.  
Vigeland, Klaasen, 
Klingen, Hofvind, 
and Skaane (2008) 
(Vestfold Study) 
18239 women by FFDM and 
324763 women by FSM 
FFDM has statistically 
significant higher cancer 
detection with fewer recalls due 
to technical issues. 
Heddson, Ronnow, 
Olsson, and Miller 
(2007) 
52172 two-view examinations 
of 24,875 women. 25901 by 
FSM, 9841 by photon counting 
DR, and 16430 by CR. 
DR has higher cancer 
detectability than FSM but this 
is statistically non-significant 
and significant lower recall rate 
and MGD.   
Del Turco et al. 
(2007) 
14385 women by FFDM and 
14385 women by FSM  
FFDM has greater detection 
rate but higher recall rate than 
FSM. 
Skaane , Hofvind, and 
Skjennald (2007) 
(follow up of Oslo II) 
16985 women by FSM and 
6944 women by  FFDM 
FFDM has significantly higher 
cancer detection rate. 
Pisano  et al. (2005) 
(DMIST
**
 trial) 
42760 women screened by both 
FFDM and SFM 
Both have equivalent 
detectability. FFDM more 
accurate for dense breast and 
(>50 years) women  
Skaane  and 
Skjennald (2004) 
(Oslo II trial) 
18054 women by FSM and 
7209 women by FFDM  
FFDM showed higher but non-
significant cancer detection 
rate. 
Skaane, Young, and 
Skjennald (2003) 
(Oslo I trial) 
3683 women underwent both 
SFM and FFDM (two view for 
each breast) 
Both FFDM and FSM showed 
comparable cancer detection 
rate. 
Lewin et al. (2002) 6736 women underwent both 
FSM and FFDM  
No statistical difference 
between them and fewer recall 
rate with FFDM. 
*Irish National Breast Screening Programme.  
 **Digital Mammographic Imaging Screening Trial. 
 
 
 
 34 
 
3.4 FFDM Physics and Instrumentation 
Mammography constitutes a real challenge for medical physics. It has to differentiate the 
attenuation coefficient of fat and glandular tissues with the lowest possible radiation dose. 
Accordingly, mammographic images have inherently low contrast and extremely high image 
resolution; about 15 lines pairs per mm is required (Hobbie & Roth, 2007). The conventional 
X-ray unit is not suitable to address these challenges, and specially designed dedicated 
mammography machines are required (Bushong, 2013). An example of a dedicated FFDM 
machine is shown in Figure (3-1). It has a ‗C‘ shaped assembly with changeable height and 
angular orientation to facilitate different mammographic positions. The upper arm of the 
assembly is where the X-ray tube is mounted, while the lower arm is where the breast 
support / X-ray image receptor is located. The distance between the X-ray tube focus and 
breast support is generally about 60 cm (Kotre & Reis, 2015). 
 
Figure (3-1) Shows the FFDM machine. 
3.4.1 X-ray Tube 
The X-ray tube is composed of a source of electrons (cathode) and a target (anode) where the 
electrons interact and convert their kinetic energy to electromagnetic radiation (X-ray). The 
electrons, before interacting with anode, are accelerated by high potential difference inside an 
evacuated tube (Bushberg, Seibert, Leidholdt, & Boone, 2002). X-ray photons generated by 
electron deceleration at the anode and are classified into two types - Bremsstrahlung X-ray 
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photons and characteristic radiation Figure (3-2). The former type (Bremsstrahlung) is 
produced when the electrons slow down and their energy is partly or wholly converted to 
[Bremsstrahlung] X-ray photons. Characteristic radiation is emitted when an electron 
interacts with an atomic electron within the anode and ejects it from its shell. Then the 
ejected electron vacancy is filled by an outer shell electron emitting X-ray photon whose 
energy is equal to the binding energy difference between the two shells (Montesdeoca, 2013). 
           
(a)                                                                          (b) 
Figure (3-2) Illustrates the X-ray production (a) Bremsstrahlung X-ray (b) Characteristic X-
ray. 
 
The anode of the mammographic X-ray tube can be made of tungsten (W), molybdenum 
(Mo), or rhodium (Rh) (Kotre & Reis, 2015). At energies required for mammographic 
imaging, the W X-ray spectrum is predominantly composed of Bremsstrahlung X-ray 
photons as well as L-shell 12-keV characteristic X-rays, which are not useful for imaging. 
The bremsstrahlung X-ray photons below 17 keV and above 24 keV are not particularly 
useful. However, the characteristic X-rays are the prominent portion of both Mo and Rh 
spectra (Bushong, 2013). The X-ray spectrum of the mammographic tube anode is optimised 
by adding filters which absorb the low energy photons, thus reducing the total number of 
photons but increasing the photons‘ average energy (Hendee & Ritenour, 2002). 
Mammography machines are therefore typically equipped with more than one target/filter 
combination to accommodate different breast thicknesses and densities (Bushong, 2013; 
Cunha, Tomal, & Poletti, 2012). Mo/Mo was the first target/filter combination used in 
dedicated mammography units; as time progressed other combinations were introduced such 
as Mo/Rh, Rh/Rh, W/Al, and W/Ag (Kotre & Reis, 2015).  
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The rotating anode design, with a small anode angulation, is employed in FFDM machines. 
This small angulation helps to reduce geometric image unsharpness by reducing the focal 
spot size (nominal focal spot) (Yaffe & Maidment, 2014). The typical nominal focal spot size 
of a mammographic X-ray tube is 0.3 mm and 0.1 mm for large and small foci (Bushong, 
2013). The large focus is usually used for conventional mammographic imaging, while the 
small one is utilised for magnified views (Kotre & Reis, 2015). Since less focal-object 
distance is used in magnification mammography, the geometric focal spot unsharpness is 
increased. To overcome this unsharpness, a smaller focal spot is required. However, the use 
of small focal spot increases the tube thermal load which is accounted for by the use of 
longer exposure time. This consequently increases the possibility of patient movement blur.   
Unlike the [helical] filament of a conventional imaging tube, the FFDM cathode filament is 
flat. The filament design results in a more focused electron beam to coincide with the 
required focus size (Smith  & Webb, 2011). In order to exploit the anode-heel effect, the X-
ray tube is positioned with the cathode toward the woman‘s chest wall so that the high 
intensity of the X-ray beam exposes the thicker side of the breast, while the thinner nipple 
side of the breast is exposed by the low intensity aspect of the beam (Yaffe & Maidment, 
2014). The X-ray tube is often tilted within the housing making the central ray parallel to the 
patient‘s chest wall. Such tilting helps to achieve an even smaller focal spot size and superior 
X-ray distribution, matching the different thicknesses of the breast regions, see Figure (3-3) 
(Bushong, 2013). In order to avoid excessive attenuation of the low energy X-ray beam, the 
glass exit window of the conventional imaging X-ray tube is replaced with beryllium. The 
beryllium window separates the evacuated area of the tube from the outer atmosphere 
directly; there is no oil or glass in the beam path (Yaffe & Maidment, 2014).  
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Figure (3-3) Shows the effect of the X-ray tube tilting inside the tube assembly (Bushong, 
2013). 
3.4.2 Breast Compression Device  
 Compression serves many purposes in conventional radiography and is extremely important 
in mammography (Bushong, 2013). The main purpose of breast compression in 
mammographic examination is to reduce breast thickness (Mercer, Hogg, Lawson, Diffey, & 
Denton, 2013). Reducing breast thickness has several advantages. Firstly, the image spatial 
resolution is improved by bringing the tissue closer to the image receptor, minimising 
magnification and maximising the impact of the focal spot size; both of which limit 
geometrical unsharpness (Bushong, 2013). Secondly, the reduced breast thickness results in 
less scattered radiation, this results in better image contrast through the reduction of scattered 
radiation (noise) (Yaffe & Maidment, 2014).  Thirdly, the reduction of breast thickness helps 
to improve image contrast by making the low energy photons, which are sometimes scattered 
when dealing with thick breast tissue, useful in the mammographic image formation process 
(Kotre & Reis, 2015). Finally, reducing breast thickness decreases the breast radiation 
absorbed dose because less radiation is required to penetrate thinner breasts. More image 
quality refinement can be obtained through breast compression due to better image 
uniformity, via uniform breast tissue distribution, and lessened motion blur by minimising 
the woman‘s movement during exposure (Bushberg et al., 2002). Also, as mentioned by 
Hogg, Szczepura, Darlington, & Maxwell (2013), the breast compression ameliorates the 
image contrast by spreading the breast tissue which in turn reduces the tissue 
superimposition. 
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Compression is not without its problems. Work by Mercer, Hogg, Lawson, et al. (2013) 
investigated the compression magnitude applied for 488 women by 14 practitioners. Mercer, 
Hogg, Lawson, et al. (2013) found that, for individual practitioner the applied compression 
magnitude may be affected by breast density, less compression was used for higher BI-
RADS women, and breast volume, wherein more compression is needed for large breasts. 
However, practitioners do not utilise the same mean breast compression. This variability in 
breast compression magnitude between practitioners was further confirmed by Mercer, Hogg, 
Szczepura, & Denton (2013) who assessed the compression force for 500 screening clients 
across three successive screening visits. It has been reported that for a client‘s three visits, the 
variation in compression force applied by same practitioner was not statistically significant. 
However, significantly different compression force was applied by different practitioners for 
the same client (Mercer, Hogg, Szczepura, & Denton, 2013). More extensively Mercer et al. 
(2015) analysed the compression force applied in three screening sites within the UK.  
Mercer et al. (2015) concluded that, with regard to applied breast compression the 
practitioner behavior was different within and between centres. 
Since compression force variations affect the breast thickness of the client, the MGD is also 
different. According to Brnic and Hebrang (2001), the analysis of required mAs in relation to 
different breast thicknesses in MLO projection showed that when the average breast 
thickness for 52 women decreased, through compression, from 50.3 mm to 47.0 mm, the 
average required mAs reduced from 49.5 to 44.1. This reduction in required mAs will reduce 
breast MGD. The effect of mAs on MGD will be further discussed in section 7.3.1 (page 
182). Overall, until now there has been no exact magnitude for the required breast 
compression, but it has been reported that the greater the compression, the better the image 
quality and lower patient dose. However, this can result in patient discomfort (Bushong, 
2013).  
All dedicated mammographic machines are supplied with a breast compression device, a 
rigid plate of radiolucent material driven by a motor. The compressed breast should be as 
uniform as possible. At the chest wall the compression plate edge should be horizontal and 
adjusted with both X-ray tube focal spot and image receptor (Yaffe & Maidment, 2014). The 
mammographic machine is usually supplied with a range of compression paddles. Each 
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paddle is designed for a specific purpose. The basic compression paddle is flat and rigid. This 
paddle is parallel to the image receptor so it can apply uniform force to the whole breast. A 
tilting paddle, also known as a flexible paddle, applies more compression at the chest wall 
side resulting in better breast fixation in mammographic position. For small breast imaging, a 
sliding compression paddle is suitable. This paddle has a smaller size than the image receptor 
and can be moved from one side to another. Smaller compression paddles are used for both 
spot views and magnification examinations. Finally, a biopsy compression paddle has an 
aperture for a biopsy needle (Kotre & Reis, 2015). 
Breast thickness is nonuniform. It is thicker closer to the chest wall than when compared to 
the nipple side. In order to compensate for this the compression paddle is usually tilted 
during breast compression. Paddle tilting results in variations in the breast thickness readout 
accuracy for fixed and flexible paddles. For fixed paddles, the readout variations for 20 
women for both CC and MLO projections, along with the variations‘ effect on breast density 
assessment, were determined by Diffey et al. (2008). A maximum readout variation of 21.2 
mm was reported by Diffey et al. (2008). On average the use of indicated breast thickness 
resulted in underestimation of 10.5% in breast volume and this affects the accuracy of 
volumetric breast density calculation.  
However, Hauge et al., (2012) extended their work to consider the readout variations across 
the paddle area of both fixed and flexible paddles of different sizes (18 X 24 cm and 24 X 30 
cm) for 8 mammographic machines (3 FSM and 5 FFDM). For these eight machines, Hauge 
et al. (2012) found that the flexible paddle resulted in greater readout variations (16 mm and 
10 mm for small and large paddles) across the paddle area than fixed paddle (5mm and 5.3 
mm for small and large paddles). Overall, the maximum thickness readout variation reported 
by Hauge et al. (2012) was 13 mm. These variations were different for each of the studied 
machines, both between and within different equipment brands. In the work by Hauge et al. 
(2012) the effect of thickness readout variations on MGD was also discussed. They found 
that breast thickness readout variation may result in up to 20% difference in calculated MGD.  
More variations in MGD may be introduced if the thickness readout variation leads to a 
different target/filter combination selection.  
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3.4.3 Grid  
In mammography not all of the X-ray photons which pass through the breast carry 
anatomical information about the breast. Some of the photons escape the breast without 
interaction and others scatter within the breast tissue and emerge from the breast at different 
angles to their entry. The latter photons possess a range of energies. It has been found that, at 
the kVp values used in mammography, about 40% of the photons which leave the breast are 
scattered radiation (Yaffe, 2010). The ratio of scatter to primary radiation determines the 
reduction amount in both image contrast and sharpness. The best method to minimise the 
effect of scatter is by using anti-scatter grids which absorb them (Qian, 2013). However, the 
use of anti-scatter grids has the disadvantage of increasing radiation dose because they also 
attenuate the primary beam (Bushberg et al., 2002). In FFDM machines the grid is integrated 
within the breast support above the image receptor. Most FFDM machines have a focused 
moving grid with 4:1 to 5:1 grid ratio. Grid ratio refers to the height of the lead strips relative 
to the width of the interspace between two strips. Grid movement during exposure is 
necessary to blur the lead strips image out of the mammogram. A 40 lines/cm is the typical 
grid frequency for mammography (Bushong, 2013; Yaffe & Maidment, 2014).  
3.4.4 Automatic Exposure Control (AEC)  
In mammography, precise estimation of the required exposure factors is not easy. This has 
led to the development of AECs, also known as photo-timers (Bushong, 2013; Yaffe & 
Maidment, 2014). In FFDM the aim of using AECs is to optimise the mammographic image 
quality (image contrast and noise) and patient radiation dose. The photo-timer is composed of 
one or more radiation detectors, ionisation chambers or solid state detectors, positioned just 
after the image receptor to detect the amount of radiation passing through the receptor. When 
they reach the required level, the exposure is terminated (Bushberg et al., 2002). Beam 
quality is determined by tube voltage and target/filter combination. The algorithm for this 
uses compressed breast thickness and transmitted exposure rate. The latter can be determined 
by very short exposure called pre-exposure. In modern mammographic machines, the digital 
image receptor itself works as an AEC depending on the information obtained by short low 
dose pre-exposure (Kotre & Reis, 2015; Qian, 2013). Although the radiation dose of this 
small pre-exposure increases the overall radiation dose, the image acquired from this pre-
exposure may not be incorporated in the final mammographic image (IAEA, 2011).   
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The performance of AEC, with regard to mammographic image quality and MGD, was 
investigated by Young, Ramsdale, Rust, & Cooke (1997) and Young, Ramsdale, & Rust 
(1996). Young et al. (1997) compared the mammographic image quality and MGD of 
standard 28 kV with automatically selected kV for Mo/Mo target/filter combination of 
Philips MammoDiagnost 3000 mammographic machine within NHSBSP service. They 
concluded that the automatic kV selection resulted in slightly better image quality with a 
slight increment in MGD. However, Young, Ramsdale, & Rust‘s (1996) work compared the 
mammographic image quality and MGD of the standard 28kV with automatically selected 
kV of different target/filter combination (Mo/Mo, Mo/Rh, and W/Rh), using a Siemens 
Mammomat 3000 machine. They found that the automatic kV selection showed 
approximately comparable image quality and MGD for thin breasted clients. For thick 
breasted clients (60 mm and more), however, the use of AEC reduced the average MGD 
from 2.9 mGy to 1.87 mGy with a small reduction in image quality (Young, Ramsdale, & 
Rust, 1996). Currently, the European Commission (2013) documents that the mammographic 
machine should be equipped with full AEC, thus neither the systems with only manual or 
semi-AEC, which select the target/filter combination and kV value only, are permitted.  
3.4.5 Generator  
High frequency generators are typically used for FFDM. This type of generator is 
characterised by its small size, fast response, stability and lack of voltage ripples (Bushberg 
et al., 2002). It is a single-phase system which rectifies the AC input into DC voltage, which 
is then fed to a special circuit where it is changed to a high frequency (5-10 kHz). The 
resulting ripple in tube voltage is about 1%. Mammographic generators are usually designed 
to produce a maximum of 600 mAs in order to avoid the excessive radiation dose to the 
patient (Bushong, 2013).     
3.4.6 Digital Mammographic Viewing Workstations 
The final stage of the digital mammographic examination is image display and interpretation 
(Wang & Geiser, 2013). The FFDM unit is supplied with two different types of viewing 
workstations. The first is the acquisition workstation, and the second is the reporting 
workstation. The acquisition workstation display is of lower quality (e.g. 3 megapixel) and is 
used by the practitioners to assess mammographic image quality. The reporting workstation, 
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however, is typically supplied with two specialist medical-grade 5 megapixel monitors 
(IAEA, 2011). A wide range of software options are available within the reporting 
workstation. These include: magnification; windowing in which both image contrast and 
brightness can be manipulated; image rotation and flip; image window inversion 
(black/white) to view both image negative and positive; measurements such as size, area and 
angle; spatial resolution filtering, which helps in image noise reduction and edge 
enhancement. All of these software tools have the advantage of post-acquisition image 
processing, allowing for mammographic image quality improvement without additional 
patient radiation dose. This is one of FFDM‘s main advantages over conventional FSM 
(James, 2004; Kotre & Reis, 2015).  
3.5 Digital Breast Tomosynthesis (DBT) 
Mammography is an essential imaging modality for breast cancer detection with about 85% 
sensitivity and 90% specificity (Destounis & Gruttadauria, 2015). It has been reported that 
mammography‘s ability to detect breast cancer reduces as breast tissue density increases. In 
fact, 41% of breast lesions in high density breasts images are obscured by breast tissue 
(ALMousa, Ryan, Mello-Thoms, & Brennan, 2014).  Mammography can detect about 80-
90% of breast cancers in low density breasts and 50-60% in dense breasts (Baptista et al., 
2014; Thomassin-Naggara et al., 2015). Reduced cancer detectability in dense breast tissue is 
a result of the tissue overlapping with the tumours in two-dimensional mammographic 
images (Blue Crossand Blue Shield Association, Kaiser Foundation Health Plan, & Southern 
California Permanente Medical Group, 2014; Diekmann & Bick, 2011). To overcome this 
problem in 2D FFDM images, a three-dimensional imaging technique known as digital breast 
tomosynthesis (DBT) has been developed (Smith, 2012). 
DBT is derived from the conventional tomography technique which depends on the relative 
motion of the X-ray source, image receptor and patient (Gilbert et al., 2015; Thomassin-
Naggara et al., 2015). The theoretical background and the earliest practical tomographic 
systems were introduced in the 1930s (Mertelmeier, Speitel, & Frumento, 2012). However, 
the first DBT images were produced by Niklason et al. (1997) around 1-2 years before the 
widespread clinical use of FFDM (Palazuelos, Trujillo, & Romero, 2014; Sechopoulos, 
2013a). Niklason et al. (1997) used the breast tomographic technique of moving X-ray tube 
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and fixed image receptor to scan the phantom of the American College of Radiology (ACR) 
and four mastectomy samples. Both types of image receptors, film-screen and digital flat 
panel detectors, were utilised in this study. They reported superior lesion visibility of 
tomographic three-dimensional images when compared to that of two-dimensional FFDM 
images for three samples, and comparable lesion visibility by both techniques for the last 
sample. The main purpose of using DBT is therefore to produce a series of low-dose 
mammographic images with high spatial resolution (per one mammographic projection), 
enabling visualisation of the breast tissue in slices. This results in the minimisation or 
elimination of breast tissue overlap. Consequently, the shape and size of tumours can be 
clearly delineated (Destounis & Gruttadauria, 2015). The total MGD of one DBT projection 
is more than that of one FFDM projection but less than that of two FFDM projections 
(Destounis & Gruttadauria, 2015). Overall, the DBT MGD of 4.5 cm PMMA phantom was 
20% higher than the MGD of FFDM for the same phantom (Strudley, Looney, & Young, 
2014).  
3.5.1 DBT Physics and Instrumentation 
DBT is a recently developed technique based on digital mammography (Palazuelos, Trujillo, 
& Romero, 2014). The image acquisition geometry of DBT is similar to that of FFDM with a 
moving X-ray tube at regular angular intervals, in a plane around the compressed breast 
which rests on static support. The X-ray tube movement range is different for each 
manufacturer. During exposure, the image receptor is either fixed or rotated to keep it 
perpendicular to the X-ray tube (Feng & Sechopoulos, 2012; Sechopoulos, 2013a). Several 
DBT prototype machines have been introduced by different manufacturers. Examples of 
these include GE Essential, Hologic Selenia Dimenssion, IMS GiottoTOMO, Philips 
MicroDose, Planmed Nuance Excel, and Siemens MAMMOMAT Inspiration. All of these 
machines have the same purpose but each has its specific characteristics. So far, the Hologic 
Selenia Dimensions machine is the only one that has been approved in America by the FDA, 
in 2011 (Destounis & Gruttadauria, 2015; Sechopoulos, 2013a).   
3.5.1.1 Image Acquisition 
The DBT machine has the same structure as FFDM units, consisting of an X-ray tube 
mounted within the arm, a breast compression paddle, a breast support and a digital image 
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receptor (Sechopoulos, 2013a). The only difference between FFDM machines is that the 
DBT X-ray tube, as well as the image receptor in some DBT brands, can rotate across an arc 
of 11
o
 to 50
o
 during exposure, depending on manufacturer design, see Figure (3-4). This 
produces between 9 and 25 images (Lim & Maxwell, 2015). For instance, the Hologic 
Selenia Dimensions has a range of 15 degrees, between -7.5 and +7.5 degrees. It generates 15 
images per view (Feng & Sechopoulos, 2012). The image acquisition process is achieved 
either by continuous exposure during X-ray tube movement, or pulsed exposure at each angle 
of tube movement. Shorter acquisition times are required for the continuous method, 
however lower image resolution can result due to motion blur. For both methods the 
acquisition time ranges from 3s to 25s per single view (Lim & Maxwell, 2015). The image 
acquisition time should be minimised to be as short as possible to avoid patient movement 
blur. For DBT imaging the required X-ray energy is slightly higher than that for FFDM. 
Therefore, the spectra of a tungsten target with Al, Rh, or Ag filters are typically used 
(Sechopoulos, 2013a; Yaffe & Maidment, 2014).   
The Sectra MicroDose from Philips is a different DBT machine design which is based on the 
slit-scan photon counting technique. In this machine, a collimated fan shaped X-ray beam 
and multi-slit linear detector are used to scan the compressed breast across an arc 
(Sechopoulos, 2013a). The geometry of this machine is completely different to that of other 
DBT units. The focal-image receptor distance of this machine is 66 cm. Also, there is a 1.93 
cm gap between the breast support and the image receptor. The rotation centre is located 104 
cm below the focal spot level (Dance, Young, & van Engen, 2011). The main advantages of 
Sectra MicroDose unit over the traditional DBT units are that less electronic noise is 
produced, there‘s a lower patient radiation dose of about 1/20, and it can determine the 
energy of a transmitted X-ray photon which is useful for both breast absorption 
measurements and breast composition (Schmitzberger et al., 2011). However, the main 
disadvantage of this machine is that it cannot be used to acquire conventional two-
dimensional images (Sechopoulos, 2013a).         
Gilbert, Young, Astley, Whelehan, and Gillan (2010) documented in NHSBSP publication 
#69 that the breast compression in DBT is the same as in FFDM and they preferred to 
achieve them both in one compression. However, a Monte Carlo study by Saunders, Samei, 
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Lo, and Baker (2009) found that a 12.5% reduction in breast compression during DBT 
examinations results in approximately the same MGD and constant lesion conspicuity for 
both breast microcalcification and mass. Work by Förnvik et al. (2010) investigated the 
effect of half compression force on image quality during DBT examination for 45 women. 
They reported equivalent image quality for both compression values. A comparable effect of 
half breast compression on image quality for 130 Malaysian women has been obtained by 
Suhaimi, Mohamed, and Ahmad (2015). Overall, more studies are required to consider the 
effect of breast compression reduction in DBT on both image quality and patient radiation 
dose. 
3.5.1.2 DBT Image Reconstruction  
The tomographic images are reconstructed from the series of projections through filtered 
back projection or iterative reconstruction algorithms (Sechopoulos, 2013b). The image 
reconstruction process is achieved by shifting the projection images with respect to the frame 
of the image. Therefore, the structures at the specific plane are visualised in the same place, 
at the frame. Then the images are added together, reinforcing the contrast of the structures‘ 
image in the selected plane and blurring out the structures in other planes. Figure (3-5) 
illustrates the tomosynthesis image reconstruction process, (Kotre & Reis, 2015). 
Tomosynthesis produces the highest spatial resolution in the planes and poorer resolution 
between them. The limited range of acquisition angles in DBT makes the data of the 
tomosynthetic projection less complete than computed tomography (CT). Therefore, the 
tomosynthesis reconstructed images are pseudo three-dimensional images of breast tissues 
(Yaffe & Maidment, 2014).     
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  Figure (3-4) Demonstrates the image acquisition process in DBT (Kotre & Reis, 2015).  
 
 
Figure (3-5) Demonstrates the image reconstruction process in DBT (a) In the level of circle 
plane and (b) In the level of square plane (Kotre & Reis, 2015). 
3.5.2 Clinical Performance of DBT (for both diagnosis and screening) 
DBT images are produced in the standard conventional 2D mammography projections 
(cranio-caudal and medio-lateral oblique) in the form of slices, similar to computed 
tomography (CT) (Skaane, 2012; Tagliafico, Tagliafico, & Houssami, 2013). The clinical 
improvement of DBT was first demonstrated using phantoms and mastectomy images 
(Gilbert et al., 2010). Many researchers have investigated the clinical benefit of DBT for 
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screening and diagnostic purposes (Skaane, 2012). Table (3-2) details the studies that 
investigated the effect of integrated DBT with 2D FFDM on breast cancer detectability, 
recall rate, and the time required for imaging. Overall, the majority of these studies 
concluded that the addition of DBT to 2D FFDM resulted in better cancer detectability, lower 
recall rates, more details about the lesion size and location, and longer acquisition and 
interpretation times when compared to just using 2D FFDM.  However, the work by Lang et 
al. (2016) was the only one which examined the use of DBT alone for screening purposes. 
Lang et al. (2016) reported that one-view (MLO) DBT screening of 7500 women showed a 
statistically significant increase in both breast cancer detection and recall rates, while this 
recall rate is still acceptably low. Accordingly, they suggested that for breast cancer 
screening the use of one-view DBT alone might be suitable (Lang et al., 2016). 
The diagnostic performance of DBT for breast mass characterisation compared to that of  
spot-view mammograms and supllemental diagnostic mammograms was considered by 
Noroozian et al. (2012) and Zuley et al. (2013). Noroozian et al. (2012) evaluated DBT 
images and spot-view mammographic images in 67 breast masses. In this study both DBT 
and spot-view mammography showed similar diagnostic efficacy in terms of mass visibility 
and BI-RADS assessment. The main limitation of this work was the small number of 
radiologists (four) who read the images. However, statistically significant higher diagnostic 
accuracy of DBT images was reported by Zuley et al. (2013) compared to supplemental 
dianostic mammograms. The conclusions of  this work were based on the image evaluation 
of 182 women who underwent both diagnostic 2D FFDM and DBT (Zuley et al., 2013). 
Regardless of the purpose of DBT usage (screening or diagnostic), it demonstrates the breast 
tissue architecture more clearly than 2D FFDM, especially in dense breasts (Destounis & 
Gruttadauria, 2015). 
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Table (3-2) Lists the studies that investigated the clinical performance of DBT compared 
to digital mammography (DM). 
Study Author Study Population Study Results 
Gur et al. (2009) 
125 examinations 
by both DM and 
DBT  
DM+DBT resulted in 30% reduction in recall 
rate, DBT showed 10% (non-significant) 
reduction in recall rate. Comparable sensitivity 
for DM, DBT, DM+DBT. 
Kopans, Gavenonis, 
Halpern and Moore 
(2011) 
119 women with 
breast calcification  
DBT can demonstrate the breast calcification 
with equal or better clarity compared to DM. 
Michell et al. (2012) 
738 symptomatic 
women  
Addition of DBT increases the accuracy of 
screen-detected soft-tissue mammographic 
abnormalities.  
Bernardi et al. (2012) 
20 for acquisition 
time,100 cases for 
each DM, 
DM+DBT 
DBT+DM increase both the acquisition and 
interpretation times. 
Mun et al. (2013) 
173 malignant 
breast lesions  by 
both DM and DBT 
DBT is significantly better than DM in the 
evaluation of small lesion size and this 
superiority increase with dense breasts.  
Haas et al. (2013) 
13158 women, 
6100 of them 
receive DBT in 
addition to DM 
Significant reduction in recall rate with 
DM+DBT especially for younger than 50 years 
and dense breast, 9.5% non-significant 
increment in cancer detectability.  
Rafferty et al. (2013) 
1192 women by 
both DM and DBT 
DM+DBT resulted in significant increase in 
diagnostic accuracy and significant decrease in 
recall rate. 
Rose et al. (2013) 
13856 examination 
by DM, 9499 by 
DM+DBT 
DBT result in significant decrease in recall rate 
and increase cancer detection rate especially in 
invasive cancer. 
Ciatto et al. (2013) 
(STORM study) 
7292 women by 
both DM and DBT 
DBT significantly increase breast cancer 
detection and can reduce recall rate. 
Skaane  et al. (2013) 
(Oslo trial) 
12621 women by 
both DM and DBT  
DBT significantly increase cancer detectability 
and decrease the false-positive rate.  
Dang, Freer, 
Humphrey, Halpern 
and Rafferty (2014) 
1502 by DM+DBT 
and 2163 by DM  
The use of DBT with DM in screening increase 
the interpretation time. 
Friedewald et al. 
(2014) 
281187 by DM, 
173663 DM+DBT 
DM+DBT results in decrease in recall rate and 
increase in cancer detection rate. 
Thomassin-Naggara 
et al. (2015) 
155 lesion 
diagnosed by DM, 
DBT, biopsy 
The addition of DBT improves breast cancer 
detection by reducing the percent of 
undiagnosed cancer.  
Gilbert et al. (2015) 
(TOMMY trial) 
7060 women 
screened by both 
FFDM and DBT  
Borderline significant increase in sensitivity (p 
= 0.07) from  87%  for DM to 89% for 
FFDM+DBT, the difference increase for 
invasive cancers & dense breast 
Lang et al. (2016) 
MBTST(Malmo trial)  
7500 screened by 
MLO DBT &  DM 
One-view DBT has significant increase in 
cancer detection and recall rate.  
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3.6 Anatomical Characteristics of the Breast in Mammographic Images 
In mammograms, the breast tissue pattern is primarily created by the shadow of fatty 
components as well as the functional element (glandular tissue) of the breast (Kopans, 2007). 
The differential radiographic contrast of these elements enables X-ray breast imaging to 
occur (Wentz & Parsons, 1997). Breast composition differs among women, through the 
relative proportions of fatty and glandular tissue, the higher the proportion of glandular 
tissue, the more dense the breast. Since the glandular tissue attenuates X-ray more than 
adipose tissue, the radiolucent fat arises as dark areas, whereas dense glandular tissue appears 
as light areas, see Figure (3-6) (Boyd  et al., 2007; Boyd et al., 2010). However, these 
attenuation differences are small, therefore high contrast mammographic imaging systems 
are required to make breast anatomy visible (Wentz & Parsons, 1997).  
As was noted in section 3.5.2 (page 46), mammography examinations may require 
supplementary views in addition to the two basic CC / MLO views (Yankaskas & Gill, 
2005). The basic mammographic views were the CC and lateral, used until the late 1970s 
wherein the MLO view was first described by Lundgren (1977). The MLO view depended on 
the anatomical fact that when the arm is raised the breast will appear continuous with the 
pectoral muscle in caudo-medial direction (Lundgren, 1977). It has been found that the use of 
single-view mammography results in a higher recall rate and leads to reduction in 
mammographic breast cancer detectability, wherein 11% - 25% of breast cancers can be 
missed (Kopans, 2007).  The radiation dose limit for standard mammographic views was 
determined by the European Commission, IPEM and NHSBSP to be less than 2.5 mGy per 
image (European Commission, 2006; IPEM, 2005; Strudley et al., 2014). Since the pectoral 
muscle is displayed in MLO view, the breast MGD is more than in CC view. This MGD 
difference between CC and MLO may be up to 30% (Gomes et al., 2011). 
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Figure (3-6) Breast MLO image illustrates the radiographic appearance of different breast 
tissues (Darlington, 2015).  
Breast imaging is performed while the breast is compressed onto the image receptor. As 
mentioned in section 3.4.2 (page 37), breast compression helps to improve image quality and 
reduces the breast radiation dose (Kita, Highnam, & Brady, 1998). The compression should 
be sufficient to prevent the slip of breast tissue during exposure but not too much as to cause 
patient discomfort. Sometimes, pain may result from skin pinch during compression; in this 
case the compression should be stopped and released (Kopans, 2007).   
3.6.1 Cranio-caudal (CC) Projection 
CC projection is one of the routinely obtained projections when using conventional, two-
dimensional breast X-ray imaging (Kopans, 2007). In CC projection, the X-ray beam is 
directed to enter the superior aspect of the breast and leave through the inferior aspect. The 
image receptor is positioned parallel in the horizontal orientation and perpendicular to the 
central ray (Magnus, 1995). The breast should be positioned on the AEC device. CC 
projection is used to visualise the beast tissue as a whole, except the most lateral and axillary 
portion (European Commission, 2006). The ideal CC projection should visualise several 
important anatomical structures including: the sharp shadow of the pectoral muscle on the 
border of the image; the shadow of retro-mammary fat tissue; the medial and lateral 
glandular tissue without folds; a symmetrical view of the right and left breasts; and the nipple 
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seen in profile, Figure (3-7) (Gomes et al., 2011; European Commission, 2006). Another 
positioning consideration when producing CC images is to set the height of the breast support 
correctly in relation to the infra-mammary angle (Smith, Szczepura, Mercer, Maxwell, & 
Hogg, 2015; European Commission, 2006). The typical compressed breast shape in CC 
projection is semi-circular with approximately 10 cm between the nipple and the chest wall 
and an approximate breast base length of 20 cm for an ‗average‘ woman (Feng , Patel, & 
Sechopoulos, 2013). The average compressed breast area in the CC projection, which was 
assessed in 880 British women by Diffey (2012), was 157.6 cm
2
. A similar result (157.3 cm
2
) 
was reported by Boone, Lindfors, Cooper, and Seibert (2000).  
 
1. Represent the shadow of pectoral muscle. 
2. The shadow of retro-mammary fat line. 
3. Shadow of medial breast tissue. 
4. Lateral glandular tissue shadow. 
5. Nipple shadow in profile. 
 
  
Figure (3-7) Shows a diagram of the breast anatomical criteria that should be seen in typical 
CC projection (IAEA, 2005). 
3.6.2 Medio-lateral Oblique (MLO) Projection  
The MLO projection visualises the whole breast tissue in one view; especially the supero-
lateral part of the breast which is more commonly affected by cancer than other breast parts 
(Magnus, 1995). For this reason the MLO projection is chosen for DBT imaging. The typical 
MLO projection should image the breast from the axilla down to include the infra-mammary 
angle. Unlike other radiography areas, the word oblique in mammography refers to the breast 
compression plane (Kopans, 2007). Much more care is required to produce MLO images 
than CC images because an imperfect MLO projection affects the image quality criteria more 
than that in CC (IAEA, 2005). In MLO projection, the X-ray beam enters the breast through 
supero-medial aspect and leaves it through the infero-lateral aspect (Magnus, 1995). The 
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image receptor is set at an angle of approximately 45
o
 from horizontal, but can range from 
40
o
 to 60
o
 depending on the woman‘s body habitus (Mercer, Hill, Kelly, & Smith, 2015). 
According to the European Commission (2006), the breast anatomical criteria that should be 
seen in MLO images are: the infra-mammary angle, although the visualisation of this angle 
as a whole is affected by breast size , it is strongly related to breast positioning; supero-lateral 
glandular tissue, this criteria can be easily achieved; the shadow of nipple and retro-glandular 
adipose tissue; the symmetrical image of both breasts with no recognised skinfold; the 
reproduction of the pectoral muscle in the image angle, which is one of the most important 
anatomical criteria to indicate the correct positioning in MLO projection, see Figure (3-8) 
(Gomes et al., 2011; Bentley, Poulos, & Rickard, 2008; European Commission, 2006). In the 
upper posterior margin of the image, the pectoral muscle should be visualised as a triangular 
shadow with a mean value of its length and the width at approximately 140 mm and 46 mm 
(Spuur, Poulos, Currie, & Rickard, 2010). The shape and size of the pectoral muscle in the 
mammogram image generally depends on individual body variations, thorax length and 
muscle development, and positioning angulation (Bentley, Poulos, & Rickard, 2008). The 
breast area demonstrated in the MLO mammogram is greater than that in CC by 
approximately 17.7 cm
2
 (Diffey, 2012). Kunosic (2012) stated that in MLO projection the 
mean compressed breast thickness is 20-23% higher than that in CC projection, but other 
researchers found that this increment to be around 5mm (Dellie, Rao, Admassie, & 
Meshesha, 2013; Helvie, Chan, Adler, & Boyd, 1994; IAEA, 2005).  
 
 
1. Shadow of pectoral muscle. 
2. Infra-mammary angle. 
3. Superio-lateral glandular tissue. 
4. Shadow of retro-glandular fat tissue. 
5. Shadow of the nipple in full profile.  
 
 
Figure (3-8) Shows a diagram of the breast anatomical criteria that should be seen in typical 
MLO projection (IAEA, 2005). 
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3.6.3 Supplementary Mammographic Projections  
Diagnostic mammography can include extra projections in addition to the standard 
projections (CC and MLO). These supplementary mammographic projections are usually 
performed for either symptomatic women with palpable breast abnormality, breast discharge, 
painful breasts, or abnormal skin changes, or for women with suspected or positive screening 
results (Yankaskas & Gill, 2005). Due to chest geometry, the extreme medial and extreme 
lateral tissues of the breast cannot be included in the CC/MLO standard mammographic 
projections, and supplementary projections are usually utilised to investigate the lesions in 
these aspects of the breast (Kelly, 2015; Kopans 2007).  However, these increase patient 
radiation dose by 3.9 - 5.2 mGy depending on the number of projections (Destounis & 
Gruttadauria, 2015).  
3.7 Screening Mammography 
Early diagnosis and treatment of breast cancer is the key to reduce mortality. Mammography 
is considered to be a cost effective technique for the early detection of breast cancer and for 
many years it has remained to be the recommended modality for both diagnosis and 
screening (Nsiah-Akoto, Andam, Adisson, & Forson, 2011). Screening mammography 
involves the evaluation of asymptomatic women with the intention of detecting impalpable 
breast cancer early in its growth, when recovery is still possible (Kopans, 2007). The first 
attempt to use X-ray breast imaging as a tool for the early detection of breast cancer was in 
1960 by Robert Egan. He used mammography and clinical breast examination to screen 2000 
healthy asymptomatic women and identified occult carcinoma in 53 of them (Nass et al., 
2001).  
The suitable measure for screening mammography benefit is its contribution to the reduction 
in breast cancer mortality (Marmot et al., 2013). The first screening mammography trial to 
show a reduction in breast cancer mortality, by using mammography only, was the Swedish 
two-county trial which demonstrated a reduction of 30% in breast cancer mortality among 
women aged between 40 and 74 years (Tabár et al., 2011). The most reliable information 
about screening mammography is provided by the randomised controlled trials. In Table (3-
3) all the randomised trials of mammographic breast cancer screening are summarised. Since 
a very long time is required for follow up in these trials, most of the randomised controlled 
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trials for screening mammography assessment are from the 1980s and earlier. However, 
many developments in breast cancer treatment and diagnosis (mammography) have occurred 
since this work (Marmot et al., 2012). Therefore, the effect of screening mammography has 
continuously been investigated by many researchers throughout the world as time has 
progressed.  
Table (3-3) Summarises the common randomised trials of mammographic breast cancer 
screening. 
Screening trial 
Trial 
start 
date 
Participant 
age range 
(year) 
Breast cancer mortality reduction 
New York Health 
Insurance Plan (HIP) 
(Shapiro, 1997)  
1963 40-69  
25% reduction in breast cancer mortality 
for women aged 40–49 and 50–59 at time 
of entry. 
Malmö trial 
(Andersson et al., 1988) 1976 44-68  
Mortality reduction is age dependent; no 
overall reduction but 20% reduction for 
women aged 55 year and older. 
Swedish Two-County 
(Tabár et al., 2011) 
1977 40-74 
30% reduction in breast cancer mortality 
resulted from screening mammography. 
Edinburgh trial 
(Alexander et al., 1994) 1978 45-64  
20% reduction in breast cancer mortality 
resulted from screening mammography 
for women 50 years and older.  
Canada trial  
(Miller et al., 2014) 
1980 40-59  
No resulted reduction in breast cancer 
mortality due to screening mammography. 
Stockholm trial  
(Frisell, Lidbrink, 
Hellstrom, & Rutqvist, 
1997) 
1981 40-64  
In women 40-49 year there was tendency 
for mortality reduction, 50-64 year 
women showed better survival with 
screening mammography.  
Göteborg  trial 
(Bjurstam et al., 2003) 
1982 39-59  
20-30% reduction in breast cancer 
mortality and this reduction may be 
achieved for younger than 50 year old 
women by short screening interval.  
UK Age trial  
(Moss et al., 2015) 1990 39-41  
Annual screening mammography for 
women 40-49 year results in mortality 
reduction. 
 
The recurrent evaluations of the Swedish two-county trial outcome data demonstrated that 
the relative breast cancer mortality remained constant despite the continuous increase in 
breast screening invitations. However, the absolute number of lives saved due to screening 
has increased with time. This is because long screening time is required to reduce the breast 
cancer mortality. Accordingly, long-term follow up is necessary to prove the benefit effect 
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from screening on breast cancer deaths. Overall, a significant and substantial reduction in 
breast cancer mortality due to screening mammography has been reported by the latest 
update of Swedish two-county trial (Tabár et al., 2011). These results are consistent with 
outcome data of other screening trials (Shapiro, 1997; Andersson et al., 1988; Alexander et 
al., 1994; Frisell, Lidbrink, Hellstrom, & Rutqvist, 1997; Bjurstam et al., 2003; Moss et al., 
2015). The Canadian screening trial was the only one which documented that screening 
mammography does not affect breast cancer mortality (Miller et al., 2014).  
In the UK, Marmot et al. (2012) assessed the performance of the UK mammography 
screening programme by reviewing the results of 11 relevant randomised trials. Marmot and 
his colleagues concluded that the UK mammography screening programme should continue 
as it resulted in approximately 20% reduction in breast cancer mortality. In the US, the ACS 
(2013a) reviewed evidence too, along with the International Agency for Research on Cancer 
(IARC)(2015) and the US Preventive Services Task Force (Nelson et al., 2016). They 
illustrated that screening mammography significantly reduces breast cancer mortality for 
women aged 50-69 years. The Norwegian mammography screening programme invites 
women aged 50-69 years for biennial screening mammography. The effect of this on breast 
cancer mortality was studied on four groups of women by Kalager, Zelen, Langmark, and 
Adami (2010). They reported that only one third of the reduction in breast cancer mortality 
was due to screening mammography and the other two thirds were attributed to the 
improvement in breast cancer management and treatment. Consequently, the absolute 
reduction in breast cancer deaths resulting from the Norwegian mammography screening 
programme was attributed as 10%.  
Gotzsche and Jorgensen (2013) reviewed and critically analysed data from the 
mammography screening trials and the meta-analysis studies; they documented that breast 
cancer mortality reduction is mainly due to the improvement in breast cancer awareness and 
treatment and a minor reduction was brought about by mammography. They also reported 
that breast cancer mortality reduction is not a reliable measure for screening mammography 
performance because of overdiagnosis and overtreatment which may result in unnecessary 
mastectomies and deaths. Accordingly, they recommended the reassessment of screening 
mammography because of the errors associated with published screening trials and 
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overdiagnosis. Similarly, work by Harding et al. (2015), who investigated the breast cancer 
incidence and mortality in the US counties over 10 years (2000 - 2010), reported that the 
prominent effect of screening mammography in US population was overdiagnosis and the 
breast cancer mortality reduction was not significant. Harding et al. (2015) built their 
conclusions on the fact that there was no reduction in the rate of large breast cancers 
detection. To this day breast cancer screening remains a controversial area (Gøtzsche & 
Jørgensen, 2013; Independent UK Panel on Breast Cancer Screening, 2013).  
Since the introduction of screening mammography there have been ongoing debates about its 
harms versus its benefits. Djulbegovic and Lyman (2006) stated that screening 
mammography could not be recommended unless its benefits outweigh its harms.  However, 
several disadvantages of screening mammography have been identified in literature. Firstly, 
its false negative rate, which is its inability to detect all breast cancers. Secondly, its false 
positive rate (wrong diagnosis), which results in time wasted in extra examinations and 
undesired anxiety. Finally, overdiagnosis, which results in the treatment of low risk breast 
cancers that may not always cause health problems (Gøtzsche, Hartling, Nielsen, & 
Brodersen, 2012; Jin, 2014; NHSBSP, 2003). The performance of any screening programme 
should be assessed by three important parameters. These parameters are sensitivity, 
specificity, and the positive predictive value. Programme sensitivity is the proportion of truly 
diagnosed cancer cases to the total number of actual cancer cases in the participants. 
Programme specificity is defined as the ratio of women truly identified without cancer. 
Positive predictive value is the ratio of the actual number of cancer cases against the number 
of abnormal cases detected by the programme. These parameters can be calculated using the 
following equations (Forrest, 1986; Nass et al., 2001): 
            
                             
                                        
 
 
            
                   
                                         
 
  
 57 
 
                          
                   
                                        
 
 
The performance of any screening programme depends on the participant‘s age (Jin, 2014). It 
has been found that annual screenings from 20-29 years of age may result in more radiation-
induced cancer deaths than it prevents (Berrington de Gonzalez & Reeves, 2005). For women 
aged under 39, screening mammography is not recommended due to the low breast cancer 
incidence rate within this age group and the lack of evidence of cancer death reduction 
(Toward Optimized Practice [TOP] Working Group for Breast Cancer Screening, 2013). A 
reduction in breast cancer mortality of 4 deaths per 10000 screened women is achieved for 
women aged 40-49 years and 5-8 per 10000 women for the 50-59 years age group. The 
highest reduction, 12-21 cases per 10000 screened women, occurs in women aged 60-69 
years (Nelson et al., 2016). The importance of screening mammography in breast cancer 
death reduction extends to women aged 70-74 years (IARC, 2015). The net benefit of 
screening mammography is also related to lifetime risk of radiation-induced cancer, which is 
an age dependent factor because younger tissues are more radiosensitive. According to 
NHSBSP (2003), the risk of radiation-induced breast cancer reduces from 16 per million per 
mGy to 4.2 per million per mGy as women‘s age increase from 40 to 75 years.   
Some researchers consider that the reduction in breast cancer mortality of less than 10%, by 
screening mammography, has no net benefit because of the radiation risk. Consequently they 
do not recommend screening mammography before the age of 50 years (Berrington de 
Gonzalez & Reeves, 2005; Djulbegovic & Lyman, 2006). This has added another 
controversial point of screening mammography. In this context, the recommendations of the 
Swedish mammography screening programme were changed twice by the National Board of 
Health and Welfare in Sweden (Olsson et al., 2000). The first change was in 1987 to exclude 
women aged 40-49 years from screening mammography and the second, in 1998, re-included 
them in the screening programme (Lind, Svane, Kemetli, & Tornberg, 2010). Malmgren, 
Parikh, Atwood, and Kaplan (2014) studied the screening outcomes of 1162 women aged 75 
years and older. They found that for this age group the obvious mammographic cancer 
detectability is comparable to that of younger women (younger than 75 years). Beyond the 
age of 50 years the risk of radiation induced cancer is considered acceptable due to the 
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reported benefits of screening mammography (Agt, Fracheboud, Steen, & Koning, 2012; 
Dellie et al., 2013). This relates directly to the central aim of this thesis; which has been 
considered in section 1.2 (page 1). Overall screening trials demonstrated a 20% - 30% 
reduction in breast cancer mortality due to screening mammography. Consequently, the risk 
of radiation-induced cancer from screening mammography is considered small and 
acceptable when compared to this mortality reduction. 
The risk-benefit argument resulted in the introduction of organised mammography screening 
programmes in many countries. It must also be noted that the recommendations for screening 
mammography differ between countries. These differences are related to the age of screening 
commencement, cessation age of the screens, and the time interval between screens, Table 
(3-4). The majority of mammography screening programmes (i.e. Belgium, Croatia, Cyprus, 
Denmark, Finland, Germany, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, 
Slovenia, Spain / Catalonia, Switzerland) include women aged 50-69 years. However, other 
countries (i.e. Australia, Canada, Iceland, India, Japan, Korea, Nigeria, Sweden, United 
States, and Uruguay) extend screening mammography to those at 40 years and may continue 
after 70 years. The New Zealand, Portuguese, and Spine (Navarra) mammography screening 
programmes cover women aged 45-69 years. Because of the early incident breast cancer in 
China, women aged 40-59 are invited for screening mammography. Biennial screening 
mammography is recommended by most of the mammography screening programmes except 
in the United States, United Kingdom, Malta and China. The US recommends annual 
screening and the others recommend triennial screening (Lerda et al., 2014; ICSN, 2015). 
 The effect of the screening frequency change from annual to biennial was studied by 
Coldman et al. (2008) in British Columbia. They used the data from the mammography 
screening programme of British Columbia (SMPBC) between 1988 and 2005. In the first 
decade of SMPBC (1988 -1997) annual screening was recommended. However, after July 
1997 SMPBC had started to invite women for biennial screenings. Coldman et al. (2008) 
analysed the data of 658151 women to compare breast cancer detectability and mortality 
during these two periods. They found that this alteration in mammographic screening 
frequency affected neither the breast cancer detection rate nor the mortality rate. 
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Table (3-4) Illustrates the recommendations of mammography screening programmes in 
different countries across the world for women with an average risk of developing breast 
cancer (Lerda et al., 2014; ICSN, 2015). 
Country(s) 
Age of 
screening 
Time interval 
between screens 
Number 
of screens 
Australia, Japan, Korea, United State 
(AAFP, NCI, and USPSTF) 
40-75 2 years 18 
Belgium, Croatia, Cyprus, Denmark, 
Finland, Germany, Italy, Latvia, 
Lithuania, Luxembourg, Norway, Poland, 
Slovenia, Spain (Catalonia), Switzerland 
50-69 2 years 10 
Canada , France, Israel, Netherlands 50-74 2 years 13 
China 40-59 3 years 7 
Czech  44-75 2 years 16 
Estonia  50-62 2 years 7 
Hungary 45-65 2 years 11 
Iceland 40-69 2 years 15 
India  
40-74 
1 year (40-49) 
2 years (50-74) 
23 
Ireland 50-64 2 years 8 
Malta 50-60 3 years 4 
New Zealand, Portugal, Spain (Navarra) 45-69 2 years 13 
Nigeria 40-70 2 years 16 
Sweden 
40-74 
18 months (40-49) 
2 years (50-74) 
19 
United Kingdom 47-73 3 years 9 
United State (ACOG) 
40-75 
2 years (40-49) 
1 year (50-75) 
31 
United State (ACS, ACR, and NCCN) 40-75 1 year 36 
Uruguay 
40-69 
2 years (40-49) 
1 year (50-69) 
25 
 
All the above explained screening categories in Table (3-4) are recommended for average 
breast cancer risk women. Some mammography screening programmes exclude high risk 
women, considering them as special cases (e.g. the Australian programme) (Cancer 
Australia, 2014), while other programmes have a specially designed screening category for 
them, (e.g. Canada, US and UK programmes), see Table (3-5) (ACS, 2013b; ICSN, 2015; 
Nelson et al., 2009; NHSBSP, 2013b). Some programmes also use other imaging modalities 
for screening, for instance ultrasound or magnetic resonance imaging in addition to screening 
mammography (NHSBSP, 2013).   
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Table (3-5) Illustrates the recommendations of mammography screening programmes in 
different countries across the world for women with a high risk of breast cancer (ACS, 
2013b; ICSN, 2015; Nelson et al., 2009; NHSBSP, 2013b). 
Country(s) 
Age of 
screening 
Time interval 
between screens 
Number 
of screens 
Canada  
40-74 
1 year (40-49) 
2 years (50-74) 
23 
United Kingdom  40-73 1 year 34 
United State (ACS) 30-75 1 year 46 
United State (NCCN) 25-75 1 year 51 
 
In the UK, the Forrest report (1986) recommended the introduction of single view (MLO) 
screening mammography for women aged 50-65 years with an interval of 3 years (Forrest, 
1986). In 1988, the NHSBSP started to invite women aged 50-64 years for MLO, triennial 
screening mammography. In 2000, the NHS Cancer Plan proposed additional expansion in 
NHSBSP by using two views (MLO and CC) in screening mammography and extending the 
screening age to include women aged 64-70 years (NHSBSP, 2006). The latest age extension 
in NHSBSP commenced in 2012, to include women aged 47-73. This age extension was 
predicted to be completely implemented by 2016 (NHSBSP, 2014). These extensions 
approximately duplicated the number of screens within a woman‘s lifetime and hence the 
cumulative MGD is duplicated also. The consequent increase in risk of radiation-induced 
cancer is mainly attributed to earlier screening commencement because breast tissue radio-
sensitivity decreases with age (NHSBSP, 2003).  According to NHSBSP (2013b) publication 
#74, high risk women should be invited for annual screening mammography from 40 years 
old.   
In 2009, the US Preventive Services Task Force changed their recommendation of screening 
mammography to be biennial for women aged 50-74 years (Nelson et al., 2009). However, 
the American Medical Association, American College of Radiology, American Cancer 
Society, and National Comprehensive Cancer Network have considered the annual screening 
mammography starting from 40 years old to be superior (Nelson et al., 2016). For high risk 
women, such as those with a family history of cancer, the American Cancer Society stated 
that annual screening mammography should start at 30 years old and continue as long as the 
women were in good health (ACS, 2013b). Nevertheless, the National Comprehensive 
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Cancer Network (NCCN) and the American Academy of Family Physicians (AAFP) 
recommended that the annual screening mammography for high risk women should 
commence either at 25 years old or from the earliest age of cancer onset in the client‘s family 
(5-10 years before the youngest breast cancer case in the family) (Tirona, 2013; Vetto, Luoh, 
& Naik, 2009). Screening frequency recommendation is critical as it directly relates to the 
mammographic radiation risk; the radiation risk of annual is twice that of biennial screening.  
Since breast tissues younger than 40 years are very radio-sensitive, mammographic radiation 
of early high risk women screening should be considered carefully. Early screening 
mammography radiation risk causes an additional breast cancer lifetime risk for women 
younger than 40 years.   
3.8 Chapter Summary  
Since the first use of X-rays for breast tissue imaging, a great development has been made in 
both mammographic equipment and techniques. In the early stages the main purpose of these 
developments was to produce better mammographic images (improve mammographic image 
quality). After that, the researchers started to consider both mammographic image quality and 
patient radiation dose. The most revolutionary development was the production of a 
dedicated mammography machine. This machine‘s use of Mo/Mo target/filter combinations 
reduced breast radiation dose and improved mammographic image quality. The introduction 
of other target/filter combinations (Mo/Rh, W/Rh) led to further reductions in radiation dose 
without affecting the mammographic image quality. Although the use of anti-scatter grids 
improved image quality, they increased the patient radiation dose. Both image quality and 
patient dose were improved with developments in breast compression devices. Finally, the 
development of image recording methods from conventional radiography films to 
xeroradiography and industrial films, then finally to film-screen decreased the radiation dose 
several times. After this the introduction of digital detectors resulted in more image quality 
and a lower radiation dose. 
Although FFDM has better breast cancer detectability than film-screen mammography, 
FFDM still has the same limitations as film-screen. DBT has been developed to overcome 
the 2D image limitation by producing pseudo 3D images of the breast tissue. Many 
controversial points about screening mammography have been identified in the literature. 
 62 
 
The most controversial point is the net benefit of screening mammography due to the high 
reported overdiagnosis rate. Another is the screening programme design (starting / cessation 
ages and frequency of screening). These controversies lead to major differences in screening 
mammography recommendations throughout the world. Surprisingly the radiation risk 
variation due to recommendations differences is not considered. Overall, mammography has 
been considered as a cost-effective technique for breast cancer screening, and the radiation 
risk, which generally related to MGD, is minimal and accepted. 
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Chapter Four 
Mammography Dosimetry 
 
4.1 Chapter Overview  
This chapter will demonstrate the dosimetric considerations of mammography, including a 
general background about the risk of radiation-induced cancer and the minimal radiation dose 
for this risk occurrence. In this context, the two models, linear no-threshold and threshold, 
are discussed. Literature from different data sources (e.g. childhood cancers following early 
life irradiation, cancers following recurrent CT examinations, and cancer incidence in 
medical radiation workers and in high radiation background areas residence) are reviewed to 
investigate the reliability of these two models. Mammography dosimetry is then discussed in 
regard to three areas: MGD, its importance and limitations, with the corresponding 
calculation methods; the radiation dose for other organs from mammography; and the 
effective dose and effective risk from screening mammography. 
The last three sections of this chapter contain detailed explanations about mammography 
dosimetric tools, including Monte Carlo simulation software, direct dose measurement 
instruments and breast tissue equivalent materials, respectively. Monte Carlo simulation 
software is of great importance in mammographic studies. In addition to its importance in 
dosimetric studies, to obtain MGD conversion factors, Monte Carlo simulation software is 
used to develop three-dimensional mammographic imaging modalities (e.g. digital breast 
tomosynthesis and dedicated breast computed tomography). Monte Carlo simulation 
softwares are available in different forms and several of them can be used in mammographic 
studies, especially those designed to simulate electron/photon transport (e.g. PENELOPE and 
MCNPX (Di Maria et al., 2011). Different dose measurement instruments are utilised in 
dosimetric studies (e.g. ionisation chambers, semiconductor detectors, thermo-luminescence 
detectors, and optically stimulated luminescence dosimeters), and each type of these 
dosimeters are suitable to be used in different circumstances. For instance, thermo-
luminescence detectors are more likely to be used for in vivo dose measurement due to their 
small size and tissue equivalency. Since mammography examination uses ionising radiation 
(X-ray), dose measurement experiments cannot be directly performed on patients. Therefore, 
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breast tissue equivalent materials are used to make breast phantoms necessary for assessing 
MGD. Different breast tissue equivalent materials and their properties are discussed in the 
last section of this chapter. 
4.2 Risk of Low Radiation Dose 
According to epidemiologists, the term ―risk‖ is utilised to describe the association of data 
(cancer incidence and radiation exposure) in two different styles: relative risk, which is the 
ratio of cancer incidence rate in an exposed population to that in an unexposed population; 
and absolute risk, which is the simple rate of cancer incidence in a specific population (NAS, 
2006). Several methods can be used to express radiation lifetime risk:  
1) ELR (Excess Lifetime Risk), which compares cancer incidence or mortality in two groups 
of the same population - one of them is [theoretically] exposed to radiation and the other is 
not;  
2) REID (Risk of Exposure Induced-Death), which compares the death rate of specific causes 
in [theoretically] unexposed and exposed groups of a certain age and gender;  
3) LLE (Loss of Life Expectancy), which gives an impression of the period of life lost due to 
radiation;  
4) LAR (Lifetime Attributable Risk), which gives an account of excess mortality or incidence 
of cancer over a study period, with the backgrounds defined by a [theoretically] unexposed 
population (ICRP, 2007). 
The radiation risk refers to the damage produced by ionising radiation due to energy 
deposition in tissues. This energy may result in ionisation within the tissues if the photons 
pass near an orbital electron and provide sufficient energy for the electron to be liberated 
from the atom (Statkiewicz-Sherer, Visconti, & Ritenour, 2010). The amount of damage is 
related to radiation dose, type of radiation, whether it is internal or external, time of 
exposure, radiation distribution (type of exposed tissue), and the individual‘s sensitivity 
which is influenced by gender and age (HPA, 2011). Females are at higher risk of radiation-
induced cancer than males (Balonov & Shrimpton, 2012). Younger patients are at a higher 
risk because they have a longer remaining life span. For example, the risk of radiation 
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damage for a 20 year old patient is twice that of a 40 year old patient. The latter has double 
the risk when compared to a 60 year old patient. The radiosensitivity of young children is 3-4 
times more than that of adults (Lin, 2010).  
In general, the radiation interactions with tissue are either direct, wherein the radiation 
energy is directly transferred to the DNA causing structural changes in its molecules; or 
indirect interaction, where the radiation energy is absorbed by water molecules forming free 
radicals which in turn cause damage to DNA molecules. It has been found that for X-rays 
with 100 mGy, 30-40% of the DNA damage is due to direct interaction and the remaining 
60-70% of the damage results from indirect interactions (Suzuki & Yamashita, 2012). The 
adverse health effects of radiation can be classified into two groups: deterministic effects, 
which follow high radiation doses and result in relatively immediate and predictable tissue 
reactions and damage (this damage can occur within minutes, hours, days and even weeks); 
and stochastic effects, which follow low radiation doses and may result in cancer 
development (ICRP, 2007). Development is based on probability. The lag period between 
irradiation and cancer development for stochastic effects is at least 5 years and may reach to 
10 or 20 years (Lin, 2010).  
Stochastic effects usually occur due to mutations in DNA which occur randomly. In general, 
the probability of stochastic effects‘ occurrence increases as the radiation dose increases. The 
dose-response curve determines the probability of stochastic effects‘ occurrence, with 
radiation dose being the root cause. Both linear and linear-quadratic dose-response curves are 
used to describe the relationship. However, the severity of the resultant disease is not related 
to radiation dose because the cancer produced by a 2 Sv radiation dose is not more severe 
than cancer produced by 0.2 Sv radiation dose. Stochastic effects are classified into radiation-
induced cancer and reproductive cell damage, which affects sperm and ova and causes 
defects in offspring (Statkiewicz-Sherer et al., 2010). For radiological doses ranging from 5 
to 100 mSv, data from life-span studies (LSS) of atomic bomb survivors revealed that the 
risk of radiation-induced cancer was strongly related to the radiation dose received. However, 
for lower doses and since more than 60% of the LSS cohort received radiation doses between 
5 and 100 mSv, no strong evidence is available to describe the relationship between the risk 
of radiation-induced cancer and these low doses (Brenner, 2014).          
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Persistent controversy exists in literature regarding the risk of radiation-induced cancer from 
low dose ionising radiation. This creates a big challenge for epidemiological studies. In this 
context the controversy arises in questions about the dose threshold of cancer production, 
linearity and gradient of dose-response curves (Griffey & Sodickson, 2009). Overall, there 
are two opposing risk models to estimate the risk of low radiation doses. The first adopts the 
linear no-threshold principle. According to this model any dose, however small, can result in 
cancer incidence. However, the second model proposes that there is a specific threshold for 
radiation-induced cancer and below this threshold the radiation dose can be considered as 
safe (Prasad, Cole, & Hasse, 2004). Although, the ICRP (2007) and the National Academy of 
Sciences (NAS) (2006) have adopted the linear no-threshold (LNT) model, United Nations 
Scientific Committee on the Effects of Atomic Radiation UNSCEAR (2008) considered the 
LNT to be uncertain at radiation doses less than 100 mSv and it is no longer recommended 
for radiation-induced cancer assessment from such doses. This motivates many researchers to 
investigate the reliability of this model using different data sources.  
Dobrzynski, Fornalski, and Feinendegen (2015) evaluated the risk of radiation-induced 
cancer and early childhood death for populations living in regions with different natural 
background radiation. They concluded that the risk of radiation-induced cancer due to such 
small doses and dose rates tends not to exist or is lower than expected by the LNT model. 
This can be explained by the adaptive physiological mechanism of tissues. In conclusion, 
Dobrzynski et al. (2015) found that for low doses and low dose rates, the LNT model is 
likely to be exaggerating the risk of radiation-induced cancer (Dobrzynski et al., 2015). The 
analysis of LSS cohort data for participants who received radiation doses ranging between 0-
150 mSv illustrated that the risk of radiation-induced solid cancers is linear but at less than 
100 mSv the cancer incidence increment is statistically insignificant (Suzuki & Yamashita, 
2012).  
The feasibility of the LNT model has also been investigated using cancer risk data in children 
after diagnostic and/or therapeutic radiation exposure (Kleinerman, 2006; Linet, Kim, & 
Rajaraman, 2009). Kleinerman (2006) reviewed several major studies that investigated 
childhood cancers following benign disease radiation treatment and diagnostic procedures. 
This study reported that the rates of brain, thyroid, breast, skin (non-melanoma) cancers, and 
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leukemia, were seen to be increased due to childhood irradiation. He also found that cancer 
risk increases with dose increment (Kleinerman, 2006). More recently Linet et al. (2009) 
highlighted studies that investigated the association of maternal prenatal and postnatal 
newborn irradiation with childhood cancers. They stated that the data about this relationship 
is limited and more research is required (Linet et al., 2009).  
Some investigators evaluated the low dose risk of radiation-induced cancer in patients 
subjected to recurrent CT scan examinations. A retrospective cohort study for the assessment 
of CT examinations‘ subsequent risk of radiation-induced leukemia and brain tumours was 
carried out by Pearce et al. (2012). Pearce et al. (2012) analysed data for patients younger 
than 22 years who had attended CT scan examinations within the UK NHS between 1985 
and 2002, with the follow-up process continuing until the end of 2008. They found that when 
patient radiation cumulative dose increased from 5 mSv to approximately 50 mSv the relative 
risk of radiation-induced leukemia became 3.18, and 2.82 for brain tumours when the 
cumulative dose increased from 5 mSv to approximately 60 mSv. Similarly, Mathews et al. 
(2013) evaluated the cancer incidence in 680,211 patients (0-9 years old) who had undergone 
CT scan examinations between 1985 and 2005 with follow-up until 2007. A 24% increase in 
different tissue cancers was noted when compared to the general Australian population 
within the same age range (Mathews et al., 2013).  
Since radiologists and radiographers were the initial occupational groups exposed to low 
radiation doses, the risk of radiation-induced cancer from low radiation doses was also 
assessed by retrospective analysis of the epidemiological cancer data in eight cohorts of 
radiologists and radiographers. In total, the data from more than 270,000 radiologists and 
radiographers working in different countries was analysed. The study cohorts were three 
cohorts from the US (radiologists, radiographers, and radiographers working in the US army 
during War World II), one UK radiologists cohort, Danish radiation therapy cohort, Japanese 
radiographers cohort, Chinese medical radiation workers and Canadian radiation workers 
(medical and industrial) cohorts. It has been found that there was an increased risk of 
leukemia in early radiation workers who worked before 1950. Solid cancer data was 
inconsistent and showed an insignificant increase in risk of different cancer types. In general, 
the risk of radiation-induced cancer in radiation workers (e.g. radiologists and radiographers) 
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tends to be zero or negligible in recent years (Yoshinaga, Mabuchi, Sigurdson, Doody, & 
Ron, 2004). According to Vaiserman (2010), this gradual reduction in the risk of radiation-
induced cancer among radiation workers is attributed to the noteworthy developments in 
radiation protection.    
The risk of radiation-induced cancer within the mammographic dose range was 
experimentally estimated by Brenner et al. (2002). In this work, C3H10T½ cells were 
irradiated in vitro using a 15–25 keV mono-energetic X-ray beam. The analysis of oncogenic 
transformation indicated that mammography increases the risk of breast cancer development 
by approximately two fold. This effect is age dependent making screening mammography 
commencing at the age of 50 more beneficial than that which commences at 40 (Brenner et 
al., 2002). 
Tubiana, Feinendegen, Yang, and Kaminski (2009) considered that radiation doses below 
100 mSv are safe (the threshold for risk of radiation-induced cancer). They provided 
evidence for this from radiation biological data and the results of epidemiological studies. 
The biological data includes the protective mechanisms that cells exhibit after exposure to 
low dose radiation, which are considered sufficient to protect the cell from DNA damage and 
oncogenic changes. With regard to epidemiological studies, Tubiana et al. (2009) concluded 
that the linear no-threshold model is not consistent and unsuitable for describing the risk of 
low dose radiation-induced cancer. Nevertheless, LSS found the linear and linear-quadratic 
dose-response relationships are applicable for all cancer types, especially solid cancers 
(Ozasa et al., 2012).  
In conclusion, the accurate determination of radiation-induced cancer from low radiation 
dose is not easy. The limited data available about the risk from low radiation dose (used in 
conventional radiography) has resulted in controversy and uncertainty (Brenner, 2014; de 
González & Darby, 2004). According to the available data, the risk of radiation-induced 
cancer from low dose radiation is very small but unlikely to be zero (Wall et al., 2006). 
Therefore, the linear no-threshold model may be the best reasonable risk model for 
describing the relationship between the exposure to low energy radiation and solid cancer 
incidence (ICRP, 2007; Little, Wakeford, Tawn, Bouffler, & Gonzalez, 2009; NAS, 2006). 
To overcome uncertainty about the LNT model (Dobrzynski et al., 2015), Wall et al. (2006) 
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recommended the classification of low dose radiation cancer risk into four categories, as 
illustrated in Table (4-1). 
Table (4-1) Lists the four categories of low dose radiation risk 
described by Wall et al. (2006). 
Risk category 
Risk of radiation-induced cancer 
(case/10
6
) 
Negligible risk Less than 1 
Minimal risk 1-10 
Very low risk More than 10-100 
Low risk More than 100-1000 
 
4.3 Mammography Dosimetry 
Medical radiation exposure includes the radiation resulting from therapy and imaging, 
whether it is diagnostic or screening procedures. Medical imaging represents the major 
source of man-made ionising radiation for people (Olarinoye & Sharifat, 2010; Zenone et al., 
2012).
 
In the UK, radiographic examinations constitute 90% of artificial radiation sources 
and have resulted in a 23% increase of the UK per caput dose between 1998 and 2008 (Hart, 
Wall, Hillier, & Shrimpton, 2010). In the US, however, a six fold increase in medical 
radiation exposure was reported between 1980 and 2012, making medical radiation to be the 
cause of 50% of the US per caput dose (Linet et al., 2012).  Therefore, for all radiographic 
procedures image quality should be produced with the least possible radiation dose; doses 
should be kept as low as reasonably achievable (ALARA) (Uffmann & Schaefer-Prokop, 
2009).  
Mammography is the most common imaging modality of the breast used for both screening 
and diagnosis. Since the breast cancer incidence is growing in many countries, the number of 
women undergoing mammography is also increasing (Bluekens et al., 2015). Mammography 
is the fifth most common X-ray examination in the UK and the sixth largest source of 
ionising radiation to the UK population from diagnostic imaging (Hart et al., 2010). 
Accordingly, there is a growing need for health professionals to be more conscious of the 
radiation risk associated with mammography especially for screening practice where 
asymptomatic healthy women are invited (Bosmans & Marshall, 2013). Extra attention 
should be exercised when assigning a woman into a high risk cancer category in which early 
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onset and more frequent mammography screening is required (Yaffe & Mainprize, 2011). 
Overall, it is necessary for any medical screening procedure involving X-radiation to be 
justified in term of its benefits and risk from ionising radiation.  
With more than 50 years of mammography development, massive changes have been made 
in mammographic dosimetry. It has been reported that breast radiation dose is reduced from 
about 150 mGy when using industrial film to less than 2 mGy for FFDM (Huda, Nickoloff, 
& Boone, 2008). Incident radiation exposure (R) at breast surface and the entrance surface 
dose (ESD), which is measured by TLD at the breast surface, were the early quantities used 
to determine the radiation risk of mammography (Dance, Skinner, & Carlsson, 1999). 
However, since mammography uses low energy X-ray photons, the dose inside the breast 
rapidly reduces as the depth increases (Di Maria et al., 2011). Accordingly, different 
quantities were suggested as measures for mammographic radiation risk, such as midline 
breast dose and total breast energy (Dance et al., 1999). Work by Karlsson, Nygren, 
Wickman, and Hettinger (1976) proposed the use of breast glandular tissue radiation dose as 
a measure for mammographic radiation risk. Karlsson et al. (1976) utilised a mixture of 
alcohol and water as a breast phantom to study dose distribution within the breast. They also 
compared the radiation dose of different image receptors which resulted in equivalent 
mammographic image qualities. Later, in 1987, a mean glandular dose (MGD) for breast 
dosimetry was recommended for use by the ICRP (Dance et al., 1999). Mammography is a 
common screening practice and it is considered to be one of the most highly optimised 
techniques (Huda et al., 2008).  
4.3.1 Mean Glandular Dose (MGD) 
The risk of radiation-induced cancer from breast X-ray examination is small and is generally 
related to mean glandular dose (MGD) (Myronakis, Zvelebil, & Darambara, 2013). MGD is 
the amount of energy imparted from ionising radiation per unit mass of breast glandular 
tissue; glandular tissue has the highest radiation sensitivity among breast tissues (IAEA, 
2011). MGD is utilised as a standard quantity in breast dosimetry, which is an essential part 
in quality control protocols of mammography and is recommended by several international 
committees such as ICRP, NCRP, and IPEM. MGD is fundamentally related to target/filter 
combination (radiation spectrum), X-ray tube output (kV, mA, and time), breast density 
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(glandularity), and breast size (compressed breast thickness) (Dance, 1990; Di Maria et al., 
2011; IPEM, 2005). The effect of client age on MGD was investigated by Beckett and Kotre 
(2000) and Suad, Suada, Samek, Amila, and Samir (2013). Both studies reported lower MGD 
in older women than in younger because both breast density and compressed breast thickness 
decrease with age. Beckett and Kotre (2000) analysed their data in more detail and found that 
there is a linear inverse relationship between client age and the reduction percentage of 
required mAs.   
Direct estimation of MGD is difficult and it has to be calculated from multiplying the 
incident air kerma by conversion factors, obtained by Monte Carlo simulation, as published 
by Dance, Skinner, Young, Beckett, and Kotre (2000a). This method is recommended in 
IPEM report 89 (IPEM, 2005), IAEA (2011), and the European Commission (2006). 
However, conversion factors published by Wu, Gingold, Barnes, and Tucker (1994) have 
been recommended by the American College of Radiology (Tsai, Chong, Ho, & Tyan, 2010). 
MGD is considered to be an important element of mammographic quality assurance 
programmes. This is because it can be used as a parameter to evaluate the mammographic 
system performance, patient risk assessment, and different mammographic imaging 
techniques with regards to dosimetry (Säbel & Aichinger, 1996). Accordingly, MGD has 
been of great interest to a large number of researchers (Assiamah, Nam, & Keddy, 2005; 
Benevides, 2005; Di Maria et al., 2011; Dong et al., 2011; Geeraert, Klausz, Muller, Bloch, 
& Bosmans, 2012; Nsiah-Akoto, Andam, Adisson, & Forson, 2011; Oliveira et al., 2007; 
Sookpeng & Ketted, 2006; Tsai et al., 2010; Tyler, Strudley, Hollaway, & Peet, 2009; 
Zeidan, 2009). For instance, Hauge, Pedersen, Sanderud, Hofvind, and Olerud (2012) 
compared the MGD of 24 film-screen mammography systems with that of 7 FFDM systems 
using population based data from a Norwegian screening programme. They used data from 
50 women for each machine and found that the average MGD value from FFDM machines 
was lower than that of FSM by 0.3 mGy (Hauge et al., 2012). Work by McCullagh, Baldelli, 
and Phelan (2011) calculated the MGD from the BreastCheck, the screening programme of 
Ireland, to assess clinical dose performance of 28 FFDM systems for three different 
manufacturers (Hologic, GE Healthcare and Sectra). Similar MGD values were reported for 
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Hologic and GE Healthcare machines. However, the Sectra photon-counting FFDM 
machines gave the lowest MGD value (McCullagh et al., 2011).  
MGD values for three AEC operation modes (DOSE [dose], STD [standard], CNT [contrast]) 
of the GE Senographe 2000DS FFDM system were analysed by Chen et al. (2012). Chen et 
al. (2012) concluded that the MGD differences in the three modes were mainly attributed to 
the mAs selected by the system. Also, the MGD, together with image quality, are usually 
used to evaluate the mammographic system performance. In this context, Ciraj-Bjelac et al. 
(2012) investigated the image quality and MGD in 17 Asian, African and Eastern European 
countries. They expressed concerns about the recorded MGD value in some countries (Ciraj-
Bjelac et al., 2012). The outcome performance of two CR mammographic systems (Siemens 
Mammomat 3000 Nova with Kodak Direct View CR850 digitiser and Fuji CR system model 
Profect ONE with HR-BD image plate) in Brazil were assessed by Oliveira  et al. (2011) and 
Jakubiak, Gamba, Neves, and Peixoto (2013), using both MGD and mammographic image 
quality. Both studies utilised a PMMA breast phantom for MGD calculation and CDMAM 
phantom for image quality assessment. Diagnostic mammography MGD was estimated in 
Ethiopia by Dellie, Rao, Admassie, and Meshesha (2013). Dellie et al. (2013) used Dance‘s 
conversion factors to calculate the MGD from incident air kerma. They concluded that the 
MGD of diagnostic mammography in Ethiopia was within the accepted ranges recommended 
by the Institute of Physics and Engineering in Medicine (IPEM) and the American College of 
Radiology (ACR) which are 2 mGy and 3 mGy, respectively (Dellie et al., 2013).  
The main limitation of MGD calculations using conversion factors is that, during Monte 
Carlo simulation, a homogenous breast phantom of different breast densities was used. As 
concluded by Sechopoulos, Bliznakova, Qin, Fei, and Feng (2012), the use of this 
homogenous phantom results in significant MGD overestimation. The greatest value of MGD 
overestimation has been recorded at low photon energies and this overestimation decreases as 
the photon energy increases. The result of this work, agrees with that of previously published 
work by Dance et al. (2005) who reported that the use of conversion factors may result in up 
to a 43% difference in calculated MGD due to glandular tissue spatial distribution. 
Accordingly, Geeraert, Klausz, Muller, Bloch, and Bosmans (2015) calculated the MGD for 
six breast phantoms with different glandular tissue distributions. Different MGD values have 
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been recorded for different phantoms. Therefore, Geeraert et al. (2015) suggested the use of 
total energy imparted in glandular tissue (GIE) instead of MGD. 
4.3.2 Mammography: Dose to Organs Other Than the Examined Breast  
Surprisingly few investigators have considered the radiation dose received by organs and 
tissues, other than the examined breast, from mammography. Most of these investigators 
utilised mathematical models to simulate mammography. Sechopoulos, Suryanarayanan, 
Vedantham, D‘Orsi, and Karellas (2008) utilised the Geant4 Monte Carlo toolkit to simulate 
four-view film-screen mammography. Sechopoulos and colleagues estimated the radiation 
dose to all body tissues other than breast. They concluded that the doses were extremely 
small and that the Rh/Rh target/filter combination resulted in higher organ doses than those 
from Mo/Mo and Mo/Rh target/filter combinations. They also found that the second and third 
highest radiation dose, after examined breast, was received by the pectoral muscle and 
contralateral breast, respectively (Sechopoulos  et al., 2008). The same procedure has more 
recently been used by Sechopoulos and Hendrick (2012) to estimate the radiation dose 
received by the thyroid gland during mammography. They considered the thyroid dose to be 
negligible in regard to radiation-induced cancer because four-view mammography would 
result in 1 cancer case per 166 million women. Sechopoulos and Hendrick (2012) also argued 
that the use of a thyroid shield may result in discomfort to the women and interfere with 
positioning which may cause image artifacts. Leidens, Goes, and Nicolluci (2013) used the 
Monte Carlo PENELOPE toolkit to estimate lung, heart and red bone marrow radiation dose 
during standard CC mammography with film-screen systems. They reported that only the 
lung received a considerable radiation dose (0.14% of the examined breast dose), while doses 
to the heart (0.033%) and bone marrow (0.0013%) were negligible (Leidens et al., 2013).  
A study by Whelan, McLean, and Poulos (1999) used TLDs for the direct measurement of 
radiation dose received by women‘s skin overlying the thyroid during standard screening 
mammography (CC and MLO views for each breast) and diagnostic mammography. For 
more accurate measurements, two sachets, each one comprising three TLDs, were fixed on 
both sides of the women‘s necks. This study concluded that the average measured thyroid 
dose, which was 0.04 mGy, was insignificant compared to the 4 mGy dose received by the 
breast. Hatziioannou et al. (2000) also utilised TLDs accommodated inside an upper body 
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anthropomorphic Lucite phantom, which was made of Perspex slices designed to simulate 
female body contour. This was done to investigate the in vivo measurement of dose to the 
breast, sternum red bone marrow (SRBM), thyroid, liver, lung, stomach, and oesophagus 
during screening mammography using a Giotto mammography machine with Mo/Mo 
target/filter combination. Three PMMA breast phantoms of different thickness (2 cm, 4.5 cm, 
and 6 cm) were used in this study to replicate 2.3 cm, 4.9 cm and 6.5cm breast thickness, 
respectively. They found that the breast dose contributes over 98% of the overall effective 
dose. SRBM and thyroid receive a radiation dose between 0.4-1.27 and 0.05-0.17 µGy/mAs, 
respectively, and the other organ doses were negligible (Hatziioannou et al., 2000). The main 
limitations of this study are that the simulated mammographic positions were CC and ML 
(90
o
 angle) for each breast, and the homogenous Lucite phantom is not a good simulator of 
the different body tissues. 
Other organ radiation dose from digital breast tomosynthesis (DBT) and dedicated breast CT 
were investigated by Baptista et al. (2015) and Sechopoulos, Vedantham, Suryanarayanan, 
D'Orsi, and Karellas (2008). Baptista et al. (2015) utilised Monte Carlo MCNPX toolkit with 
mathematical ―Laura‖ voxel phantom to estimate the organ dose from the CC position using 
W/Rh target/filter combination from both digital mammography and DBT. For both digital 
mammography and DBT the estimated organs dose data showed that the radiation dose 
received by the ipsilateral lung and thyroid ranked as second and third highest dose in 
relation to examined breast. However, their work did not extend to include all the body 
organs and only considered the dose received by breasts, thyroid, lungs, liver, kidneys, 
ovaries and uterus. Monte Carlo Geant4 toolkit software was used to simulate dedicated 
breast CT by Sechopoulos et al. (2008). The aim of Sechopoulos et al.‘s (2008) work was to 
evaluate body organs‘ radiation doses from different kVp (40-80) breast CT. They found that 
the radiation dose received by all organs increases as the kVp increases. For instance, the 
surface radiation dose of the sternum, which was the highest among other organs‘ dose, 
increases from 3.52% to 7.18% of the examined breast dose when the kV is increased from 
40-80 kV. Finally, they considered that any radiation dose less than 0.1% of the examined 
breast dose is negligible (Sechopoulos et al., 2008). 
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In summary, there is evidence to suggest that the radiation dose received by organs other than 
the breast requires further consideration as the radiation dose and the risk associated with it is 
not captured by MGD. For a more thorough and accurate estimation of the radiation risk 
from mammography, the dose to all organs should be taken into account.  
4.3.3 Mammographic Effective Dose and Effective Risk 
The internationally accepted method for estimating the risk from an X-ray procedure is to use 
effective dose. Effective dose has enabled doses to be summed from whole and partial body 
exposure from external radiation of various types to estimate the risk of cancer development 
(ICRP, 2007). As recommended by the ICRP, effective dose is not suitable for 
epidemiological evaluations or the assessment of individual exposure and risk, but can be 
used as a radiation protection quantity by comparing it with reference values. The calculation 
of the effective dose depends on tissue weighting factors which are regularly updated by the 
ICRP based on the available evidence from epidemiological data (Nuclear Energy Agency 
[NEA], 2011). Since the ICRP considered that it is more suitable for radiation protection 
calculations to utilise averaged gender and age tissue weighting factors, effective dose does 
not take into account an individual‘s age and gender. Accordingly, Brenner (2008) 
recommended the replacement of effective dose by effective risk.  
Effective risk is a useful quantity which was originally proposed by Brenner (2008). It is a 
more suitable quantity for epidemiological assessment of radiation risk than effective dose 
(Brenner, 2012). Effective risk is a good indicator of the radiation dose that the patient 
received (Brenner  & Huda, 2008). In contrast to effective dose, which averages cancer 
incidence, cancer mortality, life shortening, and heredity risks, the only focus of effective 
risk is cancer incidence arising from the exposure to ionising radiation. The effective risk of 
developing cancer is less for people who have 20 years to live compared to those who have 
60 years, because it is related to tissue specific, age specific, and gender specific lifetime 
attributable risk (LAR). Therefore, the calculation of effective risk involves summing the 
products of age, and gender lifetime-attributable risk of cancer incidence, per unit equivalent 
dose for each type of tissue and the dose received by that tissue. The effective risk 
calculation is not more complicated or difficult than the calculation of the effective dose. 
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However, the data from the effective risk calculation are more understandable to the general 
public than that produced by effective dose calculation (Brenner, 2012).  
Brenner‘s recommendation (Brenner, 2008) to replace effective dose by effective risk has 
been criticised by Dietze, Harrison, and Menzel (2009) for a number of reasons. Firstly, they 
consider that the continuous change in tissue weighting factor is not a reasonable criticism 
for the ICRP because the continuous update of tissue weighting factors increases their 
reliability. Secondly, with regard to age, they stated that the ICRP discussion in their 
recommendations (2007) suggests the need to find another alternative quantity to consider 
the individual‘s age, but not as a replacement for effective dose. Finally, Dietze et al. (2009) 
suggest that the effective risk is not suitable for all radiation protection applications such as 
the assessment of radiation dose received by astronauts. Also, Huda was not enthusiastic 
about the introduction of effective risk because he considered the main advantage of the 
effective risk calculation is to compare different types of non-uniform exposures 
qualitatively. However, this can be achieved by comparing the effective dose of a specific 
procedure with that of annual background radiation (Brenner  & Huda, 2008). In fact, 
effective risk is a more suitable quantity for the evaluation of radiation-induced cancer from 
screening mammography than effective dose because this examination is continuously 
repeated at different ages during women‘s lifetime. Accordingly, effective risk is adopted 
into this thesis as the main tool for assessing radiation risk from screening mammography 
when comparing different mammography screening programmes. 
Before the suggestion of effective risk by Brenner (2008), some investigators used radiation-
induced cancer as a dosimetric measure for radiation risk assessment of each organ 
separately. For example, Sulieman et al. (2007) calculated the risk of radiation-induced 
cancer in thyroid, testes and ovaries from paediatric micturating cystography using the direct 
surface dose measurement by TLDs placed on the child‘s skin. The radiation-induced fatal 
cancer for each organ (thyroid, ovaries, and testis) was then calculated using ICRP 60 LAR 
factors. However, Perisinakis et al. (2001) calculated the risk of radiation-induced cancer in 
all body organs from radiofrequency catheter ablation procedures by multiplying the 
effective dose by the total LAR reported in BEIR V report by National Academy of Siences. 
In the work of Perisinakis et al. (2001), organ radiation doses were measured using a Rando 
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phantom loaded with dosimeters. Although many researchers used the effective risk concept, 
after Brenner‘s proposal for radiation risk assessment from different radiographic 
examination, they did not use the term ―effective risk‖, see Table (4-2). It can be seen that all 
the studies in Table (4-2) used the term lifetime attributable risk (LAR), and this may result 
in misunderstanding as to whether it refers to cancer incidence in specific tissue or in all 
body tissues. However, only Li et al. (2011) used the term risk index to indicate the effective 
risk.  
The lifetime attributable risk of radiation-induced breast cancer from mammography has 
been calculated by Hendrick (2010) and more recently by Yaffe and Mainprize (2011). 
Hendrick (2010) calculated the incidence and mortality of radiation-induced cancer from 
mammographic imaging procedures. Yaffe and Mainprize (2011) assessed the LAR of 
radiation-induced breast cancer following mammography at different client ages. 
Beemsterboer, Warmerdam, Boer, and de Koning (1998) and Freitas-Junior, Correa, Peixoto, 
Ferreira, and Tanaka (2012) justified screening mammography with regard to breast cancer 
mortality reduction and risk of radiation-induced breast cancer from screening 
mammography in the Netherlands and Brazil, respectively. In general, both studies found 
that radiation risk from mammography was small and that the benefits outweigh the risks. 
The number of lives saved by early screening mammography in BRCA mutation carriers was 
compared to the number of radiation-induced breast cancer by Berrington de Gonzalez, Berg, 
Visvanathan, and Robson (2009) and Jansen-van der Weide et al. (2010). Berrington de 
Gonzalez et al. (2009) concluded that there was no net benefit of early screening before 35 
years of age for BRCA mutation carriers. However, there was a 1.3 fold additional breast 
cancer risk due to the exposure of high breast cancer risk women to low radiation doses 
reported by Jansen-van der Weide et al. (2010).   
Nevertheless, the above authors did not progress their work to include effective lifetime risk 
of radiation induced-cancer from screening mammography; they only considered the 
examined breast radiation risk. Therefore, in this thesis the effective risk of radiation-induced 
cancer from screening mammography will be assessed, for different female ages and 
country-based screening programmes, considering the radiation dose received by all body 
tissues in addition to the examined breast. 
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Table (4-2) Lists studies that utilised effective risk for radiation-induced cancer 
assessments from different radiographic examinations.  
Study Author Examination Study Details 
Huang, Law, and 
Khong (2009) 
Whole-body 
PET/CT 
Rando phantom and TLDs used for organ 
dose measurement. LAR calculated using 
BEIR VII method utilised for total LAR 
calculation.   
Griffey and 
Sodickson (2009) 
Emergency multiple 
or repeated CT 
Cumulative effective dose and BEIR VII 
report total LAR were used.  
Huang  et al. 
(2010) 
ECG-gated 
coronary CT 
angiography 
ImPACT Monte Carlo software used for 
organ dose estimation then LAR calculated 
using BEIR VII method utilised for total LAR 
calculation.  
Li et al. (2011) Paediatric chest CT 
Monte Carlo simulation for organ dose 
estimation. The risk index calculated using 
Brenner‘s equation. 
Johnson et al. 
(2014) 
Children with heart 
disease imaging 
Child ATOM phantom used for effective dose 
calculation. Then total LAR of all cancers 
from BEIR VII multiplied by effective dose. 
Seo et al. (2015) 
Neck X-ray 
radiography 
PCXMC and BEIR VII LAR factors were 
used to calculate total LAR.  
Law et al. (2016) 
Spine radiography 
for scoliosis patient 
PCXMC and BEIR VII LAR were used to 
calculate total LAR during patient lifetime.  
4.4 Dose Modeling  
4.4.1 Monte Carlo (MC) Simulation 
Advances in computer technologies have led to the introduction of Monte Carlo (MC) 
methods to simulate complex problems (Guimarães, Moralles, & Okuno, 2008). MC 
simulation was developed in the 1940s by scientists working on nuclear weapons. It is a class 
of numerical methods based on the utilisation of random numbers (Salvat, Fernández-Varea, 
& Sempau, 2011). The simulation accuracy of MC software is strongly related to the 
accuracy of the probability functions (Ye, Brezovich, Pareek, & Naqvi, 2004). The main 
purpose of using MC simulation is to solve complex mathematical and physical problems.  
MC can be used for the simulation of radiation transport and interactions such as random 
sequences (Salvat et al., 2011). Accordingly, it is of great interest to radiation physics 
scientists (Salvat & Fernández-Varea, 2009). The extensive work of several groups 
throughout the world resulted in the introduction of different MC codes that simulate the 
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process of radiation energy transfer to matter. This allows accurate calculations to be made 
for medical physics, radiation dosimetry and radiation protection (Guimarães et al., 2008).  
In diagnostic radiology different codes of MC are used, depending on the situation being 
simulated. The irradiation simulation can achieve both image quality and dose characteristic 
of different techniques (Delis, Spyrou, Costaridou, Tzanakos, & Panayiotakis, 2007). Some 
of these codes used in diagnostic radiology are EGS, MCNP, PENELOPE and GEANT4. 
EGS (Electron Gamma Shower) is available in different versions (e.g EGSnrc and EGS4) 
and widely used in medical physics for the calculation of ionisation chamber response 
(Assiamah, 2004). EGS is a general purpose code used for the simulation of coupled 
electrons/photons (Ye et al., 2004). The MCNP (Monte Carlo N-Particle transport) code has 
also been distributed in different versions (e.g. MCNP4, MCNP5) (Assiamah, 2004). This 
code was primarily supplied to simulate neutron and photon transport in nuclear reactors, but 
has since been extended to be used for electron transport. It is now the general purpose code 
for neutron, photon, electron or coupled neutron/photon/electron simulations. It also allows 
the simulation of 3D systems composed of many homogeneous bodies (Ye et al., 2004).  
The acronym PENELOPE is derived from (PENetration and Energy LOss of Positron and 
Electron) (Lin, Tung, & Tsai, 2011). PENELOPE is used to simulate coupled electron/photon 
transport within any material and for a wide range of energies. Like MCNP, PENELOPE has 
the flexibility of 3D system simulations (Ye et al., 2004). PENELOPE was designed to assess 
low energy X-ray beam absorbed dose. In this context, PENELOPE has been found to have 
excellent agreement with EGS4 and MCNP4 (Lin et al., 2011). Both MCNP and PENELOPE 
were evaluated in comparison to experimental data and good agreement was concluded by 
Assiamah (2004). GEANT4 is a freely available code based on C++, utilised to simulate 
particle transport within matters (Guimarães , Moralles, & Okuno, 2007). 
X-ray tube quality control is essential in diagnostic X-ray. It is a measure of X-ray tube 
performance and usually determined by the first and second HVL, homogeneity and the 
mean energy of the X-ray spectrum. Also, the determination of inherent and total filtration is 
required to reduce patient radiation dose. MC simulation is a powerful technique used for 
these purposes (Pozuelo, Gallardo, Querol, Verdu, & Rodenas, 2012). Work by Pozuelo et al. 
(2012) used both PENELOPE and MCNP5 MC software to evaluate the QC of the diagnostic 
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imaging X-ray tube. X-ray spectrum is an essential factor for the evaluation of image quality 
and patient radiation dose in radiography. Experimental evaluation of X-ray spectrum 
requires special equipment which has limited availability. Therefore, MC simulation is 
widely used as an accurate method for X-ray spectrum studies, even ones with complex 
imaging geometries. Also, MC can track secondary radiation in addition to primary beam. 
For X-ray photon simulation, some researchers have written their own computer code, while 
others used MC general purpose codes such as EGS4 and MCNP (Taleei & Shahriari, 2009). 
EGS, PENELOPE, and GEANT4 are widely used to simulate the X-ray spectra of diagnostic 
X-ray machines. Compared to the available data from measurements, the X-ray spectra 
generated by MC codes are very accurate (Salehi, Ya Ali, & Yusoff, 2012).  
Mathematical heterogeneous human body phantoms are usually used with MC for organ dose 
assessment during imaging procedures. Within these phantoms, body tissues and organs are 
mathematically described considering their shape, size and location. Radiation doses are 
calculated by the determination of the average radiation energy imparted in each organ. 
Different human body phantoms are available for use in radiation dosimetry (e.g. Medical 
Internal Radiation Dose [MIRD] phantom, Christy phantom, Female/Male Adult voXel 
[FAX/MAX] phantoms) (Kramer et al., 2004). To facilitate the use of MC with such 
mathematical phantoms, they are programmed together and distributed in an executable 
form. PCXMC is one of these executable programmes based on MC and the mathematical 
human body Christy phantom to assess the organ doses from different radiographic 
examinations (Servomaa & Tapiovaara, 1998). PCXMC is often described as an industry 
standard MC simulation for the estimation of dose to patients from different medical imaging 
procedures. 
MC is also used to simulate the different types of dosimeters to assess their dose 
measurement performance. For instance, Guimarães  et al. (2007) used a GEANT4 toolkit to 
simulate the angular dependence of TLD response. In this work the simulation was achieved 
in three steps. The first step was the X-ray generation; the second, X-ray beam filtration; the 
third, the X-ray detection process (Guimarães  et al., 2007). Lin et al. (2011) also used the 
Monte Carlo PENELOPE to investigate the accuracy of mammographic beam HVL 
estimation by TLDs.  
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4.4.2 Mammography Simulation 
MC simulation is an important tool in the development and optimisation of mammographic 
imaging techniques. It can be used to evaluate each part of the imaging system separately 
(image receptor, X-ray spectrum and system geometry) (Bliznakova, Sechopoulos, Buliev, & 
Pallikarakis, 2012). For instance, the promising performance of the Cadmium Zinc Telluride 
(CZT) detector for digital mammography was concluded by Alsager and Spyrou (2007) who 
used MC MCNPX to assess CZT detector performance (Alsager & Spyrou, 2007). Cunha, 
Tomal, and Poletti (2013) studied three mammographic spectra produced by different 
target/filter combinations (Mo/Mo, Rh/Rh and W/Rh) using PENELOPE 2008. They 
investigated the effect of a copper (Cu) filter on the X-ray spectra of different 
mammographic anodes in contrast enhancement digital mammography (Cunha et al., 2013). 
Delis, Spyrou, Panayiotakis, and Tzanakos (2005) used the DOsimetry SImulation Studies 
(DOSIS) programme based on MC to investigate the effect of different mammographic 
imaging parameters (e.g. tube voltage and added filter) on radiation energy and dose 
distribution within the breast. They found for 6 cm breast thickness and for Mo/Mo 
target/filter combination the use of 30 kV tube voltage resulted in lower ESD (by 42%) than 
25 kV (Delis et al., 2005). Finally, the scatter radiation in DBT was estimated by Diaz et al. 
(2014) using GEANT4 toolkit. 
Currently MC simulation is widely used in new diagnostic modality development. It is of 
great importance in designing, testing and performance prediction of new imaging modalities 
before their manufacture and prior to be approved for clinical use. Amongst those tested in 
this manner are breast imaging systems and their applications that produce 3D image (DBT 
and breast CT). For more accurate results, the simulation process is usually followed by 
experimental validation. Traditionally this is achieved by breast modelling and radiation 
simulation using MC software to obtain breast images (Bliznakova  et al., 2010). For 
instance, Ma and Alghamdi (2011) used the MCNPX MC to produce a mammographic 
image for the realistic computational breast phantom that they developed (Ma & Alghamdi, 
2011). 
The breast is often simulated using the geometrical structure of standard breast described in 
work by Dance (1990). According to Dance (1990), the standard breast is semicircular with 
 82 
 
4.5 cm thickness and 16 cm diameter. The central region of the breast consists of 50:50 
mixture of glandular and adipose tissues. This mixture is surrounded by 0.5 cm adipose tissue 
to simulate the breast skin adipose tissue (Dance, 1990). The elemental composition of 
glandular and adipose tissues described by Hammerstein et al. (1979) is usually used. The 
resultant density of this composition is 1.02 g/cm
3
 and 0.93 g/cm
3
 for glandular and adipose 
tissue (Dance, 1990). This phantom has been widely used to establish the conversion factors 
which are utilised to calculate MGD from incident air kerma for different breast thicknesses, 
breast densities and target/filter combinations (Dance et al., 2000a; Dance, Young, & van 
Engen, 2009), or to investigate the effect of scatter radiation on mammographic image 
quality of conventional 2D and 3D DBT images (Baptista et al., 2014; Dance, Persliden, & 
Carlsson, 1992). On the other hand, complex mathematical breast phantoms are useful tools 
in studies on complicated breast imaging modalities (Bliznakova  et al., 2010). The use of 
such realistic breast phantoms is becoming common in mammographic studies in several 
different ways. Firstly, they are used for breast dosimetry in order to investigate dose 
distribution within the breast (Dance et al., 2005) and other organs‘ radiation dose 
assessment from different mammographic modalities (Sechopoulos  et al., 2008; 
Sechopoulos et al., 2008). Secondly, to investigate the effect of breast compression reduction 
on lesion conspicuity in DBT (Saunders, Samei, Lo, & Baker, 2009). Thirdly, to produce 3D 
mammographic images through newly introduced modalities to assess the mammographic 
image quality (Duarte, Caldeira, Soares, Silva, & Janela, 2010). 
As previously discussed in section 4.3.1 (page 70) MGD cannot be directly measured and its 
calculation is dependent on conversion factors derived by MC simulation for each breast 
thickness, breast density and beam quality (HVL and target/filter combination). These factors 
are used to calculate the MGD either from incident air kerma as described by Dance et al. 
(2000a), or from radiation exposure at the breast surface as described by Wu et al. (1994). 
Since the conversion factors published by Wu et al. (1994) were for a maximum breast 
thickness of 8 cm, Boone (1999) extended these conversion factors to accommodate for 
thicker breasts of up to 12 cm thickness. Dance, Young, and van Engen (2011) and Dance 
and Young (2014) extended the conversion factors published by Dance et al. (2000a) to 
accommodate the MGD calculations for DBT and contrast enhancement digital 
mammography, respectively. However, some investigators utilised MC simulation for direct 
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estimation of the MGD (Cassola & Hoff, 2010; Myronakis et al., 2013). Di Maria et al. 
(2011) validated the mammographic dose values (MGD, ESD and BSF) estimated by two 
different Monte Carlo methods (PENELOPE and MCNPX) with those experimentally 
obtained by TLD. They found that the variations in MGD obtained by the three methods are 
negligible (Di Maria et al., 2011).       
In mammography, MC simulation is not only used to investigate the optimisation of 
mammographic image quality and MGD (Delis et al., 2005), but it is also used for screening 
mammography protocol optimisation (Jansen & Zoetelief, 1995). Jansen and Zoetelief (1995) 
developed a computer MC based model called (MBS) to analyse the net benefit of different 
mammography screening categories in relation to the risk of radiation-induced breast cancer 
and breast cancer mortality reduction by screening mammography. This model is based on 
random selection depending on relevant parameters, including age of tumour start, rate of 
tumour growth and thresholds of tumour detection. This model is characterised by its ability 
to consider the risk of radiation-induced fatal breast cancers, the probability of 10 years 
survival (as a function of tumour size), distributions of tumour onset and the growth rate of 
the tumour. The output of this model includes the number and size (diameter) of the observed 
tumours without screening, number of tumours detected by screening, number of tumours 
detected between two successive screens, breast cancer mortality reduction as a result of 
screenings, and the risk of radiation-induced cancer from screenings. The validation of this 
model was based on the data of the Swedish two-county trial (Jansen & Zoetelief, 1995). 
This model has been extended by Jansen and Zoetelief (1997a) to calculate the net screening 
benefit in terms of lifetime gain due to screening. Work by Jansen and Zoetelief (1997b) used 
the same mathematical MC model to investigate the net benefit of different screening 
frequencies (half annual, annual, biennial and triennial) for different age intervals (0-39 year, 
40-45 year, 46-51year, 52-57 year…etc). However, the main disadvantage of this model is 
that since it was based on the Swedish two-county trial, it was affected by the trial 
uncertainties as discussed by Gotzsche and Jorgensen (2013).       
Since this thesis has a demonstrable interest in scattered radiation dose, both PENELOPE and 
Geant4 are the most suitable MC methods to simulate screening mammography (Leidens et 
al., 2013; Sechopoulos & Hendrick, 2012; Sechopoulos  et al., 2008). A significant period of 
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time within the first year of this PhD study was spent attempting to simulate the clinical 
situation of screening mammography using PENELOPE. However, no acceptable results 
have been obtained due to the complexity of the computer coding required. Another trial has 
been undertaken using PCXMC, but the radiation beam cannot be made to run parallel to a 
patient‘s body as it has not been designed to simulate mammography examinations. 
Overall, although the in vivo dose measurements using dosimeters accommodated inside a 
physical phantom are difficult and time consuming, they are more accurate than dose 
estimation by Mote Carlo modelling. The accuracy of MC calculations is affected by the 
mathematical phantom used to simulate a patient‘s body and by the radiation field 
characterisation (radiation quality and field geometry) utilised in radiological examination 
(Fulea, Cosma, & Pop, 2009). For CT dose calculations the use of MC simulation results in 
18-40% underestimations. These underestimations are mainly attributed to the differences 
between physical and mathematical phantoms, wherein simplified geometrical shapes of the 
organs are used in mathematical phantoms (Tootell, Szczepura, & Hogg, 2014). Groves et al. 
(2004) compared the measured organs‘ radiation dose by TLDs with those estimated by an 
MC simulation from whole body CT examination. They found an 18% underestimation in 
organ radiation dose for MC simulation compared with those measured by TLDs (Groves et 
al., 2004).    
4.5 Radiation Dose Measurement Instrumentation 
In diagnostic radiology the measurement of air kerma or absorbed dose is required in many 
situations. In some countries, it is required by legislation. It is also required to optimise 
image quality and patient dose (Hourdakis, 2014). Since the radiation doses from diagnostic 
radiology are small, accurate and long-term stability dosimeters are required (IAEA, 2007). 
There are several types of radiation dosimeters used in diagnostic radiologic practice. Most 
of these dosimeters are either ionisation chambers or solid state detectors which include 
thermo-luminescence dosimeters (TLD), optically stimulated luminance dosimeters (OSL), 
and semiconductor detectors (Bushong, 2013). The choice of the most suitable dosimeter 
depends on the clinical situation in which the measurements are required (Lemoigne & 
Caner, 2011). For instance, the measuring instrument should have the same properties 
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(absorb the same amount of energy) as the medium in which the dose is measured (Hendee & 
Ritenour, 2002; Hobbie & Roth, 2007). 
4.5.1 Ionisation Chambers 
An ionisation detector consists of two electrodes contained within an air filled chamber. An 
electric field across the two electrodes is used to collect the charges produced in the air by 
the ionisation. Since the ionisation chambers used in diagnostic radiology are vented air, a 
correction factor should be applied to the reading from the dosimeter. The correction factor is 
calculated using the following equation: 
kTP =(P0.T) / (P.T0) 
Where P, T are the pressure and temperature of the ambient and P0, T0 are the pressure and 
temperature of the reference condition - 101.3 kPa and 293.2 K. The ionisation detectors are 
available in different types (Hourdakis, 2014). 
4.5.1.1 Free-Air Ionisation Chambers 
This type of detector is used by standard laboratories as a reference to calibrate the simpler 
dosimeters. For the accurate measurement of ionisation in the chamber, the range of liberated 
electrons by incident radiation should be less than the distance between the two electrodes of 
the detector. The measurement accuracy of this type of detector is within ± 0.5%. Free-Air 
ionisation chambers are fragile and too large for routine use (Hendee & Ritenour, 2002). 
4.5.1.2 Chambers for Dose or Air Kerma Measurement 
This is the most common type of ionisation chamber. It is commercially available in two 
different designs, either as two parallel plates (disk shape) or as a cylindrical shape. The disk 
shaped detectors are widely used in radiography, fluoroscopy, and mammography. However, 
because of the uniform sensitivity of cylindrical detectors around their central axis, they are 
only used with the x-ray beams which have effective volumes of 3-6 cm
3
 (Hourdakis, 2014). 
4.5.1.3 Kerma Area Product (KAP) Chambers 
A KAP chamber is a large surface area detector mounted on the X-ray tube housing 
encompassing the entire radiation field in order to include all extra-focal and focal radiation 
in its measurement. Accordingly, it is made of transparent material for both X-ray and light. 
KAP chambers are used to measure kerma-area product as a quantity for patient exposure 
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monitoring. If the X-ray attenuation by air is neglected, the kerma-area product is same along 
the central X-ray beam (IAEA, 2007). Depending on their use and calibration, the KAP 
chambers measure either incident radiation or transmitted radiation (Hourdakis, 2014).    
4.5.2 Semiconductor Detectors 
Because of the small size and instantaneous response of semiconductor detectors, they are 
widely used in diagnostic radiology (IAEA, 2007). There are two types of semiconductor 
detectors, namely, silicon diodes and metal oxide semiconductor field effect transistors 
(MOSFETs) (Hourdakis, 2014).  
4.5.2.1 Silicon Diode Detectors 
When a silicon p-n junction diode dosimeter is exposed to X-ray, electron-holes are formed 
in the diode body resulting in an electrical current in the reverse direction. The magnitude of 
generated electrical current is proportional to the radiation dose. The main advantages of 
diode dosimeters over ionisation chambers are their higher sensitivity and reproducibility. 
However, the diode dosimeter sensitivity is dependent on dose rate and diode temperature 
(Lemoigne & Caner, 2011).  
4.5.2.2 MOSFET Detectors 
The MOSFET detector consists of silicon transistor capacitors. One of the capacitor 
electrodes is replaced by semiconductor material. The incidence of X-ray on the gate region 
of the MOSFET will produce electron-holes pairs. The holes will move toward the silicon-
gate interface producing a change in the current of the n-type channel. Consequently, a shift 
in the threshold voltage of the gate bias will occur. The value of this shift is directly 
proportional to the absorbed dose. Therefore, during irradiation MOSFET requires a 
connection to a bias voltage. This type of detector is mostly used for patient dosimetry 
(Hourdakis, 2014).  
4.5.3 Thermo-luminescence Detectors (TLD) 
4.5.3.1 Principle 
Thermo-luminescence is a phenomenon of light emission from an insulator or a 
semiconductor, resulting from previous energy absorption from a source of ionising 
radiation. It was initially discovered in 1663. Since then, many theories have been proposed 
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to explain the thermo-luminesce of semiconductors or insulators. The explanation which 
depends on the electronic energy band theory is the most acceptable one (Rivera, 2012). In 
perfect semiconductor or insulator crystals most of electrons occupy the valence band which 
is detached from the conduction band, the highest energy level, by a forbidden gap (Bos, 
2007).  
According to a one trap-one centre model, there are two levels in the forbidden band gap: T 
level, which is located down to the conduction band above the Fermi level of equilibrium; 
and R level which is located above the valence band and below the equilibrium Fermi level. 
At equilibrium, both these levels are empty (Bos, 2007). The absorption of radiation energy 
by thermo-luminescent material may result in the liberation of valence electrons to 
conduction band creating positive holes in the valence band. Then, the negative charge 
carriers, the electrons, are trapped in T level and positive ones, the holes, are trapped in the R 
level. The increased temperature speeds the return to equilibrium by de-trapping the electrons 
which are released to conduction band and then recombine with holes at luminescent centres 
in the R level. Since this process involves electron movement from high energy level to 
ground state, light quanta are emitted (Bos, 2001a). The ratio of emitted visible light energy 
to the absorbed ionising radiation energy is called the luminescence intrinsic efficiency (Bos, 
2007). In order to increase the luminescence intrinsic efficiency of a material, more energy 
levels are localised in the forbidden band gap by adding impurities to that material (Bos, 
2001a).  
In brief, the thermo-luminescence process occurs in several steps: a) the production of 
electron-hole pairs in thermo-luminescence material by the absorption of ionising radiation 
energy, b) the trapping of the charge carriers in R and T levels, c) the de-trapping of charge 
carriers by temperature rising, d) light production by recombination of charge carriers in 
luminescence centres at R level (Bos, 2001b).  
4.5.3.2 Thermo-luminescence Dosimetry 
Tissue equivalency of some thermo-luminescent materials led to the first utilisation of 
thermo-luminescence as a radiation dosimeter in the middle of twentieth century. The perfect 
dosimetric material should have an atomic number similar to that of human tissue which is 
7.42 (Bos, 2001b; Kitis, Furetta, Prokic, & Prokic, 2000). In addition to tissue equivalency, 
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several characteristics are required for good thermo-luminescence dosimeters: a) linearity, a 
linear response over wide range of radiation dose; b) sensitivity, the amount of light 
produced per unit absorbed dose; c) independency of radiation energy; d) simple glow curve, 
resulting in a simple heating protocol; e) good mechanical strength and static chemical 
activity; f) low fading (Kortov, 2007; Rivera, 2012). The fading composes of two 
components: pre-fade, which is the decrease in thermo-luminescence dosimeter response to 
radiation; and post-fade, which is the reduction in the storage signal in thermo-luminescence 
dosimeter with time (Luo, 2008). 
Owing to their suitable dosimetric characteristics, TLDs are extensively used in many 
medical and personal monitoring applications. TLDs are applied in different areas such as 
radiotherapy and diagnostic radiology (Moscovitch & Horowitz, 2007). In diagnostic 
radiology, the main application area of TLDs is personal dosimetry (Olko, 2010). TLDs are 
also widely used by many quality assurance programmes for radiation dose measurement 
because they can assess radiation doses with backscatter when they are placed on patients or 
phantoms (European Commission, 1996; Gaona, Nieto, Góngora, Arreola, & Enríquez, 
2007). Since radiotherapy aims to maximise the radiation dose to tumour tissue and minimise 
it to normal tissue, it is necessary to use suitable dosimeters for assessing this purpose. The 
most suitable dosimeters are TL dosimeters because they have the ability for in vivo dose 
measurement (Venables, Miles, Aird, Hoskin, & Group, 2004).  
There are currently several commercial groups of TLDs. According to the material from 
which dosimeters are manufactured, they are classified into LiF, CaF2, and Al2O3 groups. The 
LiF group include TLD-100, TLD-100H, TLD-600, and TLD-600H. TLD-100 was the first 
used TL dosimeter. It is characterised by its good tissue equivalency (Z=8.04), its sensitivity 
to low doses, its wide range of linear response (10µGy-10Gy), and its slow fading rate of 
around 5-10% per year. TLD-100H dosimeters can be used in diagnostic radiology and are 
around 20 times more sensitive than TLD-100 detectors. They have a wider dose range (1 
µGy – 20 Gy), and lower fading rate of around 3% per year. The TLD-600 H dosimeter is 
used for neutron dosimetry. The main drawback of the CaF2 group is their fading rate - 16% 
per 2 weeks and 15% per three months for TLD-200 and TLD-400. TLD-500 which is made 
of Al2O3 has a useful dose range of 0.05 µGy – 10 Gy, with a 3% per year fading rate 
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(Kortov, 2007). The selection of dosimeter depends on the application in which the dosimeter 
is to be used. For diagnostic radiology the required dose range is 0.001-10 mSv, while that 
for radiotherapy is 0.1-100 mSv (Rivera, 2012).  
The main advantages of TLDs are their accuracy and precision. Their small physical size, 
availability in different forms and tissue equivalency make TLDs suitable for in vivo 
measurements and they can be used within phantoms to measure the radiation dose at 
different depths and locations. Moreover, TLDs are easy to handle because they are not 
sensitive to light. Other important characteristics of TLDs are they are independent of 
radiation direction in their measurements, and consequently the backscatter is included in 
their readings. Despite the advantages listed above, TLDs have many drawbacks. Firstly, 
they cannot give instant measurements because the readout and calibration processes are time 
consuming. Secondly, TLDs allow only one time reading during heating because of the 
signal efface during the readout procedure. Finally, in some types of TLDs the storage signal 
may fade with time due to the effect of temperature or light (Olko, 2010; Rivera, 2012).  
 4.5.4 Optically Stimulated Luminescence Dosimeters (OSLD) 
OSLDs were developed in the late 1990s. The operating principle of these dosimeters is 
similar to that of TLDs where the luminescence process is stimulated by laser lighting rather 
than heat (Canadian Nuclear Safety Commission [CNSC], 2012). These detectors are made 
of aluminium oxide (Al2O3) which emits visible light. The amount of emitted light is 
proportional to the absorbed dose. For occupational radiation monitoring purposes OSLD is 
preferred over TLDs (Bushong, 2013).  
Within this thesis the organs dose measurement was performed using TLD 100-H 
dosimeters. The selection of TLDs 100-H was based on their human tissue equivalency 
making them more suitable for in vivo dosimetry where they are accommodated inside 
human body physical phantom. Since the focus of this study is the other organ radiation dose 
resulting from scattered radiation (small dose), the high sensitivity of TLDs and their linear 
response at low energies makes them suitable for dose measurements. The possibility of 
using a large number of TLDs for many organs dose measurement at the same time is of 
great importance in this work. This enables the dose measurement received by all body 
organs at single exposure. However, the main disadvantages of using TLDs are: it is a time 
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consuming process and has a small percent of error.  More details about the using of TLDs 
and the errors associated with their readings are available in methodology chapter (section 
5.2.1, page 100). 
4.6 Breast Tissue Equivalent Materials 
Anthropomorphic phantoms made of tissue substitutes have been used extensively to 
physically represent human anatomy and mimic its radiation attenuation characteristics in 
dosimetric studies (Winslow, Hyer, Fisher, Tien, & Hintenlang, 2009). The purpose of using 
phantoms in dosimetric studies is to simulate the patient‘s radiation exposure during specific 
radiological procedures in order to assess organ radiation dose or to mimic conditions for 
reference calibration of a dosimeter system or beam (e.g. radiotherapy beam calibrations by 
the use of water phantoms) (Green, Palethorpe, Peach, & Bradley, 1999). Materials that have 
similar X-ray scattering and absorption to tissue are useful phantom materials (Farquharson, 
Spyrou, al-Bahri, & Highgate, 1995). Additional requirements for phantom material are that 
they should remain stable/constant over time, especially those with complex designs which 
need to be used for a long time. Phantoms are also necessary for the evaluation of 
radiographic equipment by the interpretation of phantoms images (Byng, Mainprize, & 
Yaffe, 1998).  
In mammography, breast tissue equivalent materials are widely used to produce phantoms 
which simulate female breast. Breast phantoms are essential devices for the evaluation of 
mammographic equipment performance including X-ray field uniformity, AEC consistency, 
primary to scatter radiation ratio, grid and image receptor performance (IAEA, 2011). Since 
mammography is associated with biological effects to human breast tissues (Ossati, 2015), 
phantoms are also utilised for the assessment of mammographic image quality (resolution 
test) and for the accurate measurement of radiation dose (Argo, Hintenlang, & Hintenlang, 
2004; Poletti, Goncalves, & Mazzaro, 2002). Phantom materials are models for simulating 
the X-radiation interaction with breast tissues and therefore they should have similar 
elemental composition and density to real breast tissue. These materials should scatter and 
absorb X-ray similar to breast tissues. In other words, phantom materials should have mass 
attenuation coefficients similar to that of breast tissues (Farquharson et al., 1995; Poletti et 
al., 2002).  
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There are many kinds of phantoms used to simulate breast tissue for mammography-related 
experiments (Sobotka et al., 2012). Poly(methyl methacrylate) (PMMA) slabs of different 
thicknesses have been used by many international organisations as a model to simulate breast 
tissue (Dance et al., 2009). The European Commission (1996) stated that although PMMA is 
not an exact tissue substitute, it can be used to simulate an average breast to enable correct 
operation for the X-ray machine under automatic exposure control. Glandular tissue dose 
may also be calculated by converting the dosimeter reading. The PMMA phantom of 
standard breast has a thickness of 45 mm either rectangular ≥150 mm X 100 mm or 
semicircular with a radius of ≥100 mm (European Commission, 2006). NHSBSP (2009) use 
a 45 mm thickness PMMA phantom to measure the radiation dose to a standard breast which 
has a thickness of 53 mm. Other breast thicknesses and compositions are simulated by 
different thicknesses of PMMA slabs. Moreover, IAEA (2011) propose PMMA slabs of 20, 
45, 70 mm thicknesses as a basic requirement for digital mammography system quality 
assurance. The thickness precision for slabs should be ±0.5 mm and the shape either 
rectangular ≥150 mm X 100 mm, or semicircular with radius ≥120 mm. Regarding the area 
of the breast phantom, it is not considered to be an important quantity since it causes only 
small variations in measured radiation dose (Dance, 1990), this difference may be as little as 
3% (Benevides  et al., 2011).  
Since many recent automatic exposure control (AEC) systems depend on breast thickness, 8 
mm thickness polystyrene spacers are utilised to make the PMMA thickness equal to the 
thickness of simulated breast (European Commission, 2013). However, the use of spacer may 
affect the radiation scattering profile of the phantom (Bouwman et al., 2013). To avoid 
spacer issues, Bouwman et al. (2013) recommended the use of PMMA slabs with 
polyethylene (PE) slabs to make the phantom thickness equal to that of simulated breast. The 
use of PMMA-PE slabs as breast simulators in dose estimation studies gives a maximum 
error of 10% or less (Bouwman et al., 2013). 
The mammographic accreditation phantom is another type of mammographic phantom which 
simulates a 45 mm thick compressed breast of about 50% glandularity. It is designed to 
comply with the phantom specifications of the Mammography Quality Standard Act 
(MQSA) and the American College of Radiology (ACR) quality control programmes. The 
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mammography accreditation phantom is a 102 mm X 108 mm X 44 mm-thick phantom. It is 
made of a 7 mm wax block and contains many test objects. The wax block is placed on a 34 
mm thick PMMA base and covered with 3 mm thick PMMA (Cardinal Health, 2003). These 
phantoms are produced by Nuclear Associates and Computerised Imaging Reference System 
(CIRS). The main disadvantage of this type of phantom is that there is a big radiological 
difference between these phantoms and real breast tissue at low X-ray energies (Argo et al., 
2004).  
CIRS photo-timer consistency testing slabs (BR-12) are resin type slabs used to simulate 
breast tissue. These slabs are designed to comply with ACR and MQSA recommendations 
for mammography quality assurance. CRIS slabs are available in different glandular 
equivalencies but those equivalent to 47% glandularity breast are widely used. They are 
better than PMMA slabs because their thickness is tightly controlled in the manufacturing 
process and they simulate breast tissue accurately (Computerized Imaging Reference 
Systems [CIRS], 2013). BR-12 fabricated inside a PMMA box has also been used as breast 
tissue substitute in the commercially available ‗Rachel‘ breast phantom. The design of this 
phantom was firstly described by Yaffe , Byng, Caldwell, and Bennett (1993) and it was 
based on matching the optical densities distributed within the mammographic image with the 
BR-12 thickness required to produce the same optical density. In the early stage of this 
phantom‘s development the mammographic optical densities were calibrated against PMMA 
thicknesses which produce the same optical densities in the mammographic image (Caldwell 
& Yaffe, 1990), then Yaffe  et al. (1993) improved the work to use BR-12 instead of PMMA. 
Poletti et al. (2002) studied the scattering properties of CIRS slabs, they stated that the 
adipose tissue equivalent material in CIRS slabs is a good simulator for breast adipose tissue, 
but for glandular tissue it is bad simulator.  
Hydrophilic materials which are commercially known as bio-gels are polymers insoluble in 
water, but are swollen by it. When these materials are fully hydrated, they will be in 
equilibrium with their environment. The amount of uptake water to reach the equilibrium is 
dependent on the number of hydrophilic centres in the chains of the monomer (Farquharson 
et al., 1995). Two types of these materials, known as ED4C and ED1S, have been 
experimentally tested as breast tissue equivalent materials by Farquharson et al. (1995). They 
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used a finely collimated photon beam and high purity germanium detector to assess the linear 
attenuation coefficient of the gels under different hydration conditions. They found that both, 
in dry and completely hydrated states, are unsuitable to simulate adipose tissue because their 
linear attenuation coefficients are higher than that of adipose tissue and that of the overall 
breast tissue. However, the gels were found to be good simulators for human body soft tissue 
(Farquharson et al., 1995).  
A template of an epoxy resin was used to build a series of breast phantoms called BRTES. 
Different chemicals were added to this template to get the required radiological features. 
These chemicals are polyethylene powder, magnesium oxide powder, phenolic microspheres, 
and a hardener (Jeffamine). The phantoms of this series can be made to simulate different 
breast thicknesses and densities depending on the compositions of the materials used. By 
changing the ratios of these compounds, the physical properties and mass attenuation 
coefficients can be varied thereby resulting in different breast densities. In order to facilitate 
the dosimetric comparison with the ACR phantom, BRTES phantoms have been designed to 
have approximately the same dimensions (108 mm X 108 mm). The correlation of 
compressed breast thickness with breast density was considered when these phantoms were 
created. Despite their advantages, the accuracy of BRTES phantoms may be affected by the 
mixing process of different compounds and air bubble formation within the mixture (Argo et 
al., 2004).    
Polyvinyl alcohol (PVAL) dissolved in 50:50 mixture of water and ethanol has been used to 
simulate breast tissue (Price, Gibson, Tan, & Royle, 2010). The linear attenuation coefficient 
of the resultant PVAL gel was measured using a tungsten anode beam with 30 kV and 4 
mAs, filtered by 30 μm molybdenum to obtain a mono-energetic characteristic beam of 
molybdenum (17.5kV photons). Price et al. (2010) found, at this energy, the linear 
attenuation coefficient of the PVAL was acceptable (0.76 – 0.86 cm−1 for 5% - 20% 
weight/volume) compared to that of breast with 50% glandularity (0.8 – 0.9 cm−1 in different 
publications). A 0.02 difference in effective atomic number between phantom material and 
50% glandular breast tissue has been reported by Koukou et al. (2015). Although, the PVAL 
gel was unstable over time, its low cost and mechanical properties, being similar to breast 
tissue, encourage many researchers to use it as a breast tissue substitute. The same phantom 
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composition with simulated lesions made of PVAL mixed with radiographic contrast agent 
was used by Ossati (2015) to analyse the effects of breast compression magnitude on lesion 
visibility. Moreover, Koukou et al. (2015) utilised the same phantom design with simulated 
calcification lesions to assess the mammographic image quality and MGD of dual energy 
images.  
There are many other kinds of anthropomorphic breast phantoms made of different breast 
tissue equivalent materials. One of these phantoms is made from a mixture of refined lard as 
an adipose tissue equivalent material and fresh egg white to simulate the glandular tissue 
(Freed et al., 2011). The mixing process should be achieved in controlled laboratory 
conditions. Depending on the mold shape in which the mixture is poured, this phantom can 
simulate both compressed and non-compressed breasts. For mammographic use the mixture 
can be put into a compressed breast mold with 4.5 cm thickness, while for MRI use the non-
compressed breast mold can be used. Its instability over time, lack of simulated breast skin 
and the advanced chemical laboratory required to produce this phantom are its main 
drawbacks (Freed et al., 2011). 
On the other hand, Saito (2007) used a homemade phantom to assess mammographic image 
quality and MGD of dual energy subtraction mammography. The compressed breast phantom 
used in Saito‘s (2007) work was a box of PMMA filled with olive oil to simulate the breast 
adipose tissue, and PMMA spheres of different diameter to simulate the glandular tissue 
distributed within breast fat. A blend of distilled water and olive oil in flexible plastic 
containers, to simulate different breast thicknesses and thereby different breast densities, was 
also used to simulate breast tissues in both the FFDM and DBT examinations to assess MGD. 
Distilled water was used as a glandular tissue equivalent material and olive oil analogs for 
breast adipose tissue (Feng & Sechopoulos, 2012). In brief, water is the best material to 
simulate glandular tissue in breast phantoms because it has a linear scattering coefficient 
similar to that of glandular tissue (Poletti et al., 2002). 
Although PMMA does not accurately simulate breast tissue, it is the most common material 
used as a breast tissue substitute by many international dosimetry protocols and many 
researchers because it is cheap, available, and consistent over time. PMMA is manufactured 
as slabs in order to simulate compressed breasts of different thicknesses. However, the main 
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limitation of the PMMA phantom is that its thickness is less than the thickness of the 
simulated breast. For the simulation of average breast which is 53 mm, a 45 mm PMMA 
thickness is required. To overcome this issue, the European Commission (2006) and IAEA 
(2011) recommended the use of 8 mm thickness polystyrene spacers between PMMA slabs. 
The use of polystyrene spacer results in X-ray scattering different from that resulted from 
breast tissue due to air gaps within the phantom. Therefore, in this work additional slabs of 
polyethylene are utilised with PMMA slabs to make the phantom thickness equal to 
simulated compressed breast thickness as recommended by Bouwman et al. (2013). More 
information about the PMMA-polyethylene phantom design used in this thesis is presented in 
section 5.2.3 (page 111).  
4.6 Chapter Summary 
Cancer incidence is the prominent stochastic effect of radiation exposure. Controversy about 
the risk of radiation-induced cancer at low radiation dose levels (diagnostic radiology range) 
has been outlined in the reviewed literatures. Presently LNT is the most reasonable model to 
describe the association of cancer incidence with low radiation dose. LTN is recommended 
by the ICRP and the Academy of Sciences. According to the LNT model, no radiation dose, 
however small, is safe and risk free. For mammography, since the glandular tissue is the 
radiosensitive portion of the breast, MGD is widely used to quantify the radiation risk. 
However, the radiation risk to other organs from mammography is not captured by MGD, 
suggesting that whilst MGD is a simple approach to quantifying risk, it does have limitations. 
Effective dose is the internationally accepted method used for considering the radiation risk 
to all body tissues from an X-ray examination. Effective dose calculations are dependent on 
the tissue weighting factors published by the ICRP. These factors are averaged for both sex 
and age. Since women at different ages are the target of screening mammography, a more 
reliable quantity is required to quantify the radiation risk from screening mammography; 
such an approach would take into account gender and age. On reviewing the literature it can 
be proposed that the use of effective risk as an alternative method to describe the risk of 
radiation-induced cancer from screening mammography would be reasonable, as it takes into 
account gender and age. Effective risk calculations are not more complicated than effective 
dose calculations and they are heavily dependent on age/tissue specific lifetime attributable 
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risk (LAR), as published in the BEIR VII report by the National Academy of Sciences. 
Moreover, the generated data from effective risk calculations may be more understandable by 
general public than effective dose calculations. 
Dosimetric studies cannot be directly undertaken on patients because hazardous ionising 
radiation is involved. Therefore, two alternative methods can be used. The first method 
includes the use of computer programmes based upon Monte Carlo simulations. These were 
initially used to develop nuclear weapons and then their use was extended to medical physics 
simulations. In the second method, human body tissue equivalent materials can be used to 
construct phantoms which use with different types of dosimeters to evaluate the radiation 
dose received by body tissue and organs during specific radiological procedures. In 
mammography, PMMA is the most commonly used material to simulate compressed breast 
tissue. The main disadvantage of the PMMA phantom is that the equivalent thickness of 
PMMA is less than the thickness of simulated breast. To overcome this problem the 
European Commission recommend the use of polystyrene spacers between the PMMA slabs, 
but this may affect the X-ray scattering by the phantom and the use of PMMA-PE phantom is 
more reasonable method.  
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Chapter Five 
Material and Methods 
 
5.1 Chapter Overview 
The aim of this thesis is to develop a new method for estimating radiation risk from screening 
mammography. According to this method, the effective risk is used as a quantity to assess the 
radiation risk. An experimental approach is used for the calculation of the effective lifetime 
risk of radiation-induced cancer from screening mammography for different client ages and 
different country-based mammography screening programmes. To achieve this, an accurate 
measurement of radiation dose received by the examined breast and other body tissues was 
required. An ATOM dosimetry phantom, a bespoke breast phantom designed from best 
available evidence, TLD dosimeters and a range of mammography machines were used. A 
flowchart in Figure (5-1) demonstrates the main six stages of the methods used in this PhD 
thesis.  
This chapter includes a comprehensive explanation of the materials and methods used in this 
thesis. The initial section comprises of the materials and methods utilised for organs dose 
measurement during screening mammography. Firstly, the errors associated with organs dose 
measurement due to the uncertainty of the dosimeters are considered. These errors include 
homogeneity and reproducibility errors associated with TLDs. Next, the calibration method 
for TLDs against a solid state dosimeter, used to convert TLD charge to a radiation dose 
value, is explained. The TLDs were accommodated inside a human tissue equivalent ATOM 
dosimetry phantom in order to directly measure the radiation dose received by 20 types of 
radio-sensitive tissues including brain, salivary glands, thyroid, oesophagus, thymus, heart, 
lung, stomach, liver, gall bladder, spleen, pancreas, adrenals, kidneys, intestine, urinary 
bladder, ovaries, uterus, bone marrow (in different locations), and the contralateral breast 
tissues. Two breast phantoms were used; one to simulate the examined breast in a CC 
projection and the other to simulate the breast in an MLO projection. Both the ATOM 
phantom (loaded with TLDs) and the breast phantom were positioned on sixteen FFDM 
systems in order to replicate typical screening mammography scenario. For each machine 
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four exposures were performed; CC and MLO for each breast. Three exposures were made 
for each projection in order to further minimise random error.  
The latter sections concentrate on the calculation of examined breast MGD, effective dose 
and the risk of radiation-induced cancer from screening mammography. Internationally 
recommended procedures have been used to calculate MGD, effective dose, and effective 
risk for 25-75 year old clients using organ doses data measured from sixteen FFDM systems. 
As described by IPEM (2005), the examined breast MGD was calculated using incident air 
kerma and conversion factors. Tissue weighting factors listed by the ICRP (2007) were 
utilised to calculate the effective dose for one screening visit for each of the sixteen FFDM 
systems. The effective risk was calculated using BEIR VII report lifetime attributable risk 
factors. The effective risk values are finally used to calculate the total effective risk during a 
female‘s lifetime. The total effective risk data were subsequently utilised to establish three 
risk models that can be easily used by practitioners to assess the total effective risk value for 
different screening categories generating more understandable data for general public than 
MGD or effective dose. One of these models was based on mathematical regression and the 
other two models were based on data extrapolation from a series of graphs. The main purpose 
of these risk models is to provide an accurate and easy method for the determination of 
radiation-induced cancer from screening mammography. 
The last section comprises of the method for using a contralateral breast shield in order to 
minimise unnecessary radiation dose to breast tissue. In this section details about the design 
and equivalent lead thickness estimation for the contralateral breast shield have been 
included.   
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Figure (5-1) A flowchart illustrating the methods used in this PhD thesis. 
 
TLDs 
preparation 
• Determination of errors associated with TLD readings due to 
sensitivity and reproducibility. 
• TLDs calibration against a solid state dosimeter. 
• TLDs annealing before each measurement. 
 
Organ dose 
measurement 
• Examined breast MGD calculation (incident air kerma measurement 
and HVL estimation) 
• Other organ dose measurement by TLDs accommodated inside ATOM 
phantom positioned in contact with breast phantom on FFDM. 
• Data reliability investigation 
 
Effective risk 
calculation 
• Extrapolation of LAR for each year of female life using three different 
methods (best fit lines, linear relationship, and step approach)   
• Calculation of the effective risk of one screening mammography 
session for each year of female lifetime between 25-75 year. 
 
Total effective 
risk 
calculation 
• Total effective risk calculation for 48 worldwide screening 
programmes of different screening commencement/cessation ages and 
frequencies.  
 
Effective risk 
modelling 
• Three methods have been used to model the total effective risk of any 
screening category in related to commencement/cessation ages and 
frequency of screening (mathematical regression, graphical 
extrapolation of total effective risk, and graphical extrapolation with 
including MGD variations of different FFDM machines).  
 
Contralateral 
breast shield 
• Determination of the contralateral breast dose contribution in effective 
dose and effective risk). 
• Contralateral breast shield design (shape and lead thickness) 
• Determination of contralateral breast shield effect on total effective 
risk of worldwide screening programmes for 4 FFDM machines. 
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5.2 Organ Dose Measurement 
280 Harshaw TLD-100H dosimeters (Thermo Scientific, USA) (section 4.5.3.2, page 87) 
were placed inside a CIRS adult ATOM dosimetry phantom (CIRS Inc, Norfolk, Virginia, 
USA) in order to measure the absorbed radiation dose to body tissues and organs during 
screening mammography and for a complete screening visit (cranio-caudal [CC] and medio-
lateral oblique [MLO] for each breast, sections 3.6.1 on page 50 and 3.6.2 on page 51). The 
selection of radiosensitive organs to which radiation absorbed doses were measured 
depended on the ICRP (103) recommendations (ICRP, 2007). 
5.2.1 TLDs  
TLD-100H (LiF:Mg,Cu,P) dosimeters (Thermo Scientific, USA) were used to measure organ 
radiation dose during screening mammography. This type of dosimeter was chosen because 
of their sensitivity, size and tissue equivalency making them suitable for in vivo dose 
measurements. TLD-100H dosimeters are 20-50 times more sensitive than TLD-100. This 
high sensitivity is essential because of the relatively small radiation doses measured within 
this thesis. The small size (0.125 X 0.125 X 0.035 inches) of TLD-100H dosimeters 
minimises any resultant X-ray field distortion. Another important characteristic of TLD-
100H dosimeters is their tissue equivalency (Zeff TLD = 8.04 compared to Zeff tissue = 7.42) 
which makes them have similar response to radiation as would human tissue (Kitis, Furetta, 
Prokic, & Prokic, 2000; Triolo, Brai, Bartolotta, & Marrale, 2006). TLD-100H dosimeters 
used in this thesis can measure radiation doses over a wide range, 1 pGy - 10 Gy, with a 
linear response across this energy range. The fading rate of these dosimeters is negligible, 
approximately 3% per year (Thermo Scientific, 2015), making them more suitable for this 
thesis because TLDs were irradiated in hospitals and read out in the university laboratory at 
different points. Consequently, systematic errors such as those resulting from dosimeter 
energy response, dosimeter size, and radiation field perturbation by dosimeters are minimised 
with the use of TLD-100H (Camargo-Mendoza, Poletti, Costa, & Caldas, 2011). Since the 
TLDs are sensitive to small scratches and surface contamination, which may affect the light 
emission process, they were carefully handled by the use of Dymax 5 vacuum tweezers 
(Charles Austen Pumps, Surry, UK), see Figure (5-2). Mechanical tweezers and fingers are 
not recommended to be used for TLD handling (Thermo Scientific, 2015).    
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(a)                                                                               (b) 
Figure (5-2) Illustrates TLD handling (a) Vacuum pump (b) TLDs handling by vacuum 
tweezers. 
5.2.1.1 TLDs Reading 
The TLD reading system comprised of a Harshaw 3500 TLD reader (Thermo Scientific, 
USA) with WinREMS software installed on a personal computer (PC), Figure (5-3). The 
reader consists of a drawer containing a metallic tray suitable for a single TLD, wherein the 
irradiated TLD is heated, then a photomultiplier tube (PMT) receives the thermo-luminescent 
light emitted by the TLD and converts it to an electronic signal and an electrometer records 
the output signal of the PMT. The intensity of emitted thermo-luminescent light is related to 
the reader heating rate of irradiated TLD. The graphical plot of light intensity versus 
temperature is the TLD glow curve, see Figure (5-4). The use of a constant heating rate is 
essential for accurate dose measurements by TLDs (Izewska & Rajan, 2005); the Harshaw 
3500 TLD reader is automatically controlled for rate. 
The TLD-100H reading process in the Harshaw 3500 TLD reader has four phases. The first 
phase, known as preheat phase, persists for approximately 12 seconds in which the TLD is 
heated to 134
o
C. After 134
o
C has been achieved the TLD light signal is detected. The 
acquisition phase ends at 239
o
C after 30 seconds. After this the annealing phase continues for 
10 seconds. The purpose of the anneal phase is to clear the TLDs of all residual exposure 
(signal). Finally the cooling phase cools the annealed TLD from 239
o
C to 60
o
C. In order to 
provide a consistent temperature during reading and to avoid any background light signals 
being produced by the TLD reader metallic tray and by the impurities in the air, the TLDs are 
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read in a constant pressure nitrogen atmosphere provided by a regulated compressor tank 
(Collins, 2005; Savva, 2010).    
 
Figure (5-3) Shows the TLD reading system. 
 
 
 
Figure (5-4) Shows a TLD 100H glow curve. 
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5.2.1.2 TLDs Preparation 
Prior to use, TLDs underwent a process of preparation which included annealing and 
determining errors associated with their readings. These errors are mainly attributed to 
differences in sensitivity between TLDs and the consistency of TLDs. As recommended by 
the manufacturer (Thermo Scientific, 2015), TLDs were annealed at 240
o
C for 10 minutes in 
a special rapid cooling high temperature (TLD/3) model oven (Carbolite, England, UK) using 
an annealing tray, see Figure (5-5). This oven is equipped with a Eurotherm 3508 
temperature programmable controller which allows accurate annealing temperature 
regulation. The main purpose of the annealing process is to ensure that TLDs are free from 
any residual charge. TLD overheating should be avoided as this can affect TLD sensitivity 
(Thermo Scientific, 2015). After annealing, an aluminium block is used to ensure a rapid 
cooling rate because the TLD cooling rate may affect its energy response (Lisa, Claire, 
Helen, Mamoon, & Tomas, 2004). According to Furetta and Weng (1998) the TLDs 
sensitivity is dramatically changed as the cooling rate changes. However the selection of best 
cooling rate depends on the TLDs material.  
According to the European Commission (1996) the total uncertainty in TLD dosimetric 
measurements should be less than 10%. Therefore, the TLDs sensitivity and consistency 
were established. As discussed in section 3.4.1 (page 34), the mammographic X-ray beam is 
designed to be non-uniform to accommodate breast thickness uniformity differences. 
Therefore, a Wolverson Arcoma Arco Ceil general radiography X-ray machine (Arcoma, 
Annavägen, Sweden) was used to expose the TLDs to investigate their sensitivity and 
consistency. For more accuracy, the X-ray beam uniformity of this machine is tested using an 
Unfors Multi-O-Meter solid state dosimeter (Billdal, Sweden). The dosimeter reading is 
recorded at the four sides of the X-ray field for the same exposure factors, see Figure (5-6). 
There is a difference in dosimeter readings across the anode and cathode axis due to the 
anode heel effect but this was negligible across the other perpendicular axis. Therefore, 
during the exposure to calculate sensitivity and consistency, the TLDs were arranged to be as 
close as possible to the midline between anode and cathode sides to minimise anode-heel 
effect, see Figure (5-7).  
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(a)                                                                        (b) 
Figure (5-5) Shows the TLD annealing equipment (a) Annealing oven (b) Annealing tray on 
an aluminium cooling block. 
 
Figure (5-6) Illustrates dose measurements using Unfors Multi-O-Meter solid state dosimeter 
for X-ray beam uniformity investigation.
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Figure (5-7) Illustrates the TLD positioning during exposure. The TLDs are positioned as 
close as possible to the central ray to minimise the impact of the anode-heel effect. 
 
For improved TLD reading accuracy the sensitivity factor for each TLD should be estimated 
(Costa et al., 2010) using the following equation:   
    
  
 
 
Where Ecc is the correction coefficient for a given TLD, R is the individual TLD reading, 
and Ri is the average reading of all TLDs in the batch (Shirazi, Mahdavi, Khodadadee, 
Ghaffory, & Mesbahi, 2008).  However, since a large number of TLDs were used, all TLDs 
were exposed three times and according to their average response they were divided into five 
groups of homogeneous sensitivity. The sensitivity difference (coefficient of variance, 
standard deviation of TLD readings divided by the average of these readings) for each group 
was less than 3%; see Table (5-1) which contains the TLDs readings summary for sensitivity 
investigation.  
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Table (5-1) Demonstrates the TLD readings for sensitivity investigation.   
TLDs 
group 
TLDs readings (nC)* Coefficient of 
variance (%) Minimum Maximum Average SD 
Group 1 33.20 35.95 35.00 0.79 2.26 
Group 2 36.24 38.71 37.73 0.64 1.70 
Group 3 38.77 40.96 39.84 0.65 1.63 
Group 4 41.01 43.57 42.18 0.75 1.78 
Group 5 43.64 47.14 44.74 0.89 1.98 
*(nC) means nano-Coulomb 
 
For TLD consistency estimation, all TLDs were exposed and read three times with time 
intervals of around five days between each exposure, see Table (5-2) which includes the 
readings for 100 randomly selected TLDs after exposing them to an X-ray beam at the same 
exposure factors on the three different occasions. TLD responses were analysed using SPSS 
22.0 (IBM, Armonk, New York, USA) to determine TLD consistency (Intraclass 
Correlation). The calculated consistency was 99%. The total uncertainty of the dose results, 
which was due to both sensitivity and consistency, was 4%. To improve accuracy further, the 
average background signal of three unexposed TLDs was subtracted from the readings of 
exposed TLDs (Sulieman et al., 2007). As described by Tootell, Szczepura, and Hogg 
(2013), the TLDs were calibrated against an Unfors Multi-O-Meter solid state detector 
(Billdal, Sweden) as a reference dosimeter; this was placed on three slabs (1 cm thick each) 
of Perspex scatterer (Tootell et al., 2013), see Figure (5-8). To minimise possible errors due 
to TLD response energy dependence, a calibration was accomplished for each 
mammographic machine to be used in organs dose measurement using the same beam 
qualities as that utilised for phantom exposure (Olgar, Bor, Berkmen, & Yazar, 2009).The 
aim of the calibration process is to convert the output charge reading of TLDs to their 
equivalent radiation dose. 
 
Figure (5-8) Demonstrates the TLD calibration process against the Unfors solid state 
dosimeter on three Perspex slabs.   
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Table (5-2) Shows the consistency of TLD readings on three different occasions. 
TLD 
number 
TLD readings (nC) TLD 
number 
TLD readings (nC) TLD 
number 
TLD readings (nC) 
R1 R2 R3 R1 R2 R3 R1 R2 R3 
1 5.61 5.87 5.43 34 5.22 5.30 4.99 67 4.83 4.93 4.59 
2 4.37 4.48 4.19 35 5.53 5.56 5.40 68 5.44 5.28 4.98 
3 5.70 5.68 5.44 36 5.42 5.48 5.17 69 4.75 4.75 4.59 
4 5.76 5.96 5.56 37 5.10 5.06 4.81 70 5.00 5.06 4.79 
5 5.71 5.86 5.52 38 5.21 5.22 5.01 71 5.95 6.05 5.74 
6 5.71 5.81 5.55 39 5.14 5.20 5.00 72 6.00 5.87 5.65 
7 6.11 6.18 5.84 40 4.98 5.08 4.82 73 4.88 4.92 4.58 
8 5.63 5.65 5.46 41 5.15 5.22 4.97 74 5.50 5.59 5.29 
9 5.70 5.56 5.20 42 5.20 5.07 4.69 75 4.82 4.93 4.70 
10 6.22 6.17 5.95 43 5.61 5.63 5.33 76 5.46 5.47 5.15 
11 5.79 5.83 5.26 44 4.89 4.98 4.63 77 5.25 5.25 4.95 
12 5.96 5.89 5.66 45 4.83 5.02 4.70 78 4.92 4.97 4.67 
13 5.60 5.65 5.34 46 5.14 5.16 4.87 79 5.69 5.71 5.33 
14 6.00 6.04 5.69 47 4.91 4.97 4.73 80 5.02 5.15 4.88 
15 5.29 5.28 5.05 48 4.93 4.97 4.74 81 4.76 4.82 4.89 
16 5.50 5.56 5.26 49 5.04 5.07 4.82 82 5.12 5.09 4.79 
17 6.10 6.20 6.00 50 5.59 5.59 5.43 83 5.07 5.17 4.95 
18 5.38 5.33 5.06 51 5.56 5.59 5.33 84 4.52 4.57 4.28 
19 5.77 5.80 5.61 52 5.21 5.27 5.09 85 4.50 4.55 4.36 
20 6.01 6.07 5.88 53 4.97 5.02 4.75 86 4.75 4.86 4.59 
21 5.92 5.95 5.64 54 5.38 5.51 4.90 87 4.73 4.91 4.53 
22 5.57 5.65 5.36 55 5.23 5.29 5.20 88 5.03 4.90 4.68 
23 5.22 5.11 4.68 56 5.38 5.39 5.16 89 4.61 4.67 4.45 
24 6.08 6.05 5.77 57 5.03 5.06 4.79 90 4.67 4.75 4.56 
25 5.08 5.15 4.90 58 5.24 5.22 5.06 91 5.14 5.38 5.15 
26 5.13 5.14 4.84 59 5.51 5.64 5.26 92 4.98 4.95 4.74 
27 5.55 5.56 5.30 60 5.47 5.54 5.29 93 4.94 4.99 4.83 
28 5.44 5.51 5.18 61 5.04 4.93 4.71 94 5.35 5.33 5.04 
29 5.46 5.59 5.37 62 5.70 5.67 5.44 95 5.01 4.92 4.74 
30 5.67 5.72 5.44 63 5.62 5.75 5.41 96 4.84 4.80 4.61 
31 5.77 5.86 5.58 64 4.98 4.94 4.75 97 4.60 4.68 4.41 
32 5.53 5.56 5.33 65 5.18 5.26 4.95 98 4.65 4.69 4.47 
33 5.28 5.31 5.05 66 5.36 5.42 5.13 99 4.99 4.93 4.75 
Intraclass Correlation-Consistency = 99% 100 5.20 5.07 4.69 
Usually the calibration process is accomplished for a complete batch of TLDs because the 
calibration of individual TLDs is too time consuming and the individual approach shows 
only a minimal improvement in accuracy compared with the batch approach (the sensitivity 
difference of TLDs within any batch was less than 3%). For greater precision, the dose-TLD 
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response curve was utilised to obtain the TLD calibration factor (Shirazi et al., 2008), see 
Figure (5-9). In this figure the solid state dose readings are presented on Y-axis against 
charge TLD readings on X-axis (R
2
 = 99.75%). The R
2
 value gives an indication that TLDs 
response is linear at this dose range. The establishment of the dose-TLD response curve 
requires TLD responses for at least five different radiation doses (e.g. at 10, 30, 50, 70, and 
90 mAs) using the same beam quality (kV and filtration). In each case, the average of three 
TLD responses was used to minimise random error. Consequently, for TLD calibration a 
total of 15 TLDs are required in addition to another three for background measurement and 
correction. The whole process of TLD calibration was repeated for each TLD group and for 
each mammographic machine used in the organ dose measurement.  
 
Figure (5-9) Represents a sample of calibration curve of TLDs against Unfors solid state 
dosimeter. 
 5.2.2 Anthropomorphic ATOM Dosimetry Phantom 
To simulate a women‘s body, an adult ATOM dosimetry phantom, model 701, (CIRS Inc, 
Norfolk, Virginia, USA) was used, see Figure (5-10). The ATOM phantom is 173 cm high 
and weighs 75 kg with chest dimension of 23 cm (AP) by 32 cm (left to right / side to side). 
It is made from resins and polymers by CIRS computer models which consider the tissue to 
be simulated, x-ray imaging modality energy level, and raw material to be utilised. The 
phantom comprises of 39 cross-sectional contiguous slices which are 25 mm thick. Within 
the slices there are pre-drilled holes which are placed at specific positions in 20 
 109 
 
radiosensitive organs. Using the manufacturer's TLD location map (CIRS Tissue Simulation 
and Phantom Technology, 2012), the absorbed radiation dose for each organ was calculated 
by averaging the radiation dose values inside the organ. The number of TLDs used for each 
organ are listed in Table (5-3). These numbers have been determined by the manufacturer, 
for this phantom model, and are consistent with other researchers (Tootell et al., 2013).   
 
Figure (5-10) Shows the ATOM dosimetry phantom used to simulate women‘s body during 
screening mammography. 
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Table (5-3) Demonstrates the number of TLDs utilised for dose measurements inside each 
organ (280 TLDs in total).  
Organ 
No. of 
TLDs 
Organ 
No. of 
TLDs 
Adrenal 2 Pancreas  5 
Brain 11 Pelvis BM
* 
17 
Clavicle BM
* 
4 Ribs BM
* 
18 
Cranium BM
* 
4 Salivary glands 6 
Cervical spine BM
* 
2 Scapulae BM
* 
16 
Gall bladder 5 Spleen  12 
Heart  2 Sternum BM
* 
4 
Intestine  16 Stomach  14 
Kidneys  16 Thoraco-lumber spine BM
* 
8 
Liver  29 Thymus  4 
Lungs  36 Thyroid  6 
Mandible BM
*
 6 Urinary Bladder (UB) 13 
Oesophagus  3 Uterus 3 
Ovaries  2 
Contralateral breast (8 for each 
side) 
16 
*
BM means bone marrow. 
 
A breast attachment, from the manufacturer, was used to measure the radiation absorbed dose 
received by contralateral breast. The breast attachment is designed to simulate a standard 
breast in standing position with 50% glandularity and 350 cm
3
 breast volume. The breast 
attachments have a grid of 20 holes in each breast to accommodate the detectors (CIRS 
Tissue Simulation and Phantom Technology, 2012). As described by Parker et al. (2008) 
eight TLDs were used to measure the radiation dose received by each breast attachment. 
These TLDs were distributed depending on the anatomical quarters of the breast wherein 
four TLDs positioned in upper, lower, medial, and lateral aspects of the breast attachment 
and the other four TLDs positioned in midpoint of each breast‘s anatomical quarter, see 
Figure (5-11). Whatever their location all the TLDs were arranged to be in the midpoint 
antero-posteriorly within the breast attachment. The contralateral breast dose was obtained by 
averaging the TLD readings within the breast attachment. 
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Figure (5-11) Shows dosimeters holes in left and right breast attachments. The circled holes 
were used for TLD accommodation. 
5.2.3 Breast Phantom 
Since this thesis focuses on organ radiation dose measurement from scattered radiation 
during screening mammography, it is necessary to use a breast phantom which has X-ray 
scattering similar to that of standard breast, which is 53 mm thick and 50% glandularity. 
Breast phantom thickness, composition, shape, and area are essential factors which determine 
the phantom‘s X-ray scattering (Boone, Lindfors, Cooper, & Seibert, 2000). To simulate a 
standard breast 45 mm PMMA slabs have been used. However, this phantom thickness is less 
than that of a simulated breast. Therefore, the European Commission (2006) and the IAEA 
(2011) recommended the use of U-shaped 8 mm radiolucent polystyrene spacer between 
PMMA slabs and compression paddle to replicate standard breast thickness. However, the 
use of spacers resulted in air gaps within the phantom which affect X-ray scattering by the 
phantom (Boone et al., 2000; Bouwman et al., 2013). Therefore, a breast phantom described 
by Bouwman et al. (2013) was used as a standard breast for the purpose of this thesis. 
Bouwman‘s design consists of a 53.0 mm thick phantom containing 32.5 mm thick 
Poly(Methyl Methacrylate) (PMMA) and 20.5 mm thick polyethylene (PE) slabs. The PE 
slabs were placed above and the PMMA slabs beneath. The shape and area of the PMMA-PE 
phantom depends on the mammographic breast projection. For the average breast in CC 
projection, the shape of the compressed breast is approximately semicircular with a 95 mm 
radius. However, because the pectoral muscle is included in the MLO projection a 
rectangular phantom with 100 mm X 150 mm was used with a required thickness of PMMA 
(32.5 mm) and polyethylene (25.5 mm) (Diffey, 2012; Wang et al., 2013). Consequently, as 
recommended by the IAEA (2011) breast thickness in MLO position is 5 mm thicker than in 
CC position. 
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5.2.4 Positioning of the ATOM and Breast Phantoms 
The ATOM and breast phantoms were positioned using a full field digital mammography 
system to simulate a woman‘s position during screening mammography. In order to minimise 
errors due to differences in ATOM phantom positioning in relation to the range of 
experiments to be carried out at the same or different hospital sites, several lines were drawn 
on the ATOM phantom chest wall, see Figure (5-12). The lines (1) and (2) were useful for 
CC projection to determine the vertical and horizontal position of the CC breast phantom, 
respectively. The other three lines were for MLO projection. Line (3) was for the upper 
boarder of the MLO phantom while line (4) was for the lower boarder. Finally line (5) 
represented the transverse midline in the MLO phantom. 
 
Figure (5-12) Shows the breast phantoms position lines on ATOM phantom chest wall. 
Lines (1) and (2) are for CC positioning, and lines (3), (4), and (5) are for the MLO 
positioning. 
5.2.4.1 Positioning phantoms for MLO 
For MLO projection simulation (Figure 5-13), the gantry was tilted to 47
o
. This value of 
angulation is determined depending on ATOM phantom body contour (Mercer , Hill, Kelly, 
& Smith, 2015). The MLO phantom was centred on the detector on the chest wall side and 
the compression paddle with standard compression (100 N) was used to fix it in position. The 
ATOM phantom was arranged in contact with the breast phantom where the midpoint in the 
side of the breast phantom coincides with the centre point in the breast site on the ATOM 
phantom. The detector was placed against the ribs with its corner in the axilla (Lee, 
Stickland, Wilson, & Evans, 2003; Mercer  et al., 2015). 
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5.2.4.2 Positioning phantoms for CC 
The CC projection (Figure 5-14) was achieved with a vertical X-ray beam / perpendicular to 
the floor. Initially, the CC breast phantom was centred on the detector on the chest wall side 
and fixed in position by the compression paddle using standard compression (100 N). The 
midpoint in the side of the breast phantom was arranged to coincide with the centre point in 
the breast site on the ATOM phantom, which faced the mammography system (Kopans 2007; 
Mercer  et al., 2015). 
                                     
Figure (5-13) ATOM and MLO breast     
phantoms on FFDM system in MLO 
position. 
Figure (5-14) ATOM and CC breast 
phantoms on FFDM system in CC 
position.
The MLO and CC projections explained above were carried out for both breasts to imitate a 
clinical screening mammography event. Since automatic exposure control (AEC) is the most 
commonly used technique in screening mammography, it was also adopted to expose the 
breast phantom for the experimental work in this thesis. For each projection (CC and MLO 
for each breast) the phantom was exposed three times and then the results were averaged to 
minimise random error. TLDs were then collected and read to obtain the organ radiation dose 
for a ‗complete screening event‘. 
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5.3 Estimation of Examined Breast Dose 
Examined breast MGD was calculated as recommended by IPEM (2005) (Report 89) using 
the equation defined by Dance, Skinner, Young, Beckett, and Kotre (2000): 
MGD=K.g53.c53.s 
Where K is the incident air kerma for the phantom, g53 is a factor to convert the incident air 
kerma to MGD for a 53 mm thick standard breast, c53 is a conversion factor which allows for 
the density of a 53 mm thick standard breast, s is the spectral correction factor. The values 
for the above factors are listed in same IPEM (2005) report (89), except s factor for W/Ag 
target/filter combination which was taken from IAEA quality assurance programme for 
digital mammography, for different half-value layers (HVL) between 0.30 and 0.60 mm Al. 
For harder x-ray beams (HVL more than 0.60 mm Al) the factors presented in European 
Commission (2013) mammographic quality assurance guidelines were used. Tables (5-4) 
and (5-5) list g53 and s factors used in this thesis, respectively. 
In this thesis the c53 correction factor was not used (considered equal to 1) in the calculation 
of MGD as this factor is used for the correction of MGD from the equivalent glandularity of 
the phantom which is 29% to 50% glandularity breast. The use of this factor would mean that 
the MGD would be calculated for a 50% glandularity breast. This would introduce 
uncertainties since the other organ doses are measured for a 29% glandularity breast (the 
representing glandularity of used breast phantom).  
Table (5-4) Lists g53 factor for different HVL (European Commission, 2013; IPEM, 2005) 
HVL g53 factor 
0.30 0.155 
0.35 0.177 
0.40 0.198 
0.45 0.220 
0.50 0.245 
0.55 0.272 
0.60 0.295 
0.65 0.317 
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Table (5-5) Lists s factor for different target/filter combinations (IPEM, 2005) 
Target/filter combination s factor 
Mo/Mo 1.000 
Mo/Rh 1.017 
Rh/Rh 1.061 
W/Rh 1.042 
W/Ag
* 
1.042 
* 
this value is taken from IAEA (2011) 
 
5.3.1 Incident Air kerma Measurement 
The incident air kerma was measured using the Unfors Multi-O-Meter solid state dosimeter 
(Billdal, Sweden). This solid state dosimeter was used because it is more accurate than TLDs 
for two reasons, namely, it is a direct dose measurement tool which can avoid small errors 
associated with the TLD calibration process and backscatter is not included in the Unfors 
Multi-O-Meter solid state dosimeter reading. The use of TLDs for incident air kerma 
measurement requires division of the measured kerma value by a backscatter factor to 
eliminate the effect of backscatter (Nelson & Hill, 2011). The measurement process was 
performed using the method described by IAEA (2011). According to this method the Unfors 
Multi-O-Meter solid state dosimeter was attached to the lower surface of the compression 
paddle at the midpoint, approximately 4 cm from the chest wall. The height of compression 
paddle was arranged to replicate the breast thickness. Incident air kerma was measured using 
the same exposure factors which were used for all exposures of the breast phantom for each 
mammography machine used within this thesis (IAEA, 2011).  
5.3.2 Half-Value Layer (HVL) Estimation 
The thickness of a specific material required to attenuate the air kerma of a narrow X-ray 
beam to half of its value is known as the half-value layer (Ma et al., 2001). Mammographic 
X-ray beam half value layer is a parameter of great importance in MGD calculation (IPEM, 
2005). In this thesis the HVL of the mammographic X-ray beam was experimentally derived 
according to the procedure described by IPEM (2005) in report 89. An Unfors solid state 
dosimeter and high purity aluminium foils of thickness ranging from 0.1 mm to 0.6 mm with 
0.1 mm steps were used. The foils were placed in front of the X-ray beam window with the 
compression paddle midway between the foils and detector. During HVL assessment the 
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presence of the compression paddle is essential for accurate results. Hourdakis, Boziari, and 
Koumbouli (2009), who investigated the effect of the compression paddle on mammography 
dosimetric measurements, found that compression paddle results in beam hardening and 
hence higher HVL. Tung et al. (2010) found the use of TLDs for HVL determination is 
associated with ±7% difference compared to HVL estimated by other dosimeters type. 
Therefore, TLDs are not recommended to be used for HVL assessment (Tung et al., 2010). 
Finally, as recommended by the European Commission (1996), the HVL was graphically 
derived by an interpolation method. This was done by plotting the detector readings 
algorithms against the relevant foil thickness. For this purpose and to increase the accuracy 
of the extrapolated HVL, at least five points were used to draw the graph; see Figure (5-15). 
The HVL was estimated for each of the sixteen FFDM machines studied within this thesis. 
For same FFDM machine, the HVL of each CC and MLO projections has been assessed 
separately, if beam of different quality had been selected by AEC, see Table (5-4).  
 
Figure (5-15) Shows the graphical extrapolation method of HVL.  
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Table (5-6) Illustrates the HVL (mm Al) for CC and MLO beams for each studied 
machine. 
Mammographic 
machine number 
CC beam 
HVL  
MLO beam 
HVL  
Mammographic 
machine number 
CC beam 
HVL  
MLO beam 
HVL  
(1) 0.40 0.50 (9) 0.45 0.45 
(2) 0.60 0.65 (10) 0.55 0.55 
(3) 0.40 0.45 (11) 0.45 0.45 
(4) 0.40 0.45 (12) 0.55 0.55 
(5) 0.45 0.45 (13) 0.45 0.45 
(6) 0.45 0.50 (14) 0.45 0.45 
(7) 0.60 0.60 (15) 0.60 0.60 
(8) 0.65 0.65 (16) 0.60 0.60 
 
5.4 Effective Dose Estimation 
As described by the ICRP (2007), the calculation of female effective dose includes the 
radiation dose received by 14 radiosensitive tissues (red bone marrow, colon, lung, stomach, 
breast, ovaries, urinary bladder, oesophagus, liver, thyroid, bone surface, brain, salivary 
glands and skin) within the body in addition to the dose received by the 13 less radiosensitive 
tissues. The latter are referred to as remainder tissues (adrenals, extra thoracic region, gall 
bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa, pancreas, small intestine, 
spleen, thymus, and uterus). The following equation, with ICRP (2007) publication 103 
tissue weighting factors (Table 5-7), was used for the calculation of screening 
mammography effective dose:  
E= ∑wT HT 
Where E is the effective dose, wT and HT are the tissue weighting factor and radiation 
absorbed dose by tissue T, respectively. Breast tissue radiation dose includes the overall dose 
of both examined and contralateral breasts. As reported by Linet et al. (2012) MGD was used 
to represent examined breast radiation dose. Bone marrow radiation absorbed dose was 
calculated using Cristy (1981) red bone marrow distribution as recommended by the ICRP 
(1995). This was achieved by summation of the radiation dose received by bone marrow in 
each site multiplied by its percentage in that site. Since the bone surface and skin have low 
radio-sensitivity, wT of each is 0.01, and small part of them is exposed to radiation during 
mammography, their radiation dose is negligible and not considered in the calculations. With 
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regard to remainder tissues, the radiation dose to the extra thoracic region, lymphatic nodes, 
muscle and oral mucosa were excluded because the ATOM phantom did not have dosimeter 
locations for these structures.  The effect of this is likely to be negligible and to compensate 
the available 9 remainder tissue doses were averaged.  This approach has been reported by 
Tootell et al. (2013). 
Table (5-7) Lists ICRP (2007) publication 103 tissue weighting factors. 
Tissue wT 
Red bone marrow 0.12 
Colon 0.12 
Lung 0.12 
Stomach 0.12 
Breast 0.12 
Gonads 0.08 
Urinary bladder 0.04 
Oesophagus 0.04 
Liver 0.04 
Thyroid 0.04 
Bone surface 0.01 
Brain 0.01 
Salivary glands 0.01 
Skin 0.01 
Remainder tissues (Adrenals, Extrathoracic region, Gall bladder, 
Heart, Kidneys, Lymphatic nodes, Muscle, Oral mucosa, 
Pancreas, Small intestine, Spleen, Thymus, Uterus or Prostate 
0.12 
Total 1.00 
 
5.5 Effective Risk Calculation and Screening Programme Total Effective 
Risk Assessment 
The effective risk was calculated using the equation described by Brenner (2012) as follows: 
R=∑rTHT 
Where R is the effective risk, rT is the lifetime attributable risk (LAR) of radiation-induced 
cancer for tissue T per unit equivalent dose to that tissue, and HT is the equivalent dose 
received by tissue T. 
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The lifetime attributable cancer risk of different tissues (rT) were taken from BEIR VII – 
Phase 2 report of National Academy of Sciences (NAS) (2006). Since these values are only 
presented for each decade of female age (Table 5-8), they were plotted graphically against 
age in order to extrapolate an approximate value for each year of female life. For this purpose 
three approaches have been used. 
Table (5-8) Lifetime attributable risk of radiation-induced cancer for tissues which 
received radiation dose during screening mammography for each decade of female age as 
listed in Table 12D-1 of the BEIR-VII report (NAS, 2006). 
Tissue
*
 
Lifetime Attributable Risk (cases /10,000 persons /Gy) at different ages 
20 30 40 50 60 70 80 
Breast 429 253 141 70 31 12 4 
Stomach 52 36 35 32 27 19 11 
Liver 14 10 10 9 7 5 2 
Lung 346 242 240 230 201 147 77 
Thyroid 113 41 14 4 1 0.3 0 
Other 323 207 181 148 109 68 30 
*
The LAR values for colon, ovaries, uterus and urinary bladder are not presented because 
they don’t receive radiation dose during screening mammography.  
 
In the first approach curve fitting was used. For all tissue types the change (reduction) in 
tissue radio-sensitivity (LAR) between the ages of 20 and 30 is completely different from 
that after the age of 30, see Figure (5-16) for lung tissue. Accordingly, in order to minimise 
the error in the fitting process two lines of best fit were created for each type of tissue. The 
first one obtains the LAR for years 21-29 inclusive and the second determines the LAR for 
years 31-39, 41-49, 51-59, 61-69, and 71-79 inclusive. Since the best fit line of linear 
relationship between two points (risk for ages 20 and 30 years) has been used in the first fit 
line, the coefficient of determination (R
2
) has to be 1 as there are only two points available to 
plot the graph, see Figures (5-17) and (5-18). However, in the second best fit line a second 
order polynomial relationship has been used for all tissue types (R
2
 > 0.99) except for thyroid 
tissues where an exponential relationship has been used (R
2
= 0.9984), see Figures (5-19) 
and (5-20). This was done because the R
2
 of second order polynomial relationship of thyroid 
tissue was (0.95). 
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Figure (5-16) Demonstrates the lung tissue radio-sensitivity change (LAR change) against 
age. This provides an illustration of the complete difference in tissue LAR change for those 
aged 20-30 compared to older ages. 
 
 
Figure (5-17) Shows the lifetime attributable risk of radiation-induced cancer in breast and 
thyroid tissues for women age 20-30 years using a linear relationship. 
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Figure (5-18) Shows the lifetime attributable risk of radiation-induced cancer in lung, 
stomach, liver, and other tissues for women age 20-30 years using a linear relationship. 
 
 
Figure (5-19) Shows the extrapolation of the lifetime attributable risk of radiation-induced 
cancer in breast and thyroid tissues for women age 30-80 years using a polynomial 
relationship for breast tissue and an exponential relationship for thyroid tissue. Breast tissue 
LAR increment between 70 and 80 year is due to curve fitting error. 
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Figure (5-20) Shows the extrapolation of the lifetime attributable risk of radiation-induced 
cancer in lung, stomach, liver, and other tissues for women age 30-80 years using a 
polynomial relationship. 
The second approach depends on the use of linear relationships between the risk values for 
successive decades to extrapolate the LAR value for each year of female lifetime as 
recommended by Li et al. (2011), see Figures (5-21) and (5-22). 
For the third approach, a stepping method was used in which the same risk value has been 
used for whole decade (i.e. the same risk value has been used for age 20-29, 30-39…etc.), 
see Figures (5-23) and (5-24). 
Using the three approaches, the experimental dose data of each FFDM machine (Appendix 
A) were used to calculate the radiation effective risk for females aged 25-75 years, the 
earliest and the latest possible ages of screening mammography (Appendix B). For the 
effective risk calculation other tissues were not indicated in the BEIR VII. Therefore, the 
other tissue dose was determined from the radiosensitive tissues as indicated in the ICRP to 
include: the radiation dose to brain, bone marrow, adrenals, heart, kidneys, gall bladder, 
pancreas, spleen, thymus, oesophagus and salivary glands. Finally, the total radiation 
effective risk, during a woman‘s life, from screening mammography was calculated for 
different country-based mammography screening programmes listed in Table (3-4) (page 59) 
and Table (3-5) (page 60).   
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Figure (5-21) Demonstrates the extrapolation of the lifetime attributable risk of radiation-
induced cancer in breast and thyroid tissues using a linear relationship between two 
successive decade values. 
 
 
Figure (5-22) Demonstrates the extrapolation of the lifetime attributable risk of radiation-
induced cancer in lung, stomach, liver and other tissues using a linear relationship between 
two successive decade values. 
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Figure (5-23) Demonstrates the extrapolation of the lifetime attributable risk of radiation-
induced cancer in breast and thyroid tissues using a stepping approach. 
 
 
 
Figure (5-24) Demonstrates the extrapolation of lifetime attributable risk of radiation-
induced cancer in lung, stomach, liver and other tissues using a stepping approach. 
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5.6 Mammographic Machines  
In order to validate the method, organ radiation dose measurement and radiation effective 
dose/risk estimation were repeated for sixteen full field digital mammography (FFDM) 
machines. These are from the actual machines used in the NHSBSP. All of the machines fell 
within the quality control programme of NHSBSP which includes: evaluation of beam 
alignment, detector performance, AEC, image display monitors, image display printers, 
image quality, and radiation dose (NHSBSP, 2009). The mammography machines were from 
four different manufacturers. Eight were Seno Essential from GE Healthcare with a Rh/Rh 
target/filter combination. Five machines were Hologic: three Selenia and two Selenia 
Dimensions. Two of the Selenia machines had a Rh/Rh and the other had a Mo/Mo 
anode/filter. The Selenia Dimensions machines had a W/Rh target/filter combination. The 
two Siemens Mammomat Inspiration machines had a W/Rh anode/filter combination. 
Finally, One Giotto machine from IMS had a W/Ag target/filter combination. In order to 
differentiate each machine from the others, each one was given a unique number. For this 
purpose the numbers from 1 to 16 have been used (Table 5-9). For the first two machines the 
whole process was repeated three times in order to investigate experimental repeatability.   
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Table (5-9) The sixteen FFDM machines used in this study. 
Machine 
Number 
Machine Brand 
Target/filter 
combination 
1* Hologic Selenia  Mo/Mo 
2* Hologic Selenia Rh/Rh 
3 Hologic Selenia Dimensions  W/Rh 
4 Hologic Selenia Rh/Rh 
5 GE Seno Essential  Rh/Rh 
6 GE Seno Essential Rh/Rh 
7 Hologic Selenia Dimensions W/Rh 
8 Giotto  W/Ag 
9 GE Seno Essential Rh/Rh 
10 GE Seno Essential Rh/Rh 
11 GE Seno Essential Rh/Rh 
12 GE Seno Essential Rh/Rh 
13 GE Seno Essential Rh/Rh 
14 GE Seno Essential Rh/Rh 
15 Siemens Mammomat Inspiration W/Rh 
16 Siemens Mammomat Inspiration W/Rh 
*Mammography machines exposure to a further two retests 
in order to evaluate the reliability of the experimental data 
acquired from the FFDM machines.   
 
5.7 Pilot Experiment 
A pilot experiment was conducted. The main purpose of the pilot experiment was to assess 
the feasibility of the proposed method. In this experiment the data was collected from one 
FFDM machine (machine number 1 / Hologic Selenia / Table (5-9)) which had a Mo/Mo 
target/filter combination. This pilot experiment required two visits to the FFDM machine. 
The first visit included organ dose measurement as previously described in section 5.3 and 
examined breast entrance air kerma measurement for MGD calculation. The purpose of the 
second visit was to calibrate the TLDs and HVL assessment. TLDs were calibrated against 
the Unfors solid state dosimeter. As recommended by Olgar et al. (2009), TLDs were 
calibrated by the same mammographic machine because the TLDs sensitivity is dose 
dependent. Since different kV values have been selected for CC and MLO breast phantoms 
(by AEC), the HVL was assessed for each to derive a more accurate MGD calculation. 
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During each visit three TLDs from each TLD group were used to assess background 
radiation; this was subtracted from the other TLDs, which were used for organ dose 
measurement readings. 
During the first visit the exposure factors selected by the AEC were recorded so they could 
be replicated for kerma measurement, HVL assessment and TLD calibration. Three 
exposures were made for each projection to minimise the random error. Then all TLDs were 
collected and read to obtain organ doses as previously described in section 5.2.2. The organ 
dose calculations together with calculated MGD (section 5.3) were used to obtain an 
effective dose. The total effective risk during female lifetime was then calculated for the 
NHSBSP screening programme for the UK average and high breast cancer risk categories; 
this was based upon screening age commencement, cessation age and also the screening 
interval (the time between screening events). This required the calculation of effective risk 
for women aged 40-73 because in the UK the average risk women are invited for triennial 
screening mammography between the ages of 47 and 73, while the high risk women aged 40-
73 are invited for annual screening mammography.       
The main outcome of this pilot experiment was that firstly, the required angle for MLO 
position was determined by an expert practitioner and fixed for the whole next work. 
Secondly, the errors due to ATOM phantom positioning in relation to breast phantom were 
identified and for more consistent positioning additional lines were drawn on the ATOM to 
improve reproducibility of position. Finally, since the contralateral breast received the 
highest radiation dose when compared to other organs, the potential importance of using a 
contralateral breast shield was raised; this resulted in an additional component to the thesis – 
an evaluation of a secondary radiation breast shield to minimise dose to the contralateral 
breast. The result of this pilot experiment was presented as a scientific poster in the UKRC 
2015 (M.Ali, England, & Hogg, 2015). The method for this thesis together with pilot 
experiment results was also published (M.Ali, England, McEntee, & Hogg, 2015).  
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5.8 Effective Risk Modeling   
In some countries an individual has the right to know the risk of radiation associated with any 
radiological examination. One could argue this is especially important in screening 
mammography as healthy (asymptomatic) women are involved. This is part of the European 
Commission legislation (European Commission, 2014). To comply with this requirement and 
in order to make data suitable for daily use in screening mammography centres, three 
methods have been used in this thesis to model the risk of radiation-induced cancer from 
screening mammography. All these methods are based on total effective risk calculation. The 
main purpose of all of the modelling methods was to produce an estimate of screening 
mammography effective risk without the need for complex and time consuming calculations, 
this is important because time is critical in clinical work. However, when undertaking this 
work the accuracy of these models was found to be different. In general, the first and second 
models (sections 5.8.1 and 5.8.2, respectively) can be considered as preliminary steps that led 
to the development of the final more accurate model (third model / section 5.8.3). The first 
and second models involve the effective risk prediction depending on the average risk value 
for the sixteen studied machines, age of commencement/cessation of screens, number of 
screens, and time interval between successive screens (screening frequency). The additional 
factor that is likely to help improve the accuracy of the resultant data from the third model 
was the inclusion of MGD variations of the different sixteen studied FFDM machines.    
5.8.1 Multiple Regression for Total Effective Risk Modelling (First Effective Risk 
Model)  
Regression is a statistical concept used to assess the effect of one or more independent 
variables on an outcome (dependent) variable (Zou, Tuncali, & Silverman, 2003). The 
importance of regression models in medical studies is seen in two different areas. The first 
area is to investigate the effect of an explanatory factor or factors on an outcome variable 
after adjusting other explanatory variables. The second area represents the most common one 
and includes the building of predictive models for the dependent variable in relation to 
independent variables (Gareen & Gatsonis, 2003; Zou, Tuncali, & Silverman, 2003). 
According to the number of independent variables the regression models are either simple 
regression when the effect of one independent variable is evaluated against an outcome 
 129 
 
dependent variable; or multiple regression when the effect of more than one variable is 
investigated on an outcome variable (Gareen & Gatsonis, 2003). 
In diagnostic imaging research regression is increasingly used (Gareen & Gatsonis, 2003). 
The regression model construction is, generally, based on research question and data nature. 
Sometimes the regression model may be invalid when the assumption on which the model is 
built is incorrect and hence the data generated by the regression model is also incorrect 
(Gareen & Gatsonis, 2003). In this thesis an effective risk model was built based on multiple 
linear regression using the average effective risk values for the sixteen mammography 
machines to predict the total effective risk of any screening programme throughout the world 
(as dependent variable) from commencement/cessation ages of screening and screening 
frequency. 
The reliability of a regression model is dependent on sample size of collected data. Although 
the pervasive rule determined required sample size for regression by the number of predictors 
(10-15 cases of data per each predictor), but Field (2013) stated that the required sample size 
for regression is determined by the strength of relationship being measured and the required 
statistical power. Generally he reported that the bigger the sample size, the better the 
regression model is generated. Therefore, in order to improve the statistical power, two 
hundred and seventy four different screening scenarios were proposed which comprised of 
different commencement / cessation ages (25-75 years) and time intervals between screens. 
For each proposed lifetime interval, such as 25-75 years, 30-75 years, and 30-70 years, three 
different screening categories with regard to screening frequency (annual, biennial, or 
triennial) were used (Appendix C). These three screening frequencies were chosen because 
these are the only ones recommended by worldwide screening programmes. Lifetime risk 
data, arising from the 274 scenarios was analysed using SPSS 22.0 software (IBM, Armonk, 
New York, USA) to generate a mathematical regression model and to assess the relationship 
between total effective risk and different time intervals and commencement/cessation ages. 
5.8.2 Graphical Extrapolation of Total Effective Risk (Second Effective Risk Model) 
In addition to regression modelling a further approach was used to estimate total effective 
risk – graphical extrapolation. Since tissue radio-sensitivity decreases with age, especially 
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after 70, and most of the screening programmes end at 70 or slightly higher, the end age of 
screening in this total effective risk model is set to 75 years.  
To establish this model the average total effective risk data of the sixteen machines was used 
to present the relationship between screening commencement age and total effective risk 
graphically. In this model, 50 different screening commencement ages (25-74 years) were 
selected and the total effective risk for three different screening frequencies (annual, biennial, 
and triennial) was calculated. Consequently, the total effective risk extrapolation graph 
contains three relationship lines; one for each screening frequency. The same method has 
been used to generate a model for each set of extrapolated LAR factors.      
5.8.3 Graphical Extrapolation of Total Effective Risk with Including MGD Variation 
(Third Effective Risk Model)  
This model is the final and a more comprehensive model in which the effect of MGD 
variations of different mammographic machine on the total effective risk was considered. 
The same scenarios used to generate the previous model (section 5.8.2) were also used to 
generate this model. However, before generating the risk model, the relationship between the 
MGD and total effective risk for each scenario was established using the data from the 16 
FFDM machines to accommodate the effect of MGD variations of different FFDM machines 
on women‘s total effective risk (Appendix D). The resultant graphs of this risk model 
present the relationship between screening commencement age and MGD conversations 
factor to total effective risk. Therefore, the total effective risk can be determined for any 
screening category (commencement age and screening frequency) at recorded MGD.   
5.9 Contralateral Breast Shield Intervention Study 
One important characteristic of good radiographic practice is that the radiation dose to the 
patient is kept as low as possible with adequate and consistent image quality. Many steps can 
be taken to reduce the radiation dose (Iball & Brettle, 2011). Protective radiation shielding is 
widely used to protect radiosensitive body tissues and organs from potential damage resulting 
from ionising radiation. Radiosensitive areas have been determined by the ICRP (2007) and 
they include those tissues with higher tissue weighting factors (Table 5-7). These organs and 
tissues may be selectively protected by the use of specific area shielding. Specific area 
shields are available in two different types, namely, contact shields such as gonads shield and 
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shadow shields which are fixed in the X-ray tube within primary beam field such as both 
breast and gonad shield which used for scoliosis patients during full spine imaging 
(Statkiewicz-Sherer, Visconti, & Ritenour, 2010).  
The main purpose of using specific area shielding is to protect the radiosensitive tissues from 
the primary X-ray beam. However, in this thesis a breast shield has been used to protect the 
contralateral breast tissue, which is one of the radiosensitive tissues with a 0.12 tissue 
weighting factor (ICRP, 2007), from scattered radiation during screening mammography 
because in the pilot study the contralateral breast received the highest radiation dose after 
examined breast. Previous studies found that the use of specific area shielding against 
scattered radiation during radiography may significantly reduce organ dose and effective 
dose (Iball & Brettle, 2011). The theoretical effect of a contralateral breast shield (by 
considering the contralateral breast radiation dose equal to zero) showed that it can reduce 
both the effective dose and effective risk by approximately 1.5%, see Table (5-10) and Table 
(5-11) for effective dose and effective risk, respectively.  
Accordingly, the effect of the contralateral breast shield was experimentally investigated on a 
women‘s organ doses, effective dose (for one screening visit), and total effective risk (during 
a women‘s lifetime) for different worldwide screening programmes. In this thesis the 
contralateral breast shield was made from a redundant lead rubber protective apron. 
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Table (5-10) Demonstrates the effect of contralateral breast dose on the 
effective dose of one screening session. 
Machine 
number 
Effective dose (µGy) 
Reduction (%) Including all 
organ dose 
Excluding contralateral breast 
dose 
1 325.85 322.66 0.98 
2 315.72 312.16 1.13 
3 248.50 242.79 2.30 
4 232.94 228.64 1.85 
5 244.87 241.92 1.21 
6 216.36 213.57 1.29 
7 343.73 338.40 1.55 
8 270.33 265.71 1.71 
9 223.16 220.62 1.14 
10 259.70 256.57 1.21 
11 204.45 202.20 1.10 
12 241.28 238.09 1.32 
13 226.97 224.00 1.31 
14 230.89 227.88 1.31 
15 214.93 211.57 1.56 
16 210.65 208.37 1.08 
Mean (SD) 250.65 (42.70) 247.20 (42.18) 1.38 (0.34) 
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Table (5-11) Shows the effect of contralateral breast dose on effective risk of one 
screening session at different female ages (25-75 years) - average value for the sixteen 
machines with standard deviation (SD). 
Age (year) Reduction (%)
*
, Mean (SD) Age (year) Reduction (%)
*
,  Mean (SD) 
25 1.39 (0.33) 51 1.39 (0.33) 
26 1.39 (0.33) 52 1.39 (0.33) 
27 1.39 (0.33) 53 1.39 (0.33) 
28 1.39 (0.33) 54 1.39 (0.33) 
29 1.39 (0.33) 55 1.39 (0.33) 
30 1.39 (0.33) 56 1.39 (0.33) 
31 1.39 (0.33) 57 1.39 (0.33) 
32 1.39 (0.33) 58 1.39 (0.33) 
33 1.39 (0.33) 59 1.38 (0.32) 
34 1.39 (0.33) 60 1.38 (0.32) 
35 1.39 (0.33) 61 1.38 (0.32) 
36 1.39 (0.33) 62 1.38 (0.32) 
37 1.39 (0.33) 63 1.38 (0.32) 
38 1.39 (0.33) 64 1.37 (0.32) 
39 1.39 (0.33) 65 1.37 (0.31) 
40 1.39 (0.33) 66 1.37 (0.31) 
41 1.39 (0.33) 67 1.36 (0.31) 
42 1.39 (0.33) 68 1.36 (0.30) 
43 1.39 (0.33) 69 1.35 (0.30) 
44 1.39 (0.33) 70 1.34 (0.30) 
45 1.39 (0.33) 71 1.33 (0.29) 
46 1.39 (0.33) 72 1.33 (0.29) 
47 1.39 (0.33) 73 1.33 (0.29) 
48 1.39 (0.33) 74 1.33 (0.29) 
49 1.39 (0.33) 
75 1.37 (0.38) 
50 1.39 (0.33) 
*
Reduction (%) represents the reduction percentages in effective risk when contralateral 
breast dose is equal to zero. These were calculated using LAR extrapolated by a best fit 
line method. Approximately the same reduction values were found for the other two sets 
of extrapolated LAR data. 
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5.9.1 Testing of the Lead Protective Apron 
Before using the protective lead apron in the experiment, it was tested as described by Oyar 
and Kislalioglu (2012) using a Wolverson Arcoma Arco Ceil general radiography X-ray 
machine (Arcoma, Annavägen, Sweden) with 100 kV and 20 mAs. During exposure, the 
apron‘s images were recorded using a 35 X 43 cm AeroDR 1417 digital radiography cassette 
(KONICA MINOLTA, Tokyo, Japan)  to investigate the presence of any defects (fractures, 
cracks, or holes in the lead apron). The X-ray beam was collimated according to the detector 
size. The focal-film distance was arranged as in conventional radiography to be 110 cm. The 
intact area (defect free area) of the apron was determined and used for manufacturing the 
contralateral breast shield.  
5.9.2 Determination of Apron Equivalent Lead Thickness 
Different materials have been used to manufacture X-ray protective aprons. These materials 
are mainly composed of heavy metals (e.g. copper, yttrium, tin, antimony, barium, tungsten, 
and lead). However, the protective efficiency of all protective aprons, regardless the material 
from which they are made, is expressed as lead-equivalent thickness (Mori, Koshida, 
Ishigamori, & Matsubara, 2014). Since the contralateral breast shield aims to protect the 
breast from low energy X-ray radiation (scatter radiation), a low equivalent lead thickness is 
required. According to KIRAN (2010), a 0.25 mm equivalent lead thickness is sufficient to 
absorb approximately 96% of a 80 kV primary beam, while for 50 kV BC Centre for Disease 
Control (2016) reported that 0.25 mm lead equivalency can provide up to 99.5% protection. 
Prior to designing the contralateral breast shield, the equivalent lead thickness of used apron 
material was experimentally measured. Lead equivalent thickness measurement method 
described by Mori et al. (2014) was used. This method was based on the computational 
method using the equation of apron attenuation. 
I = Io e
-µx 
I and Io represent the radiation doses with and without lead equivalent material, respectively. 
The µ is the linear attenuation coefficient of the lead and x is the equivalent lead thickness. 
The utilisation of this equation requires the use of a mono-energetic beam because µ values 
are available for each photon energy. Therefore, before using the equation for the lead 
material, it was applied to aluminium foils of known thicknesses to find the µ value of the 
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aluminium material and therefore the effective energy of the beam could be determined using 
Hubbell and Seltzer (1996) tables of X-ray attenuation coefficients. Then the same beam was 
used to obtain the equivalent lead thickness. This procedure has been repeated for same mAs 
with three different X-ray beams with different energies of 40, 80 and 120 kV to minimise 
any errors. The average calculated equivalent lead thickness of apron material at the three 
energies was 0.225 mm (0.234, 0.193 and 0.249 mm, respectively). This value is slightly 
lower than the nominal equivalent lead thickness of the apron which is 0.25 mm. Similarly, 
Mori et al. (2014) found that the calculated equivalent lead thickness of aprons is usually less 
than the nominal thickness.             
5.9.3 Contralateral Breast Shield Design  
The contralateral breast shield designed for this thesis was suitable for use with the ATOM 
phantom; it is not suitable for clinical use due to a lack of a fixation mechanism. It was 
designed to comply with two basic requirements as follows: 
 It can accommodate the ATOM phantom‘s breast attachment well to provide 
maximal protection against radiation. 
 It should not interfere with breast support and compression paddle of the 
mammographic machine.  
Accordingly pieces of paper were first used to develop a series of different shield shapes.  
These prototypes were tested to see whether they could comply with the basic requirements 
or not. A suitable design was determined to be a diverging cone, see Figure (5-25). 
Diverging rather than a symmetric cone was chosen because the symmetric cone may 
interfere with breast support and compression paddle of the mammography system. Then the 
chosen design was used to make the lead contralateral breast shield.   
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Figure (5-25) Illustrates the designed contralateral breast shield. 
 
5.9.4 Data Collection with the Use of Contralateral Breast Shield  
In order to investigate the effect of the contralateral breast shield on breast dose, effective 
dose, and effective risk, the whole procedure of organ dose measurement was repeated for 
four FFDM machines. These machines were selected after grouping the original sixteen 
machines into four categories according to their calculated effective risk values. One machine 
was chosen from each category. In order to find the effect of the contralateral breast shield, 
organ dose measurements without and with contralateral breast shield were repeated within 
the same week. The same procedure previously explained in section 5.2 was used to measure 
organ dose, see Figure (5-26). After organ dose measurement the effective dose and effective 
risk along with total effective risk of worldwide screening programmes calculations were 
repeated.     
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(a)                                                                         (b) 
Figure (5-26) Shows contralateral breast shield intervention (a) In CC projection, (b) In 
MLO projection. 
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Chapter Six 
Results 
 
6.1 Chapter Overview 
This chapter presents the results of this PhD thesis. In general screening mammography 
dosimetric data from sixteen FFDM machines are included. This data is represented in two 
different ways, namely absorbed dose (µGy) and effective risk (case/10
6
), which is the 
number of radiation-induced cancers. Following this, based on the data acquired, a novel 
method has been established to assess the risk of radiation-induced cancer from screening 
mammography.  
Within this chapter the results are organised into four main sections. Results of organ dose 
measurements and the examined breast MGD are the focus of the first section. Dose 
measurement reliability data have also been considered in this section. The results of LAR 
factors extrapolated by three different methods and total effective risk of worldwide 
screening programmes are illustrated in the second section. The third section includes graphs 
and data from the mathematical modelling of total effective risk. In this context, resultant 
data of three different risk models are demonstrated. Correlation coefficients of the 
relationship between total effective risk during a woman‘s lifetime and different screening 
commencement/ending ages, number of screens and time interval between screens along with 
risk regression model (the first risk model) are presented for the three LAR extrapolation 
methods.  
Following this, for the three extrapolation methods, the graphs of the second and third risk 
models are introduced. Since the majority of screening programmes end between the ages of 
70 and 75 and during this time the tissues become more radio-resistant, the cessation age of 
screening has a small effect on the total effective risk of the screening programme. 
Accordingly in these two risk models the cessation of screening mammography is considered 
to be constant at the age of 75 years. The purpose of the second risk model is to provide an 
easy method to obtain the total effective risk of various screening recommendations of 
different screening commencement ages and frequencies. However, the MGD variability of 
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the different FFDM machines has not been considered in this model because the average risk 
value across the sixteen machines has been used. Therefore, the third risk model is 
introduced to overcome this limitation by generating a set of conversion factors that can be 
used to assess total effective risk of any screening programme depending on screening 
parameters (i.e. commencement age and frequency of screening) and the women‘s MGD 
established during the initial mammogram. Finally, the effect of a contralateral breast shield 
data on both contralateral breast dose and effective risk is shown in the last section.  
6.2 Organ Dose Data 
As mentioned in methodology chapter (section 5.2.2, page 108), the radiation dose of 20 
radiosensitive tissue were measured using TLDs accommodated inside the ATOM dosimetry 
phantom. The phantom was exposed, under normal breast screening conditions, across 
sixteen different FFDM machines. In the first step and in order to investigate organ dose 
measurement reliability, the organs‘ radiation doses were measured on three occasions for 
two FFDM machines (machines number 1 and 2). This demonstrated a minor level of 
variation across the three visits. These variations are greater for the first FFDM machine than 
those obtained by the second FFDM machine; see Figure (6-1) and Figure (6-2) for the first 
and second machine, respectively. In these Figures error bars were used to present the mean 
organ doses (µGy) ± 1SD for the three visits, for machine 1 and machine 2. The effect of 
such measured dose variations on the total effective risk of worldwide screening programmes 
is subsequently presented in Table (6-1) for machine 1; and Table (6-2) for machine 2 (for 
all three LAR extrapolation methods). For both tables, the first column lists worldwide 
screening programmes sorted in ascending order according to their total effective risk. 
Opposite each screening programme in the second, third, and fourth columns of the tables, 
the average total effective values with standard deviation (SD), of the sixteen machines, 
calculated using each of LAR sets are presented.   
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Figure (6-1) Demonstrates the organ dose variations (mean ± 1SD) measured across three 
different visits for machine number 1. 
 
 
Figure (6-2) Demonstrates the organ dose variations (mean ± 1SD) measured across three 
different visits for machine number 2. 
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Table (6-1) Lists the variations in total effective risk, calculated using LAR factors 
extrapolated by the three methods, of worldwide screening programmes which resulted 
from the variations in organ doses as measured on three visits for machine 1. 
Programme
*
 
Total effective risk (case/10
6
), Mean (SD) of the 
three visits 
Method 1 Method 2 Method 3 
Malta 50.57 (0.05) 51.85 (0.05) 69.13 (0.07) 
Estonia  77.40 (0.08) 81.64 (0.09) 101.78 (0.10) 
Ireland 81.10 (0.09) 87.45 (0.09) 109.46 (0.11) 
United Kingdom 84.75 (0.09) 93.19 (0.10) 129.92 (0.13) 
Belgium, Croatia, Cyprus, Denmark, 
Finland, Germany, Italy, Latvia, 
Lithuania, Luxembourg, Norway, 
Poland, Slovenia, Spain (Catalonia), 
Switzerland 
85.55 (0.10) 96.25 (0.11) 124.83 (0.13) 
Canada , France, Israel, Netherlands 88.64 (0.11) 104.05 (0.12) 133.81 (0.14) 
Hungary 142.63 (0.14) 148.81 (0.15) 213.70 (0.20) 
New Zealand, Portugal, Spain 
(Navarra) 
146.32 (0.15) 156.67 (0.16) 229.06 (0.21) 
China 147.26 (0.13) 145.00 (0.13) 190.83 (0.17) 
Czech  163.44 (0.17) 176.85 (0.18) 238.05 (0.23) 
Iceland 229.20 (0.22) 235.05 (0.22) 298.55 (0.27) 
Nigeria 230.46 (0.22) 238.05 (0.23) 301.55 (0.28) 
Australia, Japan, Korea, United States 
(AAFP, NCI, and USPSTF) 
232.29 (0.23) 242.85 (0.24) 307.54 (0.29) 
Sweden 270.71 (0.26) 279.89 (0.27) 374.04 (0.34) 
Uruguay 305.88 (0.31) 324.16 (0.32) 423.38 (0.40) 
United States (ACOG) 311.81 (0.33) 339.15 (0.35) 441.35 (0.43) 
India  366.72 (0.35) 372.91 (0.35) 481.27 (0.43) 
United States (ACS, ACR, and 
NCCN) 
446.24 (0.45) 469.22 (0.46) 615.08 (0.57) 
Canada  366.72 (0.35) 372.91 (0.35) 481.27 (0.43) 
United Kingdom  444.46 (0.44) 465.02 (0.45) 609.09 (0.56) 
United States (ACS) 942.16 (0.84) 968.21 (0.86) 1238.06 (1.07) 
United States (NCCN) 1318.68 (1.15) 1344.74 (0.17) 1766.34 (1.51) 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
*
The programmes are ordered according to total effective risk calculated using LAR 
extrapolated by best fit lines method. 
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Table (6-2) Lists the variations in total effective risk, calculated using LAR factors 
extrapolated by the three methods, of worldwide screening programmes which resulted 
from the variations in organ doses as measured on three visits for machine 2. 
Programme 
Total effective risk (case/10
6
), Mean (SD) 
Method 1 Method 2 Method 3 
Malta 48.48 (0.04) 49.67 (0.03) 66.21 (0.04) 
Estonia  74.20 (0.07) 78.21 (0.05) 97.49 (0.06) 
Ireland 77.76 (0.07) 83.78 (0.06) 104.85 (0.07) 
United Kingdom 81.27 (0.08) 89.28 (0.06) 124.44 (0.08) 
Belgium, Croatia, Cyprus, Denmark, 
Finland, Germany, Italy, Latvia, 
Lithuania, Luxembourg, Norway, 
Poland, Slovenia, Spain (Catalonia), 
Switzerland 
82.05 (0.08) 92.22 (0.06) 119.58 (0.08) 
Canada , France, Israel, Netherlands 85.04 (0.10) 99.70 (0.07) 128.20 (0.09) 
Hungary 136.70 (0.11) 142.54 (0.09) 204.66 (0.11) 
New Zealand, Portugal, Spain 
(Navarra) 
140.27 (0.12) 150.08 (0.10) 219.39 (0.13) 
China 141.07 (0.09) 138.86 (0.08) 182.73 (0.09) 
Czech  156.69 (0.14) 169.42 (0.11) 228.01 (0.13) 
Iceland 219.63 (0.16) 225.13 (0.13) 285.92 (0.16) 
Nigeria 220.84 (0.17) 228.01 (0.13) 288.80 (0.16) 
Australia, Japan, Korea, United States 
(AAFP, NCI, and USPSTF) 
222.63 (0.17) 232.61 (0.14) 294.54 (0.17) 
Sweden 259.42 (0.19) 268.08 (0.16) 358.21 (0.20) 
Uruguay 293.18 (0.24) 310.52 (0.19) 405.50 (0.23) 
United States (ACOG) 298.93 (0.26) 324.90 (0.21) 422.74 (0.25) 
India  351.38 (0.25) 357.16 (0.20) 460.89 (0.25) 
United States (ACS, ACR, and 
NCCN) 
427.69 (0.34) 449.45 (0.27) 589.09 (0.33) 
Canada  351.38 (0.25) 357.16 (0.20) 460.89 (0.25) 
United Kingdom  425.97 (0.33) 445.42 (0.27) 583.34 (0.33) 
United States (ACS) 902.53 (0.57) 927.20 (0.49) 1185.53 (0.60) 
United States (NCCN) 1263.04 (0.74) 1287.70 (0.66) 1691.33 (0.84) 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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For the sixteen FFDM machines, the examined breast received the highest radiation dose 
during ‗screening mammography exposures‘ where total MGD from one screening visit (for 
both CC and MLO projections) ranged between 1.678 mGy and 2.431 mGy with a mean 
(95% CI) of 2.019 (1.871-2.166) mGy. All of the machines showed that MGD for the MLO 
projection was higher than that of the CC projection. However, the variation percentage of 
MGD between MLO and CC projections is different amongst the 16 machines. It ranged 
from slightly more than 1% to just under 29%, approximately 14% on average; see Table (6-
3) which demonstrates the CC and MLO projections MGD (mGy) along with percentages of 
MGD difference between them for each of the 16 machines. These MGD variations between 
CC and MLO will be more discussed in section 7.3.1 on page 182.  
 
Table (6-3) Shows examined breast MGD for the sixteen FFDM machines. 
Machine 
number 
MGD (mGy) Percentage 
Difference (%) 
Total MGD 
(mGy) CC view MLO view  
1 1.160 1.271 8.733 2.431 
2 1.050 1.273 17.517 2.323 
3 0.843 1.164 27.577 2.007 
4 0.811 1.082 25.046 1.893 
5 0.927 1.082 14.325 2.009 
6 0.825 0.949 13.066 1.774 
7 1.169 1.637 28.589 2.806 
8 0.983 1.219 19.360 2.202 
9 0.854 0.977 12.590 1.831 
10 1.060 1.071 1.027 2.131 
11 0.825 0.853 3.283 1.678 
12 0.921 1.055 12.701 1.976 
13 0.918 0.941 2.444 1.859 
14 0.930 0.961 3.226 1.891 
15 0.787 0.969 18.782 1.756 
16 0.771 0.959 19.604  1.730 
Mean  
(95% CI) 
0.927  
(0.865-0.989) 
1.091  
(0.998-1.185) 
14.242  
(9.898-18.586) 
2.019 
(1.871-2.166) 
 
 
For organs other than the examined breast, it was found that for some the radiation dose was 
zero and this means that either these organs do not receive radiation dose during screening 
mammography exposure or the dose received by these organs is below the sensitivity 
threshold of the TLDs. However, some organs received radiation dose ranging from less than 
1µGy to more than 25 µGy; see Figure (6-3) which shows the average organs‘ dose for the 
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sixteen machines with 95% CI. The organ dose values for each machine are presented in 
Appendix A. In general the three highest organ doses after the irradiated/examined breast are 
received by the contralateral breast, sternum red bone marrow and thyroid, in descending 
order respectively. The organs which received an average radiation dose of ≥0.1 µGy are 
presented in Table (6-4) as a percentage of the MGD.  The first column of this table lists the 
organs which received a radiation dose of ≥0.1 µGy, the second column contains the average 
organ‘s doses together with their standard deviation (SD) of the studied machines and the 
final column presents the average organ‘s doses as percentages of average MGD with (SD).     
 
 
 
 
Figure (6-3) Demonstrates the mean organ doses across the sixteen machines (circles) with 
95% CI (error bars) for one screening visit (CC and MLO projections for each breast). 
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Table (6-4) The mean organ doses for the sixteen FFDM machines from one 
screening visit along with their percentages in relation to the average 
examined breast MGD. 
Organ 
Radiation dose, 
mean (SD), µGy 
Organ‘s dose percentages, 
mean (SD) , % MGD 
Brain  0.912 (1.214) 0.048 (0.071) 
Salivary  2.789 (0.934) 0.139 (0.048) 
Thyroid  9.453 (3.050) 0.467 (0.133) 
Oesophagus  0.256 (0.214) 0.013 (0.012) 
Thymus  2.426 (1.232) 0.119 (0.058) 
Heart  0.393 (0.226) 0.020 (0.012) 
Lung  3.061 (1.056) 0.151 (0.046) 
Liver  0.689 (0.289) 0.034 (0.013) 
Gall bladder 0.188 (0.161) 0.009 (0.008) 
Adrenals  0.102 (0.140) 0.005 (0.006) 
Stomach  0.422 (0.210) 0.021 (0.009) 
Cranium (BM) 1.563 (1.394) 0.081 (0.082) 
Mandible (BM) 2.789 (0.934) 0.139 (0.048) 
Cervical spine (BM) 0.300 (0.341) 0.016 (0.020) 
Clavicles (BM) 9.250 (5.253) 0.451 (0.241) 
Scapulae (BM) 0.169 (0.142) 0.009 (0.008) 
Sternum (BM) 19.074 (6.121) 0.942 (0.251) 
Ribs (BM) 3.569 (1.313) 0.175 (0.053) 
Contralateral breast 28.749 (8.541) 1.419 (0.346) 
Examined breast (MGD) 2018.498 (300.327) 100.000 
 
Many factors may affect the organ‘s radiation dose during screening mammography. 
Target/filter combination is one of these factors. As earlier mentioned in Table (5-9) (page 
126) four different target/filter combinations have been considered in this thesis (Rh/Rh, 
W/Rh, W/Ag and Mo/Mo). However, the number of machines of different target/filter 
combinations may cause some concern about drawing definitive conclusions from the results 
because only one W/Ag and one Mo/Mo target/filer combinations were included. In general, 
it can be noted that for the majority of organs the Rh/Rh target/filter combination resulted in 
the lowest radiation dose. It produces the lowest breast tissue radiation dose for both 
examined and contralateral breasts. Figure (6-4) shows the average examined breast MGD ± 
1SD of each target/filter combination presented as error bars. Also the same graph type (error 
bars ± 1SD) has been used to demonstrate the average contralateral breast dose of different 
target/filter combinations, see Figure (6-5). For most other tissue types, other than breast 
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tissue, Rh/Rh resulted in lowest dose; see Figure (6-6) where error bars (mean ± 1SD) have 
been used to present average organ radiation dose, of one screening event exposures, for 
different target/filter combinations. 
 
Figure (6-4) Shows mean MGD ± 1SD for the different target/filter combinations. 
  
 
 
 
Figure (6-5) Shows mean contralateral breast dose ± 1SD for different target/filter 
combinations. 
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The product of X-ray tube current and exposure time (mAs), beam half-value layer (HVL), 
and MGD are other factors which may affect the organs radiation dose during screening 
mammography. Spearman's rho correlation coefficients, for non-parametric data, 
demonstrate that most organ doses are weakly (not statistically significant) correlated to 
beam HVL. On the contrary, a moderate to strong correlation has been found between the 
radiation dose for most organs and mAs, see Table (6-5) which comprises both Spearman's 
rho correlation coefficient and correlation P-value for organs which received more than 0.1 
µGy radiation dose.  
Backward multiple linear regression models have been established for further assessment of 
the relationship between radiation dose of each organ and ‗mAs, HVL and MGD‘ in order to 
investigate the possibility of predicting individual organ radiation dose. Regression 
modelling was not significantly better than expressing mean values when predicting some 
organs doses.  Regression modelling can, however, predict up to 87% of dose variability for 
other organs, see Table (6-6). For each organ dose, the regression model data are presented 
in one row within Table (6-6). For Table (6-6), the first column includes the dependent 
variable (the organ dose to be predicted), while the regression model predictors‘ coefficients 
with 95% CI are presented in the second column. The R
2
 and adjusted R
2
 of the regression 
models are seen in the third and fourth columns of the table, respectively. The fifth column 
contains the regression equations that can be used to predict the organ doses. The standard 
errors associated with each regression equation output are listed in the last column of the 
table.    
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Table (6-5) Lists Spearman's rho correlation of different organs doses with MGD, 
mAs, and beam HVL using organs dose data from the sixteen FFDM machines. 
Spearman's rho correlation MGD mAs HVL 
Brain  
Correlation Coefficient -0.088 -0.355 -0.335 
P-value 0.745 0.178 0.204 
Salivary glands 
Correlation Coefficient 0.394 0.429 -0.252 
P-value 0.131 0.097 0.346 
Thyroid 
Correlation Coefficient 0.688 0.771 0.085 
P-value 0.003 0.000 0.756 
Oesophagus  
Correlation Coefficient 0.015 0.024 -0.553 
P-value 0.957 0.931 0.026 
Thymus 
Correlation Coefficient 0.394 0.818 0.076 
P-value 0.131 0.000 0.781 
Heart 
Correlation Coefficient 0.371 0.415 -0.130 
P-value 0.158 0.110 0.630 
Lung 
Correlation Coefficient 0.668 0.650 0.022 
P-value 0.005 0.006 0.935 
Liver 
Correlation Coefficient 0.465 0.247 -0.162 
P-value 0.070 0.356 0.550 
Gall bladder  
Correlation Coefficient 0.106 0.250 -0.008 
P-value 0.696 0.350 0.976 
Adrenals  
Correlation Coefficient 0.051 -0.083 -0.714 
P-value 0.850 0.760 0.002 
Stomach 
Correlation Coefficient 0.532 0.288 -0.107 
P-value 0.034 0.279 0.694 
Cranium (BM) 
Correlation Coefficient 0.059 -0.232 -0.356 
P-value 0.829 0.387 0.176 
Mandible (BM) 
Correlation Coefficient 0.394 0.429 -0.252 
P-value 0.131 0.097 0.346 
Cervical spine(BM) 
Correlation Coefficient -0.124 -0.198 -0.575 
P-value 0.648 0.463 0.020 
Clavicles (BM) 
Correlation Coefficient 0.506 0.876 0.077 
P-value 0.046 0.000 0.777 
Scapulae (BM) 
Correlation Coefficient -0.088 -0.176 -0.519 
P-value 0.745 0.513 0.039 
Sternum (BM) 
Correlation Coefficient 0.382 0.709 0.176 
P-value 0.144 0.002 0.513 
Ribs (BM) 
Correlation Coefficient 0.644 0.624 0.073 
P-value 0.007 0.010 0.789 
Contralateral breast 
Correlation Coefficient 0.671 0.732 0.234 
P-value 0.004 0.001 0.383 
MGD 
Correlation Coefficient 1.000 0.426 0.289 
P-value - 0.072 0.277 
Highlighted cells represent the significant P-values (P<0.05) 
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Table (6-6) Demonstrates the multiple linear regression data for each organ dose. 
Dependent 
variable 
Predictor(s) 
Coefficient 
(95% CI) 
Equation R
2
 
Adj. 
R
2
 
Std. 
error of 
estimate 
Salivary 
glands dose 
(SGD) 
mAs = 0.014 
(0.002 - 0.026) 
SGD = 1.624 + 0.014 mAs 30% 25% 0.807 
Thyroid dose 
(TD) 
MGD = 0.004 
(0.001-0.007) 
mAs = 0.063 
(0.040-0.086) 
HVL = –10.569 
(–20.947 - –0.191) 
TD = 1.909 + 0.004 MGD 
+ 0.063 mAs – 10.569 
HVL 
83% 79% 1.415 
Oesophagus 
dose (OD) 
HVL = –1.314 
(–2.583 - –0.045) 
OD = 0.925 – 1.314 HVL 26% 21% 0.190 
Thymus dose 
(THD) 
mAs = 0.030 
(0.023 - 0.038) 
THD = –0.115 + 0.030 
mAs 
83% 82% 0.522 
Lung dose 
(LD) 
mAs = 0.020 
(0.008 - 0.032) 
LD = 1.397 + 0.020 mAs 49% 45% 0.783 
Adrenals 
(AD) 
HVL = –1.192 
(–2.003- –0.381) 
AD = 0.333 – 1.192 HVL 45% 36% 0.112 
Mandible 
dose (MD) 
mAs = 0.014 
(0.002 - 0.026) 
MD = 1.624 + 0.014 mAs 30% 25% 0.807 
Clavicles 
(CLD) 
MGD = 0.004 
(0.000 - 0.008) 
mAs = 0.119 
(0.086 - 0.152) 
CLD = –8.064 + 0.004 
MGD + 0.119 mAs 
87% 84% 2.073 
Scapulae 
(SCD) 
HVL = –0.864 
(–1.710 - –0.017) 
SCD = 0.609 – 0.864 HVL 26% 20% 0.127 
Sternum 
dose (SD) 
 MGD = 0.006 
(0.000 - 0.013) 
mAs = 0.114 
(0.059 - 0.169) 
SD = –3.528 + 0.006 MGD 
+ 0.114 mAs 
73% 68% 3.444 
Ribs dose 
(RD) 
MGD = 0.002 
(0.000 - 0.004) 
mAs = 0.019 
(0.004 - 0.034) 
RD = –1.466 + 0.002 
MGD + 0.019 mAs 
58% 52% 0.911 
Contralateral 
breast dose 
(CD) 
 MGD = 0.011 
(0.000 - 0.022) 
mAs = 0.133 
(0.044 - 0.222) 
CD = – 4.589 + 0.011 
MGD + 0.133mAs 
63% 58% 5.551 
Regression model is not significant for brain, heart, liver, gall bladder, stomach, 
cranium (BM), cervical spine (BM) radiation doses, and MGD. 
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6.3 Effective Risk Data 
Effective lifetime risk refers to an individual‘s chance of acquiring a radiation-induced 
cancer. Since effective risk calculations include organ radiation doses and LAR factors which 
decrease with age as tissue becomes more radio-resistant, its value also decreases with age. If 
organ radiation doses resulting from screening mammography are considered to be constant 
during a female‘s lifetime, the changes in effective risk during a female‘s lifetime are only 
dependent on LAR reduction with age, see Table (6-7), Table (6-8) and Table (6-9) for the 
three LAR extrapolation methods. The effective risk values listed in these tables represent the 
average effective risk (case/10
6
) for the sixteen FFDM machines, with 95% confidence 
interval (CI) for each year of female life. The effective risk values for each machine are 
presented in Appendix B.  
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Table (6-7) Presents mean calculated effective risk values using LAR extrapolated by 
best fit lines method (method 1) for each year of female life with 95% CI. 
Age 
(year) 
Effective lifetime risk (case/10
6
) Age 
(year) 
Effective lifetime risk (case/10
6
) 
Mean 95% CI Mean 95% CI 
25 70.00 [64.88 - 75.12] 51 14.10 [13.07 - 15.13] 
26 66.38 [61.53 - 71.24] 52 12.93 [11.99 - 13.88] 
27 62.77 [58.18 - 67.36] 53 11.82 [10.96 - 12.69] 
28 59.16 [54.83 - 63.48] 54 10.76 [9.98 - 11.55] 
29 55.54 [51.48 - 59.60] 55 9.76 [9.04 - 10.47] 
30 51.93 [48.13 - 55.72] 56 8.81 [8.16 - 9.45] 
31 48.59 [45.04 - 52.15] 57 7.91 [7.33 - 8.49] 
32 46.36 [42.97 - 49.75] 58 7.06 [6.54 - 7.58] 
33 44.18 [40.95 - 47.41] 59 6.27 [5.81 - 6.73] 
34 42.06 [38.98 - 45.13] 60 5.53 [5.12 - 5.93] 
35 39.99 [37.06 - 42.91] 61 4.84 [4.49 - 5.20] 
36 37.97 [35.19 - 40.74] 62 4.21 [3.90 - 4.52] 
37 36.00 [33.37 - 38.63] 63 3.63 [3.36 - 3.89] 
38 34.09 [31.60 - 36.58] 64 3.10 [2.87 - 3.33] 
39 32.23 [29.88 - 34.59] 65 2.63 [2.44 - 2.82] 
40 30.43 [28.20 - 32.65] 66 2.21 [2.05 - 2.37] 
41 28.68 [26.58 - 30.78] 67 1.84 [1.71 - 1.98] 
42 26.98 [25.01 - 28.95] 68 1.53 [1.41 - 1.64] 
43 25.34 [23.48 - 27.19] 69 1.27 [1.17 - 1.36] 
44 23.75 [22.01 - 25.48] 70 1.06 [0.98 - 1.14] 
45 22.21 [20.58 - 23.83] 71 0.90 [0.84 - 0.97] 
46 20.72 [19.21 - 22.24] 72 0.80 [0.74 - 0.86] 
47 19.29 [17.88 - 20.70] 73 0.75 [0.70 - 0.81] 
48 17.91 [16.60 - 19.22] 74 0.75 [0.70 - 0.81] 
49 16.59 [15.38 - 17.80] 
75 0.75 [0.69 - 0.80] 
50 15.32 [14.20 - 16.44] 
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Table (6-8) Presents mean calculated effective risk values using LAR extrapolated by 
linear relationship method (method 2) for each year of female life with 95% CI. 
Age 
(year) 
Effective lifetime risk (case/10
6
) Age 
(year) 
Effective lifetime risk (case/10
6
) 
Mean 95% CI Mean 95% CI 
25 70.00 [64.88 - 75.12] 51 13.62 [12.62 - 14.61] 
26 66.38 [61.53 - 71.24] 52 12.82 [11.88 - 13.76] 
27 62.77 [58.18 - 67.36] 53 12.02 [11.14 - 12.90] 
28 59.15 [54.83 - 63.48] 54 11.22 [10.40 - 12.04] 
29 55.54 [51.48 - 59.60] 55 10.42 [9.66 - 11.18] 
30 51.93 [48.13 - 55.72] 56 9.62 [8.92 - 10.32] 
31 49.63 [46.00 - 53.26] 57 8.82 [8.17 - 9.46] 
32 47.34 [43.87 - 50.80] 58 8.02 [7.43 - 8.61] 
33 45.04 [41.75 - 48.33] 59 7.22 [6.69 - 7.75] 
34 42.74 [39.62 - 45.87] 60 6.42 [5.95 - 6.89] 
35 40.45 [37.49 - 43.41] 61 6.03 [5.59 - 6.47] 
36 38.15 [35.36 - 40.94] 62 5.64 [5.22 - 6.05] 
37 35.86 [33.23 - 38.48] 63 5.25 [4.86 - 5.63] 
38 33.56 [31.11 - 36.01] 64 4.85 [4.50 - 5.21] 
39 31.27 [28.98 - 33.55] 65 4.46 [4.14 - 4.79] 
40 28.97 [26.85 - 31.09] 66 4.07 [3.77 - 4.37] 
41 27.51 [25.50 - 29.53] 67 3.68 [3.41 - 3.95] 
42 26.06 [24.15 - 27.96] 68 3.29 [3.05 - 3.53] 
43 24.60 [22.81 - 26.40] 69 2.90 [2.69 - 3.11] 
44 23.15 [21.46 - 24.84] 70 2.51 [2.32 - 2.69] 
45 21.69 [20.11 - 23.28] 71 2.34 [2.17 - 2.51] 
46 20.24 [18.76 - 21.72] 72 2.18 [2.02 - 2.34] 
47 18.78 [17.41 - 20.16] 73 2.01 [1.86 - 2.16] 
48 17.33 [16.06 - 18.60] 74 1.84 [1.71 - 1.98] 
49 15.87 [14.71 - 17.03] 
75 1.68 [1.55 - 1.80] 
50 14.42 [13.36 - 15.47] 
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Table (6-9) Presents mean calculated effective risk values using LAR extrapolated 
by step method (method 3) for each year of female life with 95% CI. 
Age 
(year) 
Effective lifetime risk (case/10
6
) Age 
(year) 
Effective lifetime risk (case/10
6
) 
Mean 95% CI Mean 95% CI 
25 88.07 [81.63 - 94.51] 51 14.42 [13.36 - 15.47] 
26 88.07 [81.63 - 94.51] 52 14.42 [13.36 - 15.47] 
27 88.07 [81.63 - 94.51] 53 14.42 [13.36 - 15.47] 
28 88.07 [81.63 - 94.51] 54 14.42 [13.36 - 15.47] 
29 88.07 [81.63 - 94.51] 55 14.42 [13.36 - 15.47] 
30 51.93 [48.13 - 55.72] 56 14.42 [13.36 - 15.47] 
31 51.93 [48.13 - 55.72] 57 14.42 [13.36 - 15.47] 
32 51.93 [48.13 - 55.72] 58 14.42 [13.36 - 15.47] 
33 51.93 [48.13 - 55.72] 59 14.42 [13.36 - 15.47] 
34 51.93 [48.13 - 55.72] 60 6.42 [5.95 - 6.89] 
35 51.93 [48.13 - 55.72] 61 6.42 [5.95 - 6.89] 
36 51.93 [48.13 - 55.72] 62 6.42 [5.95 - 6.89] 
37 51.93 [48.13 - 55.72] 63 6.42 [5.95 - 6.89] 
38 51.93 [48.13 - 55.72] 64 6.42 [5.95 - 6.89] 
39 51.93 [48.13 - 55.72] 65 6.42 [5.95 - 6.89] 
40 28.97 [26.85 - 31.09] 66 6.42 [5.95 - 6.89] 
41 28.97 [26.85 - 31.09] 67 6.42 [5.95 - 6.89] 
42 28.97 [26.85 - 31.09] 68 6.42 [5.95 - 6.89] 
43 28.97 [26.85 - 31.09] 69 6.42 [5.95 - 6.89] 
44 28.97 [26.85 - 31.09] 70 2.51 [2.32 - 2.69] 
45 28.97 [26.85 - 31.09] 71 2.51 [2.32 - 2.69] 
46 28.97 [26.85 - 31.09] 72 2.51 [2.32 - 2.69] 
47 28.97 [26.85 - 31.09] 73 2.51 [2.32 - 2.69] 
48 28.97 [26.85 - 31.09] 74 2.51 [2.32 - 2.69] 
49 28.97 [26.85 - 31.09] 
75 2.51 [2.32 - 2.69] 
50 14.42 [13.36 - 15.47] 
As discussed in section 3.7 (page 53) worldwide screening mammography programmes 
recommendations are different, variations are possible relating to screening commencement 
age, number of screens, time interval between screens, and cessation age of screening. These 
differences result in large variations in total effective risk of worldwide screening 
programmes. Tables (6-10), (6-11), and (6-12) demonstrate the average, for the sixteen 
FFDM machines, total effective risk (case/10
6
) with 95% CI of worldwide screening 
programmes in ascending order for the three extrapolated LAR methods. Total effective risks 
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of worldwide screening programmes for each FFDM machine are presented in Appendix E. 
In general, the lowest total effective risk results from the Maltese screening programme for 
average risk women (42.21 [39.12 - 45.30], 43.28 [40.11 - 46.44], and 57.67 [53.46 - 61.89] 
case/10
6
 for the three LAR methods), while the highest total effective risk results from the 
American screening programme for high risk women recommended by National 
Comprehensive Cancer Network (NCCN) (1099.67 [1019.25 - 1180.09], 1121.36 [1039.36 - 
1203.36], and 1472.73 [1365.04 - 1580.42] case/10
6
 for the three LAR methods). The 
variations in total effective risk of worldwide screening programmes resulted from LAR 
extrapolation method are shown in Figure (6-7). In this figure the average total effective risk 
of worldwide screening programmes along with ±1 SD errors bar are presented for all the 
three LAR extrapolation methods. In general the third extrapolation method (‗step‘ method) 
resulted in the highest total effective risk for all worldwide screening programmes.  
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Table (6-10) Illustrates total effective risk (mean [95% CI] for the sixteen FFDM 
machines) of worldwide screening programmes using LAR factors extrapolated by 
method 1. 
Programme 
Total effective risk (case/10
6
) 
Mean 95% CI 
Malta 42.21 [39.12 - 45.30] 
Estonia  64.62 [59.89 - 69.35] 
Ireland 67.72 [62.76 - 72.68] 
United Kingdom 70.77 [65.59 - 75.95] 
Belgium, Croatia, Cyprus, Denmark, Finland, 
Germany, Italy, Latvia, Lithuania, Luxembourg, 
Norway, Poland, Slovenia, Spain (Catalonia), 
Switzerland 
71.45 [66.22 - 76.68] 
Canada , France, Israel, Netherlands 74.06 [68.64 - 79.49] 
Hungary 119.04 [110.33 - 127.75] 
New Zealand, Portugal, Spain (Navarra) 122.15 [113.21 - 131.08] 
China 122.83 [113.85 - 131.81] 
Czech  136.45 [126.46 - 146.43] 
Iceland 191.25 [177.26 - 205.24] 
Nigeria 192.30 [178.24 - 206.37] 
Australia, Japan, Korea, United States (AAFP, NCI, 
and USPSTF) 
193.86 [179.67 - 208.04] 
Sweden 225.89 [209.37 - 242.42] 
Uruguay 255.30 [236.62 - 273.98] 
United States (ACOG) 260.32 [241.27 - 279.37] 
India  305.96 [283.58 - 328.34] 
United States (ACS, ACR, and NCCN) 372.42 [345.18 - 399.67] 
Canada  305.96 [283.58 - 328.34] 
United Kingdom  370.92 [343.79 - 398.06] 
United States (ACS) 785.82 [728.35 - 843.30] 
United States (NCCN) 1099.67 [1019.25 - 1180.09] 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (6-11) Illustrates total effective risk (mean [95% CI] for the sixteen FFDM 
machines) of worldwide screening programmes using LAR factors extrapolated by 
method 2. 
Programme 
Total effective risk (case/10
6
) 
Mean 95% CI 
Malta 43.28 [40.11 - 46.44] 
Estonia  68.15 [63.16 - 73.14] 
Ireland 73.01 [67.66 - 78.35] 
United Kingdom 77.79 [72.10 - 83.48] 
Belgium, Croatia, Cyprus, Denmark, Finland, 
Germany, Italy, Latvia, Lithuania, Luxembourg, 
Norway, Poland, Slovenia, Spain (Catalonia), 
Switzerland 
80.37 [74.49 - 86.25] 
Canada , France, Israel, Netherlands 86.90 [80.54 -  93.25] 
China 120.94 [112.10 - 129.79] 
Hungary 124.18 [115.10 - 133.27] 
New Zealand, Portugal, Spain (Navarra) 130.76 [121.20 - 140.33] 
Czech  147.61 [136.81 - 158.41] 
Iceland 196.11 [181.77 - 210.46] 
Nigeria 198.86 [184.37 - 213.35] 
Australia, Japan, Korea, United States (AAFP, NCI, 
and USPSTF) 
202.64 [187.82 - 217.46] 
Sweden 233.53 [216.45 - 250.61] 
Uruguay 270.53 [250.74 - 290.31] 
United States (ACOG) 283.08 [262.38 - 303.79] 
India  311.11 [288.36 - 333.86] 
United States (ACS, ACR, and NCCN) 391.55 [362.91 - 420.19] 
Canada  311.11 [288.36 - 333.86] 
United Kingdom  388.03 [359.65 - 416.41] 
United States (ACS) 807.51 [748.46 - 866.56] 
United States (NCCN) 1121.36 [1039.36 - 1203.36] 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (6-12) Illustrates total effective risk (mean [95% CI] for the sixteen FFDM 
machines) of worldwide screening programmes using LAR factors extrapolated by 
method 3. 
Programme 
Total effective risk (case/10
6
) 
Mean 95% CI 
Malta 57.67 [53.46 - 61.89] 
Estonia  84.93 [78.72 - 91.14] 
Ireland 91.35 [84.67 - 98.03] 
United Kingdom 108.41 [100.48 - 116.34] 
Belgium, Croatia, Cyprus, Denmark, Finland, 
Germany, Italy, Latvia, Lithuania, Luxembourg, 
Norway, Poland, Slovenia, Spain (Catalonia), 
Switzerland 
104.19 [96.57 - 111.81] 
Canada , France, Israel, Netherlands 111.71 [103.54 - 119.89] 
China 159.13 [147.50 - 170.77] 
Hungary 178.26 [165.22 - 191.29] 
New Zealand, Portugal, Spain (Navarra) 191.10 [177.12 - 205.07] 
Czech  198.62 [184.09 - 213.15] 
Iceland 249.04 [230.82 - 267.25] 
Nigeria 251.54 [233.15 - 269.94] 
Australia, Japan, Korea, United States (AAFP, NCI, 
and USPSTF) 
256.56 [237.80 - 275.32] 
Sweden 311.99 [289.17 - 334.81] 
Uruguay 353.22 [327.39 - 379.06] 
United States (ACOG) 368.27 [341.34 - 395.21] 
India  401.41 [372.05 - 430.76] 
United States (ACS, ACR, and NCCN) 513.12 [475.59 - 550.65] 
Canada  401.41 [372.05 - 430.76] 
United Kingdom  508.10 [470.95 - 545.26] 
United States (ACS) 1032.39 [956.90 - 1107.88] 
United States (NCCN) 1472.73 [1365.04 - 1580.42] 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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A Spearman's rho correlation coefficient demonstrated that there was a strong correlation 
between the total effective risk of worldwide screening programmes and screening 
commencement age, cessation age of screening, time interval between screens, and number 
of screens during female life time; see Table (6-13). In spite of the small number of 
worldwide screening recommendations (n = 22 cases, number of worldwide screening 
recommendations) used in the regression, a further investigation of the relationship between 
total effective risk and associated factors using a backward regression model shows that the 
commencement age does not significantly affect the total effective risk and because of this it 
has been excluded from regression model by the SPSS. This was the same for the total 
effective risk calculated using the LAR factors extrapolated by each of the three methods; see 
Table (6-14). This table shows the predictors‘ coefficients, regression equation, R2, and 
standard error of estimate for each extrapolation method.    
 
 
Table (6-13) Shows Spearman's rho correlations between total effective risk of 
worldwide screening programmes (N=22) and each of commencement/cessation ages and 
frequency of screening for the three LAR calculation methods. 
LAR Extrapolation  
Method 
Screening Age Screening Frequency 
Commencement Cessation 
Number of 
screens 
Time 
interval 
(Method 1) -0.915 0.709 0.960 -0.877 
(Method 2) -0.897 0.721 0.971 -0.892 
(Method 3) -0.901 0.726 0.970 -0.884 
All values presented in this table were statistically significant (P<0.001) 
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Table (6-14) Demonstrates the backward regression models which estimate the effect of 
different factors on total effective risk calculated using LAR factors extrapolated by the 
three methods   
Method 
Predictors coefficient 
(95% CI)
*
 
Regression Equation R
2**
 
Std. error 
of estimate 
M1 
E = –8.885 
(–18.271 - 0.501) 
T = 155.257 
(41.639 - 268.874) 
N = 26.893 
(21.093 - 32.694) 
R = 57.993 – 8.885 E + 155.257 T 
+ 26.893 N 
91% 79.867 
M2 
E = –8.624 
(–17.837 - 0.589) 
T = 152.656 
(41.135 - 264.176) 
N = 27.179 
(21.485 - 32.872) 
R = 48.606 – 8.624 E + 152.656 T 
+ 27.179 N 
92% 78.393 
M3 
E = –11.212 
(–23.342 - 0.918) 
T = 200.635 
(53.808 - 347.461) 
N = 35.378 
(27.882 - 42.873) 
R = 60.027 – 11.212 E + 200.635 
T + 35.378 N 
92% 103.211 
*
R, total effective risk; N, number of screens; E, ending age of screening; T, time interval 
between screens. 
**
R
2 
approximately equal to adjust R
2
 for the three models. 
 
6.4 Effective Risk Modelling Data 
6.4.1 Mathematical Regression Model  
To obtain a good regression model capable of predicting the total effective risk of different 
screening programmes with more precision than the one established with the small sample 
size (n=22 cases) (Table (6-14), section 6.3), additional data were generated to create 274 
screening scenarios; these were subsequently analysed. Spearman's rho correlations of these 
data revealed that the commencement age of screening and the number of screens were the 
most important factors affecting the total effective risk of any screening programme (both are 
correlated strongly with total effective risk); see Table (6-15) which contains both 
correlation coefficient and P-value for the three LAR extrapolation methods. Since the time 
interval between screens does not significantly affect the output total effective risk of the 
backward regression model, it is excluded by SPSS; see Table (6-16). In the first column of 
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Table (6-16) the LAR extrapolation methods are listed. Then the regression model data 
including predictors‘ coefficients, regression equation, R2, and standard error of estimates are 
contained in the next columns, respectively. 
 
Table (6-15) Shows Spearman's rho correlations between the total effective risk of 274 
proposed screening programmes and each of the commencement/cessation ages and 
frequency of screening for the three LAR methods. 
LAR Extrapolation  
Method 
Screening Age Screening Frequency 
Commencement Cessation 
Number of 
screens 
Time 
interval 
 (Method 1) -0.876 -0.368 0.692 -0.399 
 (Method 2) -0.865 -0.346 0.714 -0.420 
 (Method 3) -0.856 -0.332 0.727 -0.433 
All values presented in this table were statistically significant (P<0.001) 
 
 
Table (6-16) Demonstrates the backward regression models which are established to 
predict the total effective risk of any screening programme using LAR factors 
extrapolated by the three methods.   
Method 
Predictors coefficient  
(95% CI)
*
  
Regression Equation R
2**
 
Std. error 
of estimate 
M1 
C = –8.049  
(–9.508 - –6.590) 
E = –6.379  
(–7.928 - –4.829) 
N= 17.248  
(15.828 - 18.668) 
R = 734.676 – 8.049 C – 6.379 E 
+ 17.248 N 
86% 93.249 
M2 
C=–7.763  
(–9.189 - –6.338) 
E= -6.085 
(–7.599 - –4.571) 
N = 17.569  
(16.181 - 18.957) 
R= 705.170 –7.763 C – 6.085 E + 
17.569 N 
87% 91.127 
M3 
C = –9.980 
(–11.817 - –8.144) 
E = -7.730 
(–9.681 - –5.779) 
N = 23.248 
(21.459 - 25.036) 
R= 900.962 – 9.980 C –7.730 E + 
23.248 N 
87% 117.411 
*
R, total effective risk; N, number of screens; C, commencement age of screening; E, 
ending age of screening. 
**
R
2 
= adjusted R
2
 for the three models. 
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6.4.2 Graphical Extrapolation of Total Effective Risk  
 If screening mammography cessation age is set at a constant level (75 years old) for all 
screening programmes, the factors that affect the total effective risk will be reduced down to 
only two (commencement age and screening frequency). The resultant graphical relationship 
between screening commencement age (year) on the X-axis and average total effective risk 
(case/10
6
) for the sixteen FFDM machines on the Y-axis is demonstrated in Figure (6-8), 
Figure (6-9) and Figure (6-10) for the three LAR extrapolation methods. Each of these 
figures contains three relationship lines; one for each screening frequency (annual, biennial, 
and triennial). Consequently, these graphs can be used to predict the total effective risk 
during a female‘s life for any screening commencement age and frequency by interpolation 
method.  
 
Figure (6-8) Represents the relationship between the total effective risk and the screening 
commencement age of different screening frequencies. Total effective risk calculated using 
LAR factors extrapolated by the best fit lines method (method 1). 
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Figure (6-9) Represents the relationship between the total effective risk and the screening 
commencement age of different screening frequencies. Total effective risk calculated using 
LAR factors extrapolated by the linear relationship method (method 2). 
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Figure (6-10) Represents the relationship between the total effective risk and the screening 
commencement age of different screening frequencies. Total effective risk calculated using 
LAR factors extrapolated by the step method (method 3). 
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6.4.3 Extrapolation of Total Effective Risk Using Baseline MGD Values  
Using the data of sixteen FFDM machines, the relationship between MGD (µGy) and the 
total effective risk (case/10
6
) of each screening scenario, of specific screening 
commencement age and frequency (Appendix D) resulted in set of conversions factors 
(case/10
6
/µGy); see Tables (6-17), (6-18), and (6-19). In these tables, opposite each 
screening commencement age between ages 25 and 75 (first and third columns of the tables), 
three conversion factors (second and fourth columns in the tables) are presented; one 
conversion factor for each screening frequency (annual, biennial, and triennial). These factors 
enable total effective risk to be obtained for any screening programme, of specific screening 
commencement age and frequency, whilst considering individual MGD which would be 
derived from an initial mammogram for each FFDM machine. Consequently, the graphs in 
Figures (6-8), (6-9), and (6-10) have been developed to generate the graphs as illustrated in 
Figures (6-11), (6-12), and (6-13), respectively. The only difference in these graphs (Figures 
(6-11), (6-12), and (6-13)) compared with the former graphs (Figures (6-8), (6-9), and (6-
10)) is that the total effective risk is presented as a percent of MGD. In other words, the X-
axis of the graphs still indicates the screening commencement age (year), while on the Y-axis 
the total effective risk represented as a percent of MGD.  
 
 
 
 
 
 
 
 
 167 
 
Table (6-17) Lists the relationship factors between the total effective risk of the screening 
programme and the MGD based on the data collected from the 16 FFDM machines. These 
factors are for method 1 of LAR extrapolation. 
Commencement 
age (year) 
Conversion factor 
% MGD (case/10
6
/µGy) Commencement 
age (year) 
Conversion factor 
% MGD (case/10
6
/µGy) 
Annual Biennial Triennial Annual Biennial Triennial 
25 54.48 28.13 19.33 51 6.20 3.29 2.33 
26 51.01 26.35 18.15 52 5.51 2.91 2.05 
27 47.73 24.67 17.00 53 4.86 2.59 1.83 
28 44.62 23.06 15.87 54 4.28 2.27 1.63 
27 41.68 21.56 14.86 55 3.75 2.01 1.41 
30 38.93 20.13 13.89 56 3.26 1.74 1.24 
31 36.36 18.81 12.93 57 2.83 1.53 1.09 
32 33.95 17.56 12.11 58 2.43 1.30 0.92 
33 31.66 16.40 11.32 59 2.08 1.13 0.81 
34 29.47 15.26 10.53 60 1.77 0.95 0.70 
35 27.38 14.21 9.81 61 1.50 0.82 0.57 
36 25.40 13.17 9.13 62 1.26 0.68 0.5 
37 23.52 12.23 8.44 63 1.05 0.58 0.43 
38 21.74 11.29 7.83 64 0.87 0.47 0.33 
39 20.05 10.44 7.25 65 0.72 0.40 0.29 
40 18.45 9.60 6.66 66 0.59 0.31 0.25 
41 16.94 8.85 6.14 67 0.48 0.27 0.18 
42 15.52 8.10 5.65 68 0.39 0.20 0.16 
43 14.19 7.43 5.15 69 0.31 0.18 0.14 
44 12.93 6.76 4.72 70 0.25 0.13 0.09 
45 11.75 6.17 4.31 71 0.20 0.12 0.08 
46 10.65 5.58 3.90 72 0.15 0.08 0.08 
47 9.63 5.07 3.54 73 0.11 0.07 0.04 
48 8.67 4.56 3.21 74 0.07 0.04 0.04 
49 7.78 4.11 2.87 
75 0.04 0.04 0.04 
50 6.96 3.67 2.59 
When using this table to calculate total effective risk the commencement age and frequency 
of screening examinations must be selected and the relevant conversion factor can then be 
multiplied by the MGD.   
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Table (6-18) Lists the relationship factors between the total effective risk of the screening 
programme and the MGD based on the data collected from the 16 FFDM machines. These 
factors are for method 2 of LAR extrapolation. 
Commencement 
age (year) 
Conversion factor 
% MGD (case/10
6
/µGy) Commencement 
age (year) 
Conversion factor 
% MGD (case/10
6
/µGy) 
Annual Biennial Triennial Annual Biennial Triennial 
25 55.56 28.71 19.69 51 7.58 3.99 2.78 
26 52.09 26.85 18.51 52 6.90 3.59 2.49 
27 48.80 25.24 17.36 53 6.27 3.31 2.30 
28 45.69 23.56 16.22 54 5.67 2.96 2.11 
27 42.76 22.13 15.22 55 5.12 2.72 1.86 
30 40.01 20.63 14.25 56 4.60 2.40 1.71 
31 37.43 19.38 13.29 57 4.12 2.20 1.55 
32 34.98 18.06 12.47 58 3.69 1.92 1.34 
33 32.63 16.92 11.68 59 3.29 1.76 1.23 
34 30.40 15.71 10.83 60 2.93 1.53 1.11 
35 28.28 14.69 10.12 61 2.61 1.40 0.95 
36 26.28 13.59 9.45 62 2.31 1.21 0.87 
37 24.39 12.69 8.71 63 2.03 1.11 0.80 
38 22.61 11.70 8.12 64 1.77 0.93 0.65 
39 20.95 10.91 7.56 65 1.53 0.85 0.59 
40 19.40 10.04 6.94 66 1.31 0.69 0.54 
41 17.96 9.36 6.46 67 1.11 0.62 0.41 
42 16.60 8.60 6.01 68 0.93 0.49 0.37 
43 15.31 8.00 5.50 69 0.77 0.44 0.33 
44 14.09 7.31 5.09 70 0.62 0.32 0.22 
45 12.94 6.78 4.72 71 0.50 0.30 0.21 
46 11.87 6.17 4.28 72 0.38 0.20 0.19 
47 10.87 5.70 3.95 73 0.27 0.18 0.10 
48 9.94 5.16 3.64 74 0.17 0.09 0.09 
49 9.08 4.77 3.28 
75 0.08 0.08 0.08 
50 8.29 4.31 3.01 
When using this table to calculate total effective risk the commencement age and frequency 
of screening examinations must be selected and the relevant conversion factor can then be 
multiplied by the MGD.   
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Table (6-19) Lists the relationship factors between the total effective risk of the screening 
programme and the MGD based on the data collected from the 16 FFDM machines. These 
factors are for method 3 of LAR extrapolation. 
Commencement 
age (year) 
Conversion factor 
% MGD (case/10
6
/µGy) Commencement 
age (year) 
Conversion factor 
% MGD (case/10
6
/µGy) 
Annual Biennial Triennial Annual Biennial Triennial 
25 72.97 38.66 25.53 51 10.36 5.53 3.66 
26 68.60 34.30 24.81 52 9.64 4.82 3.35 
27 64.24 34.30 22.62 53 8.93 4.82 3.35 
28 59.88 29.94 21.17 54 8.21 4.11 2.95 
27 55.51 29.94 20.45 55 7.50 4.11 2.63 
30 51.15 25.57 18.26 56 6.78 3.39 2.63 
31 48.58 25.57 16.80 57 6.07 3.39 2.24 
32 46.00 23.00 16.08 58 5.35 2.68 1.92 
33 43.43 23.00 15.69 59 4.64 2.68 1.92 
34 40.86 20.43 14.23 60 3.93 1.96 1.52 
35 38.29 20.43 13.51 61 3.61 1.96 1.20 
36 35.71 17.86 13.11 62 3.29 1.64 1.20 
37 33.14 17.86 11.66 63 2.97 1.64 1.20 
38 30.57 15.28 10.94 64 2.65 1.33 0.88 
39 27.99 15.28 10.54 65 2.34 1.33 0.88 
40 25.42 12.71 9.09 66 2.02 1.01 0.88 
41 23.99 12.71 8.37 67 1.70 1.01 0.57 
42 22.55 11.28 7.97 68 1.38 0.69 0.57 
43 21.12 11.28 7.65 69 1.06 0.69 0.57 
44 19.68 9.84 6.93 70 0.75 0.37 0.25 
45 18.25 9.84 6.53 71 0.62 0.37 0.25 
46 16.81 8.41 6.22 72 0.50 0.25 0.25 
47 15.38 8.41 5.50 73 0.37 0.25 0.12 
48 13.94 6.97 5.10 74 0.25 0.12 0.12 
49 12.50 6.97 4.78 
75 0.12 0.12 0.12 
50 11.07 5.53 4.06 
When using this table to calculate total effective risk the commencement age and 
frequency of screening examinations must be selected and the relevant conversion factor 
can then be multiplied by the MGD.   
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Figure (6-11) Represents the relationship between the total effective risk as a percent of 
MGD and the screening commencement age of different screening frequencies. Total 
effective risk calculated using LAR factors extrapolated by best fit lines method (method 1). 
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Figure (6-12) Represents the relationship between the total effective risk as a percent of 
MGD and the screening commencement age of different screening frequencies. Total 
effective risk calculated using LAR factors extrapolated by linear relationship method 
(method 2). 
 172 
 
 
Figure (6-13) Represents the relationship between the total effective risk as a percent of 
MGD and the screening commencement age of different screening frequencies. Total 
effective risk calculated using LAR factors extrapolated by step method (method 3). 
6.5 Shield Intervention Data 
Analysis of effective dose for the sixteen FFDM machines demonstrates that the contralateral 
breast dose is the second highest contributor, after examined breast MGD, to the effective 
dose for one screening session; see Table (6-20). For the sixteen machines, the effective dose 
of one screening session (second column of the table) along with the contribution of the 
examined breast MGD (third column), contralateral breast dose (fourth column), and other 
organ doses (fifth column) to the overall effective dose are seen in Table (6-20). Since organ 
dose measurements were repeated for FFDM machines 1 and 2 (three times on different 
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occasions to investigate reliability), each of these machines has three sets of data (‗visit 1‘, 
‗visit 2‘, and ‗visit 3‘). An average value for the three visits has been calculated to represent 
the overall value for these machines. The average ± 1SD contralateral breast dose 
contribution was (1.346% ± 0.31) of the effective dose. Accordingly, the effect of 
contralateral breast shield was investigated on organ dose for four FFDM machines; 
justification for the four machines is indicated within the methods chapter (section 5.9.4, 
page 136). It was found that the contralateral breast shield greatly reduces the contralateral 
breast dose; see Table (6-21) which demonstrates the organ doses data for the four FFDM 
machines measured without and with the use of the contralateral breast shield.  
Table (6-20) Radiation effective dose of one screening visit along with examined breast 
MGD, contralateral breast, and other tissue contribution in ED for the 16 FFDM machines. 
Machine 
Number 
Effective dose 
(µSv) 
Contribution percent in effective dose (%) 
Examined breast Contralateral breast Other tissue
*
 
1 
visit 1 295.958 98.565 1.052 0.383 
visit 2 296.151 98.501 1.163 0.336 
visit 3 295.672 98.660 1.019 0.321 
2 
visit 1 283.565 98.281 1.288 0.431 
visit 2 283.311 98.369 1.246 0.385 
visit 3 283.236 98.395 1.230 0.375 
3 248.504 96.930 2.301 0.769 
4 232.944 97.496 1.846 0.658 
5 244.873 98.430 1.206 0.364 
6 216.363 98.383 1.291 0.326 
7 343.731 97.977 1.550 0.473 
8 270.333 97.777 1.709 0.514 
9 223.155 98.458 1.138 0.404 
10 259.702 98.438 1.206 0.356 
11 204.445 98.467 1.098 0.435 
12 241.280 98.304 1.324 0.372 
13 226.972 98.295 1.309 0.396 
14 230.892 98.276 1.306 0.418 
15 214.934 98.012 1.563 0.425 
16 210.655 98.549 1.084 0.367 
Mean(SD) 255.334(37.27) 98.228(0.42) 1.346 (0.31) 0.425(0.11) 
*
 Other tissue includes all body tissue other than breast (examined and contralateral 
breasts) which received radiation dose from screening mammography exposures. 
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Table (6-21) Shows the effect of a contralateral breast shield on organs doses (µGy) for 
the selected four FFDM machines. 
Organ 
Machine 2
**
 Machine 8
**
 Machine 10
**
 Machine 11
**
 
without with without with without with without with 
Brain 0.82 0.54 0.00 0.00 0.68 1.92 0.17 1.46 
Salivary glands 4.36 3.71 2.78 2.80 1.84 2.40 1.22 1.84 
Thyroid 14.41 15.21 8.71 9.38 6.40 7.25 5.40 5.50 
Oesophagus 0.04 0.08 0.00 0.00 0.03 0.35 0.14 0.07 
Thymus 3.55 4.38 1.87 2.91 1.22 1.55 0.71 0.96 
Heart 0.77 0.06 0.00 0.03 0.00 0.54 0.00 0.15 
Lung 3.01 3.10 3.07 3.77 2.33 2.74 1.99 1.93 
Liver 1.61 0.46 0.63 0.76 0.44 0.78 0.46 0.43 
Gall bladder 0.42 0.10 0.00 0.00 0.00 0.29 0.05 0.10 
Adrenal 0.46 0.00 0.00 0.00 0.00 0.13 0.00 0.00 
Kidney 0.33 0.04 0.00 0.00 0.00 0.15 0.03 0.16 
Spleen 0.31 0.00 0.06 0.00 0.00 0.27 0.01 0.00 
Pancreas 0.09 0.01 0.00 0.00 0.00 0.14 0.00 0.00 
Stomach 1.64 0.25 0.23 0.43 0.32 0.41 0.24 0.21 
Intestine 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 3.33 2.05 0.06 0.32 1.66 2.82 0.91 2.84 
Mandibles (0.8%)
*
 4.36 3.71 2.78 2.80 1.84 2.40 1.22 1.84 
C-spine (3.9%)
*
 0.00 0.21 0.00 0.00 0.06 0.75 0.00 0.47 
Clavicles (0.8%)
*
 17.14 19.46 12.62 9.21 3.78 3.67 3.17 3.39 
Scapulae (2.8%)
*
 0.00 0.02 0.00 0.00 0.02 0.33 0.04 0.18 
Sternum (3.1%)
*
 27.98 24.07 29.65 24.54 16.74 12.78 12.32 11.12 
Ribs (16.1%)
*
 3.74 3.72 4.31 4.81 2.84 2.97 2.54 2.29 
T/L spine (28.4%)
*
 0.20 0.00 0.00 0.00 0.01 0.07 0.00 0.00 
Pelvis (27.4%)
*
 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Total BM dose 1.95 1.70 1.74 1.66 1.15 1.12 0.90 0.99 
Urinary bladder 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Uterus 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Ovaries 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Contralateral breast 35.20 1.93 41.40 0.01 22.85 1.24 22.76 1.66 
* These percentages represent the portion of bone marrow (BM) in different locations. They 
were adapted from ICRP report 70 (1995). 
**Machine 2 is Hologic Selenia, machine 8 is Giotto, and both machines 10 and 11 are GE 
Seno Essential. 
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The resultant reduction in total effective risk of worldwide screening programmes by the use 
of the contralateral breast shield, described in section 5.9.3 (page 135), for the four FFDM 
machines ranges from 0.75% to 1.68%, see Tables (6-22), (6-23), and (6-24) for the three 
LAR extrapolation methods. The first column of these tables includes the worldwide 
screening programmes. Opposite to each programme the reduction percentages in total 
effective risk due to the contralateral breast shield described in this thesis are listed in second, 
third, fourth, and fifth columns for machines 2, 8, 10, and 11, respectively.    
Tables (6-22) Demonstrates the effect of a contralateral breast shield on the total effective 
risk of worldwide screening programmes calculated using LAR factors extrapolated by 
method 1.  
Programme 
Total effective risk reduction percent (%) 
Machine 
2 
Machine 
8 
Machine 
10 
Machine 
11 
Australia, Japan, Korea, United States 
(AAFP, NCI, and USPSTF) 
1.44 1.62 0.95 1.07 
Belgium, Croatia, Cyprus, Denmark, 
Finland, Germany, Italy, Latvia, 
Lithuania, Luxembourg, Norway, Poland, 
Slovenia, Spain (Catalonia), Switzerland 
1.45 1.55 0.89 1.06 
Canada , France, Israel, Netherlands 1.46 1.52 0.86 1.06 
China 1.43 1.66 0.98 1.08 
Czech  1.44 1.59 0.92 1.07 
Estonia  1.44 1.59 0.92 1.07 
Hungary 1.44 1.61 0.94 1.07 
Iceland 1.43 1.64 0.96 1.07 
India  1.43 1.64 0.97 1.07 
Ireland 1.45 1.58 0.91 1.07 
Malta 1.44 1.61 0.93 1.07 
New Zealand, Portugal, Spain (Navarra) 1.44 1.60 0.93 1.07 
Nigeria 1.43 1.63 0.96 1.07 
Sweden 1.43 1.63 0.96 1.07 
United Kingdom 1.45 1.57 0.91 1.07 
United States (ACOG) 1.44 1.59 0.65 1.07 
United States (ACS, ACR, and NCCN) 1.44 1.62 0.75 1.07 
Uruguay 1.44 1.61 0.94 1.07 
Canada  1.43 1.64 0.97 1.07 
United Kingdom  1.44 1.62 0.95 1.07 
United States (ACS) 1.42 1.67 0.90 1.08 
United States (NCCN) 1.42 1.68 0.94 1.08 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Tables (6-23) Demonstrates the effect of a contralateral breast shield on the total effective 
risk of worldwide screening programmes calculated using LAR factors extrapolated by 
method 2. 
Programme 
Total effective risk (case/10
6
) 
Machine 2 Machine 8 Machine 10 Machine 11 
Australia, Japan, Korea, United 
States (AAFP, NCI, and USPSTF) 
1.43 1.63 0.95 1.07 
Belgium, Croatia, Cyprus, 
Denmark, Finland, Germany, Italy, 
Latvia, Lithuania, Luxembourg, 
Norway, Poland, Slovenia, Spain 
(Catalonia), Switzerland 
1.45 1.58 0.91 1.07 
Canada , France, Israel, Netherlands 1.45 1.56 0.89 1.07 
China 1.43 1.66 0.98 1.08 
Czech  1.44 1.60 0.93 1.07 
Estonia  1.44 1.60 0.93 1.07 
Hungary 1.44 1.62 0.95 1.07 
Iceland 1.43 1.64 0.96 1.07 
India  1.43 1.65 0.97 1.07 
Ireland 1.44 1.59 0.92 1.07 
Malta 1.44 1.61 0.94 1.07 
New Zealand, Portugal, Spain 
(Navarra) 
1.44 1.61 0.94 1.07 
Nigeria 1.43 1.63 0.96 1.07 
Sweden 1.43 1.64 0.96 1.07 
United Kingdom 1.44 1.59 0.92 1.07 
United States (ACOG) 1.44 1.61 0.93 1.07 
United States (ACS, ACR, and 
NCCN) 
1.43 1.63 0.95 1.07 
Uruguay 1.44 1.62 0.95 1.07 
Canada  1.43 1.65 0.97 1.07 
United Kingdom  1.43 1.63 0.95 1.07 
United States (ACS) 1.42 1.67 0.99 1.08 
United States (NCCN) 1.42 1.68 1.00 1.08 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Tables (6-24) Demonstrates the effect of a contralateral breast shield on the total effective 
risk of worldwide screening programmes calculated using LAR factors extrapolated by 
method 3. 
Programme 
Total effective risk (case/10
6
) 
Machine 2 Machine 8 Machine10 Machine11 
Australia, Japan, Korea, United 
States (AAFP, NCI, and USPSTF) 
1.43 1.65 0.97 1.07 
Belgium, Croatia, Cyprus, Denmark, 
Finland, Germany, Italy, Latvia, 
Lithuania, Luxembourg, Norway, 
Poland, Slovenia, Spain (Catalonia), 
Switzerland 
1.44 1.61 0.93 1.07 
Canada , France, Israel, Netherlands 1.44 1.59 0.92 1.07 
China 1.42 1.68 1.00 1.08 
Czech  1.43 1.63 0.96 1.07 
Estonia  1.44 1.62 0.95 1.07 
Hungary 1.43 1.66 0.98 1.08 
Iceland 1.43 1.66 0.98 1.08 
India  1.43 1.67 0.99 1.08 
Ireland 1.44 1.62 0.94 1.07 
Malta 1.43 1.64 0.96 1.07 
New Zealand, Portugal, Spain 
(Navarra) 
1.43 1.65 0.97 1.07 
Nigeria 1.43 1.65 0.98 1.08 
Sweden 1.43 1.66 0.98 1.08 
United Kingdom 1.43 1.63 0.95 1.07 
United States (ACOG) 1.43 1.63 0.96 1.07 
United States (ACS, ACR, and 
NCCN) 
1.43 1.65 0.97 1.07 
Uruguay 1.43 1.64 0.97 1.07 
Canada  1.44 1.62 0.94 1.07 
United Kingdom  1.43 1.65 0.97 1.07 
United States (ACS) 1.42 1.68 1.00 1.08 
United States (NCCN) 1.41 1.70 1.01 1.08 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Chapter Seven 
Discussion 
 
7.1 Chapter Overview 
The objective of screening mammography is to detect breast cancer early when treatment and 
recovery are more likely to be successful. However, since the introduction of screening 
mammography there has been a great debate about the risks versus benefits; see section 3.7 
on page 53. To understand the radiation risk associated with mammography many 
researchers have focused on screening mammography. The majority of researchers have used 
MGD as a parameter to quantify the radiation risk. In contrast others have used the years of a 
woman‘s life lost due to radiation-induced cancer from screening mammography. In this PhD 
thesis a novel method is proposed to quantify radiation risk from screening mammography. 
This method includes the calculation of effective risk of radiation-induced cancer as a 
parameter to assess mammography radiation risk. The effective risk calculation is no more 
difficult than the effective dose calculation. It takes the individuals‘ age and gender into 
account, and generates data that is likely to be more understandable to the general public 
when compared to MGD. In other words, for general public, it is probably easier to 
understand the risk of screening mammography in terms of radiation-induced cancer cases 
per million screened women rather than in mGy, in the case of MGD, or in mSv, in the case 
of effective dose.   
Within this chapter the results demonstrated in chapter 6 will be discussed. This chapter will 
be divided into six major sections. The measured organ dose reliability study is the focus of 
the first section (Dose Measurement Reliability). The discussion of reliability data includes 
the measured organ doses from two FFDM machines. For each of the machines, the organ 
doses were measured on three separate occasions and analysed to obtain the coefficients of 
variance for each of the organ doses and the overall intra-class correlation using statistical 
software. The radiation dose to each organ along with factors affecting this dose will be 
discussed separately in a subsection within the second section (Organ Radiation Doses) of 
this chapter. Compared to previous published studies, which estimated the organ doses by 
Monte Carlo simulation, the measured organ doses in this thesis are larger. This can be 
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attributed to some limitations of Monte Carlo software in the exact simulation of the 
mammographic machine and mathematical phantom positioning.  
The third section (Effective Risk) concentrates on total effective risk, during a female‘s 
lifetime and it explores the data of worldwide screening programmes to demonstrate the 
differences amongst these programmes. This includes the discussion of effective risk from 48 
screening programmes (44 for average risk women and 4 for high risk women) of 22 
different screening recommendations with different screening commencement/cessation ages 
and frequencies. The total effective risk modelling, during female lifetime, will be discussed 
in the fourth section (Effective Risk Modelling). In this context three different risk models 
are discussed. The first model, which is based on mathematical regression, is characterised 
by a large percentage error (approximately 30%) for the three LAR extrapolation methods. 
The second model is based on the use of a graphical representation of total effective risk 
against screening commencement age for each screening frequency separately. In this model 
(second model) interpolated total effective risk values are based on average organ dose for 
the 16 FFDM machines. To include the organ dose variations of different FFDM 
mammography machines, the third risk model was established based on the linear 
relationships between total effective risk and MGD from different FFDM machines. This was 
conducted because the MGD contributes to up to 98% of the effective risk and all other 
organs approximately 2%.      
The effect of a contralateral breast shield on measured organs dose and calculated effective 
risk is the focus of the fifth section (Contralateral Breast Shield Effect). Organ dose data from 
four FFDM machines without and with the use of a contralateral breast shield are discussed 
in this section. The contralateral breast shield can reduce contralateral breast tissue radiation 
dose by 95%. Consequently the total effective risk reduces by approximately 1.5% with the 
use of a contralateral breast shield. Finally, the limitations of this thesis, proposed future 
work to address these limitations and recommendations are the focus of the sixth section 
(Limitations, Future Work and Recommendations). 
7.2 Dose Measurement Reliability  
Reliability is a measure of random error associated with measurement processes and gives an 
indication of the method‘s precision (Field, 2013). In this thesis the main purpose of 
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reliability estimation is to investigate the possibility of obtaining consistent organ doses 
measured by the same FFDM machine under the same experimental conditions on three 
different occasions. As mentioned earlier in section 6.2 (page139) the reliability study 
involves data from three separate visits (organ doses measurement) for two FFDM machines.  
The reliability study for FFDM machine 1 (Figure (6-1), page 140) illustrates that there are 
some differences among measured organ doses across the three visits. These differences 
affect the measured radiation doses to the brain, salivary glands, thyroid, thymus, adrenals, 
stomach, mandible, clavicles, sternum and contralateral breast. Variations for mandible, 
clavicles, and sternum bone marrow radiation doses do not result in a large difference in the 
total bone marrow radiation dose (mean ± 1SD) 1.35 ± 0.10 µGy (coefficient of variation 
(CV) = 7.41%). With regard to the differences in measured organ dose to brain, salivary 
glands, thymus, and contralateral breast dose, although large standard deviations (SD) have 
been recorded for each, these SD values can be considered acceptable when compared with 
their mean values. For instance, for contralateral breast dose a SD of 1.89 µGy is acceptable 
when compared to 26.58 µGy mean dose (CV = 7.11%). The only organs that showed large 
differences in their measured organ doses are adrenal glands and stomach, where the mean ± 
1SD for these was 0.51 ± 0.46 µGy (CV= 90.00%) and 0.36 ± 0.21 µGy (CV= 35.00%, 
respectively.  
On the other hand, slightly smaller differences in measured organs doses, between the three 
visits, are seen for FFDM machine 2 (Figure (6-2), page 140), when compared to those of 
machine 1. For the three visits, the largest noticeable differences are recorded for radiation 
doses to brain, cervical spine bone marrow, cranium bone marrow, and the heart; the values 
(mean ± 1SD) were 0.50 ± 0.84 µGy (CV > 100%), 0.23 ± 0.40 µGy (CV > 100%), 1.08 ± 
0.86 µGy (CV = 79.63%), and 0.33 ± 0.18 µGy (CV = 54.55%), respectively. In spite of the 
large variations in cranium and cervical spine bone marrow radiation doses in addition to 
small variations in mandible, clavicles and sternum bone marrow doses, the total bone 
marrow radiation dose does not show large differences between the three visits (1.49 ± 0.16 
µGy, CV = 10.74%). As for FFDM machine 1 data, the variations in radiation dose to 
salivary glands, thymus, and contralateral breast are considered acceptable because their SD 
values are considered small when compared to their mean values.   
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A large part of the dose differences can be attributed to the inconsistency of the AECs 
because different exposure factors were recorded for the three visits; see Table (7-1). For 
FFDM machine 1 the variation in exposure factors amongst the three visits was higher than 
the level recommended by the European Commission (2006) which suggests a maximum 
mAs variation of 5%. However, this FFDM machine met the routine QA standards 
performed by physics support within the NHSBSP and it was in constant use for routine 
breast screening. The exposure factors variations for machine 2 were within the acceptable 
range of the European Commission (2006). The mAs variations for machine 2 were 3.1% and 
0.7% for CC and MLO projections, respectively. The effect of exposure factors (kV and 
mAs) on organ radiation doses has been reported by Hatziioannou et al. (2000) who found 
that some Lucite phantom organ radiation doses (e.g. sternum bone marrow and thyroid 
doses) are related to both kV and mAs. Also, the random nature of the X-ray beam and some 
experimental errors, such as those arising from phantom positioning, may contribute to these 
organ dose differences. However, as mentioned earlier in section 5.2.4 (page 112), the 
positioning error was minimised by the use of additional lines drawn on the ATOM phantom 
chest wall.  
Although both machines 1 and 2 are of same brand (Hologic Selenia), their AEC systems 
used different exposure factors to expose same breast phantom. This may be attributed to the 
different target/filter combinations of these machines wherein the machine 1 had a Mo/Mo 
target/filter combination while machine 2 had a Rh/Rh combination. Also, the X-ray tube age 
may be considered another cause for exposure factors difference which are used by the 
machines. It can be seen in Table (7-1) the use of lower kV by machine 2 resulted in higher 
required mAs to produce equivalent image quality.    
Overall, in spite of the organ dose differences, the consistency statistical analysis 
demonstrates an excellent agreement between the organ radiation doses measured on the 
three visits for each of the two FFDM machines (ICC > 99% for both machines). Moreover, 
these dose differences during the repeated measures on the three occasions do not produce 
important changes, which are not detectable statistically (ICC =1),  in calculated total 
effective risk of worldwide screening programmes; see Table (6-1) (page 141) for FFDM 
machine 1 and Table (6-2) (page 142) for FFDM machine 2. 
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Table (7-1) Demonstrates the exposure factor variations amongst the three visits for 
FFDM machine 1 and FFDM machine 2. 
FFDM 
Machine 
Projection 
Visit 1 Visit 2 Visit 3 
Coefficient of 
Variation (%) 
kV mAs kV mAs kV mAs kV mAs 
1 
CC 29.0 65.5 29.0 65.5 28.0 76.8 2.0 9.4 
MLO 30.0 67.6 29.0 73.3 29.0 77.0 2.0 6.5 
2 
CC 28.0 124.5 29.0 118.2 28.0 125.2 2.0 3.1 
MLO 29.0 129.5 29.0 131.2 29.0 130.0 0.0 0.7 
 
7.3 Organ Radiation Doses 
7.3.1 Examined Beast Radiation Dose  
As recommended internationally, radiation dose to glandular tissue (MGD) is used to 
indicate the breast radiation dose during screening mammography (IAEA, 2011; IPEM, 
2005). As mentioned earlier in section 5.3 (page 114) the method described by Dance, 
Skinner, Young, Beckett, and Kotre (2000a), has been recommended in the UK and all 
European countries and is used to calculate the examined breast MGD. Compared to the 
other available method of MGD calculation, described by Wu, Gingold, Barnes, and Tucker 
(1994), the MGD calculated by Dance, Skinner, et al. (2000a) method gives a higher result 
by approximately 9-21% depending on target/filter combination (Tsai, Chong, Ho, and Tyan, 
2010) 
For the sixteen FFDM machines the total MGD (for both CC and MLO projections) ranged 
between 1.678 mGy (for FFDM machine 11) and 2.806 mGy (for FFDM machine 7) with a 
mean (95% CI) value of 2.019 (1.871 - 2.166) mGy; see Table (6-3) on page 143. These 
MGD values are lower than expected for a standard breast (with 53 mm thickness and 50% 
glandularity) because they were calculated for breasts with 29% glandularity (without the use 
of breast composition correction factor, c53 factor); see section 5.3 on page 114. This was 
undertaken in order to make both the calculated MGD and measured organs dose consistent 
for 29% breast glandularity, which was simulated by a PMMA-PE phantom. The standard 
breast composition recommended by mammographic international protocols has 50% 
glandularity (IAEA, 2011; IPEM, 2005), however as reported by Yaffe  et al. (2009), breast 
glandularity used in this thesis (29%) represents the most common breast density. Yaffe  et 
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al. (2009) studied breast composition in 2831 Canadian women and found 95% of their study 
participants had a breast density of less than 45%. 
Since two breast phantoms were used to simulate the examined breast for CC and MLO 
projections, the MGD was calculated for each projection separately and the sum of these 
doses was used to represent the total breast MGD. For all FFDM machines the MGD of the 
MLO projection is higher than that of the CC projection; see Table (6-3) on page 143. The 
maximum difference (28.59%) was for FFDM machine 7 (Hologic Selenia Dimensions), 
while the minimum value (1.03%) was for machine 10 (GE Seno Essential). The mean (95% 
CI) difference, for the sixteen FFDM machines, between MLO MGD and CC MGD is 14.24 
(9.90 - 18.59) %. This difference is lower than that of film-screen mammography reported by 
Gomes et al. (2011). For 63 women Gomes et al. (2011) found that MGD for CC film-screen 
mammography was 30% lower than that of the MLO projection. The variations amongst the 
sixteen FFDM machines in this thesis could be attributed to the AEC system of the different 
FFDM machines, image receptor, and/or target/filter combination (wide range of FFDM 
machines has been included). In general, MGD variation between CC and MLO is more 
related to the FFDM machine brand than to machine‘s target/filter combination.  
 FFDM machines of the same model from the same manufacturer show similar MDG 
percentage differences. For instance, FFDM machines 3 and 7 are both Hologic Selenia 
Dimensions and have a 27.58% and 28.59% difference between CC and MLO MGDs, 
respectively. Also, there is an 18.78% and 19.60% CC and MLO MGD differences recorded 
for FFDM machines 15 and 16 - which are both Siemens Mammomat Inspiration. However, 
FFDM machines of same target/filter combination of two different brands showed different 
MGD variations between CC and MLO; machine 4 (Hologic Selenia, Rh/Rh) has 25.046 % 
and machine 5 (GE Seno Essential, Rh/Rh) has 14.325 % MGD difference between CC and 
MLO. Overall, the wide difference in MGD between CC and MLO is because some AEC 
systems are likely to be more sensitive to small changes in breast thickness than others. 
Target/filter combination is one of the factors which can affect examined breast MGD 
(Dance, Thilander, et al., 2000b). Figure (6-4) (page 146) demonstrates the MGD data for 
the four different target/filter combinations included within this thesis. In Figure (6-4) (page 
146), average MGD ± 1SD error bars are presented for both Rh/Rh and W/Rh target/filter 
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combinations. However, for Mo/Mo and W/Ag combinations, the MGD value of one FFDM 
machine is presented for each because only a single FFDM machine of these combinations 
was included in this study. It can be seen, in Figure (6-4) (page 146), that the SD for W/Rh 
(503.57 µGy) is larger than that of Rh/Rh (184.97 µGy). This large SD for W/Rh 
combination is because W/Rh machines were from two different manufacturers (2 Hologic 
Selenia Dimensions and 2 Siemens Mammomat Inspiration). The two Hologic Selenia 
Dimensions machines (FFDM machines 3 and 7) gave higher MGD than the two Siemens 
Mammomat Inspiration FFDM machines (FFDM machines 15 and 16); see Table (6-3) on 
page 144. Overall, for the four combinations of targets and filters, the Rh/Rh combination 
resulted in the lowest MGD (1936.31 ± 184.97 µGy) while the highest value of MGD was 
with the Mo/Mo combination (2430.92 µGy). This is consistent with previous work (Dance, 
Thilander, et al., 2000b; Gingold, Wu, & Barnes, 1995). Both Gingold et al. (1995) and 
Dance, Thilander, et al. (2000b) found that the estimated MGD, by Monte Carlo simulation, 
using  the Rh/Rh target/filter combination was less than that produced by the Mo/Mo and 
Mo/Rh combinations. 
According to Rezaei, Feghhi, Aghamiri, Rezaei, and Ebrahimi (2011) the Monte Carlo 
simulation of a Mo/Mo target/filter combination demonstrated that MGD is related in a linear 
fashion to both X-ray tube kV and mAs - MGD increases with an increase in kV and/or mAs. 
Since MGD data are non-parametric (not normally distributed), Spearman's rho correlation 
coefficient (r) was used to assess the relationship between MGD and mAs / HVL; see Table 
(6-5) on page 149. It was found that MGD correlates positively with mAs (MGD increases as 
mAs increases), however, this relationship was not statistically significant (r = 0.426, p = 
0.072). Also, a non-statistically significant (p = 0.277) relationship exists, with a weaker 
positive correlation (r = 0.289), between MGD and HVL. Similarly, the backward regression 
model demonstrates that both mAs and HVL do not significantly affect the MGD; see Table 
(6-6) on page 150.  
In summary, for the same breast phantom, a wide MGD range has been recorded for the 
included 16 FFDM machines. However, all of these MGD values were within the acceptable 
range determined by the respected international mammographic quality assurance 
programmes (EC, IAEA, NHSBSP). This indicates a growing need for the revision of the 
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maximum acceptable MGD reported by international mammographic protocols. The 
examined breast MGD is related to the target/filter combination, mAs, and HVL. It has been 
found that the Rh/Rh combination results in the lowest MGD. This is because the Rh/Rh 
combination produces a harder beam which results in less X-ray absorption by the breast 
tissue. Also, with a harder beam lower exposure factors can be used to produce the required 
image quality. MGD is more dependent on mAs than on beam HVL because the higher mAs 
means more X-ray photons are produced. 
7.3.2 Organ Radiation Dose (organs and tissues other than the examined breast) 
Several researchers have assessed the radiation dose to other body tissues and organs from 
mammography; here other refers to all organs with the exclusion of the examined breast. In 
all instances, their approaches were different to the methods used in this thesis. For instance, 
Sechopoulos , Suryanarayanan , Vedantham , D‘Orsi, and Karellas (2008) used Monte Carlo 
dose simulation, while Hatziioannou et al. (2000) used TLDs accommodated inside Lucite 
phantom to measure radiation dose received by several organs during craniocaudal and 
medio-lateral breast exposures. 
As indicated in section 5.2 (page 100), organ radiation doses were measured by TLDs from 
radiation exposures of CC and MLO projections for each breast. These data have been 
presented in two different ways - as absorbed doses (Figure 6-3) on page 144 and as MGD 
percentages (Table 6-4) on page 145. The tissues (‗other than  the examined breast‘) include 
brain, salivary glands, thyroid, oesophagus, thymus, heart, lung, liver, gall bladder, adrenals, 
kidneys, spleen, pancreas, stomach, intestine, bone marrow (cranium, mandible, cervical 
spine, clavicles, scapulae, sternum, ribs, thoracic and lumbar spine, and pelvis), urinary 
bladder, uterus, ovaries, and contralateral breast. 
For the sixteen FFDM machines, urinary bladder, uterus, ovaries and pelvis bone marrow do 
not receive radiation dose during screening mammography. This is because either they really 
don‘t receive a radiation dose or their radiation dose is lower than the TLDs sensitivity 
threshold. However, kidneys, pancreas, intestine, spleen, and T/L spine bone marrow receive 
negligible radiation doses (< 0.1 µGy), while the radiation dose received by the other tissues 
range between 0.10 µGy with 95% CI of (0.03 -  0.18) (for adrenals) and  28.75 (24.20 - 
33.3) µGy (for contralateral breast); see Figure (6-3) on page 144. For the majority of these 
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organs which receive a radiation dose of more than 0.1 µGy, the Rh/Rh target/filter 
combination resulted in the lowest radiation dose. Organs receiving a radiation dose more 
than 0.1 µGy will be more discussed in the following sections. 
7.3.2.1 Contralateral Breast Radiation Dose 
During screening mammography, the radiation dose to the contralateral breast was the 
second highest radiation dose to any organ after the examined breast for all sixteen FFDM 
machines. The contralateral breast dose ranged from 18.70 to 47.66 µGy with a mean (95% 
CI) of 28.75 (24.20 - 33.3) µGy; see Figure (6-3) on page 144. This radiation dose is (mean 
± 1SD) 1.419 ± 0.346 % of examined breast MGD; see Table (6-4) on page 145. A lower 
contralateral breast dose to MGD percent has been reported by Sechopoulos  et al. (2008) 
using Monte Carlo simulation. They found that the contralateral breast dose is approximately 
0.46 % of CC projection MGD and 0.59 % of MLO projection MGD at 30 kV from Rh/Rh 
target/filter combination X-ray tube. The differences between Sechopoulos and those 
reported in this thesis may be attributed to many factors. The wide range of FFDM machines 
used in this work was one likely cause. The geometrical limitation of human body 
mathematical phantoms using Monte Carlo simulation is another cause. The resultant organ 
dose underestimation by Monte Carlo compared to the measured dose, due to the geometrical 
limitation of the mathematical phantom, has previously been reported by Tootell, Szczepura, 
and Hogg (2014). Also, different simulated examined breast glandularity can affect the 
contralateral breast dose by changing the X-ray scattering profile from the examined breast. 
In this context Sechopoulos  et al. (2008) simulated the examined breast with 50%, while in 
this thesis the examined breast PMMA-PE phantom simulates 29% breast glandularity.    
Target/filter combination can be considered one of the factors which will affect the 
contralateral breast dose because the use of different combinations results in different doses 
to the contralateral breast; see Figure (6-5) on page 146. For instance, the Rh/Rh 
combination resulted in the lowest contralateral breast radiation dose 25.58 ± 4.68 µGy 
(mean ± 1SD), while the highest dose to the contralateral breast tissue resulted from the use 
of W/Ag combination 38.49 µGy.  
The statistical analysis of the relationship between contralateral breast dose and MGD, mAs 
and HVL demonstrate that contralateral breast dose correlates positively with all of these 
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factors; see Table (6-5) on page 149. The correlation coefficients were 0.671, 0.732, and 
0.234, respectively. This relationship was significant for both MGD and mAs (p < 0.05) but 
it was non-significant for HVL (p = 0.383). Further analysis of these relationships using 
backward regression (Table (6-6), page 150) shows that 63% (regression R
2
) of contralateral 
breast dose variability can be predicted by MGD and mAs with 5.551 µGy standard error 
(coefficient of variance = 19.31 %). According to this regression model, a 1 µGy increment 
in contralateral breast dose results either from mean (95%CI) of 1.1% (0.0% -  2.2%) 
increment in MGD (µGy) or from 13.3% (4.4% - 22.2%) mAs increment.  
In summary, target/filter combination, beam HVL, and mAs affect contralateral breast 
radiation dose. The Rh/Rh target filter/combination results in the lowest contralateral breast 
radiation dose. HVL has a very small effect on contralateral breast radiation dose. The mAs, 
however, is the most important factor affecting the contralateral breast radiation dose. All in 
all, the contralateral breast dose can be predicted by examined breast MGD - the higher the 
examined breast MGD, the higher the contralateral breast radiation dose. 
7.3.2.2 Bone Marrow Radiation Dose 
Bone marrow radiation dose includes the radiation dose received by bone marrow in nine 
different locations, namely, cranium, mandible, cervical spine, clavicles, scapulae, sternum, 
ribs, T/L spine, and pelvis. The bone marrow radiation dose received by each location was 
separately measured and analysed, as indicated in section 5.2.2 (page 108). In general, the 
most important factor affecting radiation dose distribution within bone marrow is related to 
the proximity to the examined breast (primary beam), being consistent with the inverse 
square law - the closer bone marrow to examined breast, the higher its radiation dose will be.  
For the sixteen FFDM machines, the value of cranium bone marrow radiation dose fluctuated 
widely. It ranged from 0.16 µGy (for FFDM machine 6) to 5.82 µGy (for FFDM machine 
11) with mean (95% CI) of 1.56 (0.82 - 2.31) µGy, see Figure (6-3) on page 144. Cranium 
bone marrow dose represents 0.0815 ± 0.082 % (mean ±1 SD) of examined breast MGD; see 
Table (6-4) on page 145. The highest cranium bone marrow dose was recorded for Rh/Rh 
target/filter combination 2.00 ± 1.61 µGy (mean ± 1SD). However, the lowest cranium bone 
marrow dose was for W/Rh combination (0.65 ± 0.20 µGy); see Figure (6-6) on page 147. 
Statistical analysis shows that there was a non-significant relationship between cranium bone 
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marrow dose and MGD, mAs and HVL using both correlation (Table (6-5), page 149) and 
regression (Table (6-6), page 150). Therefore, the different measured radiation dose to 
cranium bone marrow can be attributed to other factors such as FFDM machine design (e.g. 
differences in X-ray tube angulation within the tube assembly), random nature of the X-ray 
beam, the leakage radiation, and/or some other experimental errors. This is the same as noted 
previously in section 7.2. 
Mandible bone marrow which constitutes 0.8% of total body bone marrow (ICRP, 1995) 
received 0.139 ± 0.048 % (mean ± 1SD) of MGD during screening exposures (Table (6-4), 
page 145) which is 2.79 (2.29 - 3.29) µGy (mean with 95% CI); see Figure (6-3) on page 
144. It has been found that Rh/Rh target/filter combination causes the lowest mandible bone 
marrow dose (2.66 ± 0.85 µGy), while all other combinations (Mo/Mo, W/Rh, and W/Ag) 
result in approximately the same mandible bone marrow dose; the values were 2.89, 3.00 ± 
1.43, and 3.15 µGy, respectively, see Figure (6-6) on page 147. Although the Spearman's rho 
correlation (Table (6-5), page 149) demonstrates that the relationship between mandible 
bone marrow dose and all of MGD, mAs and HVL values was not significant, the backward 
regression model (Table (6-6), page 150) can predict 30% (regression R
2
) of mandible bone 
marrow dose variability by mAs (1 µGy per 1.4% mAs).  
Cervical spine bone marrow is one of the organs which received a very small radiation dose. 
It had 0.30 (0.12 - 0.48) µGy (mean (95% CI)); see Figure (6-3) on page 144. This wide 
range of 95% CI was due to wide range of cervical spine bone marrow doses for the 16 
FFDM machines. Cervical spine bone marrow dose was approximately zero for some FFDM 
machines, while other machines resulted in up to 1.39 µGy. The average cervical spine bone 
marrow dose constitutes 0.016 ± 0.020 % (mean ± 1SD) of the average MGD; see Table (6-
4) on page 146. FFDM machine 8 with a W/Ag target/filter combination was one of the 
FFDM machines which showed zero cervical spine bone marrow radiation dose. However, 
the Rh/Rh combination resulted in the highest cervical spine bone marrow dose 0.43 ± 0.37 
µGy (mean ± 1SD); see Figure (6-6) on page 147. The statistical analysis of cervical spine 
bone marrow doses demonstrates that it is negatively correlated to MGD, mAs, and HVL; see 
Table (6-5) on page 149. Spearman's rho correlation was only significant with beam HVL (p 
= 0.02). Further analysis of this relationship by backward regression demonstrates that it was 
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non-significant (i.e cervical spine bone marrow dose variability cannot be predicted by 
HVL); see Table (6-6) on page 150. As for cranium bone marrow radiation dose, the 
variations of cervical spine bone marrow radiation dose cannot be explained by any of the 
factors which have been investigated in this thesis (e.g. target/filter combination, MGD, 
mAs, and HVL). Accordingly it could be attributed to other factors (e.g. FFDM machine 
design, unaware experimental error and the random nature of the X-ray beam) as earlier 
discussed in this section on page 187.   
As seen in Figure (6-3) on page 144, clavicular bone marrow received the second highest 
bone marrow dose after sternum bone marrow. It was 9.25 (6.45 – 12.05) µGy (mean with 
95% CI). This dose represents 0.451 ± 0.241% (mean ± 1 SD) of the examined breast MGD; 
see Table (6-4) on page 145. Lower clavicular bone marrow radiation dose has been reported 
by Sechopoulos  et al. (2008) using a Monte Carlo methodology; radiation dose to bone 
marrow of the ipsilateral clavicle constituted 0.09 % and 0.04% of MGD for CC and MLO 
projections, respectively. This underestimation could have two explanations. Firstly, this 
radiation dose represents the dose to the ipsilateral clavicle bone marrow, while the dose to 
the contralateral clavicle bone marrow was not included. Secondly, as described by Tootell et 
al. (2014), the geometric shapes of organs within the mathematical phantoms were simplified 
resulting in underestimated organ doses. 
Both Mo/Mo and W/Rh target/filter combinations resulted in high and approximately equal 
radiation dose levels to clavicular bone marrow. The dose values were 13.11 µGy and 12.83 
± 4.71 µGy (mean ± 1SD), respectively. However, lower clavicular bone marrow radiation 
dose values were recorded W/Ag and Rh/Rh combinations (8.88 µGy and 7.47 ± 5.26 µGy, 
respectively); see Figure (6-6) on page 147. These clavicular bone marrow radiation dose 
variations amongst different target/filter combinations can be explained by the fact that the 
use of harder beam (of W/Ag and Rh/Rh combinations) reduces the required exposure factors 
especially the mAs.  
Clavicular bone marrow dose strongly and significantly correlates with MGD (r = 0.506, p < 
0.05) and mAs (r = 0.876, p < 0.05), while it did not correlate with beam HVL (r = 0.077); 
see Table (6-5) on page 149.  Accordingly, for the 16 FFDM machines 87% (regression R
2
) 
of clavicular bone marrow dose variability can be explained by MGD and mAs variations; 
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see Table (6-6) (page 150) which contains full details of the backward regression model for 
the relationship between clavicular bone marrow dose and MGD and mAs. In summary, the 
target/filter combination and mAs are the most important factors affecting clavicular bone 
marrow radiation dose and this radiation dose can be predicted by examined breast MGD. 
High examined breast MGD is associated with high clavicular bone marrow radiation dose.   
Scapulae bone marrow dose tends to be negligible 0.17 (0.09 - 0.24) µGy (mean with 95% 
CI) and constitutes approximately 0.009 ± 0.008 % (mean ± 1SD) of MGD. Since it is a very 
small radiation dose no large differences can be recognised in Figure (6-6) (page 147) 
amongst the different target/filter combinations. In general, the lowest scapulae bone marrow 
dose was recorded for Mo/Mo combination (0.09 µGy), while the highest value was for 
W/Ag combination (0.24 µGy). Spearman's rho correlation shows that scapulae bone marrow 
dose only correlated with beam HVL and this had a correlation coefficient (r) of -0.519, see 
Table (6-5) on page 149. This means that a harder beam results in lower scapulae bone 
marrow dose. The effect of beam HVL on scapulae bone marrow dose was further estimated 
by backward regression and was found to be 1 µGy scapulae bone marrow dose per 86.4% 
HVL (mm Al); see Table (6-6) on page 150. In summary, the scapulae bone marrow 
radiation dose was very small and constitutes only 2.8% of total bone marrow radiation dose 
(ICRP, 1995). Accordingly, the effect of this radiation dose can be considered negligible.    
Sternum bone marrow radiation dose was the highest bone marrow dose and the third highest 
organ dose after the examined and contralateral breasts; see Figure (6-3) on page 144. The 
high radiation dose to sternum bone marrow can be explained by its close proximity to the 
primary beam. For the 16 FFDM machines, the sternum bone marrow radiation dose ranged 
between 12.86 µGy (FFDM machine 11) and 32.50 µGy (FFDM machine 7) with a mean 
(95% CI) of 19.07 (15.81 - 22.34) µGy. Compared to MGD, the sternum dose was 0.942 ± 
0.251% (mean ± 1SD) of breast MGD; see Table (6-4) on page 145. Sternum bone marrow 
dose has been estimated using Monte Carlo modelling by Sechopoulos  et al. (2008). The 
simulated sternum bone marrow radiation dose was less than the measured dose in this thesis. 
Sechopoulos  et al. (2008) found that sternum bone marrow dose constitutes 0.49% and 
0.23% of MGD for CC and MLO projections, respectively. The difference between estimated 
(Sechopoulos  et al. (2008)), by Monte Carlo, and measured radiation doses (this thesis) 
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could be attributed to the geometrical limitation of mathematical phantoms as earlier 
discussed in this section.  
Using sternum bone marrow radiation dose, the 16 FFDM machines can be classified into 
two groups; see Figure (6-6) on page 147. The first group includes the FFDM machines with 
W/Ag and W/Rh which result in high sternum bone marrow dose (24.91 and 24.02 ± 7.56 
µGy, respectively). The second group of FFDM machines comprises those which gave low 
sternum bone marrow doses (Mo/Mo and Rh/Rh target filter combinations). The sternum 
bone marrow dose for this group was 17.16 µGy for Mo/Mo combination and 16.70 ± 4.70 
µGy for Rh/Rh combination. For the Rh/Rh target/filter combination, the sternum bone 
marrow radiation dose was consistent with radiation dose to bone marrow in other organs, 
being the lowest compared to other combinations. However, for Mo/Mo, sternum bone 
marrow dose was inconsistent when compared to the bone marrow radiation dose in other 
organs, discussed earlier in this section. This because of only one Mo/Mo FFDM machine 
was included in this thesis. Accordingly, more research is required to understand the impact 
of FFDM machines with Mo/Mo target/filter combination.  
The relationship between sternum bone marrow dose and MGD, mAs and HVL using 
Spearman's rho correlation (Table (6-5) on page 149) demonstrates that there is a weak and 
non-statistically significant positive correlation between sternum bone marrow dose and both 
MGD and HVL (r < 0.5, p > 0.05). However, there is a strong and significant positive 
correction with mAs (r = 0.709, p = 0.002). The sternum bone marrow radiation dose-mAs 
relationship was also investigated by Hatziioannou et al. (2000) who reported that the 
measured sternum bone marrow dose inside a Lucite phantom is directly related to mAs. A 
further analysis of this relationship by backward regression modelling (Table (6-6) on page 
150) demonstrates that 73% (regression R
2
) of sternum bone marrow variability can be 
predicted by both MGD and mAs where 1 µGy reduction in sternum bone marrow dose can 
be achieved either by 0.6% reduction in MGD (µGy) or by  11.4% reduction in mAs. The 
standard error of estimate for this regression model was 3.444 µGy (18.06 %). In summary, 
the sternum bone marrow receives the highest radiation dose of all bone marrow locations 
due to its close proximity to the examined breast. Also, similar to the examined breast, the 
sternum bone marrow is related to target/filter combination and mAs. 
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The bone marrow of the ribs received the third highest bone marrow dose after sternum and 
clavicles bone marrow; see Figure (6-3) on page 144. It was 3.57 (2.87 – 4.27) µGy (mean 
with 95% CI) and this was 0.175 ± 0.053% (mean ± 1SD) of the examined breast MGD. This 
measured dose was comparable with previously estimated values by Sechopoulos  et al. 
(2008) using Monte Carlo simulation. Sechopoulos  et al. (2008) found that the radiation 
dose within the bone marrow of the ribs for Rh/Rh target/filter combination with 30 kV tube 
voltage is 0.14% of examined breast dose for CC projection and 0.17% for MLO projection. 
With regard to the effect of target/filter combination on rib bone marrow dose, both Rh/Rh 
and Mo/Mo combinations resulted in approximately the same rib bone marrow dose (3.03 ± 
0.69 and 3.23 µGy, respectively) which was the lowest dose. However, the W/Ag 
combination caused the highest rib bone marrow dose (5.64 µGy); see Figure (6-6) on page 
147.  
Statistical evaluation of the relationship between the ribs bone marrow radiation dose and 
MGD, mAs and HVL (Table (6-5) on page 149) demonstrates that there is a statistically 
significant and strong positive correlation (r > 0.5, p < 0.05) between ribs bone marrow dose 
and MGD and mAs; a very weak / negligible correlation exists between ribs bone marrow 
dose and HVL (r = 0.073). The additional evaluation of these relationships by regression 
modelling shows that the relationship coefficients for MGD and mAs were 0.002 and 0.019, 
respectively, per 1 µGy ribs bone marrow dose where 58% (regression R
2
) of ribs bone 
marrow dose variations attributed to MGD and mAs variations; see Table (6-6) page 150. In 
summary, the rib bone marrow radiation dose was high, compared to other organ doses, 
because of its proximity to the primary beam. For the ribs, the bone marrow dose is 
dependent on target/filter combination (Rh/Rh results in the lowest ribs bone marrow dose) 
and mAs; it can be predicted by MGD values. 
7.3.2.3 Thyroid Radiation Dose 
Exposing the phantom to a complete screening exposures shows that the thyroid is one of the 
organs which receives a relatively high radiation dose - 9.45 (7.83 – 11.08) µGy (mean with 
95% CI). On average for the 16 FFDM machines, thyroid dose was the third highest radiation 
dose after ‗breast tissues‘ (including examined and contralateral breast) and sternum bone 
marrow (Figure (6-3) on page 144) and constitutes 0.467 ± 0.133 % (mean ± 1SD) of 
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examined breast MGD; see Table (6-4) on page 145. However, for seven FFDM machines 
(FFDM machines 1 to 4, 7, 15, and 16) the clavicular bone marrow dose was higher than that 
of thyroid dose; see (Appendix A). The thyroid dose measured in this thesis was 
approximately 10 times that estimated by Sechopoulos and Hendrick (2012) who used Monte 
Carlo simulations (0.467% compared to 0.045% of MGD). Again, it is possible that the 
simplified organ geometry used in Monte Carlo simulation could be the cause of this 
underestimation (Tootell et al., 2014). However, the estimated thyroid dose from measured 
skin radiation dose overlying women‘s thyroid during screening mammography by Whelan, 
McLean, and Poulos (1999) was approximately 40 µGy which is 4 times the thyroid dose 
measured in this thesis (9.45 µGy). In their calculations Whelan et al. (1999) considered the 
thyroid dose to be 10 % of skin dose. This percent could be the source of error in their 
calculations (estimated thyroid radiation dose), as 10% was a mathematical assumption.  
The statistical analysis investigating the factors affecting the thyroid radiation dose shows 
that thyroid dose is related to target/filter combination, MGD, mAs and HVL. The highest 
thyroid dose was recorded for FFDM machines which used W/Rh 11.31 ± 4.70 µGy (mean ± 
1SD), while the lowest recorded thyroid dose was for Rh/Rh combination 8.64 ± 2.42 µGy 
(mean ± 1SD); see Figure (6-6) on page 147. The lower Rh/Rh thyroid radiation dose 
compared with other target/filter combinations could be due to the low exposure factors 
required with the hard beam of Rh/Rh target/filter combination. A statistically significant 
strong positive correlation has been shown between thyroid dose and each of MGD (r = 
0.688, p = 0.003) and mAs (r = 0.771, p = 0.000); see Table (6-5) on page 149. Although the 
thyroid dose was approximately not correlated with HVL (r = 0.085), the backward 
regression model was significant and with higher regression R
2
 (83%) when all the predictors 
(MGD, mAs, and HVL) were included; see Table (6-6) on page 150. Using this regression 
model, a 1 µGy reduction in thyroid radiation dose can be achieved by decreasing either 
MGD (0.4%) or mAs (6.3%). However, 10.569 times increment in HVL is required to reduce 
the thyroid dose by 1 µGy. This thyroid dose-mAs relationship is approximately consistent 
with that previously published work by Hatziioannou et al. (2000) who reported that 1 µGy 
thyroid radiation dose increment results from 0.10 ± 0.02 mAs. Also, Whelan et al. (1999) 
found that the thyroid radiation dose during mammography correlates significantly to mAs.   
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In summary, the thyroid radiation dose from screening mammography exposures tends to be 
high compared to the body tissues and organs. Thyroid dose is related to target/filter 
combination and mAs. Since a harder beam is produced by Rh/Rh target/filter combination, 
lower exposure factors will be required resulting in a lower thyroid dose. Overall the thyroid 
dose can be predicted by MGD; higher MGD is associated with higher thyroid radiation 
dose.      
7.3.2.4 Lung Radiation Dose 
Lung tissue is radiosensitive with a 0.12 tissue weighting factor (ICRP, 2007). For the 16 
FFDM machines the mean (95% CI) radiation dose of lung tissue from exposures of a single 
screening event (Figure (6-3) on page 144) was 3.06 (2.50 – 3.62) µGy with a minimum of 
2.04 µGy (FFDM machine 6) and a maximum of 5.66 µGy (FFDM machine 3). This lung 
radiation dose (0.151 ± 0.046 % of MGD) is comparable with that estimated for film-screen 
mammography by Leidens, Goes, and Nicolluci (2013) (0.14% of MGD) who used 
PENELOPE Monte Carlo simulation. However, a lower estimated lung radiation dose 
(approximately 0.07% of MGD) has been reported by Sechopoulos  et al. (2008). The 
underestimated lung tissue dose by Sechopoulos  et al. (2008) could be due to two reasons, 
namely, it represents the dose to the ipsilateral lung only and the mathematical phantom 
limitations as mentioned earlier in section 7.3.2.2.  
Different lung tissue radiation doses have been recorded for different target/filter 
combinations (Figure (6-6) on page 147); the highest dose resulted from the use of W/Ag 
(4.43 µGy) and both Rh/Rh and Mo/Mo caused approximately equal lung tissue dose (2.66 ± 
0.56 µGy and 2.67 µGy, respectively) which was the lowest lung tissue radiation dose. In 
general since the Mo/Mo target/filter combination produces the least hardening beam, the use 
of Mo/Mo requires higher exposure factors and will result in higher organ doses. However, 
the use of only one Mo/Mo FFDM machine in this thesis adds a limitation to the 
generalisability of the Mo/Mo target/filter combination results. The effect of MGD, mAs and 
HVL on lung radiation dose was investigated by using Spearman's rho correlation (Table (6-
5) on page 149) for non-parametric data. Both MGD and mAs significantly (p < 0.05) affect 
the lung dose, while the HVL was not significant (p > 0.05). The effect magnitude evaluation 
by backward regression modelling (Table (6-6) on page 150) demonstrates that 49% 
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(regression R
2
) of lung dose variation is attributed to mAs variation where lung dose is 
directly related to mAs with a factor of 1 µGy per 2% mAs.  
In summary, lung tissue is radio-sensitive and receives several micro Grays of radiation from 
screening mammography exposures. This radiation dose is related to X-ray tube target/filter 
combination, where Rh/Rh resulted in the lowest lung tissue dose, mAs and examined breast 
MGD. MGD can considered a good indicator for the prediction of lung tissue radiation dose. 
7.3.2.5 Salivary Glands Radiation Dose 
Salivary glands are a relatively low radio-sensitive tissue with 0.01 tissue weighting factor 
(ICRP, 2007). They received 0.139 ± 0.048 % (mean ± 1SD) of MGD during screening 
exposures (Table (6-4) on page 145) which is 2.79 (2.29 - 3.29) µGy (mean with 95% CI); 
see Figure (6-3) on page 144. The hardest beam (produced by Rh/Rh target/filter 
combination) caused the lowest salivary glands radiation dose (2.66 ± 0.85 µGy), while all 
other combinations (Mo/Mo, W/Rh, and W/Ag) resulted in similar salivary glands doses; the 
values were 2.89, 3.00 ± 1.43, and 3.15, respectively; see Figure (6-6) on page 147. The low 
salivary glands radiation dose of Rh/Rh target/filter combinations is because lower exposure 
factors are sufficient for use with harder x-ray beam associated with Rh/Rh.  
Although the Spearman's rho correlation (Table (6-5) on page 149) demonstrates that the 
relationship between salivary glands dose and MGD, mAs and HVL was not statistically 
significant, backward regression modelling (Table (6-6) on page 150) can significantly 
predict 30% (regression R
2
) of salivary gland dose variability by mAs. Overall, as with 
radiation dose to other body tissues, the radiation dose to salivary glands is dependent on 
both target/filter combination and mAs. Rh/Rh resulted in the lowest salivary gland dose due 
to its harder x-ray beam. 
7.3.2.6 Thymus Radiation Dose 
Screening mammography exposures resulted in 2.43 (1.77 – 3.08) µGy (mean with 95% CI) 
radiation dose to thymus; see Figure (6-3) on page 144. This dose is equivalent to 0.119 ± 
0.058 % (mean ± 1SD) of MGD; see Table (6-4) on page 145. The estimation of thymus 
radiation dose by Sechopoulos  et al. (2008) using Monte Carlo simulation showed that it was 
0.07% and 0.04% of MGD for CC and MLO projections, respectively. This estimated dose is 
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comparable with the measured dose in this thesis because within this thesis the measured 
thymus dose was for complete screening exposures (CC and MLO projections for each 
breast), while in Sechopoulos  et al. (2008) the estimated dose was from one breast 
exposures. According to Sechopoulos  et al. (2008), the estimated thymus radiation dose 
from Rh/Rh target/filter combination was higher than that from Mo/Mo combination. 
However, the findings of this thesis shows that the Rh/Rh combination results in lowest 
thymus radiation dose (1.88 ± 0.99 µGy) and the highest one resulted from W/Rh (3.66 ± 
1.23 µGy); see Figure (6-6) on page 147. This difference in thymus radiation dose in related 
to different target/filter combinations could be attributed to Sechopoulos  et al. (2008) using 
the same number of monoenergitc X-ray photons (mAs) for all target/filter combinations. 
However, in this thesis the exposure factors were automatically selected by the AEC as 
would be the case in routine clinical practice. In general, a lower mAs was selected for harder 
beam making the thymus dose the lowest for the Rh/Rh target/filter combination.  
Thymus radiation dose showed a statistically significant strong positive correlation (r = 
0.818, p = 0.000) to mAs but it correlated weakly (r < 0.5, p > 0.05) to MGD or HVL; see 
Table (6-5) on page 149. Further analysis of this relationship by backward regression 
modelling (Table (6-6), page 150) shows that 83% (regression R
2
) of thymus radiation dose 
variation can be predicted by mAs with a factor of 1 µGy thymus dose per 3% mAs. In 
summary, the radiation dose to thymus is mainly related to target/filter combination and 
mAs. 
7.3.2.7 Brain Radiation Dose 
Brain radiation dose from screening exposures varies widely between the FFDM machines. It 
ranged between zero and 4.82 µGy with a mean (95% CI) of 0.91 (0.26 – 1.56) µGy; see 
Figure (6-3) on page 144. X-ray tube target/filter combination tends to be of negligible effect 
on brain radiation dose. This is evidenced by the large SDs of brain radiation dose for each of 
the target/filter combinations; see Figure (6-6) on page 147. The brain dose for different 
combinations were 0.12 ± 0.15 µGy for W/Rh, 0.23 µGy for W/Ag, 1.26 ± 1.41 µGy for 
Rh/Rh, and 1.32 µGy for Mo/Mo. There was no significant correlation (p > 0.05) between 
brain radiation dose and MGD, mAs and HVL; see Table (6-5) on page 149. Consequently, 
the backward regression modelling (Table (6-6), page 150) was not significantly better than 
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expressing mean value when predicting the brain radiation dose. In conclusion, the radiation 
dose to brain cannot be attributed to any of the factors explored in this thesis; it might be 
attributed to the FFDM machine design and/or the leakage radiation from the X-ray tube. 
7.3.2.8 Liver Radiation Dose 
Liver radiation dose constitutes 0.034 ± 0.013 % (mean ± 1SD) of the examined breast 
MGD; see Table (6-4) on page 145. The mean liver dose (95% CI) for the 16 FFDM 
machines was 0.69 (0.54 – 0.84) µGy; see Figure (6-3) on page 144. The analysis of liver 
radiation dose of different target/filter combinations (Figure (6-6), page 147) shows that 
W/Ag causes the highest liver radiation dose (1.21 µGy), while the lowest liver dose results 
from Mo/Mo (0.50 µGy). The liver radiation dose from the other two combinations were 
0.77 ± 0.43 µGy and 0.62 ± 0.19 µGy for W/Rh and Rh/Rh combinations, respectively. 
Although the effect of target/filter combination on liver radiation dose is not consistent with 
that of other body organs, the liver dose difference for different target/filter combinations 
was small. This variation can be attributed (imputed) to the number of FFDM machines of 
different target/filter combinations. MGD, mAs and HVL are not good predictors for liver 
radiation dose. This was indicated by both correlation analysis (Table (6-5), page 149), 
which was weak (r < 0.5) and not statistically significant (p > 0.05) for all predictors, and 
backward regression modelling (Table (6-6), page 150), which was also not significant. In 
summary, the liver radiation dose cannot be explained by the factors evaluated in this thesis. 
Accordingly, more research is required to investigate the factors which effect liver radiation 
dose during screening mammography. 
7.3.2.9 Stomach Radiation Dose 
Organ dose data demonstrate that the stomach radiation dose was 0.42 (0.31 – 0.53) µGy 
(mean with 95% CI); see Figure (6-3) on page 144. This radiation dose represents 0.021 ± 
0.009 % (mean ± 1SD) of MGD; see Table (6-4) on page 145. Both Rh/Rh and Mo/Mo 
target/filter combinations recorded equal stomach radiation dose (0.36 µGy), which was 
lower than that of the other two combinations, with a SD for Rh/Rh of 0.13 µGy. On the 
other hand, the highest stomach dose resulted when using W/Ag (0.68 µGy); see Figure (6-
6) on page 147. This is consistent with radiation dose to other body tissues where the Rh/Rh 
resulted in the lowest dose because lower exposure factors are required when a harder beam 
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is used. With regard to the stomach dose from Mo/Mo target/filter combination, it cannot be 
generalised easily because it is based on measurements from a single FFDM machine. 
Spearman's rho correlation (Table (6-5), page 149) and backward regression modelling 
(Table (6-6), page 150) shows that the stomach radiation dose is independent on MGD, mAs 
and HVL.  
7.3.2.10 Heart Radiation Dose 
Heart radiation dose from mammography was previously estimated by Leidens et al. (2013) 
and Sechopoulos  et al. (2008) using Monte Carlo simulation. Leidens et al. (2013) reported 
that the heart receives 0.033% of the MGD. However, Sechopoulos  et al. (2008) documented 
the heart radiation dose for each mammographic projection separately. For CC projection the 
estimated dose was 0.05% of MGD, while for MLO it was 0.035% of MGD (Sechopoulos  et 
al., 2008). These estimated heart radiation doses are slightly more than the measured heart 
radiation dose in this thesis which was 0.020 ± 0.012% (mean ± 1SD) of MGD (0.39 [0.27 – 
0.51] µGy, mean [95% CI]); see Table (6-4) on page 145. In the previous studies, by Leidens 
et al. (2013) and Sechopoulos  et al. (2008), only one type of FFDM machine was simulated. 
However, in this thesis a wide range of FFDM machines were included. The lower heart 
radiation dose could be a consequence of including a wide range of FFDM machines. 
Unlike Sechopoulos  et al. (2008), who reported that the Rh/Rh resulted in a heart radiation 
dose higher than Mo/Mo target/filter combination, this thesis demonstrates that the Rh/Rh 
combination results in the lowest heart radiation dose 0.34 ± 0.19 µGy (mean ± 1SD). The 
highest radiation dose resulted from W/Ag (0.58 µGy); see Figure (6-6) on page 147. This 
difference, between the previously published work and this thesis, was because Sechopoulos  
et al. (2008) calculated the organs dose of different target/filter combinations using same 
mAs. However, in this thesis the mAs was automatically selected by the AEC which 
compromises the mAs and beam hardening. Similar to stomach radiation dose (section 
7.3.2.9), heart radiation dose was not related to MGD, mAs or HVL. This is proved by both 
correlation statistical analysis and regression modelling (Table (6-5) on page 149 and Table 
(6-6) on page 150, respectively). In summary, the main factor affecting the heart radiation 
dose during screening mammography exposures was the target/filter combination. The 
variability of heart radiation dose from different mammographic machines cannot be 
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predicted by any of factors studied in this thesis (i.e. MGD, mAs and HVL). Therefore, 
further research is required investigating the factors affecting heart radiation dose from 
screening mammography.  
7.3.2.11 Oesophagus Radiation Dose 
FFDM machine 6 demonstrated that the radiation dose to the oesophagus from screening 
mammography exposures is equal to zero. This means that either the oesophagus does not 
receive radiation dose or its radiation dose is below the sensitivity of the TLDs. On the other 
hand, FFDM machine 11 results in the highest oesophagus radiation dose (0.67 µGy). The 
mean (95% CI) oesophagus radiation dose for the 16 FFDM machines is 0.26 (0.14 - 0.37) 
µGy (Figure (6-3), page 144) and this constitutes 0.013 ± 0.012 % (mean ± 1SD) of MGD; 
see Table (6-4) on page 145. Target/filter combinations show comparable oesophagus 
radiation dose (approximately 0.27 µGy), except for the W/Rh target/filter combination 
which is 0.21 µGy; see Figure (6-6) on page 147. The correlation analysis between 
oesophagus radiation dose and MGD, mAs and HVL demonstrate that HVL has a 
relationship. The oesophagus radiation dose had a moderate negative (r = -0.553, p = 0.026) 
correlation with HVL; see Table (6-5) on page 149. However, this relationship was not 
significant by backward regression modelling; see Table (6-6) on page 150. In summary, the 
radiation dose to oesophagus was small and consequently its variation cannot be easily 
predicted by target/filter combination, MGD or mAs. However, there was an inverse 
relationship between oesophagus radiation dose and HVL - a harder beam (higher HVL) 
results in a lower oesophageal radiation dose.   
7.3.2.12 Gall Bladder Radiation Dose 
The mean (95% CI) gall bladder radiation dose for the 16 FFDM machines is 0.19 (0.10 – 
0.27); see Figure (6-3) on page 144. Compared to MGD, this dose represents 0.009 ± 
0.008% (mean ± 1SD); see Table (6-4) on page 145. In Sechopoulos‘ et al. (2008) work they 
considered any organ radiation dose less than 0.01 % MGD to be negligible. However, in this 
thesis any radiation dose less than 0.1 µGy is considered to be negligible. With regard to the 
effect of target/filter combination on gall bladder radiation dose (Figure (6-6), page 147), 
Mo/Mo resulted in the lowest radiation dose to gall bladder (0.04 µGy), while W/Ag resulted 
in the highest gall bladder radiation dose (0.68 µGy). The relationship between gall bladder 
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radiation dose and MGD, mAs and HVL by correlation statistics (Table (6-5), page 149) and 
regression modelling (Table (6-6), page 150) demonstrates that gall bladder radiation dose is 
not related to any of these factors. In summary, the radiation dose to gall bladder from 
screening mammography is very small and likely to be negligible. Since the gall bladder 
radiation dose is very small, its variability cannot be explained by any of the studied factors 
and should be the subject of future work. 
7.3.2.13 Adrenals Radiation Dose 
Radiation dose to the adrenals glands from screening mammography exposures is tend to be 
negligible. It is equal to the threshold of a negligible dose (0.10 [0.03 – 0.18] µGy, mean 
[95% CI]); see Figure (6-3) on page 144. By comparison with gall bladder radiation dose 
(section 7.3.2.12), W/Ag resulted in zero adrenal radiation dose and Mo/Mo resulted in the 
highest dose (0.51 µGy); see Figure (6-6) on page 147. Since one W/Ag and one Mo/Mo 
FFDM machines were included, these findings cannot be generalised. Spearman's rho 
correlation (Table (6-5), page 149) shows that adrenal radiation dose only correlates with 
HVL (r = -0.714, p = 0.002). This means that a harder beam (higher HVL) results in lower 
adrenal radiation dose. Similarly, further analysis of this relationship (between adrenals 
radiation dose and HVL) by backward regression modelling shows that 45% (regression R
2
) 
of adrenals dose variability can be predicted by beam HVL and the relationship coefficient 
was 1 µGy adrenals dose per 1.192 HVL (mm Al); see Table (6-6) on page 150. In 
summary, the adrenals radiation dose is very small and inversely related to beam HVL. 
7.3.3 Organs Radiation Dose Summary 
During screening mammography, the contralateral breast tissue receives the second highest 
radiation dose after the examined breast. For all organs and tissues, including examined 
breast, the target/filter combination of the X-ray tube was major contributing factor affecting 
the radiation dose from screening mammography.  Rh/Rh target/filter combination resulted in 
the lowest absorbed radiation dose for most body tissues as well as for the examined breast. 
The second important factor controlling organ radiation dose was X-ray tube current; higher 
mAs values unsurprisingly resulted in higher organ doses. 
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7.4 Effective Risk  
As discussed earlier in section 4.3.3 (page 75) the effective risk refers to the number of 
radiation-induced cancers in all body tissues from exposure to ionising radiation. In this 
thesis it has been used to assess the radiation risk from screening mammography. Many 
advantages have been identified with the use of effective risk. Unlike MGD, which indicates 
the radiation risk to breast tissue only, effective risk includes the radiation risk to all body 
tissues and organs. Although the effective dose can comply with this requirement, its 
calculation is mainly dependent on tissue weighting factors which are averaged for gender 
and age. On the other hand, the effective risk calculation is dependent on lifetime attributable 
risks (LARs) which are available for each gender and from 0 to 80 years of age, stepping 
through five years intervals for ages under 20 and 10 years steps after 20 years old (BEIR VII 
report) (NAS, 2006). Screening mammography is a recurrent examination conducted at 
different ages (depending on screening programme recommendations). Tissue radio-
sensitivity changes with age and this can be accounted for with effective risk calculations. 
This makes effective risk more suitable for radiation risk assessment of screening 
mammography. Another important point is that the data generated from effective risk 
calculations is likely to be more understandable by clients/patients (cancer incidence case per 
million) than the information as illustrated by MGD or effective dose (mGy or mSv). It is 
worth mentioning also that the calculation of effective risk is no more complicated than the 
effective dose calculation.   
If the organ radiation dose is considered to be constant at different screening ages the 
effective risk would only relate to tissue radio-sensitivity change with age (LAR). For 
instance, although the radiation dose to thyroid is considered high (section 7.3.2.3), its 
contribution to effective risk of screening mammography would be small. This is true 
because the thyroid tissue radio-sensitivity decreases after the age of 40 years; see Table (5-
8) on page 119.    
Table (6-7) on page 152, Table (6-8) on page 153, and Table (6-9) on page 154 demonstrate 
the effective risk for clients aged 25-75 years (the possible age of screening mammography 
for high and normal risk clients). For the 16 FFDM machines, as the client age increases 
from 25 to 75 the mean (95% CI) effective risk decreases from 70.00 (64.88 - 75.12) to 0.75 
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(0.69 - 0.80) case/10
6
, from 70.00 (64.88 - 75.12) to 1.68 (1.55 - 1.80) case/10
6
, and from 
88.07 (81.63 - 94.51) to 2.51 (2.32 - 2.69) case/10
6
 for the three LAR extrapolation methods, 
respectively. The highest effective risk values were recorded for FFDM machine 7 which 
were 97.492 - 1.047 case/10
6
, 97.492 - 2.340 case/10
6
, and 122.662 - 3.499 case/10
6
 (for the 
three LAR sets, respectively) for ages 25-75 years. However, the lowest effective risk values 
for the three LAR methods were for FFDM machine 11 which were 57.995 - 0.621 case/10
6
, 
57.995 - 1.390 case/10
6
, and 72.964 - 2.080 case/10
6
, respectively, for ages 25-75. These 
effective risk differences between the considered FFDM machines are mainly attributed to 
MGD variations of the FFDM machines which ranged from 1.730 mGy to 2.431 mGy. 
Therefore, more consideration should be given to target/filter combination to reduce MGD. 
In spite of these differences amongst the different FFDM machines, the statistical analysis 
shows that for the first and second LAR extrapolation methods there was non-significant 
difference between these machines (Kruskal-Wallis test, p > 0.05), while the same test 
(Kruskal-Wallis test) shows that effective risk values of the 16 FFDM machines was 
significantly different (p = 0.044) for the third extrapolation method.  
Total effective risk of screening mammography refers to the total risk of radiation-induced 
cancer during the clients‘ lifetime due to the complete screening journey. The total effective 
risk of any screening programme is related to commencement/cessation ages and frequency 
of screening. The worldwide screening mammography recommendations can be classified 
into two categories, the first category includes the recommendations for average breast 
cancer risk women (Table (3-4), page 59), and the second category includes those 
recommended for high breast cancer risk clients (Table (3-5), page 60); highlighted 
programmes in Table (6-10) on page 156. Usually the high risk women are invited for earlier 
and more frequent screening mammography resulting in additional risk of radiation-induced 
cancer; see Tables (6-10) on page 156, (6-11) on page 157, and (6-12) on page 158 for the 
three LAR methods, respectively.  
The statistical analysis of the total effective risk of worldwide screening programmes shows 
significant differences amongst these programmes with regard to their total effective risk (1-
Way ANOVA test, p < 0.05 for the three LAR methods). For the 16 FFDM machines, the 
lowest mean (95% CI) total effective risk resulted from Maltese screening mammography 
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programme. It was 42.21 (39.12 - 45.30) case/10
6
 for the best lines of fit extrapolation 
method, 43.28 (40.11 - 46.44) case/10
6 
for linear relationship approach, and 57.67 (53.46 - 
61.89) case/10
6 
for step approach. In contrast, the highest total effective risk for average risk 
women resulted from United States screening programmes recommended by ACS, ACR, and 
NCCN. These figures were 372.42 (345.18 - 399.67) case/10
6
, 391.55 (362.91 - 420.19) 
case/10
6
, and 513.12 (475.59 - 550.65) case/10
6
 for the three LAR methods. These 
differences in total effective risk, of considered screening programmes, are attributed to their 
different recommendations wherein Maltese programme invite the women 50-60 years old 
for triennial screening, while the ACS, ACR, and NCCN invite the women aged 40-75 years 
for annual screening. According to risk classification by Wall et al. (2006) (Table (4-1), page 
69), the radiation risk of screening mammography is ranged from being very low risk (≤ 100 
cases/10
6
) to low risk (≤ 1000 cases/106). However, the radiation risk from some screening 
programmes designed for high risk women may exceed the threshold of low radiation risk (> 
1000 cases/10
6
), see the highlighted section in Tables (6-10) on page 156, (6-11) on page 
157, and (6-12) on page 158 for the three LAR methods, respectively. 
Not all worldwide screening programmes have published recommendations for high risk 
women because some programmes consider the high risk women as special cases that should 
not be included in a screening programme (CancerAustralia, 2014). Some programmes 
recommend breast screening by other imaging modalities (i.e MRI and/or ultrasonography) 
along with mammography (NHSBSP, 2013b). The National Cancer Comprehensive Network 
(NCCN) recommendations, in the United States, resulted in the highest total effective risk 
(1099.67 [1019.25 - 1180.09] case/10
6
, 1121.36 [1039.36 - 1203.36] case/10
6
, 1472.73 
[1365.04 - 1580.42] case/10
6
, for the three LAR extrapolation methods) because they have 
recommended annual screening mammography commences at the age of 25 years old. 
However, the high risk women recommendations of the British and Canadian programmes 
resulted in lower total effective risk than that of average risk women in the United States 
(ACS, ACR, and NCCN); see Tables (6-10) on page 156, (6-11) on page 157, and (6-12) on 
page 158 for the three LAR methods.  
Compared to previous studies, which considered the total LAR of cancer incidence in breast 
tissue only, the calculated total effective risk in this thesis, which includes the risk of 
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radiation-induced cancer in all body tissues, tends to be comparable because the MGD 
contribution in total effective risk is up to 98%. For instance, in work by Yaffe and 
Mainprize (2011) the total risk of radiation-induced breast cancer from annual screening 
mammography between 40 and 49 years was found to be 590 case/10
6
 for 3.7 mGy MGD. In 
this thesis for 2.019 (1.871-2.166) mGy MGD the total effective risk of the same screening 
regimen found there to be 231.89 (214.94 - 248.85), 224.21 (207.82 - 240.61), 289.69 
(268.51 - 310.87) case/10
6
 (mean with 95% CI) for the three LAR method. 
Similarly for 3.7 mGy MGD, Hendrick (2010) found that the total incident of breast cancer 
due to annual screening mammography between 25 - 80 years was 2040 case/10
6
. In this 
thesis for 2.019 (1.871-2.166) mGy MGD, the calculated total effective risk for annual 
screening mammography between 25 -75 years was 1099.67 (1019.25 - 1180.09), 1121.36 
(1039.36 - 1203.36), and 1472.73 (1365.04 - 1580.42) case/10
6
 for the three LAR 
extrapolation methods.  
Recently, Warren, Dance, and Young (2016) evaluated the total risk, during a female‘s 
lifetime, of radiation-induced breast cancer from the UK screening recommendations and 
found that it ranges between 30.7 and 61.2 case/10
6
/mGy of MGD. This is consistent with the 
figures in this thesis which were 70.77 (65.59 - 75.95), 77.79 (72.10 - 83.48), and 108.41 
(100.48 - 116.34) case/10
6
 for the three LAR methods and MGD of 2.019 (1.871-2.166) mGy 
(mean with 95% CI). 
With regard to factors affecting the total effective risk, statistical analysis from the 22 
different worldwide screening recommendations identified in this thesis (Table (3-4) on page 
59 and Table (3-5) on page 60) shows that there is a strong correlation (r > 0.5, p < 0.05) 
between total effective risk and screening commencement age, cessation age of screening, 
time interval between screens and number of screens; see Table (6-13) on page 160. These 
correlations are positive with cessation age of screening and number of screens, and negative 
with commencement age of screening and time interval between screens. This means that the 
total effective risk increases as cessation age of screening and number of screening increase, 
while it reduces as commencement age of screening and time interval between screens 
increase. A further analysis of these relationships by backward regression modelling 
demonstrates that the cessation age of screening, time interval between screens and number 
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of screens are sufficient to significantly predict 91% (regression R
2
), for best fit lines method, 
and 92%, for the other two LAR methods, of total effective risk variability; see Table (6-14) 
on page 161.  
The use of the third LAR extrapolation method (step approach) resulted in the highest 
calculated total effective risk. The figures calculated using the two alternative methods are 
similar but the first LAR method resulted in the lowest total effective risk; see Figure (6-7) 
on page 159. A minor difference in the ranking of worldwide screening programmes, in 
related to their resultant total effective risk, can be seen amongst the three LAR methods (e.g. 
the UK and Chinese programmes for average risk women); see Tables (6-10) on page 156, 
(6-11) on page 157, and (6-12) on page 158 for the three methods. In general, the linear 
relationship method between the decades gives the best relationship with previous published 
work (Li et al., 2011). 
7.5 Effective Risk Modelling  
The main purpose of the effective risk modelling is to establish a method that can be easily 
used in daily practice in order to obtain the total effective risk of any screening regimen from 
screening commencement/cessation ages and screening frequency. This is particularly useful 
in the discussion of screening justification (benefits versus harms) with clients, especially 
those clients invited for early and more frequent screening due to their high breast cancer 
risk. Usually statistical regression is used to investigate the effect of one or more predictors 
on outcome variable and/or to predict outcome variable value for each set of predictors.  
According to Field (2013), the minimum sample size required to establish a good regression 
model suitable for prediction is 10-15 data cases per each predictors; but Field (2013) 
reported that as a general rule of thumb a larger sample size would result in a better 
regression model. This means that the number of worldwide screening recommendations (22 
cases) is not sufficient to generate a good regression model. Accordingly, 274 screening 
regimens have been proposed from the experimental data in this thesis to generate a suitably 
powered regression model. The statistical analysis of the new regression model (with sample 
size of 274 cases) shows different results from the regression model generated with small 
sample size (22 cases); see Table (6-15) on page 162. Strong correlations (r > 0.5) exist 
between total effective risk and commencement age of screening and number of screens, 
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while the correlation was weak between total effective risk and cessation age of screening 
and time interval between screens. This is consistent with Field's (2013) opinion about the 
effect of sample size on regression modelling. For the 274 screening scenarios, backward 
regression modelling (Table (6-16), page 162) can predict more than 85% of total effective 
risk variability by commencement/cessation ages of screening and number of screens. 
However, the large standard errors (93.249, 91.127, and 117.411 case/10
6
 for the three LAR 
methods, respectively) for these regression models make them adequate for the prediction of 
total effective risk, although not exact. 
Since the majority of worldwide screening programmes recommend a screening cessation 
age of between 70 and 75 years (Table (3-4) on page 59 and Table (3-5) on page 60) and at 
these ages (after 70 years) most tissue types become highly radio-resistant, the cessation age 
has a very small effect on total effective risk. Accordingly, if we consider the cessation age to 
be constant at 75, there would be only two factors affecting the total effective risk, namely 
commencement age of screening and screening frequency. In this case it becomes possible to 
graphically represent the total effective risk against screening commencement age for each 
screening frequency; see Figures (6-8) on page 163, (6-9) on page 164 and (6-10) on page 
165 for the three LAR methods. Each of these figures contains three relationship lines - one 
for each screening frequency (annual, biennial, and triennial). These graphs might be easily 
used by practitioners and clients to obtain the total effective risk for any screening 
commencement age (25 - 74 years) and for each of the screening frequency. However, the 
main limitation of these graphs is that they are based on an average effective risk value for 
the sixteen FFDM machines. In other words, the interpolated data from these graphs are for 
the average MGD of the 16 FFDM machines which was 2.019 (1.871-2.166) mGy, mean 
(95% CI).  
To overcome the above limitation a relationship has been established between MGD and 
total effective risk, for the 16 FFDM machines, for each screening scenario of specific 
screening commencement age and frequency (Appendix D) generating a set of conversion 
factors (case/10
6
/µGy of MGD) which can be used to convert the initial MGD value from a 
client/woman to her total predicted effective risk from her lifetime FFDM screening; see 
Table (6-17) on page 167, Table (6-18) on page 168 and Table (6-19) on page 169 for the 
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three LAR extrapolation methods. These conversion factors, which are MGD percentages, 
have been plotted against the screening commencement age for each screening frequency to 
generate relationship graphs that can be used to obtain the total effective risk for a specific 
screening scenario (commencement age and frequency) in relation to the client‘s MGD; see 
Figures (6-11) on page 170, (6-12) on page 171, and (6-13) on page 172 for each of the 
LAR exploration methods, respectively. This effective risk model is the final model and 
should be easily used by practitioners and clients to obtain the total effective risk taking into 
account MGD variations of different FFDM machines for same breast thickness (53 mm) and 
composition (29% glandularity).    
7.6 Contralateral Breast Shield Effect  
As mentioned earlier in section 7.3.2.1, the contralateral breast received the second highest 
radiation dose after the examined breast; see Figure (6-3) on page 144. For the 16 FFDM 
machines, the mean ± 1SD contribution of contralateral breast dose expressed as effective 
dose percent is 1.391 ± 0.332 %, while 0.439 ± 0.119 % was from the contribution of all 
other body tissues except the examined breast; see Table (6-20) on page 173. Accordingly, 
the theoretical investigation of contralateral breast shield, by considering the contralateral 
breast dose being set to zero, leads to a 1.38 ± 0.34% (mean ± 1SD) reduction in the effective 
dose; see Table (5-10) on page 132. Effective risk reduction is age dependent, it decreases by 
1.39 ± 0.33 % for women aged 25 - 58 and this percent reduces to 1.33 ± 0.29 % at 74. Then 
at 75 years of age it increases to 1.37 ± 0.38 %. These figures were for the first LAR 
extrapolation method (best fit line method). Similar values have been recorded for the other 
two LAR extrapolation methods; see Table (5-11) on page 133. These age-dependent 
differences are due to the different patterns of tissue radio-sensitivity (LAR) as they change 
with age. 
The effect of a contralateral breast shield was experimentally investigated for 4 FFDM 
machines, which were selected according to their calculated effective risk as previously 
discussed in section 5.9.4 (page 136). For the 4 FFDM machines (FFDM machines 2, 8, 10, 
and 11) included in the shield intervention study, it was found that the contralateral breast 
shield can reduce the contralateral breast dose by more than 95%. The figures in µGy were 
(35.20 reduced to 1.93), (41.40 reduced to 0.01), (22.85 reduced to 1.24), and (22.76 reduced 
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to 1.66), respectively; see Table (6-21) on page 174. Also, a small reduction has been 
identified in sternum bone marrow dose due to the use of contralateral breast shield. Overall, 
the use of a contralateral breast shield during mammography is in itself novel work within 
this thesis. At the time of writing no previous work has been published investigating the 
effect of contralateral breast shield on breast radiation dose. 
The effect of a contralateral breast shield on total effective risk of worldwide screening 
programme demonstrates that the shield can significantly (Wilcoxon test, p < 0.05) reduce 
the total effective risk of worldwide screening programmes and the reduction percent is 
independent of LAR extrapolation method (i.e. same reduction percentages have been 
recorded for the three LAR methods of same FFDM machine). However, the reduction 
percent in total effective risk is different for the 4 FFDM machines. It ranged between 
approximately 0.95 % (for machine 10) to approximately 1.44 % (for machine 2) with minor 
differences amongst different worldwide screening programmes; see Tables (6-22) on page 
175, (6-23) on page 176, and (6-24) on page 177 for the three LAR extrapolation methods. 
Therefore, the contralateral breast shield is recommended to reduce the radiation dose to 
contralateral breast. However, more research is required to evaluate the effect of contralateral 
breast shield on examined breast MGD.  
7.7 Limitations, Future Work, and Recommendations 
The main point that could be considered as a limitation that the use of single human body 
dosimetry phantom together with two standard sized breast phantoms. This means that the 
data used in this thesis is applicable to an ‗average women with average sized breasts‘. 
Future work could use human body phantoms representing different sizes along with 
different breast phantoms for a range of different thicknesses and densities; see (Appendix 
F). In doing this data can be generated to predict the risk of radiation-induced cancer from 
screening mammography for a broader range of clients which have different breast sizes and 
glandularities and different body sizes. 
The other limitation is that according to Alonzo-Proulx, Jong, and Yaffe (2012), due to the 
aging process, the breast density decreases by approximately 2% per year between 35 and 75, 
which will result in a continuous reduction in the required mAs and hence the MGD will 
decrease with age (Beckett & Kotre, 2000). However, more research is required to confirm 
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and further evaluate this breast density reduction magnitude. This breast tissue change was 
not included in generated total effective risk data in this thesis because the same MGD has 
been used for entire screening age range (25 - 75). Again this can be addressed by using a 
series of breast phantoms with different densities to simulate the breasts of different client‘s 
ages.  
Recently, glandular tissue distribution within the breast was reported by Geeraert, Klausz, 
Muller, Bloch, and Bosmans (2015) as one of the factors affecting the MGD. Geeraert et al. 
(2015) found that MGD was different for breast phantoms, simulated within Monte Carlo 
software, with identical glandularity and thickness but with different glandular tissue 
distribution. However, the effect of glandular tissue distribution on MGD is not considered in 
this thesis because more investigations are required to improve this effect and determine its 
magnitude. 
With regard to errors associated with data derived in this thesis, two main sources can be 
identified, namely, dosimeter reading errors and the LAR extrapolation process. The use of 
more accurate dosimeters will help to improve data accuracy. Although the linear relation 
between decade LAR values is recommended in previous works (Li et al., 2011; Warren et 
al., 2016), the use of the three methods (best-fit lines, linear relationship, and step approach) 
gives an idea of the effect of LAR extrapolation process.       
Since only one FFDM machine has been included from each Mo/Mo and W/Ag target/filter 
combinations, there was a concern about the data generalisations of these two target/filter 
combinations. Accordingly, more measurements are required for FFDM machines using 
these two combinations.  
With regard to the effect of contralateral breast shield, further work is required to investigate 
the effect of the shield on examined breast MGD because the back scatter from the shield 
could increase the MGD.  
All in all, effective risk is likely to be a useful radiation protection quantity which may have 
value for radiation risk assessment and conveying this information to screening clients.  
Research should be conducted with clinicians and clients to determine what value it might 
have in practice. The method proposed in this thesis, which takes into account all body 
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tissues/organs, should be adopted in practice; it could be used alongside other quantities such 
as effective dose or MGD. MGD and effective dose are not useful quantities to use when 
assessing risk for a population or an individual who is examined over a long time period, as 
is the case for screening mammography. When referring to client risk these quantities should 
be used with greater caution. Graphical presentation of total effective risk in relation to 
screening commencement age and MGD is an easy way to obtain the total effective risk of 
any screening regimen instantly without the need for complex and time consuming 
calculations. These graphs can be used either by practitioner or screening clients after having 
the first screening session when they can know their MGD to predict the radiation risk of 
whole screening journey. This is particularly useful to consider the radiation risk of early and 
more frequent screening which recommended for women with high breast cancer risk. The 
use of contralateral breast shield could be a useful procedure to minimise the unnecessary 
radiation dose to breast tissue during screening mammography. 
 
 
 
 
 
 
 
 
 
 
 
 
 211 
 
Chapter Eight 
Conclusions 
 
8.1 Conclusions 
In this thesis, a novel method has been established to assess the radiation risk from FFDM 
screening. Total effective risk during a woman‘s lifetime has been used to determine the risk 
of radiation-induced cancer. The effective risk calculation is based on an experimental 
approach of organ dose measurement, for average adult female‘s body size and average 
breast with 53 mm thickness and 29 % glandularity, with TLDs accommodated inside an 
ATOM dosimetry phantom. The main characteristic of this method is that it can include the 
radiation dose to all body tissues in addition to examined breast MGD. Another important 
feature of the novel method is that gender and age are considered, making the method 
suitable for the investigation of radiation-induced cancer from any screening practice which 
uses ionising radiation or from any recurrent X-ray examination at different ages. The use of 
graphical representation of total effective risk data enables the extrapolation of the total 
effective risk using screening commencement age, screening frequency and MGD which 
greatly related to target/filter combination (Rh/Rh results in lowest MGD). This is an easy 
and convenient way to determine the risk of radiation-induced cancer in daily practice rather 
than the use of complicated and time consuming calculations. The use of graphs has the 
added value of being more accurate than regression modelling because mathematical 
regression is based on data fitting and this has associated error, while the use of graphs is 
based on calculated data of different screening regimens.  
The data generated from this method is not complicated and should be easily understood by 
clients, however, further work is needed to assess this and also its clinical utility. Compared 
to MGD and effective dose, which are expressed in the unit of mGy and mSv, the effective 
risk is expressed as the number of cancer cases per million and this is likely to be a very 
useful and less abstract concept which can be used to discuss screening mammography 
justification with clients, especially those classified as high risk breast cancer clients. Since 
tissue radio-sensitivity changes with age, the risk of radiation-induced cancer from screening 
mammography depends on LAR and organ dose. Sometimes, even though the organ dose 
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looks high, the risk of radiation-induced cancer is small because the tissues are more radio-
resistant due to their age. This is especially true for screening mammography above 70 years 
old, making the screening cessation age of less effect on total effective risk compared with 
commencement age of screening. 
For both effective dose and total effective risk, the MGD contribution is more than 98%, 
while all body tissues other than the examined breast contribute up to 2%. Therefore, for any 
screening programme the most important factors affecting the total effective risk are 
screening commencement age, screening frequency and MGD. Screening commencement 
age is the most important factor, for example effective risk of the four screening exposures 
(LCC, RCC, LMLO and RMLO) at 25 is more than double that at 40. Accordingly, 
significant differences have been found amongst worldwide screening programmes in 
relation to their total effective risk. The Maltese screening programme for average risk 
women results in the lowest total effective risk (42.21 [39.12 - 45.30], 43.28 [40.11 - 46.44], 
and 57.67 [53.46 - 61.89] case/10
6
 for the three LAR methods), while the American 
screening programme for high risk women recommended by National Comprehensive 
Cancer Network (NCCN) results in the highest total effective risk (1099.67 [1019.25 - 
1180.09], 1121.36 [1039.36 - 1203.36], and 1472.73 [1365.04 - 1580.42] case/10
6
 for the 
three LAR methods). Although the effective risk differences amongst the 16 FFDM 
machines are not significant statistically, the MGD variation of different FFDM machines 
should be considered.   
Contralateral breast radiation dose is the highest radiation dose after the examined breast and 
it constitutes approximately 1.5 % of the total effective risk. Data from this thesis 
demonstrates that the use of a contralateral breast shield can help to reduce the radiation dose 
received by the contralateral breast by over 95%. Further work should be undertaken to 
determine whether or not a contralateral breast shield has value within the clinical routine.  
In addition to radiation dose, client‘s age is another critical factor affecting the risk of 
radiation-induced cancer from screening mammography. For instance, although the radiation 
dose received by thyroid is large, the decline of thyroid tissue radio-sensitivity at screening 
age, after the age of 40 means this dose is of minor effect on the total effective risk. 
Therefore, screening commencement age should be carefully chosen because younger tissues 
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are more radio-sensitive. The use of contralateral breast shield could be more important in 
this case, when younger clients are invited for screening. 
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Appendices 
 
Appendix A: Measured organ doses for the sixteen FFDM machines. 
 
Table (A-1) Lists organs radiation dose, other than breast, from one 
screening visit for FFDM machine 1. 
Organ 
Absorbed dose, µGy 
Visit 1 Visit 2 Visit 3 Mean (sd) 
Brain 2.31 1.11 0.54 1.32 (0.91) 
Salivary glands  3.83 2.71 2.14 2.89 (0.86) 
Thyroid 10.42 9.53 8.57 9.51 (0.92) 
Oesophagus  0.34 0.22 0.25 0.27 (0.06) 
Thymus 3.18 2.28 2.06 2.51 (0.59) 
Heart 0.39 0.37 0.30 0.35 (0.05) 
Lung 2.94 2.61 2.46 2.67 (0.25) 
Liver 0.48 0.56 0.46 0.50 (0.06) 
Gall bladder 0.05 0.05 0.03 0.04 (0.02) 
Adrenal 0.48 0.99 0.07 0.51 (0.46) 
Kidney 0.09 0.05 0.07 0.07 (0.02) 
Spleen 0.03 0.03 0.02 0.03 (0.01) 
Pancreas 0.00 0.00 0.00 0.00 (0.00) 
Stomach 0.32 0.18 0.59 0.36 (0.21) 
Intestine 0.00 0.00 0.00 0.00 (0.00) 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 1.55 1.54 1.44 1.51 (0.06) 
Mandibles (0.8%)
*
 3.83 2.71 2.14 2.89 (0.86) 
C-spine (3.9%)
*
 0.42 0.32 0.34 0.36 (0.05) 
Clavicles (0.8%)
*
 13.71 12.65 12.96 13.11 (0.54) 
Scapulae (2.8%)
*
 0.10 0.08 0.08 0.09 (0.01) 
Sternum (3.1%)
*
 18.09 17.38 16.02 17.16 (1.05) 
Ribs (16.1%)
*
 3.47 3.17 3.04 3.23 (0.22) 
T/L spine (28.4%)
*
 0.26 0.06 0.14 0.15 (0.10) 
Pelvis (27.4%)
*
 0.00 0.00 0.00 0.00 (0.00) 
Total BM dose  1.47 1.32 1.27 1.35 (0.10) 
Urinary bladder 0.00 0.00 0.00 0.00 (0.00) 
Uterus  0.00 0.00 0.00 0.00 (0.00) 
Ovaries  0.00 0.00 0.00 0.00 (0.00) 
Contralateral breast 25.94 28.71 25.10 26.58 (1.89) 
*
These percentages represent the portion of bone marrow (BM) in 
different locations. They were adapted from ICRP report 70 (1995). 
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Table (A-2) Lists organs radiation dose, other than breast, from one 
screening visit for FFDM machine 2. 
Organ 
Absorbed dose, µGy 
Visit 1 Visit 2  Visit 3 Mean (sd) 
Brain 1.47 0.04 0.00 0.50 (0.84) 
Salivary glands  4.39 2.52 2.34 3.08 (1.14) 
Thyroid 11.63 11.33 10.01 10.991(0.86) 
Oesophagus  0.33 0.00 0.13 0.15 (0.16) 
Thymus 3.58 3.01 3.13 3.24 (0.30) 
Heart 0.43 0.13 0.44 0.33 (0.17) 
Lung 3.08 3.01 3.07 3.05 (0.04) 
Liver 0.54 0.42 0.48 0.48 (0.06) 
Gall bladder 0.18 0.01 0.10 0.10 (0.09) 
Adrenal 0.07 0.00 0.00 0.02 (0.04) 
Kidney 0.05 0.00 0.04 0.03 (0.03) 
Spleen 0.07 0.00 0.05 0.038 (0.03) 
Pancreas 0.01 0.00 0.00 0.00 (0.00) 
Stomach 0.28 0.18 0.27 0.24 (0.05) 
Intestine 0.07 0.00 0.02 0.03 (0.04) 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 2.06 0.71 0.47 1.080 (0.86) 
Mandibles (0.8%)
*
 4.39 2.52 2.34 3.08 (1.14) 
C-spine (3.9%)
*
 0.69 0.01 0.00 0.24 (0.40) 
Clavicles (0.8%)
*
 15.61 14.92 14.00 14.84 (0.80) 
Scapulae (2.8%)
*
 0.26 0.02 0.00 0.09 (0.15) 
Sternum (3.1%)
*
 22.40 20.59 20.65 21.21 (1.03) 
Ribs (16.1%)
*
 3.73 3.66 3.52 3.64 (0.11) 
T/L spine (28.4%)
*
 0.08 0.00 0.00 0.03 (0.05) 
Pelvis (27.4%)
*
 0.00 0.00 0.00 0.00 (0.00) 
Total BM dose  1.67 1.42 1.37 1.49 (0.16) 
Urinary bladder 0.00 0.00 0.00 0.00 (0.00) 
Uterus  0.00 0.00 0.00 0.00 (0.00) 
Ovaries  0.00 0.00 0.00 0.00 (0.00) 
Contralateral breast 30.44 29.41 29.02 29.62 (0.73) 
*
These percentages represent the portion of bone marrow (BM) in 
different locations. They were adapted from ICRP report 70 (1995). 
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Table (A-3) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 3. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.03 
Salivary glands 4.86 
Thyroid 16.27 
Oesophagus 0.56 
Thymus 5.28 
Heart 0.97 
Lung 5.66 
Liver 1.20 
Gall bladder 0.30 
Adrenal 0.10 
Kidney 0.04 
Spleen 0.10 
Pancreas 0.02 
Stomach 0.88 
Intestine 0.17 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 0.92 
Mandibles (0.8%)
*
 4.86 
C-spine (3.9%)
*
 0.10 
Clavicles (0.8%)
*
 17.74 
Scapulae (2.8%)
*
 0.31 
Sternum (3.1%)
*
 28.27 
Ribs (16.1%)
*
 6.11 
T/L spine (28.4%)
*
 0.11 
Pelvis (27.4%)
*
 0.00 
Total BM dose 2.16 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 47.66 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
 
 
Table (A-4) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 4.  
Organ 
Absorbed 
dose (µGy) 
Brain 0.78 
Salivary glands 4.01 
Thyroid 14.46 
Oesophagus 0.41 
Thymus 4.04 
Heart 0.55 
Lung 4.06 
Liver 0.94 
Gall bladder 0.25 
Adrenal 0.23 
Kidney 0.04 
Spleen 0.08 
Pancreas 0.01 
Stomach 0.47 
Intestine 0.02 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 2.01 
Mandibles (0.8%)
*
 4.01 
C-spine (3.9%)
*
 0.51 
Clavicles (0.8%)
*
 19.52 
Scapulae (2.8%)
*
 0.22 
Sternum (3.1%)
*
 28.00 
Ribs (16.1%)
*
 4.70 
T/L spine (28.4%)
*
 0.06 
Pelvis (27.4%)
*
 0.00 
Total BM dose 2.01 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 35.83 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
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Table (A-5) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 5. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.63 
Salivary glands 2.08 
Thyroid 7.67 
Oesophagus 0.65 
Thymus 1.93 
Heart 0.34 
Lung 2.60 
Liver 0.53 
Gall bladder 0.16 
Adrenal 0.07 
Kidney 0.03 
Spleen 0.06 
Pancreas 0.00 
Stomach 0.35 
Intestine 0.00 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 1.03 
Mandibles (0.8%)
*
 2.08 
C-spine (3.9%)
*
 0.24 
Clavicles (0.8%)
*
 5.01 
Scapulae (2.8%)
*
 0.33 
Sternum (3.1%)
*
 13.09 
Ribs (16.1%)
*
 2.66 
T/L spine (28.4%)
*
 0.11 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.02 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 24.60 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
 
 
 
Table (A-6) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 6. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.00 
Salivary glands 1.44 
Thyroid 6.93 
Oesophagus 0.00 
Thymus 0.84 
Heart 0.01 
Lung 2.04 
Liver 0.44 
Gall bladder 0.05 
Adrenal 0.00 
Kidney 0.00 
Spleen 0.02 
Pancreas 0.00 
Stomach 0.23 
Intestine 0.00 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 0.16 
Mandibles (0.8%)
*
 1.44 
C-spine (3.9%)
*
 0.00 
Clavicles (0.8%)
*
 4.42 
Scapulae (2.8%)
*
 0.00 
Sternum (3.1%)
*
 15.38 
Ribs (16.1%)
*
 2.42 
T/L spine (28.4%)
*
 0.00 
Pelvis (27.4%)
*
 0.00 
Total BM dose 0.93 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 23.28 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
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Table (A-7) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 7. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.00 
Salivary glands 3.33 
Thyroid 14.18 
Oesophagus 0.04 
Thymus 3.94 
Heart 0.41 
Lung 4.73 
Liver 1.06 
Gall bladder 0.15 
Adrenal 0.00 
Kidney 0.00 
Spleen 0.01 
Pancreas 0.00 
Stomach 0.76 
Intestine 0.00 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 0.54 
Mandibles (0.8%)
*
 3.33 
C-spine (3.9%)
*
 0.00 
Clavicles (0.8%)
*
 15.81 
Scapulae (2.8%)
*
 0.01 
Sternum (3.1%)
*
 32.50 
Ribs (16.1%)
*
 6.15 
T/L spine (28.4%)
*
 0.00 
Pelvis (27.4%)
*
 0.00 
Total BM dose 2.19 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 44.41 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
 
 
Table (A-8) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 8. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.23 
Salivary glands 3.15 
Thyroid 10.07 
Oesophagus 0.26 
Thymus 2.90 
Heart 0.58 
Lung 4.43 
Liver 1.21 
Gall bladder 0.68 
Adrenal 0.00 
Kidney 0.11 
Spleen 0.02 
Pancreas 0.03 
Stomach 0.68 
Intestine 0.02 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 0.93 
Mandibles (0.8%)
*
 3.15 
C-spine (3.9%)
*
 0.00 
Clavicles (0.8%)
*
 8.88 
Scapulae (2.8%)
*
 0.24 
Sternum (3.1%)
*
 24.91 
Ribs (16.1%)
*
 5.64 
T/L spine (28.4%)
*
 0.00 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.85 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 38.49 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
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Table (A-9) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 9. 
Organ 
Absorbed 
dose (µGy) 
Brain 1.71 
Salivary glands 2.63 
Thyroid 8.02 
Oesophagus 0.22 
Thymus 1.51 
Heart 0.24 
Lung 2.41 
Liver 0.55 
Gall bladder 0.24 
Adrenal 0.12 
Kidney 0.02 
Spleen 0.08 
Pancreas 0.08 
Stomach 0.32 
Intestine 0.02 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 2.57 
Mandibles (0.8%)
*
 2.63 
C-spine (3.9%)
*
 0.36 
Clavicles (0.8%)
*
 5.52 
Scapulae (2.8%)
*
 0.18 
Sternum (3.1%)
*
 15.58 
Ribs (16.1%)
*
 2.76 
T/L spine (28.4%)
*
 0.10 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.23 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 21.16 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
 
 
Table (A-10) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 10. 
Organ 
Absorbed 
dose (µGy) 
Brain 1.98 
Salivary glands 3.20 
Thyroid 8.53 
Oesophagus 0.21 
Thymus 1.55 
Heart 0.38 
Lung 2.47 
Liver 0.45 
Gall bladder 0.08 
Adrenal 0.00 
Kidney 0.00 
Spleen 0.01 
Pancreas 0.00 
Stomach 0.28 
Intestine 0.00 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 2.99 
Mandibles (0.8%)
*
 3.20 
C-spine (3.9%)
*
 0.46 
Clavicles (0.8%)
*
 5.93 
Scapulae (2.8%)
*
 0.15 
Sternum (3.1%)
*
 14.73 
Ribs (16.1%)
*
 2.73 
T/L spine (28.4%)
*
 0.04 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.23 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 26.10 
*
These percentages represent the portion 
of bone marrow (BM) in different 
locations. They were adapted from ICRP 
report 70 (1995). 
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Table (A-11) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 11. 
Organ 
Absorbed 
dose (µGy) 
Brain 4.82 
Salivary glands 3.79 
Thyroid 6.19 
Oesophagus 0.67 
Thymus 1.73 
Heart 0.34 
Lung 2.42 
Liver 0.45 
Gall bladder 0.07 
Adrenal 0.03 
Kidney 0.03 
Spleen 0.08 
Pancreas 0.04 
Stomach 0.18 
Intestine 0.01 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 5.82 
Mandibles (0.8%)
*
 3.79 
C-spine (3.9%)
*
 1.39 
Clavicles (0.8%)
*
 4.69 
Scapulae (2.8%)
*
 0.51 
Sternum (3.1%)
*
 12.86 
Ribs (16.1%)
*
 2.52 
T/L spine (28.4%)
*
 0.11 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.41 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 18.70 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
 
 
Table (A-12) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 12. 
Organ 
Absorbed 
dose (µGy) 
Brain 1.33 
Salivary glands 2.34 
Thyroid 8.20 
Oesophagus 0.11 
Thymus 1.17 
Heart 0.18 
Lung 2.30 
Liver 0.79 
Gall bladder 0.29 
Adrenal 0.08 
Kidney 0.13 
Spleen 0.17 
Pancreas 0.13 
Stomach 0.52 
Intestine 0.08 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 2.16 
Mandibles (0.8%)
*
 2.34 
C-spine (3.9%)
*
 0.45 
Clavicles (0.8%)
*
 4.77 
Scapulae (2.8%)
*
 0.02 
Sternum (3.1%)
*
 12.88 
Ribs (16.1%)
*
 2.62 
T/L spine (28.4%)
*
 0.04 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.07 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 26.62 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
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Table (A-13) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 13. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.17 
Salivary glands 1.80 
Thyroid 7.00 
Oesophagus 0.28 
Thymus 1.32 
Heart 0.71 
Lung 2.64 
Liver 0.87 
Gall bladder 0.02 
Adrenal 0.26 
Kidney 0.11 
Spleen 0.37 
Pancreas 0.13 
Stomach 0.50 
Intestine 0.05 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 0.51 
Mandibles (0.8%)
*
 1.80 
C-spine (3.9%)
*
 0.24 
Clavicles (0.8%)
*
 4.54 
Scapulae (2.8%)
*
 0.28 
Sternum (3.1%)
*
 15.73 
Ribs (16.1%)
*
 3.14 
T/L spine (28.4%)
*
 0.17 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.15 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 24.75 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
 
 
Table (A-14) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 14. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.63 
Salivary glands 2.20 
Thyroid 8.43 
Oesophagus 0.02 
Thymus 1.45 
Heart 0.35 
Lung 2.62 
Liver 0.74 
Gall bladder 0.29 
Adrenal 0.18 
Kidney 0.13 
Spleen 0.29 
Pancreas 0.18 
Stomach 0.51 
Intestine 0.00 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 1.62 
Mandibles (0.8%)
*
 2.20 
C-spine (3.9%)
*
 0.38 
Clavicles (0.8%)
*
 5.44 
Scapulae (2.8%)
*
 0.20 
Sternum (3.1%)
*
 17.56 
Ribs (16.1%)
*
 3.08 
T/L spine (28.4%)
*
 0.10 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.27 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 25.14 
*
These percentages represent the portion 
of bone marrow (BM) in different 
locations. They were adapted from 
ICRP report 70 (1995). 
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Table (A-15) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 15. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.13 
Salivary glands 2.21 
Thyroid 8.60 
Oesophagus 0.13 
Thymus 2.90 
Heart 0.37 
Lung 2.46 
Liver 0.48 
Gall bladder 0.17 
Adrenal 0.00 
Kidney 0.01 
Spleen 0.02 
Pancreas 0.00 
Stomach 0.31 
Intestine 0.01 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 0.69 
Mandibles (0.8%)
*
 2.21 
C-spine (3.9%)
*
 0.05 
Clavicles (0.8%)
*
 10.06 
Scapulae (2.8%)
*
 0.10 
Sternum (3.1%)
*
 17.30 
Ribs (16.1%)
*
 3.07 
T/L spine (28.4%)
*
 0.01 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.19 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 28.00 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
 
 
Table (A-16) Lists organs radiation 
dose, other than breast, from one 
screening visit for FFDM machine 16. 
Organ 
Absorbed 
dose (µGy) 
Brain 0.33 
Salivary glands 1.60 
Thyroid 6.21 
Oesophagus 0.12 
Thymus 2.52 
Heart 0.19 
Lung 2.44 
Liver 0.33 
Gall bladder 0.13 
Adrenal 0.00 
Kidney 0.05 
Spleen 0.08 
Pancreas 0.03 
Stomach 0.17 
Intestine 0.02 
B
o
n
e 
M
ar
ro
w
 (
B
M
) 
Cranium (7.6%)
*
 0.46 
Mandibles (0.8%)
*
 1.60 
C-spine (3.9%)
*
 0.05 
Clavicles (0.8%)
*
 7.74 
Scapulae (2.8%)
*
 0.00 
Sternum (3.1%)
*
 18.00 
Ribs (16.1%)
*
 2.64 
T/L spine (28.4%)
*
 0.05 
Pelvis (27.4%)
*
 0.00 
Total BM dose 1.11 
Urinary bladder 0.00 
Uterus 0.00 
Ovaries 0.00 
Contralateral breast 19.04 
*
These percentages represent the 
portion of bone marrow (BM) in 
different locations. They were adapted 
from ICRP report 70 (1995). 
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Appendix B: Effective risk data for women aged 25 -75 years resulted from 
the sixteen FFDM machines using LAR extrapolated by the three methods. 
Table (B-1) Presents effective risk for women aged 25-75 years resulted from FFDM machine 1 (3 visits). 
Age 
(year) 
Effective risk (case/106) 
Visit 1 Visit 2 Visit 3 
Method 1 Method 2 Method 3 Method 1 Method 2 Method 3 Method 1 Method 2 Method 3 
25 83.977 83.977 105.657 84.047 84.047 105.745 83.908 83.908 105.568 
26 79.641 79.641 105.657 79.708 79.708 105.745 79.576 79.576 105.568 
27 75.305 75.305 105.657 75.368 75.368 105.745 75.243 75.243 105.568 
28 70.969 70.969 105.657 71.029 71.029 105.745 70.911 70.911 105.568 
29 66.633 66.633 105.657 66.689 66.689 105.745 66.579 66.579 105.568 
30 62.297 62.297 62.297 62.349 62.349 62.349 62.247 62.247 62.247 
31 58.297 59.542 62.297 58.345 59.592 62.349 58.248 59.494 62.247 
32 55.618 56.787 62.297 55.663 56.834 62.349 55.571 56.740 62.247 
33 53.003 54.033 62.297 53.046 54.077 62.349 52.959 53.987 62.247 
34 50.453 51.278 62.297 50.494 51.319 62.349 50.410 51.234 62.247 
35 47.967 48.523 62.297 48.005 48.561 62.349 47.926 48.481 62.247 
36 45.546 45.768 62.297 45.581 45.804 62.349 45.506 45.727 62.247 
37 43.188 43.013 62.297 43.221 43.046 62.349 43.149 42.974 62.247 
38 40.895 40.258 62.297 40.926 40.288 62.349 40.857 40.221 62.247 
39 38.665 37.503 62.297 38.694 37.531 62.349 38.629 37.468 62.247 
40 36.500 34.749 34.749 36.527 34.773 34.773 36.465 34.714 34.714 
41 34.399 33.003 34.749 34.423 33.025 34.773 34.365 32.969 34.714 
42 32.362 31.256 34.749 32.384 31.277 34.773 32.329 31.224 34.714 
43 30.388 29.510 34.749 30.409 29.530 34.773 30.357 29.479 34.714 
44 28.479 27.764 34.749 28.497 27.782 34.773 28.449 27.734 34.714 
45 26.634 26.018 34.749 26.650 26.034 34.773 26.605 25.989 34.714 
46 24.852 24.272 34.749 24.867 24.286 34.773 24.824 24.244 34.714 
47 23.135 22.526 34.749 23.148 22.538 34.773 23.108 22.499 34.714 
48 21.481 20.780 34.749 21.493 20.790 34.773 21.455 20.754 34.714 
49 19.892 19.034 34.749 19.901 19.043 34.773 19.866 19.009 34.714 
50 18.366 17.288 17.288 18.374 17.295 17.295 18.341 17.263 17.263 
51 16.904 16.328 17.288 16.911 16.334 17.295 16.880 16.304 17.263 
52 15.506 15.368 17.288 15.511 15.373 17.295 15.483 15.345 17.263 
53 14.172 14.408 17.288 14.176 14.413 17.295 14.150 14.386 17.263 
54 12.901 13.449 17.288 12.904 13.452 17.295 12.880 13.427 17.263 
55 11.695 12.489 17.288 11.697 12.491 17.295 11.674 12.468 17.263 
56 10.552 11.529 17.288 10.553 11.531 17.295 10.533 11.509 17.263 
57 9.474 10.569 17.288 9.473 10.570 17.295 9.455 10.550 17.263 
58 8.459 9.609 17.288 8.458 9.610 17.295 8.440 9.591 17.263 
59 7.508 8.650 17.288 7.506 8.649 17.295 7.490 8.632 17.263 
60 6.620 7.690 7.690 6.618 7.688 7.688 6.604 7.672 7.672 
61 5.797 7.221 7.690 5.794 7.219 7.688 5.781 7.204 7.672 
62 5.037 6.752 7.690 5.033 6.750 7.688 5.022 6.736 7.672 
63 4.342 6.283 7.690 4.337 6.281 7.688 4.327 6.267 7.672 
64 3.710 5.814 7.690 3.705 5.812 7.688 3.696 5.799 7.672 
65 3.142 5.345 7.690 3.136 5.342 7.688 3.128 5.331 7.672 
66 2.637 4.876 7.690 2.632 4.873 7.688 2.624 4.862 7.672 
67 2.197 4.407 7.690 2.191 4.404 7.688 2.185 4.394 7.672 
68 1.820 3.938 7.690 1.815 3.935 7.688 1.809 3.926 7.672 
69 1.508 3.469 7.690 1.502 3.466 7.688 1.496 3.457 7.672 
70 1.259 3.000 3.000 1.253 2.997 2.997 1.248 2.989 2.989 
71 1.074 2.801 3.000 1.068 2.798 2.997 1.064 2.791 2.989 
72 0.952 2.602 3.000 0.947 2.599 2.997 0.943 2.592 2.989 
73 0.895 2.403 3.000 0.890 2.400 2.997 0.886 2.394 2.989 
74 0.892 2.204 3.000 0.888 2.201 2.997 0.884 2.195 2.989 
75 0.890 2.005 3.000 0.885 2.002 2.997 0.882 1.997 2.989 
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Table (B-2) Presents effective risk for women aged 25-75 years resulted from FFDM machine 2 (3visits). 
Age 
(year) 
Effective risk (case/106) 
Visit 1 Visit 2 Visit 3 
Method 1 Method 2 Method 3 Method 1 Method 2 Method 3 Method 1 Method 2 Method 3 
25 80.447 80.444 101.214 80.394 80.392 101.148 80.373 80.371 101.120 
26 76.293 76.290 101.214 76.242 76.240 101.148 76.224 76.222 101.120 
27 72.140 72.136 101.214 72.091 72.089 101.148 72.074 72.072 101.120 
28 67.986 67.982 101.214 67.940 67.938 101.148 67.924 67.922 101.120 
29 63.832 63.828 101.214 63.789 63.786 101.148 63.775 63.772 101.120 
30 59.678 59.674 59.674 59.637 59.635 59.635 59.625 59.622 59.622 
31 55.847 57.036 59.674 55.808 56.998 59.635 55.796 56.986 59.622 
32 53.281 54.397 59.674 53.243 54.360 59.635 53.232 54.349 59.622 
33 50.777 51.758 59.674 50.740 51.723 59.635 50.731 51.713 59.622 
34 48.334 49.119 59.674 48.299 49.086 59.635 48.290 49.076 59.622 
35 45.954 46.481 59.674 45.919 46.448 59.635 45.911 46.440 59.622 
36 43.634 43.842 59.674 43.601 43.811 59.635 43.594 43.803 59.622 
37 41.377 41.203 59.674 41.344 41.174 59.635 41.338 41.167 59.622 
38 39.180 38.565 59.674 39.149 38.536 59.635 39.143 38.530 59.622 
39 37.045 35.926 59.674 37.015 35.899 59.635 37.010 35.893 59.622 
40 34.972 33.287 33.287 34.942 33.262 33.262 34.938 33.257 33.257 
41 32.959 31.615 33.287 32.931 31.590 33.262 32.927 31.586 33.257 
42 31.008 29.942 33.287 30.981 29.919 33.262 30.977 29.915 33.257 
43 29.119 28.270 33.287 29.092 28.247 33.262 29.089 28.244 33.257 
44 27.290 26.598 33.287 27.265 26.576 33.262 27.262 26.573 33.257 
45 25.523 24.925 33.287 25.498 24.904 33.262 25.496 24.902 33.257 
46 23.817 23.253 33.287 23.793 23.233 33.262 23.791 23.230 33.257 
47 22.172 21.581 33.287 22.149 21.561 33.262 22.148 21.559 33.257 
48 20.589 19.908 33.287 20.567 19.890 33.262 20.565 19.888 33.257 
49 19.066 18.236 33.287 19.045 18.219 33.262 19.044 18.217 33.257 
50 17.605 16.563 16.563 17.585 16.547 16.547 17.584 16.546 16.546 
51 16.205 15.644 16.563 16.185 15.628 16.547 16.185 15.628 16.546 
52 14.866 14.725 16.563 14.847 14.710 16.547 14.847 14.709 16.546 
53 13.588 13.805 16.563 13.570 13.791 16.547 13.570 13.791 16.546 
54 12.372 12.886 16.563 12.354 12.872 16.547 12.354 12.872 16.546 
55 11.216 11.967 16.563 11.199 11.954 16.547 11.200 11.953 16.546 
56 10.122 11.047 16.563 10.106 11.035 16.547 10.106 11.035 16.546 
57 9.089 10.128 16.563 9.073 10.116 16.547 9.074 10.116 16.546 
58 8.117 9.209 16.563 8.102 9.197 16.547 8.103 9.198 16.546 
59 7.206 8.290 16.563 7.191 8.279 16.547 7.192 8.279 16.546 
60 6.356 7.370 7.370 6.342 7.360 7.360 6.343 7.361 7.361 
61 5.567 6.921 7.370 5.554 6.911 7.360 5.555 6.912 7.361 
62 4.839 6.472 7.370 4.827 6.462 7.360 4.828 6.463 7.361 
63 4.173 6.022 7.370 4.161 6.014 7.360 4.162 6.014 7.361 
64 3.567 5.573 7.370 3.556 5.565 7.360 3.557 5.565 7.361 
65 3.023 5.124 7.370 3.012 5.116 7.360 3.014 5.117 7.361 
66 2.540 4.675 7.370 2.529 4.667 7.360 2.531 4.668 7.361 
67 2.118 4.225 7.370 2.108 4.218 7.360 2.109 4.219 7.361 
68 1.757 3.776 7.370 1.747 3.769 7.360 1.749 3.770 7.361 
69 1.457 3.327 7.370 1.448 3.321 7.360 1.449 3.321 7.361 
70 1.218 2.877 2.877 1.209 2.872 2.872 1.211 2.873 2.873 
71 1.040 2.687 2.877 1.032 2.681 2.872 1.034 2.682 2.873 
72 0.924 2.496 2.877 0.916 2.491 2.872 0.917 2.491 2.873 
73 0.868 2.305 2.877 0.861 2.300 2.872 0.862 2.301 2.873 
74 0.866 2.114 2.877 0.858 2.109 2.872 0.860 2.110 2.873 
75 0.863 1.923 2.877 0.856 1.919 2.872 0.857 1.920 2.873 
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Table (B-3) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 3. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 70.406 70.406 88.586 
26 66.770 66.770 88.586 
27 63.134 63.134 88.586 
28 59.497 59.497 88.586 
29 55.861 55.861 88.586 
30 52.225 52.225 52.225 
31 48.878 49.919 52.225 
32 46.634 47.613 52.225 
33 44.444 45.306 52.225 
34 42.309 43.000 52.225 
35 40.227 40.693 52.225 
36 38.199 38.387 52.225 
37 36.226 36.081 52.225 
38 34.306 33.774 52.225 
39 32.439 31.468 52.225 
40 30.627 29.161 29.161 
41 28.868 27.700 29.161 
42 27.162 26.238 29.161 
43 25.511 24.776 29.161 
44 23.912 23.315 29.161 
45 22.368 21.853 29.161 
46 20.877 20.391 29.161 
47 19.439 18.930 29.161 
48 18.054 17.468 29.161 
49 16.724 16.006 29.161 
50 15.446 14.545 14.545 
51 14.222 13.741 14.545 
52 13.052 12.936 14.545 
53 11.934 12.132 14.545 
54 10.870 11.328 14.545 
55 9.860 10.524 14.545 
56 8.903 9.720 14.545 
57 7.999 8.916 14.545 
58 7.149 8.112 14.545 
59 6.352 7.307 14.545 
60 5.608 6.503 6.503 
61 4.918 6.109 6.503 
62 4.281 5.715 6.503 
63 3.697 5.321 6.503 
64 3.167 4.926 6.503 
65 2.690 4.532 6.503 
66 2.266 4.138 6.503 
67 1.896 3.744 6.503 
68 1.579 3.349 6.503 
69 1.315 2.955 6.503 
70 1.104 2.561 2.561 
71 0.947 2.392 2.561 
72 0.844 2.223 2.561 
73 0.793 2.054 2.561 
74 0.789 1.885 2.561 
75 0.793 1.716 2.561 
 
 
 
Table (B-4) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 4. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 66.023 66.023 83.073 
26 62.613 62.613 83.073 
27 59.203 59.203 83.073 
28 55.793 55.793 83.073 
29 52.382 52.382 83.073 
30 48.972 48.972 48.972 
31 45.831 46.808 48.972 
32 43.726 44.644 48.972 
33 41.671 42.480 48.972 
34 39.667 40.316 48.972 
35 37.714 38.152 48.972 
36 35.811 35.988 48.972 
37 33.959 33.824 48.972 
38 32.158 31.660 48.972 
39 30.407 29.495 48.972 
40 28.706 27.331 27.331 
41 27.056 25.960 27.331 
42 25.455 24.588 27.331 
43 23.906 23.217 27.331 
44 22.406 21.846 27.331 
45 20.957 20.474 27.331 
46 19.558 19.103 27.331 
47 18.209 17.731 27.331 
48 16.910 16.360 27.331 
49 15.661 14.988 27.331 
50 14.463 13.617 13.617 
51 13.315 12.863 13.617 
52 12.217 12.109 13.617 
53 11.169 11.355 13.617 
54 10.171 10.600 13.617 
55 9.223 9.846 13.617 
56 8.325 9.092 13.617 
57 7.478 8.338 13.617 
58 6.680 7.584 13.617 
59 5.933 6.829 13.617 
60 5.235 6.075 6.075 
61 4.588 5.706 6.075 
62 3.991 5.337 6.075 
63 3.444 4.968 6.075 
64 2.947 4.598 6.075 
65 2.500 4.229 6.075 
66 2.103 3.860 6.075 
67 1.756 3.491 6.075 
68 1.460 3.122 6.075 
69 1.213 2.752 6.075 
70 1.016 2.383 2.383 
71 0.870 2.226 2.383 
72 0.773 2.068 2.383 
73 0.727 1.910 2.383 
74 0.724 1.753 2.383 
75 0.720 1.595 2.383 
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Table (B-5) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 5. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 69.486 69.486 87.423 
26 65.898 65.898 87.423 
27 62.311 62.311 87.423 
28 58.724 58.724 87.423 
29 55.136 55.136 87.423 
30 51.549 51.549 51.549 
31 48.238 49.269 51.549 
32 46.022 46.990 51.549 
33 43.859 44.710 51.549 
34 41.749 42.431 51.549 
35 39.692 40.151 51.549 
36 37.688 37.872 51.549 
37 35.738 35.593 51.549 
38 33.840 33.313 51.549 
39 31.995 31.034 51.549 
40 30.204 28.754 28.754 
41 28.465 27.309 28.754 
42 26.779 25.865 28.754 
43 25.147 24.420 28.754 
44 23.567 22.975 28.754 
45 22.040 21.530 28.754 
46 20.566 20.085 28.754 
47 19.145 18.641 28.754 
48 17.776 17.196 28.754 
49 16.461 15.751 28.754 
50 15.198 14.306 14.306 
51 13.989 13.512 14.306 
52 12.832 12.718 14.306 
53 11.728 11.923 14.306 
54 10.677 11.129 14.306 
55 9.678 10.335 14.306 
56 8.733 9.541 14.306 
57 7.840 8.747 14.306 
58 7.000 7.952 14.306 
59 6.213 7.158 14.306 
60 5.479 6.364 6.364 
61 4.798 5.976 6.364 
62 4.169 5.588 6.364 
63 3.593 5.200 6.364 
64 3.070 4.812 6.364 
65 2.600 4.424 6.364 
66 2.183 4.036 6.364 
67 1.819 3.648 6.364 
68 1.507 3.260 6.364 
69 1.248 2.872 6.364 
70 1.042 2.483 2.483 
71 0.889 2.319 2.483 
72 0.789 2.154 2.483 
73 0.741 1.989 2.483 
74 0.739 1.824 2.483 
75 0.737 1.660 2.483 
 
 
 
Table (B-6) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 6. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 61.405 61.405 77.258 
26 58.235 58.235 77.258 
27 55.064 55.064 77.258 
28 51.894 51.894 77.258 
29 48.723 48.723 77.258 
30 45.553 45.553 45.553 
31 42.627 43.538 45.553 
32 40.668 41.523 45.553 
33 38.756 39.509 45.553 
34 36.891 37.494 45.553 
35 35.073 35.479 45.553 
36 33.302 33.464 45.553 
37 31.578 31.449 45.553 
38 29.900 29.435 45.553 
39 28.270 27.420 45.553 
40 26.686 25.405 25.405 
41 25.150 24.128 25.405 
42 23.660 22.851 25.405 
43 22.217 21.574 25.405 
44 20.820 20.297 25.405 
45 19.471 19.020 25.405 
46 18.168 17.743 25.405 
47 16.912 16.466 25.405 
48 15.702 15.189 25.405 
49 14.540 13.912 25.405 
50 13.424 12.635 12.635 
51 12.355 11.933 12.635 
52 11.332 11.232 12.635 
53 10.357 10.530 12.635 
54 9.428 9.828 12.635 
55 8.545 9.126 12.635 
56 7.710 8.424 12.635 
57 6.921 7.722 12.635 
58 6.179 7.021 12.635 
59 5.483 6.319 12.635 
60 4.835 5.617 5.617 
61 4.233 5.274 5.617 
62 3.677 4.931 5.617 
63 3.169 4.589 5.617 
64 2.707 4.246 5.617 
65 2.291 3.903 5.617 
66 1.923 3.560 5.617 
67 1.601 3.218 5.617 
68 1.326 2.875 5.617 
69 1.097 2.532 5.617 
70 0.915 2.189 2.189 
71 0.780 2.044 2.189 
72 0.692 1.899 2.189 
73 0.650 1.753 2.189 
74 0.649 1.608 2.189 
75 0.647 1.463 2.189 
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Table (B-7) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 7. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 97.492 97.492 122.662 
26 92.458 92.458 122.662 
27 87.424 87.424 122.662 
28 82.390 82.390 122.662 
29 77.356 77.356 122.662 
30 72.323 72.323 72.323 
31 67.680 69.125 72.323 
32 64.571 65.928 72.323 
33 61.536 62.731 72.323 
34 58.577 59.534 72.323 
35 55.692 56.337 72.323 
36 52.881 53.140 72.323 
37 50.145 49.942 72.323 
38 47.484 46.745 72.323 
39 44.897 43.548 72.323 
40 42.384 40.351 40.351 
41 39.945 38.325 40.351 
42 37.581 36.298 40.351 
43 35.291 34.272 40.351 
44 33.075 32.246 40.351 
45 30.934 30.219 40.351 
46 28.866 28.193 40.351 
47 26.873 26.167 40.351 
48 24.954 24.140 40.351 
49 23.109 22.114 40.351 
50 21.339 20.088 20.088 
51 19.642 18.973 20.088 
52 18.019 17.859 20.088 
53 16.471 16.745 20.088 
54 14.996 15.631 20.088 
55 13.596 14.517 20.088 
56 12.270 13.403 20.088 
57 11.018 12.289 20.088 
58 9.840 11.175 20.088 
59 8.736 10.061 20.088 
60 7.706 8.947 8.947 
61 6.750 8.402 8.947 
62 5.868 7.857 8.947 
63 5.060 7.313 8.947 
64 4.326 6.768 8.947 
65 3.666 6.223 8.947 
66 3.081 5.678 8.947 
67 2.569 5.134 8.947 
68 2.132 4.589 8.947 
69 1.768 4.044 8.947 
70 1.478 3.499 3.499 
71 1.263 3.267 3.499 
72 1.121 3.035 3.499 
73 1.054 2.804 3.499 
74 1.050 2.572 3.499 
75 1.047 2.340 3.499 
 
 
 
Table (B-8) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 8. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 76.661 76.661 96.448 
26 72.703 72.703 96.448 
27 68.746 68.746 96.448 
28 64.788 64.788 96.448 
29 60.830 60.830 96.448 
30 56.873 56.873 56.873 
31 53.223 54.360 56.873 
32 50.780 51.847 56.873 
33 48.395 49.333 56.873 
34 46.068 46.820 56.873 
35 43.801 44.307 56.873 
36 41.591 41.794 56.873 
37 39.441 39.281 56.873 
38 37.349 36.767 56.873 
39 35.315 34.254 56.873 
40 33.339 31.741 31.741 
41 31.423 30.148 31.741 
42 29.564 28.555 31.741 
43 27.764 26.962 31.741 
44 26.022 25.369 31.741 
45 24.338 23.776 31.741 
46 22.713 22.183 31.741 
47 21.146 20.590 31.741 
48 19.637 18.997 31.741 
49 18.187 17.404 31.741 
50 16.794 15.811 15.811 
51 15.460 14.935 15.811 
52 14.185 14.059 15.811 
53 12.967 13.183 15.811 
54 11.808 12.307 15.811 
55 10.707 11.430 15.811 
56 9.664 10.554 15.811 
57 8.679 9.678 15.811 
58 7.752 8.802 15.811 
59 6.884 7.926 15.811 
60 6.074 7.050 7.050 
61 5.322 6.621 7.050 
62 4.629 6.193 7.050 
63 3.993 5.764 7.050 
64 3.416 5.335 7.050 
65 2.897 4.907 7.050 
66 2.436 4.478 7.050 
67 2.033 4.049 7.050 
68 1.689 3.620 7.050 
69 1.402 3.192 7.050 
70 1.174 2.763 2.763 
71 1.004 2.580 2.763 
72 0.893 2.397 2.763 
73 0.839 2.214 2.763 
74 0.836 2.031 2.763 
75 0.832 1.849 2.763 
 
 
 
 228 
 
Table (B-9) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 9. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 63.311 63.311 79.655 
26 60.042 60.042 79.655 
27 56.773 56.773 79.655 
28 53.504 53.504 79.655 
29 50.235 50.235 79.655 
30 46.966 46.966 46.966 
31 43.951 44.890 46.966 
32 41.931 42.813 46.966 
33 39.960 40.736 46.966 
34 38.038 38.659 46.966 
35 36.164 36.583 46.966 
36 34.338 34.506 46.966 
37 32.561 32.429 46.966 
38 30.832 30.352 46.966 
39 29.151 28.275 46.966 
40 27.519 26.199 26.199 
41 25.935 24.882 26.199 
42 24.399 23.566 26.199 
43 22.912 22.250 26.199 
44 21.472 20.934 26.199 
45 20.081 19.617 26.199 
46 18.738 18.301 26.199 
47 17.444 16.985 26.199 
48 16.197 15.668 26.199 
49 14.999 14.352 26.199 
50 13.848 13.036 13.036 
51 12.746 12.312 13.036 
52 11.692 11.589 13.036 
53 10.687 10.865 13.036 
54 9.729 10.141 13.036 
55 8.819 9.418 13.036 
56 7.958 8.694 13.036 
57 7.145 7.971 13.036 
58 6.380 7.247 13.036 
59 5.663 6.524 13.036 
60 4.994 5.800 5.800 
61 4.373 5.446 5.800 
62 3.800 5.093 5.800 
63 3.276 4.739 5.800 
64 2.799 4.386 5.800 
65 2.371 4.032 5.800 
66 1.991 3.678 5.800 
67 1.659 3.325 5.800 
68 1.375 2.971 5.800 
69 1.139 2.618 5.800 
70 0.951 2.264 2.264 
71 0.812 2.114 2.264 
72 0.720 1.964 2.264 
73 0.677 1.813 2.264 
74 0.675 1.663 2.264 
75 0.673 1.513 2.264 
 
 
 
Table (B-10) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 10. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 73.697 73.697 92.723 
26 69.892 69.892 92.723 
27 66.087 66.087 92.723 
28 62.282 62.282 92.723 
29 58.477 58.477 92.723 
30 54.672 54.672 54.672 
31 51.160 52.254 54.672 
32 48.809 49.836 54.672 
33 46.515 47.418 54.672 
34 44.277 45.000 54.672 
35 42.095 42.582 54.672 
36 39.970 40.165 54.672 
37 37.900 37.747 54.672 
38 35.888 35.329 54.672 
39 33.931 32.911 54.672 
40 32.031 30.493 30.493 
41 30.187 28.961 30.493 
42 28.399 27.428 30.493 
43 26.667 25.896 30.493 
44 24.991 24.363 30.493 
45 23.371 22.831 30.493 
46 21.808 21.298 30.493 
47 20.301 19.766 30.493 
48 18.849 18.233 30.493 
49 17.454 16.701 30.493 
50 16.115 15.169 15.169 
51 14.832 14.326 15.169 
52 13.605 13.484 15.169 
53 12.434 12.642 15.169 
54 11.319 11.799 15.169 
55 10.260 10.957 15.169 
56 9.257 10.115 15.169 
57 8.311 9.272 15.169 
58 7.420 8.430 15.169 
59 6.585 7.588 15.169 
60 5.807 6.745 6.745 
61 5.084 6.334 6.745 
62 4.417 5.922 6.745 
63 3.807 5.511 6.745 
64 3.252 5.099 6.745 
65 2.754 4.688 6.745 
66 2.311 4.276 6.745 
67 1.925 3.865 6.745 
68 1.595 3.453 6.745 
69 1.320 3.042 6.745 
70 1.102 2.630 2.630 
71 0.939 2.456 2.630 
72 0.833 2.281 2.630 
73 0.783 2.107 2.630 
74 0.781 1.932 2.630 
75 0.779 1.757 2.630 
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Table (B-11) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 11. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 57.995 57.995 72.964 
26 55.001 55.001 72.964 
27 52.007 52.007 72.964 
28 49.013 49.013 72.964 
29 46.019 46.019 72.964 
30 43.026 43.025 43.025 
31 40.263 41.124 43.025 
32 38.414 39.222 43.025 
33 36.610 37.320 43.025 
34 34.849 35.418 43.025 
35 33.133 33.516 43.025 
36 31.461 31.614 43.025 
37 29.834 29.712 43.025 
38 28.250 27.811 43.025 
39 26.711 25.909 43.025 
40 25.216 24.007 24.007 
41 23.766 22.801 24.007 
42 22.359 21.596 24.007 
43 20.996 20.390 24.007 
44 19.678 19.184 24.007 
45 18.404 17.979 24.007 
46 17.174 16.773 24.007 
47 15.988 15.567 24.007 
48 14.846 14.362 24.007 
49 13.748 13.156 24.007 
50 12.695 11.951 11.951 
51 11.685 11.288 11.951 
52 10.720 10.625 11.951 
53 9.798 9.962 11.951 
54 8.921 9.299 11.951 
55 8.088 8.636 11.951 
56 7.299 7.973 11.951 
57 6.554 7.310 11.951 
58 5.853 6.647 11.951 
59 5.196 5.984 11.951 
60 4.583 5.321 5.321 
61 4.014 4.997 5.321 
62 3.489 4.673 5.321 
63 3.009 4.349 5.321 
64 2.572 4.025 5.321 
65 2.180 3.701 5.321 
66 1.831 3.376 5.321 
67 1.527 3.052 5.321 
68 1.266 2.728 5.321 
69 1.050 2.404 5.321 
70 0.878 2.080 2.080 
71 0.749 1.942 2.080 
72 0.665 1.804 2.080 
73 0.625 1.666 2.080 
74 0.623 1.528 2.080 
75 0.621 1.390 2.080 
 
 
 
Table (B-12) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 12. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 68.459 68.459 86.133 
26 64.925 64.925 86.133 
27 61.390 61.390 86.133 
28 57.855 57.855 86.133 
29 54.320 54.320 86.133 
30 50.786 50.786 50.786 
31 47.524 48.540 50.786 
32 45.340 46.294 50.786 
33 43.208 44.048 50.786 
34 41.129 41.802 50.786 
35 39.103 39.556 50.786 
36 37.128 37.310 50.786 
37 35.206 35.064 50.786 
38 33.337 32.818 50.786 
39 31.519 30.572 50.786 
40 29.754 28.326 28.326 
41 28.041 26.902 28.326 
42 26.380 25.479 28.326 
43 24.771 24.055 28.326 
44 23.214 22.632 28.326 
45 21.710 21.208 28.326 
46 20.258 19.784 28.326 
47 18.857 18.361 28.326 
48 17.509 16.937 28.326 
49 16.213 15.514 28.326 
50 14.969 14.090 14.090 
51 13.777 13.308 14.090 
52 12.638 12.525 14.090 
53 11.550 11.743 14.090 
54 10.514 10.960 14.090 
55 9.531 10.178 14.090 
56 8.599 9.396 14.090 
57 7.720 8.613 14.090 
58 6.892 7.831 14.090 
59 6.117 7.048 14.090 
60 5.394 6.266 6.266 
61 4.723 5.884 6.266 
62 4.103 5.501 6.266 
63 3.536 5.119 6.266 
64 3.021 4.737 6.266 
65 2.558 4.355 6.266 
66 2.147 3.972 6.266 
67 1.788 3.590 6.266 
68 1.481 3.208 6.266 
69 1.226 2.826 6.266 
70 1.024 2.444 2.444 
71 0.873 2.281 2.444 
72 0.774 2.119 2.444 
73 0.727 1.957 2.444 
74 0.725 1.795 2.444 
75 0.724 1.633 2.444 
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Table (B-13) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 13. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 64.392 64.392 81.014 
26 61.068 61.068 81.014 
27 57.744 57.744 81.014 
28 54.419 54.419 81.014 
29 51.095 51.095 81.014 
30 47.771 47.771 47.771 
31 44.703 45.659 47.771 
32 42.650 43.547 47.771 
33 40.646 41.435 47.771 
34 38.691 39.322 47.771 
35 36.785 37.210 47.771 
36 34.928 35.098 47.771 
37 33.121 32.986 47.771 
38 31.362 30.874 47.771 
39 29.653 28.762 47.771 
40 27.993 26.650 26.650 
41 26.382 25.311 26.650 
42 24.820 23.972 26.650 
43 23.307 22.633 26.650 
44 21.843 21.295 26.650 
45 20.428 19.956 26.650 
46 19.062 18.617 26.650 
47 17.746 17.278 26.650 
48 16.478 15.940 26.650 
49 15.259 14.601 26.650 
50 14.089 13.262 13.262 
51 12.968 12.526 13.262 
52 11.896 11.790 13.262 
53 10.873 11.054 13.262 
54 9.899 10.318 13.262 
55 8.973 9.582 13.262 
56 8.097 8.846 13.262 
57 7.270 8.110 13.262 
58 6.492 7.374 13.262 
59 5.762 6.638 13.262 
60 5.082 5.902 5.902 
61 4.451 5.542 5.902 
62 3.868 5.183 5.902 
63 3.334 4.823 5.902 
64 2.850 4.463 5.902 
65 2.414 4.104 5.902 
66 2.027 3.744 5.902 
67 1.689 3.384 5.902 
68 1.401 3.024 5.902 
69 1.161 2.665 5.902 
70 0.970 2.305 2.305 
71 0.827 2.152 2.305 
72 0.734 1.999 2.305 
73 0.690 1.846 2.305 
74 0.688 1.694 2.305 
75 0.686 1.541 2.305 
 
 
 
Table (B-14) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 14. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 65.500 65.500 82.410 
26 62.118 62.118 82.410 
27 58.736 58.736 82.410 
28 55.354 55.354 82.410 
29 51.972 51.972 82.410 
30 48.590 48.590 48.590 
31 45.470 46.442 48.590 
32 43.381 44.293 48.590 
33 41.342 42.145 48.590 
34 39.353 39.996 48.590 
35 37.415 37.848 48.590 
36 35.526 35.699 48.590 
37 33.687 33.551 48.590 
38 31.899 31.402 48.590 
39 30.160 29.254 48.590 
40 28.471 27.105 27.105 
41 26.833 25.744 27.105 
42 25.244 24.382 27.105 
43 23.705 23.020 27.105 
44 22.216 21.658 27.105 
45 20.777 20.297 27.105 
46 19.388 18.935 27.105 
47 18.048 17.573 27.105 
48 16.759 16.211 27.105 
49 15.519 14.850 27.105 
50 14.329 13.488 13.488 
51 13.189 12.739 13.488 
52 12.098 11.991 13.488 
53 11.058 11.242 13.488 
54 10.067 10.494 13.488 
55 9.126 9.745 13.488 
56 8.235 8.997 13.488 
57 7.393 8.248 13.488 
58 6.602 7.499 13.488 
59 5.860 6.751 13.488 
60 5.168 6.002 6.002 
61 4.526 5.636 6.002 
62 3.933 5.271 6.002 
63 3.391 4.905 6.002 
64 2.898 4.539 6.002 
65 2.455 4.173 6.002 
66 2.061 3.807 6.002 
67 1.718 3.441 6.002 
68 1.424 3.075 6.002 
69 1.180 2.710 6.002 
70 0.986 2.344 2.344 
71 0.841 2.188 2.344 
72 0.746 2.033 2.344 
73 0.701 1.877 2.344 
74 0.699 1.722 2.344 
75 0.697 1.567 2.344 
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Table (B-15) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 15. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 60.975 60.975 76.718 
26 57.827 57.827 76.718 
27 54.678 54.678 76.718 
28 51.530 51.530 76.718 
29 48.381 48.381 76.718 
30 45.232 45.232 45.232 
31 42.328 43.232 45.232 
32 40.383 41.232 45.232 
33 38.485 39.232 45.232 
34 36.633 37.232 45.232 
35 34.828 35.232 45.232 
36 33.070 33.232 45.232 
37 31.359 31.232 45.232 
38 29.694 29.232 45.232 
39 28.075 27.232 45.232 
40 26.503 25.232 25.232 
41 24.978 23.964 25.232 
42 23.499 22.697 25.232 
43 22.066 21.429 25.232 
44 20.680 20.161 25.232 
45 19.340 18.894 25.232 
46 18.047 17.626 25.232 
47 16.800 16.358 25.232 
48 15.600 15.091 25.232 
49 14.446 13.823 25.232 
50 13.338 12.556 12.556 
51 12.277 11.859 12.556 
52 11.262 11.162 12.556 
53 10.293 10.465 12.556 
54 9.371 9.768 12.556 
55 8.495 9.071 12.556 
56 7.666 8.375 12.556 
57 6.882 7.678 12.556 
58 6.146 6.981 12.556 
59 5.455 6.284 12.556 
60 4.811 5.587 5.587 
61 4.213 5.247 5.587 
62 3.662 4.906 5.587 
63 3.156 4.566 5.587 
64 2.698 4.225 5.587 
65 2.285 3.885 5.587 
66 1.919 3.544 5.587 
67 1.599 3.203 5.587 
68 1.326 2.863 5.587 
69 1.098 2.522 5.587 
70 0.918 2.182 2.182 
71 0.783 2.037 2.182 
72 0.695 1.892 2.182 
73 0.653 1.748 2.182 
74 0.651 1.603 2.182 
75 0.649 1.458 2.182 
 
 
 
Table (B-16) Presents effective risk for 
women aged 25-75 years resulted from 
FFDM machine 16. 
Age 
(year) 
Effective risk (case/106) 
Method 1 Method 2 Method 3 
25 59.777 59.777 75.207 
26 56.691 56.691 75.207 
27 53.605 53.605 75.207 
28 50.519 50.519 75.207 
29 47.433 47.433 75.207 
30 44.347 44.347 44.347 
31 41.500 42.387 44.347 
32 39.593 40.426 44.347 
33 37.733 38.465 44.347 
34 35.918 36.504 44.347 
35 34.148 34.543 44.347 
36 32.425 32.583 44.347 
37 30.747 30.622 44.347 
38 29.115 28.661 44.347 
39 27.528 26.700 44.347 
40 25.987 24.740 24.740 
41 24.491 23.497 24.740 
42 23.041 22.254 24.740 
43 21.636 21.011 24.740 
44 20.277 19.768 24.740 
45 18.964 18.525 24.740 
46 17.696 17.282 24.740 
47 16.473 16.039 24.740 
48 15.296 14.797 24.740 
49 14.165 13.554 24.740 
50 13.078 12.311 12.311 
51 12.038 11.628 12.311 
52 11.043 10.944 12.311 
53 10.093 10.261 12.311 
54 9.188 9.578 12.311 
55 8.330 8.895 12.311 
56 7.516 8.211 12.311 
57 6.748 7.528 12.311 
58 6.026 6.845 12.311 
59 5.349 6.162 12.311 
60 4.717 5.478 5.478 
61 4.131 5.144 5.478 
62 3.590 4.811 5.478 
63 3.095 4.477 5.478 
64 2.645 4.143 5.478 
65 2.240 3.809 5.478 
66 1.881 3.475 5.478 
67 1.568 3.141 5.478 
68 1.299 2.807 5.478 
69 1.077 2.473 5.478 
70 0.899 2.139 2.139 
71 0.767 1.997 2.139 
72 0.681 1.855 2.139 
73 0.640 1.713 2.139 
74 0.638 1.572 2.139 
75 0.636 1.430 2.139 
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Appendix C: The proposed 274 screening scenarios used to establish the regression 
model. 
Table (C-1) Lists the proposed 274 screening scenarios used for regression model. 
Age 
range 
(year) 
Screening frequency 
Age 
range 
(year) 
Screening frequency 
Age 
range 
(year) 
Screening frequency 
25-55 annual, biennial, triennial 32-67 annual, biennial, triennial 47-69 annual, biennial, triennial 
25-60 annual, biennial, triennial 32-68 annual, biennial, triennial 47-73 annual, biennial, triennial 
25-65 annual, biennial, triennial 32-70 annual, biennial, triennial 47-75 annual, biennial, triennial 
25-70 annual, biennial, triennial 32-74 annual, biennial, triennial 48-68 annual, biennial, triennial 
25-75 annual, biennial, triennial 33-73 annual, biennial, triennial 48-70 annual, biennial, triennial 
26-50 annual, biennial, triennial 35-45 annual, biennial, triennial 49-55 annual, biennial, triennial 
27-34 annual, biennial, triennial 35-50 annual, biennial, triennial 49-59 annual, biennial, triennial 
27-37 annual, biennial, triennial 35-55 annual, biennial, triennial 49-62 annual, biennial, triennial 
27-40 annual, biennial, triennial 35-70 annual, biennial, triennial 49-65 annual, biennial, triennial 
27-43 annual, biennial, triennial 35-75 annual, biennial, triennial 49-68 annual, biennial, triennial 
27-46 annual, biennial, triennial 36-72 annual, biennial, triennial 49-70 annual, biennial, triennial 
27-49 annual, biennial, triennial 37-58 annual, biennial, triennial 49-72 annual, biennial, triennial 
27-52 annual, biennial, triennial 37-61 annual, biennial, triennial 49-75 annual, biennial, triennial 
27-55 annual, biennial, triennial 37-65 annual, biennial, triennial 50-64 annual, biennial, triennial 
27-58 annual, biennial, triennial 37-67 annual, biennial, triennial 50-67 annual, biennial, triennial 
27-61 annual, biennial, triennial 37-72 annual, biennial, triennial 50-73 annual, biennial, triennial 
27-64 annual, biennial, triennial 37-75 annual, biennial, triennial 50-75 annual, biennial, triennial 
27-67 annual, biennial, triennial 38-65 annual, biennial, triennial 52-72 annual, biennial, triennial 
27-70 annual, biennial, triennial 40-60 annual, biennial, triennial 52-75 annual, biennial, triennial 
27-72 annual, biennial, triennial 40-69 annual, biennial, triennial 53-70 annual, biennial, triennial 
27-75 annual, biennial, triennial 40-74 annual, biennial, triennial 54-63 annual, biennial, triennial 
29-62 annual, biennial, triennial 40-75 annual, biennial, triennial 55-75 annual, biennial, triennial 
30-75 annual, biennial, triennial 42-65 annual, biennial, triennial 57-75 annual, biennial, triennial 
32-45 annual, biennial, triennial 42-70 annual, biennial, triennial 60-73 annual, biennial, triennial 
32-48 annual, biennial, triennial 42-72 annual, biennial, triennial 60-75 annual, biennial, triennial 
32-50 annual, biennial, triennial 42-75 annual, biennial, triennial 62-75 annual, biennial, triennial 
32-52 annual, biennial, triennial 43-71 annual, biennial, triennial 63-75 annual, biennial, triennial 
32-55 annual, biennial, triennial 44-65 annual, biennial, triennial 64-75 annual, biennial, triennial 
32-58 annual, biennial, triennial 44-70 annual, biennial, triennial 65-75 annual, biennial, triennial 
32-61 annual, biennial, triennial 44-75 annual, biennial, triennial 
66-75 annual 
32-64 annual, biennial, triennial 45-75 annual, biennial, triennial 
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Appendix D:  Relationship graphs between MGD and total effective risk. 
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Third LAR Extrapolation Method 
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Appendix E: Total effective risk of worldwide screening programmes 
resulted from the sixteen FFDM machines for the three LAR extrapolation 
methods. 
Table (E-1) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 1 (visit 1) using 
the LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 232.39 242.94 307.63 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
85.61 96.31 124.89 
Canada , France, Israel, Netherlands 88.71 104.12 133.89 
China 147.29 145.03 190.86 
Czech  163.53 176.93 238.13 
Estonia  77.44 81.68 101.82 
Hungary 142.69 148.87 213.75 
Iceland 229.28 235.13 298.63 
India  366.83 373.03 481.37 
Ireland 81.15 87.50 109.51 
Malta 50.60 51.87 69.15 
New Zealand, Portugal, Spain (Navarra) 146.40 156.75 229.13 
Nigeria 230.54 238.13 301.63 
Sweden 270.81 279.99 374.13 
United Kingdom 84.81 93.24 129.97 
United State (ACOG) 311.98 339.32 441.52 
United State (ACS, ACR, and NCCN) 446.43 469.41 615.26 
Uruguay 306.02 324.30 423.52 
Canada  366.83 373.03 481.37 
United Kingdom  444.65 465.20 609.26 
United State (ACS) 942.36 968.41 1238.23 
United State (NCCN) 1318.88 1344.94 1766.52 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-2) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 1 (visit 2) using 
the LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 232.46 243.02 307.77 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
85.60 96.32 124.91 
Canada , France, Israel, Netherlands 88.69 104.11 133.90 
China 147.37 145.11 190.98 
Czech  163.55 176.97 238.22 
Estonia  77.45 81.70 101.85 
Hungary 142.73 148.91 213.86 
Iceland 229.37 235.23 298.78 
India  366.99 373.19 481.64 
Ireland 81.16 87.51 109.54 
Malta 50.61 51.89 69.18 
New Zealand, Portugal, Spain (Navarra) 146.42 156.78 229.23 
Nigeria 230.62 238.22 301.78 
Sweden 270.91 280.10 374.32 
United Kingdom 84.81 93.25 130.01 
United State (ACOG) 312.02 339.39 441.67 
United State (ACS, ACR, and NCCN) 446.56 469.56 615.54 
Uruguay 306.09 324.40 423.69 
Canada  366.99 373.19 481.64 
United Kingdom  444.78 465.36 609.55 
United State (ACS) 942.88 968.96 1239.03 
United State (NCCN) 1319.72 1345.80 1767.76 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (E-3) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 1 (visit 3) using 
the LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 232.03 242.58 307.22 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
85.43 96.13 124.68 
Canada , France, Israel, Netherlands 88.51 103.91 133.65 
China 147.11 144.85 190.65 
Czech  163.23 176.64 237.79 
Estonia  77.30 81.54 101.66 
Hungary 142.46 148.64 213.48 
Iceland 228.95 234.80 298.25 
India  366.33 372.52 480.79 
Ireland 81.00 87.34 109.33 
Malta 50.51 51.79 69.05 
New Zealand, Portugal, Spain (Navarra) 146.14 156.49 228.82 
Nigeria 230.20 237.79 301.24 
Sweden 270.42 279.59 373.66 
United Kingdom 84.64 93.07 129.77 
United State (ACOG) 311.43 338.75 440.87 
United State (ACS, ACR, and NCCN) 445.73 468.70 614.44 
Uruguay 305.52 323.79 422.93 
Canada  366.33 372.52 480.79 
United Kingdom  443.96 464.50 608.46 
United State (ACS) 941.23 967.27 1236.91 
United State (NCCN) 1317.45 1343.49 1764.75 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-4) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 2 (visit 1) using 
the LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 222.83 232.77 294.74 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
82.14 92.30 119.67 
Canada , France, Israel, Netherlands 85.15 99.78 128.30 
China 141.17 138.95 182.84 
Czech  156.84 169.54 228.16 
Estonia  74.28 78.27 97.56 
Hungary 136.83 142.64 204.79 
Iceland 219.82 225.28 286.10 
India  351.67 357.40 461.17 
Ireland 77.84 83.85 104.93 
Malta 48.52 49.71 66.25 
New Zealand, Portugal, Spain (Navarra) 140.40 150.19 219.53 
Nigeria 221.04 228.16 288.98 
Sweden 259.65 268.27 358.43 
United Kingdom 81.35 89.34 124.53 
United State (ACOG) 299.24 325.14 423.04 
United State (ACS, ACR, and NCCN) 428.08 449.77 589.47 
Uruguay 293.46 310.74 405.77 
Canada  351.67 357.40 461.17 
United Kingdom  426.35 445.73 583.72 
United State (ACS) 903.19 927.77 1186.22 
United State (NCCN) 1263.88 1288.45 1692.29 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (E-5) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 2 (visit 2) using 
the LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 222.53 232.54 294.46 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
81.99 92.18 119.54 
Canada , France, Israel, Netherlands 84.98 99.66 128.15 
China 141.02 138.82 182.69 
Czech  156.60 169.36 227.94 
Estonia  74.16 78.18 97.46 
Hungary 136.64 142.49 204.60 
Iceland 219.54 225.06 285.84 
India  351.24 357.06 460.77 
Ireland 77.72 83.75 104.82 
Malta 48.45 49.65 66.19 
New Zealand, Portugal, Spain (Navarra) 140.19 150.03 219.32 
Nigeria 220.75 227.94 288.72 
Sweden 259.31 268.00 358.11 
United Kingdom 81.22 89.24 124.40 
United State (ACOG) 298.78 324.78 422.61 
United State (ACS, ACR, and NCCN) 427.49 449.30 588.92 
Uruguay 293.04 310.41 405.38 
Canada  351.24 357.06 460.77 
United Kingdom  425.78 445.28 583.17 
United State (ACS) 902.25 926.98 1185.27 
United State (NCCN) 1262.71 1287.42 1691.01 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-6) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 2 (visit 3) using 
the LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 222.52 232.52 294.44 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
82.00 92.19 119.53 
Canada , France, Israel, Netherlands 84.99 99.66 128.15 
China 141.01 138.81 182.67 
Czech  156.61 169.35 227.92 
Estonia  74.17 78.18 97.45 
Hungary 136.64 142.49 204.58 
Iceland 219.54 225.05 285.82 
India  351.23 357.03 460.72 
Ireland 77.72 83.75 104.81 
Malta 48.45 49.65 66.18 
New Zealand, Portugal, Spain (Navarra) 140.20 150.03 219.30 
Nigeria 220.75 227.92 288.69 
Sweden 259.31 267.99 358.08 
United Kingdom 81.22 89.24 124.40 
United State (ACOG) 298.79 324.78 422.59 
United State (ACS, ACR, and NCCN) 427.49 449.28 588.87 
Uruguay 293.05 310.40 405.35 
Canada  351.23 357.03 460.72 
United Kingdom  425.78 445.25 583.13 
United State (ACS) 902.16 926.86 1185.10 
United State (NCCN) 1262.53 1287.22 1690.70 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (E-7) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 3 using the LAR 
extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 195.69 204.51 258.73 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
72.32 81.27 105.24 
Canada , France, Israel, Netherlands 75.06 87.94 112.92 
China 123.80 121.91 160.28 
Czech  137.90 149.11 200.41 
Estonia  65.31 68.86 85.73 
Hungary 120.20 125.37 179.72 
Iceland 192.95 197.85 251.05 
India  308.60 313.78 404.54 
Ireland 68.47 73.78 92.23 
Malta 42.63 43.70 58.18 
New Zealand, Portugal, Spain (Navarra) 123.41 132.07 192.72 
Nigeria 194.06 200.41 253.61 
Sweden 227.94 235.62 314.49 
United Kingdom 71.57 78.62 109.41 
United State (ACOG) 263.10 285.96 371.65 
United State (ACS, ACR, and NCCN) 376.01 395.22 517.46 
Uruguay 257.83 273.13 356.29 
Canada  308.60 313.78 404.54 
United Kingdom  374.43 391.62 512.34 
United State (ACS) 791.90 813.69 1039.71 
United State (NCCN) 1107.57 1129.35 1482.64 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-8) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 4 using the LAR 
extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 183.14 191.43 242.27 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
67.59 75.99 98.46 
Canada , France, Israel, Netherlands 70.11 82.20 105.61 
China 115.95 114.18 150.18 
Czech  128.98 139.51 187.61 
Estonia  61.08 64.41 80.24 
Hungary 112.48 117.33 168.30 
Iceland 180.63 185.22 235.12 
India  288.93 293.80 378.92 
Ireland 64.03 69.01 86.31 
Malta 39.89 40.89 54.47 
New Zealand, Portugal, Spain (Navarra) 115.45 123.57 180.46 
Nigeria 181.64 191.43 237.50 
Sweden 213.37 220.57 294.55 
United Kingdom 66.92 73.54 102.41 
United State (ACOG) 246.08 267.53 347.88 
United State (ACS, ACR, and NCCN) 351.86 369.90 484.54 
Uruguay 241.25 255.60 333.58 
Canada  288.93 293.80 378.92 
United Kingdom  350.42 366.56 479.77 
United State (ACS) 741.78 762.24 974.26 
United State (NCCN) 1037.79 1058.26 1389.62 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (E-9) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 5 using the LAR 
extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 192.31 201.04 254.57 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
70.85 79.71 103.35 
Canada , France, Israel, Netherlands 73.42 86.17 110.80 
China 121.89 120.02 157.93 
Czech  135.33 146.42 197.06 
Estonia  64.09 67.60 84.26 
Hungary 118.08 123.20 176.89 
Iceland 189.74 194.58 247.12 
India  303.57 308.69 398.34 
Ireland 67.16 72.41 90.62 
Malta 41.87 42.93 57.22 
New Zealand, Portugal, Spain (Navarra) 121.15 129.72 189.61 
Nigeria 190.78 197.06 249.61 
Sweden 224.11 231.70 309.60 
United Kingdom 70.18 77.16 107.55 
United State (ACOG) 258.18 280.80 365.37 
United State (ACS, ACR, and NCCN) 369.44 388.45 509.14 
Uruguay 253.25 268.37 350.47 
Canada  303.57 308.69 398.34 
United Kingdom  367.97 384.97 504.18 
United State (ACS) 779.81 801.37 1024.63 
United State (NCCN) 1091.37 1112.92 1461.75 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-10) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 6 using the LAR 
extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 169.83 177.55 224.85 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
62.54 70.37 91.26 
Canada , France, Israel, Netherlands 64.80 76.07 97.83 
China 107.67 106.01 139.53 
Czech  119.49 129.30 174.04 
Estonia  56.59 59.69 74.41 
Hungary 104.28 108.80 156.24 
Iceland 167.58 171.86 218.29 
India  268.12 272.65 351.88 
Ireland 59.29 63.93 80.03 
Malta 36.97 37.91 50.54 
New Zealand, Portugal, Spain (Navarra) 106.97 114.55 167.48 
Nigeria 168.49 174.04 220.48 
Sweden 197.93 204.64 273.48 
United Kingdom 61.96 68.13 94.99 
United State (ACOG) 227.96 247.96 322.68 
United State (ACS, ACR, and NCCN) 326.25 343.06 449.71 
Uruguay 223.63 237.00 309.55 
Canada  268.12 272.65 351.88 
United Kingdom  324.96 339.99 445.33 
United State (ACS) 688.87 707.92 905.24 
United State (NCCN) 964.19 983.25 1291.53 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
 
 
 250 
 
Table (E-11) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 7 using the 
LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 270.09 282.33 357.43 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
99.58 112.00 145.17 
Canada , France, Israel, Netherlands 103.23 121.10 155.67 
China 171.11 168.48 221.67 
Czech  190.12 205.68 276.72 
Estonia  90.04 94.96 118.33 
Hungary 165.85 173.02 248.33 
Iceland 266.44 273.22 346.93 
India  426.24 433.43 559.18 
Ireland 94.36 101.73 127.28 
Malta 58.81 60.30 80.35 
New Zealand, Portugal, Spain (Navarra) 170.19 182.20 266.23 
Nigeria 267.92 276.72 350.43 
Sweden 314.71 325.36 434.63 
United Kingdom 98.62 108.40 151.04 
United State (ACOG) 362.73 394.44 513.10 
United State (ACS, ACR, and NCCN) 518.88 545.54 714.85 
Uruguay 355.71 376.93 492.10 
Canada  426.24 433.43 559.18 
United Kingdom  516.78 540.63 707.85 
United State (ACS) 1094.66 1124.89 1438.08 
United State (NCCN) 1531.78 1562.01 2051.38 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-12) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 8 using the LAR 
extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 212.62 222.25 281.30 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
78.45 88.21 114.30 
Canada , France, Israel, Netherlands 81.35 95.40 122.59 
China 134.65 132.58 174.40 
Czech  149.72 161.95 217.82 
Estonia  70.91 74.78 93.15 
Hungary 130.58 136.21 195.43 
Iceland 209.72 215.05 273.01 
India  335.48 341.12 440.00 
Ireland 74.32 80.11 100.20 
Malta 46.31 47.47 63.24 
New Zealand, Portugal, Spain (Navarra) 134.02 143.45 209.53 
Nigeria 210.90 217.82 275.77 
Sweden 247.73 256.10 342.02 
United Kingdom 77.67 85.36 118.90 
United State (ACOG) 285.64 310.57 403.89 
United State (ACS, ACR, and NCCN) 408.50 429.45 562.60 
Uruguay 280.07 296.74 387.32 
Canada  335.48 341.12 440.00 
United Kingdom  406.83 425.57 557.07 
United State (ACS) 861.33 885.09 1131.33 
United State (NCCN) 1205.06 1228.82 1613.57 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (E-13) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 9 using the LAR 
extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 175.24 183.19 231.96 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
64.57 72.64 94.18 
Canada , France, Israel, Netherlands 66.91 78.53 100.97 
China 111.06 109.36 143.90 
Czech  123.32 133.43 179.57 
Estonia  58.40 61.60 76.78 
Hungary 107.60 112.26 161.17 
Iceland 172.89 177.30 225.17 
India  276.61 281.28 362.96 
Ireland 61.20 65.99 82.58 
Malta 38.16 39.12 52.14 
New Zealand, Portugal, Spain (Navarra) 110.40 118.20 172.77 
Nigeria 173.84 179.57 227.44 
Sweden 204.21 211.13 282.10 
United Kingdom 63.96 70.31 98.01 
United State (ACOG) 235.28 255.88 332.94 
United State (ACS, ACR, and NCCN) 336.65 353.97 463.93 
Uruguay 230.77 244.55 319.35 
Canada  276.61 281.28 362.96 
United Kingdom  335.30 350.79 459.40 
United State (ACS) 710.54 730.18 933.59 
United State (NCCN) 994.41 1014.04 1331.87 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-14) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 10 using the 
LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 203.89 213.15 269.93 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
75.10 84.49 109.57 
Canada , France, Israel, Netherlands 77.81 91.34 117.46 
China 129.24 127.26 167.48 
Czech  143.46 155.23 208.94 
Estonia  67.94 71.66 89.33 
Hungary 125.19 130.61 187.56 
Iceland 201.18 206.31 262.04 
India  321.87 327.31 422.39 
Ireland 71.19 76.76 96.08 
Malta 44.39 45.51 60.67 
New Zealand, Portugal, Spain (Navarra) 128.44 137.52 201.05 
Nigeria 202.28 208.94 264.67 
Sweden 237.61 245.67 328.28 
United Kingdom 74.40 81.80 114.03 
United State (ACOG) 273.70 297.70 387.39 
United State (ACS, ACR, and NCCN) 391.68 411.85 539.85 
Uruguay 268.49 284.53 371.60 
Canada  321.87 327.31 422.39 
United Kingdom  390.12 408.16 534.59 
United State (ACS) 826.90 849.76 1086.57 
United State (NCCN) 1157.33 1180.20 1550.18 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (E-15) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 11 using the 
LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 160.67 167.95 212.63 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
59.23 66.62 86.36 
Canada , France, Israel, Netherlands 61.40 72.03 92.60 
China 101.80 100.23 131.88 
Czech  113.09 122.35 164.62 
Estonia  53.56 56.49 70.40 
Hungary 98.66 102.93 147.74 
Iceland 158.50 162.54 206.39 
India  253.57 257.84 332.67 
Ireland 56.13 60.51 75.72 
Malta 34.99 35.87 47.80 
New Zealand, Portugal, Spain (Navarra) 101.24 108.38 158.38 
Nigeria 159.38 164.62 208.47 
Sweden 187.22 193.55 258.57 
United Kingdom 58.66 64.48 89.85 
United State (ACOG) 215.76 234.63 305.23 
United State (ACS, ACR, and NCCN) 308.67 324.53 425.27 
Uruguay 211.60 224.22 292.75 
Canada  253.57 257.84 332.67 
United Kingdom  307.42 321.61 421.11 
United State (ACS) 651.22 669.20 855.52 
United State (NCCN) 911.25 929.23 1220.34 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-16) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 12 using the 
LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 189.40 198.00 250.74 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
69.76 78.49 101.78 
Canada , France, Israel, Netherlands 72.28 84.84 109.11 
China 120.06 118.21 155.57 
Czech  133.26 144.20 194.09 
Estonia  63.11 66.57 82.98 
Hungary 116.29 121.33 174.23 
Iceland 186.88 191.64 243.41 
India  298.99 304.04 392.37 
Ireland 66.13 71.31 89.25 
Malta 41.24 42.28 56.36 
New Zealand, Portugal, Spain (Navarra) 119.31 127.75 186.76 
Nigeria 187.90 194.09 245.85 
Sweden 220.72 228.21 304.95 
United Kingdom 69.11 75.98 105.93 
United State (ACOG) 254.25 276.54 359.85 
United State (ACS, ACR, and NCCN) 363.84 382.58 501.48 
Uruguay 249.40 264.31 345.19 
Canada  298.99 304.04 392.37 
United Kingdom  362.39 379.15 496.59 
United State (ACS) 768.12 789.36 1009.34 
United State (NCCN) 1075.07 1096.31 1440.00 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (E-17) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 13 using the 
LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 178.29 186.38 235.98 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
65.70 73.91 95.82 
Canada , France, Israel, Netherlands 68.09 79.90 102.74 
China 112.98 111.25 146.38 
Czech  125.47 135.76 182.68 
Estonia  59.42 62.68 78.11 
Hungary 109.48 114.21 163.97 
Iceland 175.90 180.38 229.07 
India  281.41 286.16 369.23 
Ireland 62.27 67.14 84.02 
Malta 38.82 39.80 53.05 
New Zealand, Portugal, Spain (Navarra) 112.33 120.26 175.77 
Nigeria 176.87 182.68 231.37 
Sweden 207.76 214.80 286.98 
United Kingdom 65.08 71.54 99.71 
United State (ACOG) 239.39 260.35 338.72 
United State (ACS, ACR, and NCCN) 342.51 360.12 471.97 
Uruguay 234.79 248.81 324.89 
Canada  281.41 286.16 369.23 
United Kingdom  341.13 356.89 467.36 
United State (ACS) 722.82 742.79 949.68 
United State (NCCN) 1011.54 1031.51 1354.75 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-18) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 14 using the 
LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 181.32 189.55 240.01 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
66.82 75.16 97.45 
Canada , France, Israel, Netherlands 69.25 81.26 104.48 
China 114.91 113.15 148.89 
Czech  127.61 138.07 185.80 
Estonia  60.43 63.74 79.44 
Hungary 111.34 116.16 166.76 
Iceland 178.89 183.45 232.98 
India  286.21 291.04 375.54 
Ireland 63.33 68.28 85.45 
Malta 39.48 40.48 53.95 
New Zealand, Portugal, Spain (Navarra) 114.24 122.31 178.77 
Nigeria 179.88 185.80 235.32 
Sweden 211.30 218.46 291.88 
United Kingdom 66.18 72.76 101.41 
United State (ACOG) 243.46 264.78 344.49 
United State (ACS, ACR, and NCCN) 348.34 366.26 480.02 
Uruguay 238.79 253.04 330.43 
Canada  286.21 291.04 375.54 
United Kingdom  346.94 362.97 475.33 
United State (ACS) 735.16 755.48 965.92 
United State (NCCN) 1028.84 1049.16 1377.97 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
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Table (E-19) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 15 using the 
LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 168.79 176.45 223.42 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
62.20 69.97 90.71 
Canada , France, Israel, Netherlands 64.46 75.64 97.26 
China 106.97 105.32 138.59 
Czech  118.79 128.52 172.96 
Estonia  56.25 59.33 73.95 
Hungary 103.64 108.13 155.24 
Iceland 166.53 170.77 216.87 
India  266.42 270.92 349.58 
Ireland 58.95 63.56 79.54 
Malta 36.75 37.68 50.22 
New Zealand, Portugal, Spain (Navarra) 106.34 113.86 166.41 
Nigeria 167.44 172.96 219.06 
Sweden 196.69 203.36 271.70 
United Kingdom 61.61 67.73 94.40 
United State (ACOG) 226.63 246.47 320.68 
United State (ACS, ACR, and NCCN) 324.26 340.94 446.84 
Uruguay 222.28 235.55 307.59 
Canada  266.42 270.92 349.58 
United Kingdom  322.96 337.88 442.47 
United State (ACS) 684.35 703.26 899.16 
United State (NCCN) 957.74 976.65 1282.75 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
Table (E-20) Presents the total effective risk of worldwide screening programmes resulted from FFDM machine 16 using the 
LAR extrapolated by the three methods. 
Programme 
Total effective risk (case/106) 
Method 1 Method 2 Method 3 
Australia, Japan, Korea, United State (AAFP, NCI, and USPSTF) 165.50 173.01 219.06 
Belgium, Croatia, Cyprus, Denmark, Finland, Germany, Italy, Latvia, Lithuania, 
Luxembourg, Norway, Poland, Slovenia, Spain (Catalonia), Switzerland 
60.98 68.60 88.95 
Canada , France, Israel, Netherlands 63.20 74.17 95.36 
China 104.88 103.27 135.89 
Czech  116.47 126.02 169.58 
Estonia  55.16 58.18 72.51 
Hungary 101.62 106.02 152.21 
Iceland 163.28 167.44 212.64 
India  261.23 265.63 342.76 
Ireland 57.80 62.32 77.99 
Malta 36.04 36.94 49.24 
New Zealand, Portugal, Spain (Navarra) 104.27 111.64 163.16 
Nigeria 164.18 169.58 214.78 
Sweden 192.86 199.39 266.40 
United Kingdom 60.41 66.41 92.56 
United State (ACOG) 222.21 241.67 314.42 
United State (ACS, ACR, and NCCN) 317.94 334.29 438.12 
Uruguay 217.95 230.96 301.59 
Canada  261.23 265.63 342.76 
United Kingdom  316.66 331.29 433.84 
United State (ACS) 670.99 689.53 881.60 
United State (NCCN) 939.02 957.56 1257.63 
Screening programmes designed for high breast cancer risk women are highlighted in grey. 
 
 
 255 
 
Appendix F: Proposed phantom structure to simulate breast of different 
thicknesses. 
Table (F-1) Lists proposed thickness of PMMA and PE required to 
simulate breast of 20-100 mm thickness (Bouwman et al., 2013) 
Breast thickness (mm) PMMA thickness (mm) PE thickness (mm) 
20 20.0 0.0 
30 27.5 2.5 
40 30.0 10.0 
50 32.5 17.5 
60 32.5 27.5 
70 32.5 37.5 
80 32.5 47.5 
90 35.0 55.0 
100 37.5 62.5 
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